U.S. DEPARTMENT OF COMMERCE Patent and Trademark Office 58213

## SEARCH REQUEST FORM

Art Unit: 16,2 V	ElLh	-cl/8/10 >- Phone:	Date:
858683	Serial Number:	BERCH	Requestor's

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

Minus Ninus Ninus

LJHN!

25-258

CA, CAPLUS  $\Gamma C$ **SLN Files:** SEAD CS2 H30 Ne 0e MEЗД СОИСОВД EZ piperidinyl)propyl] - (9CI) (CA INDEX NAME) CN347161-70-0 REGISTRY ВИ ANSWER 1 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma 3$ 

200.0% PROCESSED 2172 ITERATIONS PROCESSED 2172 ITERATIONS

IJ6 FUSMERS

NOWBEE OF NODES IS 16
GRAPH ATTRIBUTES:

VPR 11-7/9 UDEFAULT ECLEVEL IS LIMITED PEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

=> d l3 que stat;d l-l79 ide cbib abs L1 STR

<=> str

and 1/23/02, are encouraged to re-run these strategies. Contact the CAS Help Desk at 1-800-848-6533 in North America or 1-614-447-3698, worldwide, or send an e-mail to help@cas.org for further assistance or to receive a credit for any duplicate searches.

858688 4pmg

**LYCE S-A** 

(CH2)3

S KELEKENCES IN EITE CAPTUS (1967 TO DATE)

S KELEKENCES IN EITE CAPTUS (1967 TO DATE)

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; .(əsənaqat) TD, TG, TR. ZE' ZN' Mr' MK' NE' NT' LL' CODEN: BIXXDS' DE' 'AD EI' EK' GY' GB' GK' IE' IL' FN' WC' DK' EZ' CI' CW' CE' CC' CH' RU, WD' KZ, KC' IT' IM; EM: AI, BE, BF, BJ, BX**'** , SA 'MA 'MZ ,AZ 'NX 'TS **1**00 'MT 'LT 'xs 'IS 'ss ZE' 'OS 'zn 'sn ,AU ,ZT TT, TT, **,**UA KO, 'Ld WC' NZ' br' WD' ,AM  $\Gamma\Lambda$ 'ON 'ZW 'XW WK' WN' WM' rn' 'LT 'ST  $\Gamma B$  $\Gamma K$ rc' KB' KZ' IT' IN' IS' 15' KE' KE' KB' 'dI 'NH нв, eD' eE' CB' ŁI' CH' CW' BY' BB' BC' BK' BK' BC' CH' CH' CH' CH' CC' CC' DE' DK' DW' DC' EE' EC' as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

JP 1999-374494 19991228; JP 2000-177790 20000614.

CI

ЯΑ

$$\begin{array}{c} & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

εЯ

$$\begin{array}{c|c} M \in O \\ M \in O \\ M = CO - MH \end{array}$$

4-CTCCH4O(CH5)52' 4-CTCCH4(CH5)5NH' 3-BECCH4CONHCRNH' CCH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH'(CH3CH5)5N(CH5)3NHC2NH'XNHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CH5CH5CH5OCONH' 4-CH30' NOS: V = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

ΙI

intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3' OCHSCOOH: X = perecocycle, heterocyclylalkyl] and

as remedies for diseases mediated by autophosphorylation of PDGF KEFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives prepd. and biol. tested.

(Japanese). CODEM: E2' CA' DE' DK' CI' CW' CH' CE' CC' EI' EK' CB' CB' IE' IL' BJ, 'YZ 'NX TM; RM: AT, BE, KZ, MD, RU, TJ, YZ' BK' KC' ,MA ,WZ 'NA 'ZN , AU  $\mathtt{T}\mathtt{K}^{ullet}$ 'TS 'XS 'IS **'**5S 'ES **в**п, 'Td 'MT 'CT 'ds RO,  $^{\prime}$ L $^{\prime}$ 'ZI 'LL WD' WE' WK' WM' WX' WZ' NO' , AM ΓΛ**'** rn'  $\Gamma K$ rc' 'LT 'ST ľK' ŁI' E2' 15' KE' KC' HE' HO' ID' IT' IN' IS' CH' CW' CD' CE' CB' CH' CH' CM' CE' CO' CS' DE' DK' DM' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, .qq 321 ,2001002 1A 1E97401002 OW DESIGNATED STATES: W: AE, AG, AL, AM, PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji;

Wr' WB' NE' NT' LL' SE' SN' LD' LC' LB' ra' wc' BE'

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXD2,

ŢΛ

pharmaceutically acceptable saits are prepd. as remedies for diseases OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-BICEHdCONHCSNH' CEH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' XNHCONH' S-CICCH4CH(CH3)OCONH' S-CICCH4CHSCHSCHSOCONH' 4-CH3O' NOS; A = 4 - CH3C6H4CH2OCONH, A - FC6H4CH2OCONH, A - FC6H4CH2OCONH,

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

Urea, W-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-W'-[4-(1-CN347161-69-7 REGISTRY ВИ YNZMEK 2 OF 179 REGISTRY COPYRIGHT 2002 ACS ГЗ claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title

CAPLUS

piperidinyl)butyl]- (9CI) (CA INDEX NAME)

 $\Gamma C$ 

SE

ME

EZ

SIN Files:

3D CONCOKD

PAGE 2-A

S REFERENCES IN FILE CA (1967 TO DATE)

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; .(asanaqat) TD, TG, TR. ZE' ZN' Mr' MB' NE' NI' bI' CODEN: BIXXDS DE' 'AD 'IO EI' EK' GY' GB' GK' IE' IL' TO' WC' DK' EZ' CW' CE, CG, CH, **У**ОУ 'MZ IT' IM; EM: AT, BE, BF, BJ, KC' KZ' WD' BX**'** , SA ,MA 'AZ 'NX 'NA 'WT 'LT 'TS 'XS **к**и, 'IS '១ន 'zn 'sn 'en AU , ST TR, TT, ZE' 2D KO, 'T4 rc' rk' rn' ra' wb' wb' wc' wk' wn' wm' wx' ws' no' ns' br' rz' rL' ГВ**'** EI' CB' CD' CE' CH' CW' HB' HO' ID' IT' IN' IS' OB' KE' KC' KB' KK' BY' BB' BC' BK' BK' BC' CH' CH' CH' CH' CC' CC' DE' DK' DW' DC' EE' EC' Al 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, as remedies for diseases mediated by autophosphorylation of PDGF

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F; CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCOHH, 3-ClC6H4CH(CH3)OCOHH, 4-FC6H4CH2OCOH, 2-ClC6H4CH2OHCHCH, R4-CLC6H4CH2OCH3, OCH2COOH, 2-ClC6H4CH2CH2OCOH, R4-CLC6H4CH2OCH3, OCH2COOH, Y = heterocycle, heterocyclylalkyl] and mediated by autophosphorylation of PDGF receptors, particularly useful as Tercentaceutically acceptable salts are prepd. 3-Brc6H4CONHCSNH, CH5COOH, CH2COOH, Y = heterocycle, heterocyclylalkyl] and mediated by autophosphorylation of PDGF receptors, particularly useful as the mass of the m

II

. \$2216661 PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXD2. rn' wc' CODEN: .(əsənsqst) SE, SN, TD, TG, TR. Mr' MK' NE' NT' LL' 'ID CE' E2' CX, EI' EK' CF' CB' CK' IE' DK' DE' CW' CH' 'ອວ BJ, BŁ' RU, TM; RM: AT, BE, 'CT KZ' WD' KC' BX' , ZA ,MA 'MZ 'AZ 'nx 'NA 'ZN 'TS 'XS AU , ST TR, 'MT 'CT 'IS '9S 'ES 'dS кu, RO, 'La br' 'LL 'ON 'ZW 'XW MN, MW, WD' WC' WK' , AM rn' rn' 'LT 'ST LR, rk' rc' 1b' KE' 'SI 'NI HB' HO' ID' IF' CW, CH' CE' CD' CB' ŁI' EE' BY' BB' BC' BK' BX' BS' CY' CH' CN' CK' CN' CZ' DE' DK' DW' DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20701002 IA 1897, 126 pp. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). .lqqA .juI TO4 Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF KELEKENCE 7: 132:10601 Preparation of quinazoline and quinoline derivatives

AA

OəM

(v-gn) S N - CHS - CHS - NH -

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-BLCeHdCONHCRNH' CEH2COO' OH' CE3CeH4CHSOCONH'CH3(CH5)2OCONH'(CH3CH5)5N(CH5)3NHC2NH'XNHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH'

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, C1, F, CH3,

II

2 REFERENCES IN FILE CAPLUS (1967 TO DATE) S REFERENCES IN FILE CA (1967 TO DATE)

as remedies for diseases mediated by autophosphorylation of PDGF KEEEKENCE 1: 132:35049 Preparation of quinazoline and quinoline derivatives

ŁI' DK' 'AO EK' GY' GB' GK' IE' IL' FN' 'S∃ DE' CI' CW' CH' CE' CG' `'MZ WD' BE' B1' BE' , LT **,**טя 'ZX KC' BX**'** , ZA 'AZ 'nx TA :WA :MT ,MA 'NA ,AU ,UT 'TS 'XS 'IS '១s 'ds RO, 'zn 'sn '໑ດ 'ZI TR,MT ZE' RU,  $_{\Lambda}TT$ 'ZN 'ON 'ZW 'XW 'MW WC' WD' , AM '\T 'nT 'LT 'S7  $\Gamma K^{ullet}$ rc' WK' WN' LR, KK' Kb' IT' IN' IS' 15' KE' KE' ID' '೧೫ 'AH CW' CH' ė́р'е́в' CB' CH' CH' CK' CK' CC' DE' DK' DW' DZ' EE' EZ' BY' BB' BC' BK' BX' BS' .qq 8901 ,20701002 IA DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 20010 PCT Int. Appl. WO 2001047890

PRIORITY: JP 1999-377486 19991224; APPLICATION: WO 2000-JP9157 20001222. .AT TD, 'Ld . (asanaqat) TG, ZE' ZN' ML, MR, NE, UL, CODEN: bixxDS

JP 1999-374494 19991228; JP 2000-177790 20000614.

MeO ςЯ ьЯ εЯ

Ι OeM

OəM ΙI OəM NO2 - СО - ИН -HN

prepd. and biol. tested. intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCCH4O(CHS)S2' 4-CTCCH4(CHS)SNH' 3-BICCH4CONHCRNH' CCH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' ANHCONH' S-CTCeH#CH(CH3)OCONH' S-CTCeH#CHSCHSCHSOCONH' #-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, C1, F, CH3,

AA

CA, CAPLUS

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXD2. .(Japaneget). CODEN: SN, TD, TG, TR. ZE' Mr' MB' NE' NT' LT' rn' wc' ŁI' E2' DK' DE' CW' 'IO CH' 'ອວ CE' EB' GB' GB' IE' IL' 'AD Bl' BE' TM; RM: AT, BE, 'CI ₽U**,** KZ' WD' KG' BX**'** , ZA ,MA 'MZ 'AZ 'nx 'NΛ 'ZN ′ຮ∩ ,AU 'XS 'IS 'ĐS **,**UA br' 'ZL 'LL  $_{\mathsf{TR}}$ 'MT 'rı 'Ts ZE' 'ds RO, LT, 'ZN **K**Ŗ' 'MW ,AM **'**Λ' rc' 'NW WK' רח' 'LT 'ST ГВ, ON 'ZW 'XW WD' WC' rk' KK' ŁI' EE' 1b' KE' HB' HO' ID' IF' CH' CW' CE' CB' E2' 'SI 'NI CD' 'ZO CH' CH' CH' CK' CC' DE' DK' DW' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, .qq 321 ,20701002 IA 1897401005 OW DESIGNATED STATES: W: AE, AG, AL, AM, PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

Ι ŢΛ

CE3CeH4CHTOCONH'CH3(CH5)2OCONH'(CH3CH5)5N(CH5)3NHC2NH' ANHCONH' S-CICCH4CH(CH3)OCONH' S-CICCH4CHSCHSCHSOCONH' 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3, ЯΑ

ΙI

claimed compd. II was prepd. and biol. tested. Thus, the title mediated by autophosphorylation of PDGF receptors. pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, V = heterocycle, heterocyclyl and d-CTCCH4O(CH5)S2' d-CTCCHd(CH5)SNH' 3-BxCCHdCONHCRNH' CCH2COO' OH'

(CY INDEX NAME) 34\I20-42-0 KECIZLKX ВИ

СИ

S-nitrophenyl]- (9CI) Urea, M-[2-(dibutylamino)ethyl]-M'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-

COPYRIGHT 2002 ACS

ЗД СОИСОВД

EZ

C57 H36 N6 O6 WE

FUSMER 4 OF 179 REGISTRY

AD

**ZLN ETJGS:** 

ГC

SE

ГЗ

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; . (Japanese). TD, TG, TR. MT' MK' NE' NT' LL' SE' SN' CODEN: BIXXDS: DK' E2' E1' EK' GB' GB' IE' IL' TN' WC' CE' CC' CH' CI' CW' CX' DE' **'**N∀ KC' KZ' WD' T1, TM; RW: AT, BE, BF, BJ, BX, , SA , MA , WS AZ 'UY 'NV TT ,AT ,MT 'CI 'TS 'XS 'IS ZE' 2C' 'ds **В**О, 'ZU 'SU 'ĐU 'AU 'ZT ra' MY' MD' MG' MK' MN' MM' MX' MZ' NO' NZ' bF' ra' rı' rn'  $\Gamma B$ CD' CE' CH' CW' HB' HO' ID' IT' IN' IS' OB' KE' KC' KB' KB' KS' BY' BB' BC' BK' BK' BK' CH' CH' CH' CH' CC' CK' DE' DK' DW' DK' EE' EC' WI S0010105, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3' OCHSCOOH:  $\chi = \text{perecocycle}$ , perecocycly and d-CTCCHdO(CHS)S2' d-CTCCHd(CHS)SNH' 3-BxCCHdCONHCRNH' CCH2COO' OH' CE3CeH4CHSOCONH'CH3(CHS)POCONH' (CH3CHS)SN(CHS)3NHCRNH' ANHCONH' S-CICCH4CH (CH3) OCONH, S-CICCH4CH2CH2CH2OCONH, 4-CH30' NOS; Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

II

mediated by autophosphorylation of PDGF receptors, particularly useful as

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives prepd. and biol. tested. intimal thickening inhibitors. Thus, the title claimed compd. II was

19991224. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 PIXXD2. WL, WC' .(Japanese). SE' SN' LD' LC' LK' MR, NE' NT' LL' CODEM: 'ID EK' CH' CB' CK' IE' IL' DE' DK' ES' EI' 'AD 'WD CH' **'**50 CE' BJ, BE' TM; RW: AT, LT, КU, Ke' KZ' WD' BX**`** , ZA ,MA 'MZ ,AZ 'nX ΊΝΛ 'ZΩ ,AU ,ST 2K' 2T' '១ន TR, 'IS 'ds ug' 'TT 'WT ,UT 'ES RU, KO, 'Ld rn' 'NW 'ZX 'ON 'ZW 'XW 'MW WK' MA, MD, MG, rn' 'LT rk' rc' 'ST LR, ŁI' CH' CW' HB' HO' ID' IT' CD' CB' E2' EE' IN' IS' 15' KE' CE' AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DESIGNATED STATES: W: AE, AG, AL, AM, .qq asi ,eoroioos iA iEerpoioos ow Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF

CJ

(u-Bn) S M - CHS - CHS - MH - C

O9M

O9M

**SLN Files:** 

 $\Gamma C$ 

ЯS

pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-BICEHdCONHCRNH' CEH2COO' OH' СЕЗСЕНФСН СООИН СНЗ (СН СН СООИН) (СНЗСН С) ЗИНСВИН ХИНСОИН) S-CICCH4CH (CH3) OCONH' S-CICCH4CHSCHSCHSOCONH' 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [1; X = N, CH; R3, R4, R5, R6 independently = H, C1, F, CH3, ЯA

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title

347156-44-9 REGISTRY PN2MER 5 OF 179 REGISTRY COPYRIGHT 2002 ACS

ЗД СОИСОВД (dibutylamino)ethyl] - (9CI) (CA INDEX NAME)

CS1 H36 CT NS O4

WE EZ

CN

Urea, M-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-M'-[2-chloro-4-quinazolinyl)oxy]

CA, CAPLUS

ВИ ГЗ

ЯΑ

CI

S REFERENCES IN FILE CAPLUS (1967 TO DATE) S REFERENCES IN FILE CA (1967 TO DATE)

KEFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

WD' BŁ' RU, TJ, TM; RW: AT, BE, BX' , ZA 'MZ 'AZ **′**NX KC' KZ' 'NA ,MA 'MT 'TS ZK' 'zn 'sn **'**ഉᲘ ,AU 'ZI 'TT TK, 'LT 'IS '9S ZE' 'as **R**U, RO, 'Id bľ' 'ZN ON 'ZW 'XW 'MW WC' WD, ,AM ۲Λ, rn' 'LT 'ST rk' WK' WN' LR, rc' 'TI 'NH KK' Kb' IN' IS' 15' KE' KG' ID' HK' CW' CH' CE' CD' CB' BY' BB' BC' BK' BK' BK' CH' CH' CH' CK' CC' DE' DK' DW' DK' EE' EC' DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, .qq 8901 ,20701002 IA receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 20010 PCT Int. Appl. WO 2001047890 as remedies for diseases mediated by autophosphorylation of PDGF

.(asanagal) TD, TG, TR. 2E' 2N' Wr' WB' NE' CODEN: BIXXDS ŁI' 'AD 'IO DK' EZ' DE' EK' CH' CB' CK' IE' IL' TO' CW' CC' CH'

JP 1999-374494 19991228; JP 2000-177790 20000614; PRIORITY: JP 1999-377486 19991224; APPLICATION: WO 2000-JP9157 20001222. LT, 'TN

A FAξЯ

OəM I OeM . ςЪ В6

ΙI OəM OeM NOS HN --co-- HN

pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CJC6H4O(CH2)2S, 4-CLC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, CE3CeH4CH5OCONH'CH3(CH5)POCONH' (CH3CH5)SN(CH5)3NHC2NH' ANHCONH' S-CICCH4CH (CH3) OCONH' S-CICCH4CH5CH5CH5OCONH' 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCEH4CH(CH3)OCONH' 4-ECEH4CH5OCONH'

Title compds. [I; X = N, CH; B3, B4, B5, B6 independently = H, CL, F, CH3,

Thus, the title claimed compd. II was intimal thickening inhibitors. mediated by autophosphorylation of PDGF receptors, particularly useful as

19991224. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 **DIXXDS** ZE' 'TW .AT 'D' LD' LC' WE' NE' NI' LI' rn' wc' . (asanaqat) CODEM: ŁI' E2' DE' 'AO CH' **'**90 CE' DK' 'IO Bl' BE' EK' CH' CB' CK' IE' CW' BE' ,TA **,**UA WD' 'ZX KC' BX**'** , SA ,MA 'MZ ,AZ 'nX 'NA 'ZN ′ິຣດ 'LT TM; RM: ZN ,AU 'CI 'TS 'XS '១s RU, ₽Ľ, **'**១៣ 'ZI 'TT  $\mathsf{T}\mathsf{R}$ 'MT 'IS ZE' 'ds **,**OЯ LT, 'ZW WD' 'ST rc' 'ZX 'ON 'XW '9W , AM **'**\7 'LT  $\Gamma B$ ΓК' 'MW 'NW WK' rn' KK' KE' ŁI' E2' EE' KC' 'SI 'NI 'TI CB' 'ZO 'ar ID' нв' нα' 'W5 'H9 CE' CD' DK' DE' CA, CH, CN, CR, DW' cn' cz' BY' BB' BC' BK' BX' BS' , ZA , UA , TA .qq 321 ,20701002 1A 1867401005 OW DESIGNATED STATES: W: AE, AG, AL, AM, PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF KELEKENCE 2: 132:76901 Preparation of quinazoline and quinoline derivatives

Ι И \_ И \_ ŢΛ

II

CE3CeH4CHSOCONH'CH3(CHS)2OCONH' (CH3CHS)5N(CHS)3NHC2NH' XNHCONH' S-CICCH4CH (CH3) OCONH' S-CICCH4CHSCHSCHSOCONH' 4-CH30' MOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECeH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, AA

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTC@H4O(CH5)58' d-CTC@Hd(CH5)5NH' 3-BxC@HdCONHCRNH' C@H2COO' OH'

quinazolinyl)oxy]phenyl]- (9CI) (CA INDEX NAME) Urea, N-[2-(dibutylamino)ethyl]-N'-[4-[(6,7-dimethoxy-4-

EZ

CS1 H31 N2 O4 ЗД СОИСОВД

CA, CAPLUS

CN

347156-43-8 REGISTRY ВИ

STN Files:

AD

ГC

SE

WE

CI

 $\Gamma 3$ 

$$(n-Bu) 2^{M} - CH^{2} - CH^{2} - MH - C - MH$$

$$MeO$$

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S KEEEKENCES IN EITE CAFINS (1964 TO DATE)
S KEEEKENCES IN EITE CA (1964 TO DATE)

ЯΑ

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. **DIXXDS** SE' SN' LD' LC' .AT CODEN: (Japanese). NE' NT' bL' ML, MR, rn' wc' E2' 'IO EK' GY' GB' GK' IE' ŁI' DK' DE' 'XD CH' **'**១၁ CE' B1. CW' BE' 'LT WD' 'ZX KC' BX' , SA 'MZ TA; RW: AT, ₽U, ,MA ,AZ 'NX 'NΛ 'ZN ′ິຣດ , AU TR'MT 'LT 'TS 'XS 'IS '១ន 'ES 'ds **,**0Я KO, LT, br' 'ZN 'ZL 'LL 'ZX WD' WC' ,AM  $\Gamma\Lambda$ rn' 'SI ГΚ' rc' 'ON 'ZW 'XW 'MW WK' WN' 'LT  $\Gamma K$ KK' 15' KE' CH' CW' CE' ŁI' E2' EE' KC' 'SI HE' HO' ID' IT' IN' CD' CB' 'Zd CY' CH' CN' CK' CO' CZ' DE' DK' DW' BX' BZ' AT, AU, AZ, BA, BB, BG, BR, .qq 821 ,20701002 IA 1867401005 OW DESIGNATED STATES: W: AE, AG, AL, AM, Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

Title compds: [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCOHH, 3-CLC6H4CH(CH3)OCOHH, 2-CLC6H4CH(CH3)OCOHH, 2-CLC6H4CH2OCOHH, 2-CLC6H4CH2OCOHH, 2-CLC6H4CH2OCOHH, R4-CLC6H4CH2OCOHH, CH3(CH2)SOCOHH, (CH3CH2)SU (CH3CH2)SU (CH2)SU (CH2)S

pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3' OCHSCOOH:  $\chi = \text{peferoc} \lambda \text{cg}$  peferoc $\lambda \text{cg} \lambda \text{rg} \text{rk} \lambda \text{rg}$  sug d-CTCeH40(CH5)S2' d-CTCeH4(CH5)SNH' 3-BxCeH4CONHCRNH' CeH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC2NH' XNHCONH' S-CTCeH&CH(CH3)OCONH, 2-CTC6H&CH2CH2CH2OCONH, 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH'

claimed compd. II was prepd. and biol. tested.

mediated by autophosphorylation of PDGF receptors. Thus, the title

(CY INDEX NAME) Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N'-[2-(1-

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, C1, F, CH3,

ΙI

ANSWER 7 OF 179 REGISTRY COPYRIGHT 2002 ACS

CA, CAPLUS

STN Files:

ЗD СОИСОКD

CS2 H3J N2 O2

 $\Gamma C$ SR

WE

ES

CN

ВИ

ГЗ

ЯΑ

Searched by: Mary Hale 308-4258 CM-1 12D16

piperidinyl)ethyl]- (9CI)

347156-38-1 REGISTRY

PAGE 2-A

CH2

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S REFERENCES IN FILE CAPLUS (1967 TO DATE)

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; (Japanese). CODEN: PIXXD2. TD, TG, TR. ZE' ZN' Mr' MB' NE' NI' LI' DK' ES' EI' EB' GB' GB' IE' IL' TO' WC' CX' DE' CE' CC' CH' CI' CW' 'MZ KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, BX, , SA , MA ,AZ 'מג 'אג SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, 'XS 'IS '9s 'ES RU, RO, 2D 'Ld ΓK' rc' LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, רצ' רצ' רג' רח' eD' CE' CH' CW' HB' HO' ID' IT' IN' IS' 15' KE' KC' KB' KK' EI' CB' BY' BB' BC' BK' BK' BK' CH' CH' CH' CH' CC' CK' DE' DK' DW' DK' EE' EC' Al 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Міма, as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

$$\begin{array}{c} & & & & \\ & & &$$

ξЯ

$$\begin{array}{c} M \in O \\ M \in O \\ M = O \end{array}$$

S-CICCH4CH(CH3)OCONH, 2-CICCH4CH2CH2CH2OCONH, 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

ΙI

OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCeH4O(CHS)SS' 4-CTCeH4(CHS)SNH' 3-BxCeH4CONHCRNH' CEH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC2NH' ANHCONH'

Thus, the title claimed compd. II was intimal thickening inhibitors. mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases

KELEKENCE S: 132:76901 Preparation of quinazoline and quinoline derivatives prepd. and biol. tested.

ŁI' 'ID CE' E2 'AD CH' **'**၅၁ Bl, BŁ' EK' CH' CB' IE' DK' DE' CW' ,TA WD' 'ZX , SA 'MZ BE' 'LT KC' ,MA ,AZ 'NΛ 'ZN 'ຮ∩ ВU BX' 'UX TM; RW: 'TS 'XS '១s LT, br' **1**0° , AU 'ZJ 'LL TR'WI ZE' 'ds ,OA 'ZN 'LT 'IS ВU, 'ON 'ZW 'XW WD' ,AM **'**\\T **'**מק 'LT 'ST LR, rc' 'ZX 'MW 'NW WK' WC' rk' KK' 'TI ŁI' E2' EE' KE' KC' 1b, 'SI 'NI ID' 'ΩH HB, CW, 'HĐ CE' CD' CB' 'ZO DK' CH' CN' CK' 'AD BX' BZ' DW' DE' 'ZO 'NO AU, AZ, BA, BB, BG, BR, DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20701002 IA 1E97401002 OW Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF

**DIXXDS** .AT .(əsənaqat) SE' SN' LD' LC' Mr' MB' NE' NI' bI' ra' wc' CODEN:

19991224 APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313

CI

**BA** 

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-BTCEHdCONHCRNH' CEH2COO' OH' CE3CeH4CHTOCONH'CH3(CHT)2OCONH' (CH3CHT)5N(CHT)3NHCRNH' XNHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCCOONH' 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' ΑA

(CA INDEX NAME)

Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[2-(1-

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

CF, CAPLUS

ANSWER 8 OF 179 REGISTRY COPYRIGHT 2002 ACS

**SLN Files:** 

ЗД СОИСОКД

CS4 HS8 CJ NS O4

biperidinyl)ethyl]- (9CI)

347156-37-0 REGISTRY

AD

 $\Gamma C$ SE

WE EZ

CN

BN

 $\Gamma 3$ 

PAGE 2-A

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

KELEKENCE 1: 132:85048 Lebsrstion of dringsoline and drinoline derivatives

S REFERENCES IN FILE CA (1967 TO DATE)

JP 1999-374494 19991228; JP 2000-177790 20000614. PRIORITY: JP 1999-377486 19991224; APPLICATION: WO 2000-JP9157 20001222. .ATTD' LG' 'NS 'ES bL' . (asanagat) ML, MR, NE, NL, CODEN: BIXXDS 'XD DK' DE' 'IO **'**၅၁ EI' EK' CH' CB' CK' IE' IL' FN' WC' E2' CW' CH' 'LT BE' B1' BE' **,**UA WD' 'ZX KC' BX' , ZA ,MA 'MZ ,AZ 'NX TA : WA : MT  $\mathtt{T}\mathtt{K}^{ullet}$ 'LT .'TS 'XS 'IS 'zn 'sn **'**១೧ , AU 'ZI 'TT 'MT 'ĐS ZE' 'ds **t**UA **к**о' 'ZW 'XW 'MW WC' , AM  $\Gamma\Lambda$ NS' br' 'ON 'NW WK' WD' **'**מק 'LT 'ST ГΚ' ГВ' 'DT KK' **′**NH Kb' IT' IN' IS' 15' KE' KG' ID' HB, CW' CH' CD' CB' ŁI' CE' CY' CH' CN' CK' CN' CZ' DE' DK' DW' DZ' EE' EZ' BY' BB' BC' BK' BX' BZ' Al 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 as remedies for diseases mediated by autophosphorylation of PDGF

Searched by: Mary Hale 308-4258 CM-1 12D16

ΙĐ

ξЯ

CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' XNHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-CH3O' NOS: Y = 4-CH3C6H4CH5OCONH' 3-CTC6H4CH(CH3)OCONH' 4-EC6H4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

II

mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCeH4O(CH5)58' 4-CTCeH4(CH5)5NH' 3-BICEH4CONHCSNH' CEH2COO' OH'

intimal thickening inhibitors. Thus, the title claimed compd. II was

KEEEKENCE S: 132:76901 Preparation of quinazoline and quinoline derivatives prepd. and biol. tested.

as remedies for diseases mediated by autophosphorylation of PDGF

BX**'** ,ZA 'MZ 'nX 'NA 'zn TA : WA : MT RU, TJ, KC' KZ' WD' ,MA ,AZ 'sn .əu .Au 'LI 'TS 'XS 'IS **'**98 ZE' **,** עא br' 'ZN  $\mathtt{T}\mathtt{K}^{ullet}$ 'MT 'ds 'Ld 'ZJ 'LT RO, 'ON 'ZW 'XW 'MW 'NW WK' 'SW 'GW 'WW רת' רת' 'L'I 'ST ΓK' rc' 'ZX KB' ГВ**'** KE' KC' 1b, IF' **'**HĐ CE' ŁI' 'SI 'NI HB' HO' ID' CW, CD' CB' EE' EZ' CY' CH' CN' CB' CN' CZ' DE' DK' DW' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20701002 IA 1E67401005 OW Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji;

CODEM: .(Japanese). Mr' MB' NE' NT' LL' SE' SN' LD' LC' LB' rn' WC' 'IO CE' DK' E2' EI' EB' CB' CB' IE' CX' DE' CW' B1 BE' ce' ch'

PIXXD2.

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222.

CI

AA

CA, CAPLUS

piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

PN2MER 9 OF 179 REGISTRY COPYRIGHT 2002 ACS

**SLN Files:** 

ЗД СОИСОКД

C54 H56 N2 O4

341126-36-9 REGISTRY

ГC SR

WE

EZ

CN

ВИ

ГЗ

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCCH4O(CH5)52' 4-CTCCH4(CH5)5NH' 3-BICCH4CONHCSNH' CCH2COO' OH' СЕЗСЕНФСНТОСОИН' СНЗ (СНТ) 20СОИН' (СНЗСНТ) ТИ (СНТ) ЗИНСВИН' ХИНСОИН' S-CICCH4CH(CH3)OCONH, 2-CICCH4CH2CH2CH2CCONH, 4-AA

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[2-(1-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[2-(1-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[2-(1-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[2-(1-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[3-(1-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[3-(1-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[3-(1-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[3-(1-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[3-(1-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[3-(1-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[3-(1-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[3-(1-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[3-(1-dimethoxy-4-quinazolinyl)oxy]phenyl

PAGE 2-A

CHS

S REFERENCES IN FILE CAPLUS (1967 TO DATE) S REFERENCES IN FILE CA (1967 TO DATE)

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

'Z¥ KG' KZ' MD' KN' LY' LW: BM: BT' BE' BY' BX**'** ,MA ,WZ '\Z 'חג 'אה **'**7S 'XS 'IS '១s PT, RO, 'ZN 'ES 'OS **,**UA Tz, UA, UG, US, TT, TM, TT, TT, LS, LT, LU, LV, MA, MD, MG, MK, MW, MX, MZ, NO, NZ, PL, rc' rk' LR, CD' CE' CH' CW' HB' HO' ID' IT' IN' IS' 1B' KE' KC' KB' KB' KS' BY' BB' BC' BK' BK' BK' CH' CH' CH' CK' CC' DE' DK' DW' DK' EE' EC' receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 as remedies for diseases mediated by autophosphorylation of PDGF KEEEKENCE 1: 132:92649 Preparation of quinazoline and quinoline derivatives

CI JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; PT, (Japanese). CODEN: PIXXD2 TD, TG, TR. ZE' ZN' Wr' WB' NE' NT' DE' CX' EI' EK' GY' GB' GK' IE' IL' FN' WC' DK' EZ' CE' CC' CH' CI' CW'

ЯA

OəM

Meo

Thus, the title claimed compd. II was CE3CeH4CHSOCONH'CH3(CHS)2OCONH'(CH3CHS)SN(CHS)3NHC2NH'XNHCONH' Z-CTCeH4CH(CH3)OCONH, Z-CTC6H4CHZCHZCHZOCONH, 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, C1, F, CH3,

Ι

ςď

ξЯ

Вđ

ΙI

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives prepd. and biol. tested. intimal thickening inhibitors. mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCeH4O(CHS)SS' 4-CTCeH4(CHS)SNH' 3-BICEH4CONHCRNH' CEH2COO' OH'

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXD2. MT' MK' NE' NT' bI' SE' SN' ID' IG' IK' CODEN: .(asanaqat) rn' wc' CA' DE' DK' EZ' CI' CW' CH' CE' CC' BE' EI' EK' CH' CB' CK' IE' IL' BJ, 'LT KC' ,MA ,WZ , AZ 'nx 'NA 'ZN TM; RM: AT, BE, KZ' WD' BO' YZ' BX' 'sn , AU TR, 'LT 'TS ZE' **В**О, PT, bľ' 'MT 'XS 'IS .'9S ʻas 'ZN 'ZL 'LL RO, 'ZW 'XW 'MM' MM' WK' MA, MD, MG, רת' דת' 'LT 'ST רצ' רצ' rc' 'ZX KE' 1b, 'SI 'NI CH' CW' HB' HO' ID' IT' CD' CE' EE' ES' EI' CB' AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20701002 IA 1867401002 OW Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF

OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and d-CTCCHdO(CHS)S2' d-CTCCHd(CHS)SNH' 3-BxCCHdCONHCRNH' CCH2COO' OH' СЕЗСЕНФСН СОООН СНЗ (СНЗ ) 20СОИН (СНЗСН ССН З З З В ССИН КИНСОИН КИНСОИН СНЗ (СНЗ ) В СНЗСВИН СНЗ (СНЗ ) В СНЗ (СНЗ ) В СНЗСВИН СНЗ (СНЗ ) В СНЗ S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-Title compds. [I; X = V, CH; R3, R4, R5, R6 independently = H, CL, F, CH3, CH3O, NO2; A = 4 - CH3C6H4CH2OCOWH, A = 4 - CH3CAA

Thus, the title

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. pharmaceutically acceptable salts are prepd. as remedies for diseases

ANSWER 10 OF 179 REGISTRY COPYRIGHT 2002 ACS

347156-28-9 REGISTRY

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N'-[2-

[efp\] (3-mefp\]bpen\]) amino]efp\] - (9CI) (CA INDEX NAME)

EZ 3D СОИСОКD

SB AD C50 H33 N2 O2

CAPLUS

Searched by: Mary Hale 308-4258 CM-1 12D16

WE

**SLN Files:** 

СИ

ВИ

ГЗ

ГC

PAGE 2-A

PAGE 1-A

CHS

2 REFERENCES IN FILE CAPLUS (1967 TO DATE) S REFERENCES IN FILE CA (1967 TO DATE)

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; LT, (Japanese). CODEN: PIXXD2. TD, TG, TR. 'NS 'ES Mr' MB' NE' NT' DE' CX' 'IO CW' EI' EK' CH' CB' CB' IE' IL' TO' WC' DK' EZ' CE' CC' CH' צט, WD' KC' BX' , SA 'ZX 'MZ 'NX IT' IM; EM: AT, BE, BF, BJ, ,MA ,AZ 'ΝΛ 'TT TK, 'WT 'LT 'TS 'XS 'IS '១ಽ ZE' 'ds **к**и**,** 'zn 'sn 'sn AU , TT RO, 'Ld LT, 'Td 'ZN 'ON MY' MD' MC' MK' MN' MX' MZ' רת' רת' 'ST ΓK, ΓK, rc' CH' CW' HB' HO' ID' IT' IN' IS' OB' KE' KG' KB' KS' CD' CE' EI' CB' BY' BB' BC' BK' BK' BK' CH' CH' CH' CH' CC' CC' DE' DK' DW' DC' EE' EC' YI S0010102' 1008 bb. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

$$\begin{array}{c} & & & & \\ & & &$$

CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' XNHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-CH30' MOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

ΙI

OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCCH4O(CH5)52' 4-CTCCH4(CH5)5NH' 3-BxCCH4CONHC2NH' CCH2COO' OH'

Thus, the title claimed compd. II was intimal thickening inhibitors. mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases

as remedies for diseases mediated by autophosphorylation of PDGF KEFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives prepd. and biol. tested.

PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. Mr' MB' NE' NT' LL' SE' SN' LD' LG' LB' ra' wc' . (əsənaqst) CODEN: CE' EI' EK' CH' CB' CK' IE' E2' DK' DE' 'AD CI' CW' CH' ′ ໑ວ BJ, 'LI RU, KZ' WD' KC' BX, 'Z∀ 'NX 'ZN TM; RM: AT, BE, ,MA ,WS ,AZ 'NΛ 'IS '១s , AU 'AT ,UT 'XS 'IS ZE' 'ds **В**И, br'  $_{\mathsf{TL}}$ 'WI 'La 'ZL KO, 'ZX 'ZW 'XW 'MW 'NW WK' , AM ľ۸'n ′กๆ 'LT 'ST rc' WD' WG' רצ' רצ' 15' KE' 'SI 'NI CH' CW' HB' HO' ID' IT' EI' CB' CD' CE' EE' EZ' AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20010002 IA 1E6TP0100S OW PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji;

19991224. PIXXD2. CI

ЯA

OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCeH4O(CHS)SS' 4-CTCeH4(CHS)SNH' 3-BTCEH4CONHCSNH' CEH2COO' OH' CE3CCH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' XNHCONH' S-CICCH4CH(CH3)OCONH' S-CICCH4CHSCHSCHSOCONH' 4-ЯA

mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases

claimed compd. II was prepd. and biol. tested.

ANSWER 11 OF 179 REGISTRY COPYRIGHT 2002 ACS

CA, CAPLUS

Urea, W-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-N'-[2-

[efph7(3-mefhy1pheny1)amino]efhy1]- (9CI) (CA INDEX NAME)

ЗД СОИСОВД EZ

WE

CS8 H30 Ne Oe

SIN Files:

SEAD

ГC

CN

ВИ.

341126-27-8 REGISTRY  $\Gamma3$ 

Title compds. [I; X = M, CH; R3, R4, R5, R6 independently = H, CL, F, CH3, CH3O, MO2; A = 4 - CH3C6H4CH2OCOWH, A =

II

PAGE 2-A

CODEN: BIXXDS'

CH2

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

'IO EI' EK' CH' CB' CK' IE' IL' FO' MC' DK' ES' CA' DE' CW' CE' CG' CH' BU, TJ, TM; RW: AT, BE, BF, BJ, WD' KZ, KC' BX' , ZA 'MZ AZ 'UY 'NV ,MA 'XS 'IS °as TM, TR, TT, TZ, UA, UG, US, UZ, 'rı''rs ʻ9s ZE' КU, rn' 'ST WY' WD' WG' WK' WN' WX' WZ' NO' NZ' BF' rı, ru, LR, CH' CW' HB' HO' ID' IT' IN' IS' OB' KE' KC' KB' KB' KZ' CD' CE' BY' BB' BC' BK' BX' BZ' CY' CH' CN' CS' CA' CC' DE' DK' DW' DZ' EE' EZ' Al 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, as remedies for diseases mediated by autophosphorylation of PDGF

KELEKENCE 1: 132:35043 Lebaration of drinazoline and drinoline derivatives

TD, TG, TR.

.(əsənaqat)

The 1999-374494 19991228; JP 2000-177790 20000614.

PT, SE, SN,

CI

Mr' MB' NE' NT'

ЯA

O9M

O9M

CH3O' NOS: W = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

Ι

98

ςЯ

ЕЯ

Въ

ΙI

prepd. and biol. tested. Thus, the title claimed compd. II was intimal thickening inhibitors. mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-BTCEHdCONHCRNH' CEH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC2NH' XNHCONH' S-CTCCH4CH(CH3)OCONH' S-CTCCH4CHSCHSOCONH' 4-

19991224° APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 PIXXD2. . (asanaqat) SE, SN, TD, TG, TR. Mr' WB' NE' NT' LL' rn' wc' CODEN: E2' 'IO ŁI' EB' GB' GB' IE' IL' DK' DE' CX, CW' CH' CE' CC' BJ, 'LT RU, KC' BX' , SA 'MZ 'AZ 'NX 'ZN TM; RM: AT, BE, KZ' WD' ,MA 'NA 'ຮດ TK, 'TS 'XS 'IS '9s 2E' **,**UA KO, 'La ₽Ľ, , au , ar 'MT 'LT 'as 'ZN 'LL 'ZX 'ON 'ZW 'XW , AM rn' rn' 'LT 'ST LR, ΓK' WK' WN' WM' WD' WG' rc' 'SI 'NI 'TI CE' CD' 15' KE' KC' HB' HO' ID' CH' CW' EI' CB' EE' EZ' CY' CH' CN' CB' CO' CS' DE' DK' DM' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, DESIGNATED STATES: W: AE, AG, AL, AM, WO 2001047931 A1 20010705, 126 pp. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCCH4O(CH5)58' 4-CTCCH4(CH5)5NH' 3-BTCCH4CONHCSNH' CCH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' XNHCONH' S-CTCCH4CH(CH3)OCONH' S-CTCCH4CHSCHSCCHSOCONH' 4-Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH3OCONH, 4-FC6H4CH2OCONH,

ΙI

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases

Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[2-CN347156-25-6 REGISTRY ВИ

[efp\] (3-mefp\]ben\]) amino]efp\] - (9CI) (CA INDEX NAME)

ANSWER 12 OF 179 REGISTRY COPYRIGHT 2002 ACS

ЗД СОИСОВД EZ

 $\Gamma 3$ 

CS8 H30 CJ N2 O4 WE

**GA** SR

CAPLUS **SLN ETTES:** ГC

**byce S-A** 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S KEEEKENCES IN EIFE CYPLUS (1967 TO DATE)
S KEEEKENCES IN EIFE CY (1967 TO DATE)

JB 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; (Japanese). CODEN: PIXXD2. TD, TG, TR. MT' MB' NE' NT' LL' SE' SN' EI' EK' GF' GB' GK' IE' IL' TN' MC' DK' EZ' CW' CX' DE' CE' CC' CH' CI' WD' 'MZ **'**NX צח. ,AZ IT' IM; EM: AI, BE, BI, KC' KZ' 'YA 'ZA 'MA 'NA 'zn 'sn 'ອດ AU 'ST 'TT 'AT 'WT 'LI 'TS 'XS 'IS 'ss ZE' 'ds **к**и, RO, 'Ld 'รา WK' WN' WM' WX' WZ' NO' NZ' bF' MA, MD, MG, **'**Λ\ 'UT 'LT LR, rk' rc' CH' CW' HB' HO' ID' IT' IN' IS' 1B' KE' KC' KB' KK' KZ' EI' GB' GD' GE' BY' BB' BC' BK' BK' BC' CH' CH' CH' CH' CC' CC' DE' DK' DW' DC' EE' EC' YI S0010102' 1008 bb. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

EI

S-CICCH4CH(CH3)OCONH, S-CICCH4CH2CH2CH2OCONH, 4-CH30' NOS: V = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

Ι

II

Thus, the title claimed compd. II was

intimal thickening inhibitors. mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCCH4O(CH5)52' 4-CTCCH4(CH5)5NH' 3-BxCCH4CONHC2NH' CCH2COO' OH' СЕЗСЕНФСН СООИН СНЗ (СНЗ ) РОСОИН (СНЗСН СТВ ) ЗИНСВИН ДИНСОИН У

KELEKENCE 7: 132:76901 Preparation of quinazoline and quinoline derivatives prepd. and biol. tested.

PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. FIXXDS' . (asanaqat) ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. rn' wc' CODEN: EI' EK' CH' CB' IE' IL' DK' ES' DE' 'XD CI' CW' CH' **'**90 CE' BJ, BE' KG' KZ' WD' BN' L1' BX**'** 'Z¥ 'MA 'MZ TM; RM: AT, BE, '∀Z 'nx 'NΛ 'zn 'នព 'IS '9s **В**О, br' TZ, UA, UG, TK'WT SF' LT' 2K' ZE' 'as LT, 'TT RO, 'ZN WD' WC' WK' WN' WX' WZ' NO' , AM rn' rc' rn' 'LT 'ST LR, rk' IN' IS' 15' KE' KG' CH' CW' HB' HO' ID' IT' CE' CD' EI' CB' BY' BB' BC' BK' BK' CH' CH' CH' CK' CC' CK' DE' DK' DW' DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20010002 IA 1E97401002 OW PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF

CI

ЯΑ

19991224°

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3, CH3, MO2; A = 4 - CH3C6H4CH2COOH, A = 4 -

S-CICCH4CH (CH3) OCONH' S-CICCH4CHSCHSCCHSOCONH' 4-

d-CTCCH4O(CHS)S2' d-CTCCHd(CHS)SNH' 3-BxCCHdCONHCRNH' CCH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC2NH' XNHCONH'

OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and

II

pharmaceutically acceptable salts are prepd. as remedies for diseases

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title

ANSWER 13 OF 179 REGISTRY COPYRIGHT 2002 ACS

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]Phenyl]-N'-[2-[ethyl(3-y)]341120-54-5 RECISLEX ВИ

methylphenyl)amino]ethyl]- (9CI) (CA INDEX NAME) СИ

ЗД СОИСОВД EZ

CS8 H3I N2 O4 WE

 $\Gamma3$ 

SE

CA, CAPLUS **SLN Files:**  $\Gamma C$ 

Searched by: Mary Hale 308-4258 CM-1 12D16

**BYCE S-Y** 

CHS

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S BELEBENCES IN EITE CAPINS (1967 TO DATE)

S BELEBENCES IN EITE CAPINS (1967 TO DATE)

JB 1999-374494 19991228; JP 2000-177790 2000614. PRIORITY: JP 1999-377486 19991224; APPLICATION: WO 2000-JP9157 20001222. CODEN: BIXXDS .(əsənsqst) TD, TG, TR. 'NS ZE' LT, Wr' WB' NE' NT' ŁI' DK' 'XD '໑ຉ DE' 'ID CH' ER, GA, GB, GR, IE, IT, LU, MC, E2'  $\mathtt{CW}^{\boldsymbol{\iota}}$ **,**UЯ WD' 'ZX IT' IM; EM; BI' BE' BL' BT' BX, , ZA 'MZ ,AS KC' ,MA 'NX 'zn 'sn **1**00 ,AU 'ZI TE, 'LT 'TS 'IS 'LT 'MT 'XS **'**5S ZE' 'ds ВU, RO, NZ' br' WK' WN' WM' WX' WZ' NO' WC' WD' , AM **'**\7 **'**מת  $\text{LT}^{\boldsymbol{\prime}}$ 'ST  $\Gamma K$ rk' 'TI 'NH IN' IS' 16' KE' KG' KB' KS' ID' HBCW, 'H9 CE' CD' CB' CH' CH' CH' CK' CC' DE' DK' DW' DZ' EE' EZ' BC' BK' BX' BZ' AB, AB, Al 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 20010 PCT Int. Appl. WO 2001047890 as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

Searched by: Mary Hale 308-4258 CM-1 12D16

CI

ΑA

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXD2. MT' MB' NE' NT' bI' SE' SN' ID' IG' IB' CODEN: ra' wc' . (əsənaqat) CE' E2' 'AO CI' CW' EI' EK' CH' CB' CK' IE' DE' DK' CH' **'**၅၁ Bl, KC' BX, , ZA ,AZ 'ZN TM; RM: AT, BE, KZ, MD, RU, TJ, ,MA ,WZ 'ΩX 'NA **'**5S TR, 'TS 'XS 'IS 'ES 'Id ₽Ľ, 'MT 'LT 'as RU, 'ZI 'LL KO, 'ZX AM VJ rn**'** 'LT rc' MN, MW, MX, MZ, WD' WC' WK' 'ST rk' ГВ' EI' 15' KE' KC' CH' CW' HB' HO' ID' IT' IN' IS' CD' CE' EE' EZ' CB' YI' YN' YZ' BY' BB' BC' BK' BK' BK' CH' CH' CH' CK' CC' DE' DK' DW' DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20701002 IA 1897401002 OW PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF KELEKENCE S: 132:76901 Preparation of quinazoline and quinoline derivatives

prepd. and biol. tested. Thus, the title claimed compd. II was intimal thickening inhibitors. mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeH4O(CH5)S2' d-CTCeHd(CH5)SNH' 3-BxCeHdCONHCRNH' CeH2COO' OH' CL3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC2NH' KNHCONH' S-CICCH4CH (CH3) OCONH' S-CICCH4CHSCHSCHSOCONH' 4-

CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

ΙI OəM Meo

OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-BTCEHdCONHCRNH' CEH2COO' OH' СЕЗСЕНФСН СОООН СНЗ (СНЗ ) 20СОИН (СНЗСНЗ ) ЗИНСВИН ДИНСОИН ДИНСОИН ТИНСОИН ДИНСОИН ТИНСОИН ТИ S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSOCONH' 4-Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3, CH3O, R5, R6 independently = R5, R6, ЯA

mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases

claimed compd. II was prepd. and biol. tested.

347156-20-1 REGISTRY

Urea, N-[2-[bis(1-methylethyl)amino]ethyl]-N'-[4-[(6,7-dimethoxy-4-

duinazolinyl) oxy] -2-methoxyphenyl] - (9CI) (CA INDEX NAME)

ЗД СОИСОКД EZ CNВИ PN2MEK 14 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma3$ 

CAPLUS

26stcyed by: Mary Hale 308-4258 CM-1 12D16

`O 9 M

(i-bx)SN - CHS - CHS - NH -

STN Files:

 $\Gamma C$ 

SE

WE

OəM

S REFERENCES IN FILE CAPLUS (1967 TO DATE) S REFERENCES IN FILE CA (1967 TO DATE)

'NX BX' , SA BE' B1' WD' KC' , MA ,AZ 'zn 'sn 'TS 'ອດ , AU 'LT 'XS 'IS '១s 'ZL 'LL TR, 'WT 'ES 'ds кu, KO, 'Td 'ZN 'ON 'ZW 'XW WK' WN' WM' MD' MC' , AM rn' 'ST  $\Gamma K$ 'LT LR, 'nNH Kb' KB' KZ' IT' IN' IS' 15' KE' KG' ID' 'НВ CW' 'HĐ CE' cp' BY' BB' BC' BK' BX' BX' CH' CH' CH' CK' CC' DE' DK' DW' DX' EE' ER' .qq 8801 ,20701002 fA DESIGNATED STATES: W: AE, AC, AL, AM, AT, AU, AZ, PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Міма, as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

.(seansqst) CODEM: BIXXDS TD, TG, TR. ZE' ZN' LT, Mr' MB' NE' NI' CX' CE' DK' 'IO E2' DE' CH' GB' GK' IE' IL' TO' WC' ,AĐ EK' ŁI' CW' ′ ໑ວ 'LI 'ZX 'MZ TM; RM: AT, BE, ,UA

.pI300002 067771-0002 90 ;82219991 49478-9991 90 PRIORITY: JP 1999-377486 19991224; APPLICATION: WO 2000-JP9157 20001222.

OəM Ι OeM БЯ 9 Y Вđ ξЯ

ΙI OəM Meo NOS - CO -- NH -HN

prepd. and biol. tested. Thus, the title claimed compd. II was intimal thickening inhibitors. mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and 4-CTC6H4O(CHS)S2' 4-CTC6H4(CHS)SNH' 3-BLC6H4CONHC2NH' C6H2COO' OH' CE3CeH4CHSOCONH'CH3(CHS)POCONH' (CH3CHS)SN(CHS)3NHC2NH' ANHCONH' S-CTCeH#CH(CH3)OCONH' S-CTCeH#CHSCHSCHSOCONH' #-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECeH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, C1, F, CH3,

ЯΑ

TĐ.

CAPLUS

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXD2. ZE' SN, TD, TG, .AT rn' wc' CODEN: (Japanese). Mr' MB' NE' NT' bL' CE' ŁI' E2' DE' 'AO CI' CW' CH' 'ອວ EB' GB' GB' IE' IL' DK' BE' BJ, TM; RM: AT, BE, RU, TJ, WD' 'ZX KG' BX**'** 'Z¥ ,MA 'MZ 'YZ 'NX 'NA 'ZN 'sn , AU 'LT 'TS 'XS 'IS **'**5S 'ES RU, br' 'ZI 'TT 'AT 'MT 'ds KO, 'Ld 'ZN , AM **'**\7 rn' 'ZX 'MW 'NW WK' 'LT 'SI ГВ, rk' ON 'ZW 'XW WD' WC' rc' KB' EE' HB' HO' ID' IF' CE' CD' E2' 'ZU 15' KE' 'SI 'NI CH' CW' EI' CB' CH' CH' CH' CK' CC' DE' DK' DW' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,2001002 IA 1897401002 OW Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

Ι ŢΛ

pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCCH4O(CH5)SS' 4-CTCCH4(CH5)SNH' 3-BECCH4CONHCRNH' CCH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC2NH' XNHCONH' S-CTCCH4CH(CH3)OCONH' S-CTCCH4CHSCHSCHSOCONH' 4-

CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, C1, F, CH3,

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title

347156-19-8 REGISTRY COPYRIGHT 2002 ACS ANSWER 15 OF 179 REGISTRY

duinazolinyl)oxy]-2-nitrophenyl]- (9CI) (CA INDEX NAME)

II

ЗD СОИСОКD

Urea, N-[2-[bis(1-methylethyl)amino]ethyl]-N'-[4-[(6,7-dimethoxy-4-nrea, N-[2-[bis(1-methylethyl)amino]ethyl]]

СИ

SIN Files:

CS2 H35 Ne 0e

ГC SE

WE

ЯA

CI

ВИ

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S KELEKENCES IN EITE CAPLUS (1967 TO DATE)

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. .(Japanese). CODEN: BIXXD5' DK' ES' EI' EB' GB' GB' IE' IL' FN' WC' CE' CC' CH' CI' CW' CA' DE' KG' KZ' MD' KN' IN' IM: BM: BI' BE' BL' BN' 'YE 'ZA 'MA 'MZ , AZ 'עא' אע TZ, UA, UG, US, LZT TT, TR, TT, 'TS 'XS 'IS 'SS 'ES 'as **к**и, 'Lđ KO, ΓΛ' WY' WD' WG' WK' WN' WM' WX' WZ' NO' NZ' bΓ' ra' rı' rn' ГВ**'** rc' rk' GD' GE' CH' GW' HB' HO' ID' IT' IN' IS' 1B' KE' KG' KB' KK' KZ' BY' BB' BC' BK' BX' BZ' CH' CH' CH' CK' CC' DE' DK' DW' DZ' EE' EZ' AI 20010705, 1068 pp. DESIGNATED STATES: W: AE, AC, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Міма, as remedies for diseases mediated by autophosphorylation of PDGF KEEEEKENCE 1: 132:92649 Preparation of quinazoline and quinoline derivatives

Searched by: Mary Hale 308-4258 CM-1 12D16

OəM

OeM

S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-CH30' NOS' Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

Ι

98

ςИ

εЯ

Бđ

II

OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeH40(CH5)52' d-CTCeH4(CH5)5NH' 3-BECCH4CONHC2NH' CCH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC2NH' XNHCONH'

prepd. and biol. tested. intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases

as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXDS. ra' wc' . (asanaqat) .AT 'DL 'LD' LG' Mr' MB' NE' NT' LL' CX' CH' CI' CW' CE' EI' E2' DK' DE' EK' CF' CB' CK' IE' IL' **'**90 BE' B1' TM; RM: AT, BE, 'LI RU, KZ' WD' KC' BX' 'Z\ ~, AZ , MA 'MZ 'nx 'NΛ 'ZΩ 'TS 'XS .əu .Au 'ZL 'LL TR, 'MT 'LI 'IS 'ĐS ZE' 'ds ru, RO, 'Lđ 'ON 'ZW 'XW 'MW 'NW WK' WD' WC' , AM rn' rn' 'LT 'ST rk' rk' rc' 15' KE' 'TI HE' HO' ID' CH' CW' CD' CB' EE' 'SI 'NI CE' EI' E2' CY' CH' CN' CK' CO' CZ' DE' DK' DW' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20701002 IA 1897401002 ow .lqqA .juI TO4 Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji;

CI 19991224.

ЯA

4-CTCCH4O(CHS)SS' 4-CTCCH4(CHS)SNH' 3-BTCCH4CONHCSNH' CCH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' XNHCONH' S-CICCH4CH(CH3)OCONH' S-CICCH4CHSCHSCCOONH' 4-Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3, CH3O, NO2; A = 4 - CH3C6H4CH2OCONH, A = 4 - CH3C6H4, A = 4 - CH3C6H4,

ΙI

ANSWER 16 OF 179 REGISTRY COPYRIGHT 2002 ACS claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and

Urea, N-[2-[bis(1-methylethyl)amino]ethyl]-N'-[2-chloro-4-[(6,7-dimethoxy-Urea, N-[2-chloro-4-[(6,7-dimethoxy-Urea, N-[2-chloro-4-[(6,7-dimethox)-4-[(6,7-

CA, CAPLUS STN Files:  $\Gamma C$ SECS2 H3S CJ N2 O4 WE ЗД СОИСОКД EZ

4-quinazolinyl)oxylphenyl]- (9CI) (CA INDEX NAME)

347156-17-6 REGISTRY

СИ

ВИ

ГЗ

Searched by: Mary Hale 308-4258 CM-1 12D16

S REFERENCES IN FILE CAPLUS (1967 TO DATE) S REFERENCES IN FILE CA (1967 TO DATE)

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

Atushi (Kirin Beer Kabushiki Kaisha, Japan). receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, as remedies for diseases mediated by autophosphorylation of PDGF KELEKENCE 1: 132:35043 Preparation of quinazoline and quinoline derivatives

WD' 'MZ '∀Z 'nx ,MA 'TS 'LI 'XS 'IS 'ĐS ′zດ 'sດ ne' AU , ST TM, TR, ZE' 'dS **,**иЯ RO, 'Ld 'LL WE' WK' WN' WM' WX' WZ' NO' NZ' WD' , AM rn' rn' 'LT 'ST LR, rk' rc' 15' KE' KC' Kb' KK' 'SI 'NI 'TI ID' 'NH **НВ**, CW' CH' CD' CE' BY' BB' BC' BK' BX' BX' CH' CH' CH' CK' CC' DE' DK' DW' DX' EE' ER' DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, .qq 8001 ,2070100S IA PCT Int. Appl. WO 2001047890

CE' KO' IT' IM: KM: FI' BE' BE' BT' 'ZX KC' BX' 'Z¥

'Ld CODEN: BIXXDS . (asanaqat) TD, TG, TR. 'NS 'ES CX' 'IO DK' DE' EI' EK' CH' CB' CB' IE' IL' TO' WC' 'SE CW' CH' 'ອວ

PRIORITY: JP 1999-377486 19991224; APPLICATION: WO 2000-JP9157 20001222. Mr' MB' NE' NT'

JP 1999-374494 19991228; JP 2000-177790 2000614:

OəM БЯ 9Я ₽Я A εЯ

Ι

NOS - co — ин--HN

OəM

OəM II OəM

prepd. and biol. tested. intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3' OCHSCOOH: X = peferocycle, peferocyclylylyl and d-CTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-BxCeHdCONHCRNH' CEH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHCRNH' ANHCONH' S-CTCeH4CH(CH3)OCONH, S-CTCeH4CH2CH2CCONH, 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

Searched by: Mary Hale 308-4258 CM-1 12D16

AA

CAPLUS STN Files:  $\Gamma C$ 

Searched by: Mary Hale 308-4258 CM-1 12D16

19991224. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 PIXXD2. (Japanese). .AT WC' 'D' LD' LC' ZE' Wr' WB' NE' NT' bI' rn' CODEN: 'ID ŁI' E2' DK' DE' CX' 'HO '໑ຉ CE' CW' BE' EK' CH' CB' CK' IE' IL' Bl' EM: AT, BE, 'LT **,**UA WD' 'ZX KC' BX**'** , ZA ,MA MZ 'AZ 'NΛ 'ZN 'ຮດ 'NX :MT 'LT 'TS 'XS 'IS **'**១s **י**טא br' ,AU 'ZI 'TT TR'MT ZE' 'ds ,OA 'Ld 'ZN 'ZW rn' 'LT rc' 'ZX 'XW WD' ,AM  $\Gamma\Lambda$ 'S7  $\Gamma B$ KB' 'ON 'MW 'NW WK' WC' rk' KE' 'TI 'dI CD' CB' ŁI' EE' KC' 1b, чв, **c**W' CE' E2' 'Zd 'SI 'NI 'NH 'H9 CY' CH' CN' CK' CO' CZ' DE' DK' DW' BC' BK' BX' BS' BA, BB, , ZA , UA , TA .qq 321 ,20701002 IA 1867101002 OW YE' YG' YI' YW' DESIGNATED STATES: W: Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

claimed compd. II was prepd. and biol. tested. Thus, the title mediated by autophosphorylation of PDGF receptors. pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-BxCeHdCONHCSNH' CeH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHCRNH' XNHCONH' S-CICCH4CH(CH3)OCONH, S-CICCH4CH2CH2CCOONH, 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, C1, F, CH3, ЯΑ

CN347156-16-5 REGISTRY ВИ COPYRIGHT 2002 ACS ANSWER 17 OF 179 REGISTRY  $\Gamma$ 3

ΙI

3D СОИСОВЪ dninazolinyl) oxy]phenyl] - (9CI) (CA INDEX NAME) Urea, N-[2-[bis(1-methylethyl)amino]ethyl]-N'-[4-[(6,7-dimethoxy-4-7-d

CS2 H33 N2 O4 ME

EZ

ЯS

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S KEEEKENCES IN EITE CAPLUS (1967 TO DATE)

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; (Japanese). TD, TG, TR. CODEN: BIXXDS: MT' MK' NE' NI' bI' SE' SN' DK' E2' EI' EK' CB' CB' IE' IL' TO' WC' CE' CC' CH' CI' CW' CX' DE' 'NX , AS RU, TJ, TM; RW: AT, BE, BF, BJ, KG' KS' WD' 'YA 'ZA 'MA 'WZ 'IS 'ອດ 'TT 'AT 'MT 'CI 'TS 'XS '១ន ZE' 'as RU, RO, 'zn 'sn AU , ST 'ST LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, LR, ΓK' CD' CE' CH' CW' HB' HO' ID' IT' IN' IS' 15' KE' KC' KB' KK' BY' BB' BC' BK' BX' BZ' CH' CH' CH' CC' CZ' DE' DK' DW' DZ' EE' EZ' AI 20010705, 1068 pp. DESIGNATED STATES: W: AE, AC, AL, AM, AT, AU, AZ, receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

ΙI

intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as parmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and mediated by autophosphorylation of PDGF receptors, particularly useful as parmaceutically acceptable salts are prepd. 3-Brc6H4CONHCSNH, C6H5COO, OH, OCHSCOOCH3, OCHSCOOH, Y = heterocycle, heterocyclylatkyl] and particularly acceptable salts are prepared to the proposed salts. This is a second of the proposed salts are proposed to the proposed salts are proposed salts. The proposed salts are proposed salts are proposed salts are proposed salts. The proposed salts are proposed salts are proposed salts are proposed salts. The proposed salts are proposed salts are proposed salts are proposed salts are proposed salts. The proposed salts are proposed salts are proposed salts are proposed salts are proposed salts. The proposed salts are proposed salts are proposed salts are proposed salts are proposed salts. The proposed salts are proposed salts. The proposed salts are proposed salts are proposed salts are proposed salts. The proposed salts are pro

pharmaceurcairy acceptable sales are prepa; as remedies for diseases intimal thickening inhibitors. Thus, the title claimed compd. Il was prepa; and biol. tested.

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXD2. rn' wc' .(əsənaqst) SE, SN, TD, TG, TR. Mr' MB' NE' NT' LT' ŁI' CX, 'ID CE' DK' EZ' DE' CW' **'**១၁ EK' CB' CB' IE' IL' CH' BJ, BE' TW; RM: PT, BE, 'LT RU, KZ' WD' , ZA 'nx KC' BX**'** ,MA 'MZ ,AZ 'NΛ 'ZN 'TS , au , ar 'LL TR, 'WT ,UT 'XS 'IS '9S 'EE 'as RU, BO; LT, 'ON 'ZW 'XW 'MW rn' 'LT rc' WK' WN' MA, MD, MG, rn' 'ST ГВ' rk' 1b' KE' KG' GW' HB' HO' ID' IT' IN' IS' CE' CH, CD' CB' ŁI' E2' CY' CH' CN' CK' CN' CZ' DE' DK' DW' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, .qq 321 ,20701002 IA 1867401002 OW DESIGNATED STATES: W: AE, AG, AL, AM, PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF

ЯΑ

ГC

SR

WE

EZ

**SLN Files:** 

ЗД СОИСОВД

C53 H56 N6 06

AD

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTCCHdO(CHS)S2' d-CTCCHd(CHS)SNH' 3-BxCCHdCONHCRNH' CCH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC2NH' XNHCONH' S-CTCCH4CH(CH3)OCONH' S-CTCCH4CHSCHSOCONH' 4-

347156-13-2 REGISTRY

blrrolidinyl)ethyl]- (9CI) (CA INDEX NAME) CN

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-N'-[2-(1-

ВИ

YNZMEK 18 OF 179 REGISTRY COPYRIGHT 2002 ACS

CA, CAPLUS

 $\Gamma$ 3

Title compds. [I; X = V, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = V - CH3C6H4CH2COOH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 1-FC6H4CH2OCONH, 1-FC6

MeO NH CH2

PAGE 2-A

 $\left\langle \begin{array}{c} N \\ I \end{array} \right\rangle$ 

ĊН2

S KEEEKENCES IN EIFE CAPINS (1967 TO DATE)

S KEEEKENCES IN EIFE CA (1967 TO DATE)

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; (Japanese). CODEN: PIXXD2. TD, TG, TR. Mr' MB' NE' NT' LT' SE' SN' DK' E2' LI' LK' CF' CB' CK' IE' IL' TO' WC' CE' CC' CH' CI' CW' CA' DE' AZ KG' KZ' MD' KN' L1' LW; KM: YL' BE' BE' B1' 'YA 'ZA 'MA 'MZ 'טג 'אַא 'IS SE' 2C' 'ds RU, SK' ST' IN' IN' IL' IL' ON' OC' OR' OS' PT, RO, rs' rl' rn' rn' wb' wb' we' wk' wn' wm' wx' wz' no' ns' br' LR, rc' rk' EI' GB' GD' GE' GH' GW' HB' HA' ID' IT' IN' IS' AB' KE' KG' KB' KK' KZ' BY' BB' BC' BK' BX' BZ' CY' CH' CN' CK' CN' CZ' DE' DK' DW' DZ' EE' EZ' A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, as remedies for diseases mediated by autophosphorylation of PDGF KELEKENCE 1: 132:35043 Preparation of quinazoline and quinoline derivatives

MeO.

OeM

d-CTCeH4O(CHS)S2' d-CTCeH4(CHS)SNH' 3-BLCeH4CONHCRNH' CEH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHCRNH' ANHCONH' S-CICCH4CH (CH3) OCONH' S-CICCH4CHSCHSCHSOCONH' 4-CH30' NOS:  $Y = \emptyset$ -CH3CeH $\emptyset$ CH5OCONH' 3-CTCeH $\emptyset$ CH(CH3)OCONH'  $\emptyset$ -ECeH $\emptyset$ CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

Ι

9И

ςИ

ЕЯ

B4

II

pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and

prepd. and biol. tested. intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as

TM; RM: AT, BE, , LT RU, WD' 'ZX KC' BX**`** 'ZY , MA MZ 'YZ 'UX 'NΛ 'ZΩ TZ, UA, UG, 'LL TE, 'WI 'LT 'TS 2K 'IS **'**98 'EE aD, RU, RO, LI, WK' ,AM rc' 'ON 'ZW 'XW 'MW 'NW WD' WG' rn' rn' 'LT 'ST rk' rk' 15' KE' Ir' 'H9 CE' 'SI 'NI ID, CW' HB' HO' ep' CB' EI' E2' DESIGNATED STATES: W: AE, AG, AL, AM, .qq 3SI ,2070100S IA 186740100S OW Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

rn' wc' .(əsənaqat) .AT SE' SN' LD' LG' WE' NE' NI' LI' 'TW E2' DE' 'IO CE' EK' GY' GB' GK' IE' IL' EI' DK' 'XD CH' **'**92 CW' BE' KK' AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM,

19991224. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 PIXXD2.

ЯΑ

CA, CAPLUS

Ι

**SLN Files:** 

ЗД СОИСОКД

CS3 HS6 N6 O7

AD

Яζ

К3 И PC 2K

WE

EZ

FAGE 2-A

$$\binom{N}{1}$$

CHS

S KEEEKENCES IN EITE CAPLUS (1967 TO DATE)

S KEEEKENCES IN EITE CAPLUS (1967 TO DATE)

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; (Japanese). CODEN: PIXXD2. TD, TG, TR. Mr' WB' NE' NT' LT' SE' SN' CE' CG' CH' CI' CW' CX' DE' DK' E2' E1' EB' GB' GB' GE' IE' II' FA' WC' KC' KZ' MD' KO' LO' LW: BM: BL' BE' BL' BO' VN, YU, ZA, XW, AM, AZ, BY, LI' BO' BO' SE' SE' SE' SI' SK' SF' LO' LW' LK' LL' LS' OF' OC' OS' OS' rc' rk' rb' r2' r1' rn' rn' wb' wb' wk' wn' wm' wx' wz' no' nz' br' EI' CB' CD' CE' CH' CW' HB' HO' ID' IT' IN' IS' OB' KE' KC' KB' KK' BY' BB' BC' BK' BX' BZ' CH' CH' CH' CK' CC' DE' DK' DW' DZ' EE' EZ' AI 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

JP 1999-374494 19991228; JP 2000-177790 20000614.

$$\begin{array}{c} \mathcal{E}_{\mathcal{A}} \\ \mathcal{A} \\ \mathcal{C}_{\mathcal{A}} \\ \mathcal{$$

$$\begin{array}{c} \text{MeO} \\ \text{MeO} \\ \text{O} \\ \text{N} \\ \text{O} \\ \text{O}$$

CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECeH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

II

prepd. and biol. tested. Thus, the title claimed compd. II was intimal thickening inhibitors. mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3' OCHSCOOH: X = yeferocycle, heterocyclylalkyl] and d-CTC@HdO(CHS)S2' d-CTC@Hd(CHS)SNH' 3-BxC@HdCONHCRNH' C@HQCOO' OH' CE3CeH4CH5OCONH'CH3(CH5)POCONH' (CH3CH5)SN(CH5)BNHCRNH' ANHCONH' S-CICCH4CH(CH3)OCONH, S-CICCH4CH2CH2CH2CCOONH, 4-

ON ,AM rn' 'LT rk' 'ZX 'ZW 'XW 'MM' NM WK' WD' WG' rn' 'SI LR, rc' CD' E2' 1b' KE' 'SI 'NI HB' HO' ID' IF' CW' CH' CE' CB' ŁI' BY' BB' BC' BK' BX' CY' CH' CN' CK' CN' CZ' DE' DK' DW' , ZA , UA , TA DESIGNATED STATES: W: AE, AG, AL, AM, WO 2001047931 A1 20010705, 126 pp. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 PIXXDZ רח' SE' SN' ID' LG' LK' WI' WE' NE' NI' LL' .(asənaqat) WC' CODEN: DE' DK' E2' EI' EB' CB' CB' IE' CX, 'ID CH' **'**90 CE' CW' La, T1, TM; RW: AT, BE, KZ' WD' BO' 'ZY 'NX 'NΛ 'ZΩ 'នព KC' BX**'** ,MA 'MZ '\Z 'SK' SF' .au .au 'ZI 'LL ,AT 'MT 'LT 'IS '9S 'ES 'as RU, KO, 'Ld 'Ta

CI

**BA** 

19991224.

 $E \in SM - CHS - CHS - MH -$ 

Meo.

**SLN Files:** 

ЗД СОИСОВД

CS3 HS8 CT N2 O4

347156-06-3 REGISTRY

 $\Gamma C$ 

SE

MEEZ

CN

ВИ

ГЗ

CJ

pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-B™CCHdCONHCSNH' CCH2COO' OH' СЕЗСЕНФСНГОСОИН' СНЗ (СНГ) РОСОИН' (СНЗСНГ) ГИ (СНГ) ЗИНСВИН' ХИНСОИН' S-CICCH4CH (CH3) OCONH' S-CICCH4CHSCHSCHSOCONH' 4-

mediated by autophosphorylation of PDGF receptors. Thus, the title

1

Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[2-

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3, R1, R2, R3, R4, R5, R6 independently = H, R5, R6, R7, R1, R1, R2, R3, R4, R5, R6 independently = H, R1, R1, R1, R1, R1, R1, R2, R3, R4, R5, RЯA

II

Searched by: Mary Hale 308-4258 CM-1 12D16

CA, CAPLUS

(diethylamino)ethyl]- (9CI) (CA INDEX NAME)

PN2MER 20 OF 179 REGISTRY COPYRIGHT 2002 ACS

claimed compd. II was prepd. and biol. tested.

S REFERENCES IN FILE CAPLUS (1967 TO DATE) S REFERENCES IN FILE CA (1967 TO DATE)

DESIGNATED STATES: W: AE, AC, AL, AM, AT, AU, AZ, .qq 8001 ,20701002 IA receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 20010 as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

GB' GK' IE' IL' FN' WC' RU, WD' 'ZX BE' Bu' KG' BX**'** 'Z\ 'MZ 'NX TJ, TM; RW: AT, BE, ,MA 'YZ 'NA 'TS **'**១៣ , AU  $_{1}TT$  $\mathtt{T}\mathtt{K}^{ullet}$ ,MT 'LT 'XS 'IS '១s ZE' 3D 'Td ′ຊກ ′ຮກ ru, ко**,** 'ZT'ZN ON WD' WC' ,AM  $\Gamma\Lambda$ rn' 'LT 'SI ΓK, WK' WN' WM' WX' WI'  $\Gamma K$ rc' HO' ID' IT' IN' IS' 15' KE' KE' KB' KB' HK, CW, CH' CD' CE' EI' CB' BY' BB' BC' BK' BX' BZ' CH' CH' CH' CK' CC' DE' DK' DW' DZ' EE' EC' PCT Int. Appl. WO 2001047890

'NS 'Ld CODEN: BIXXDS (Japanese). TD, TG, TR. ZE' Mr' MB' NE' NT' ŁI' 'IO CE' DK' DE' 'AO CW' CH' **'**၅၁ EB' CB' E2'

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224;

OeM ςЯ 9 A БA εЯ

NO2 ин — со — ин-Ι OeM

OəM II OƏM

prepd. and biol. tested. Thus, the title claimed compd. II was intimal thickening inhibitors. mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3' OCHSCOOH:  $\chi = \text{perecoxc}_{\text{T}}$  perecockcy  $\chi = \text{perecoxc}_{\text{T}}$  and d-ctcehdo(CHS)S2' d-CtCeHd(CHS)SNH' 3-BxCeHdCONHCRNH' CeH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH'(CH3CH5)5N(CH5)3NHC2NH' ANHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCCOONH' 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECeH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

ЯΑ

ЕI

ГC

SE

MF.

EZ

CI

SIN Files:

C30 H33 N2 O2

AD.

CA, CAPLUS

. p2216661 PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXDZ, . (asanagat) SE' 2N' ID' IG' IK' ra' MC' Mr' MB' NE' NT' LL' CODEN: DE' CX, 'IO CE' DK' EZ' EI' EK' GF' GB' EK' IE' IL' CW' 'HD **'**90 BJ. BE' ,TA 'LT **В**И, KZ' WD' KG' BX**'** , ZA ,MA 'MZ 'AZ 'NX 'NΛ 'ZΩ 'នព TM; RW: 'LT 'TS 'XS 'IS '9s **У**ПУ br' , AU 'ZI 'LL TR'MT 'ES 'QS RO, LT, 'ZN 'ZW 'dM 'AM **'**\1 רח' rc' ON 'XW 'MW 'NW WK' WC' 'LT 'ST KK' rk' rk' 'ZX KE' 'TI 'H9 ŁI' EE' KC' 'SI 'NI CE' CD' CB' E2' DZ' 1b, HB' HO' ID' CW' 'ZB 'XB 'BB 'BB' BC' BK' BX' BZ' DK' DW' CY' CH' CK' CK' CC' DE' DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20701002 IA 1E67401005 OW PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF KELEKENCE S: 132:1001 breparation of quinazoline and quinoline derivatives

Ι И´ И́3 ŢΛ

CE3CeH4CHTOCONH'CH3(CHT)20CONH' (CH3CHT)5N(CHT)3NHCRNH' ANHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-CH3O' NOS' Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, C1, F, CH3, ЯΑ

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3' OCHSCOOH:  $\chi = \text{perecocyc}$ ; perecocyc ordination of 4-CTCCH4O(CH3)S2' 4-CTCCH4(CH3)SNH' 3-BTCCH4CONHCRNH' CCH2COO' OH'

Urea, N-[4-[6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N-[1-34/I26-02-9 REGISTRY

II

(byeultwefplt)-4-piperidinyl]- (9CI) (CA INDEX NAME)

зр соисовр

CNКИ

ГЗ

**byce** S−**y** 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S BELEBENCES IN EITE CAPIUS (1967 TO DATE)

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; LT, .(əsənaqat) TD, TG, TR. 'NS 'ES Wr' WB' NE' NT' CODEN: BIXXDS' EI' EB' GB' GB' IE' IL' TO' MC' DK' ES' CX' DE' CW' CC' CH' CI' CE' KC' WD' 'ZX BX**'** , ZA IT' IM; EM: AI, BE, BF, BJ, ,MA ,AZ 'NX RU, 'MZ 'NN 'zn 'sn ,AU 'AT ,UT 'TS 'XS 'IS '១s 'ds **'**១៣ 'ZI 'MT BO, 'Ld 'LL 'ES КU, rn' 'LT 'ST NS' br' 'ON WK' WN' WM' WX' WI' LV, MA, MD, MG, ГВ**'**  $\Gamma K$ rc' KB' KZ' IN' IS' 15' KE' KE' KB' IF' HO' ID' CE' CB' ŁI' CH' CW' HB' CD' BG' BK' BK' BK' CH' CH' CH' CH' CC' CC' DE' DK' DW' DK' EE' EE' BB' ,AA Al 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

EI

БЯ

ξЯ

 $\mathbf{F}\mathbf{A}$ 

B6

A

OeM

prepd. and biol. tested. intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-BxCeHdCONHCRNH' CeH2COO' OH' CE3CeH4CHSOCONH'CH3(CHS)POCONH'(CH3CHS)SN(CHS)3NHCRNH' ANHCONH'

DESIGNATED STATES: W: AE, AG, AL, AM, WO 2001047931 A1 20010705, 126 pp. PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF KEEERENCE S: 132:76901 Preparation of quinazoline and quinoline derivatives

PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. **DIXXDS** .AT SE' SN' LD' LC' rn' wc' . (asanaqat) Mr' MB' NE' NI' bI' CODEN: E2' DK' DE' 'AD 'IO CH' **'**50 CE' EI' EK' CH' CB' CK' IE' CW' BE' Bl, TA : WA : MT 'LI RU, WD' 'ZX KG' , ZA ,MA 'MZ ,AZ 'NΛ 'ZN 'ຮດ BX' 'nx ,AU 'LT 'TS 'ss br' 'ZI 'TT TR, ,MT 'XS 'IS ZE' 'ds RU, **КО,** 'Ld 'ZN 'ZW WD' rc' 'ZX ON 'NW , AM  $\Gamma\Lambda$ 'ST ГВ, 'XW 'MW WK' WC' ות'. 'LT rk' KK' KE' IL, KC' HB, CD' ŁI' 'ar 'SI 'NI HO' ID' CW' 'H9 CE' CB' EE' EZ' 'ZO CH' CM' CB' **,**AD DK' DW' DE' cn' cs' BY' BB' BC' BK' BX' BZ' , ZA , UA , TA

CI

**BA** 

19991224.

mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTCCHdO(CHS)S2' d-CTCCHd(CHS)SNH' 3-BxCCHdCONHCRNH' CCH2COO' OH' S-CTCeH4CH (CH3) OCONH' S-CTCeH4CHSCHSCCHSOCONH' 4-Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3, CH3O, NO2; A = 4 - CH3C6H4CH2OCONH, A = 4 - CH3C

claimed compd. II was prepd. and biol. tested.

CN347156-01-8 REGISTRY ВИ

(byenylmethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME) Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-N'-[1-

ЗД СОИСОВД EZ

CS6 H30 Ne 0e

STN Files:

WE

ГC SE

CAPLUS

26stcped by: Mary Hale 308-4258 CM-1 12D16

Meo Meo

OSN.

HN

HN

1

сн5— ьр

PAGE 2-A

PAGE 1-A

S REFERENCES IN FILE CA (1967 TO DATE)

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

(Japanese). CODEN: PIXXD2. TD, TG, TR. MT' MK' NE' NT' LL' SE' SN' CX' DE' EI' EB' CB' CB' IE' IL' TO' WC' DK' EZ' CE' CG' CH' CI' CW' KG' BX**'** , SA '∀Z IT' IM; EM: PI' BE' BE' BT' KZ' WD' BN' ,MA ,WZ 'מג 'אג **'**១೧ 'LT 'TS 'XS 'IS '១ន ู่ กช ко, 'Id 'zn 'sn AU , ST TT, TT, ,MT ZE' 'ds WD' 'Td 'ZN 'ON WC' WK' WN' WM' WX' WZ' ,AM **'**\1 rn' 'LT 'ST LR, ľK' rc' IT' IN' IS' 15' KE' KE' KB' KK' KS' CD' CE' CH' CW' HB' HO' ID' EI' CB' BY' BB' BC' BK' BK' BC' CH' CH' CH' CK' CC' DE' DK' DW' DC' EE' EC' AI 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890

APPLICATION: WO 2000-JP9157 2000-177790 20000614.

JP 1999-374494 19991228; JP 2000-177790 20000614.

п

**BA** 

19991224.

APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 PIXXD2 .AT TG, MT' MK' NE' NT' LT' SE' ZN' LD' .(əsənaqat) rn' wc' CODEN: ŁI' 'IO CE' E2' DK' DE' 'AD CW' **'**១၁ 'HD Bl, BE' EK' CH' CB' IE' 'LT **,**UA WD' 'ZX KC' , ZA 'MZ BX' ,MA 'AZ 'nx 'NA 'ZΩ ′ິຣດ TA : WA : MT , AU 'ZI 'LL  $\mathtt{T}\mathtt{K}^{ullet}$ 'MT ,UT 'TS 'XS 'IS **'**5S 2E' 'ds RU, ко, LT, bľ' 'ZN WD' 'ZX 'ZW 'NW 'WK WC' , AM **Γ**Λ**'** 'LT ГΚ' rc' 'XW 'MW 'กา 'ST LR, KK' KE' 'NI Ir' ID' **′**ΩH **,**ЯН CE' E2' EE' 1b, 'SI CD' EI' CB' 'ZO KC' CH' CW' CY' CH' CN' CK' CO' CZ' DE' DK' DW' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20701002 IA 1E67401005 OW PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-CLC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, CH3COOCH3, OCH2COOCH3, CH3COOCH3, CH3CO

 $\begin{array}{c|c} M \in O \\ M \in O \\ M = CO - MH \\ M = CO - MH \\ \end{array}$ 

PA PA OOOM OOM I

CA, CAPLUS

(byeulymethyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)

ANSWER 23 OF 179 REGISTRY COPYRIGHT 2002 ACS

**SLN Files:** 

ЗД СОИСОКД

CS6 H30 CT N2 O4

347155-98-0 REGISTRY

 $\Gamma C$ SE

WE

ES

CN

ВИ

ГЗ

ŢΛ

claimed compd. II was prepd. and biol. tested. Thus, the title mediated by autophosphorylation of PDGF receptors. pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCeH4O(CHS)SS' 4-CTCeH4(CHS)SNH' 3-BICCH4CONHCRNH' CEH2COO' OH' СЕЗСЕНФСН СООИН СНЗ (СНЗ) 20СОИН (СНЗСНЗ) ЗИ (СНЗ) ЗИНСВИН ДИНСОИН S-CICCH4CH(CH3)OCONH, 2-CICCH4CH2CH2CH2OCONH, 4-

Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[1-

Title compds. [I; X = V, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4 - CH3C6H4CH2OCONH, A = 4 - CH3CЯA

PAGE 2-A

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S REFERENCES IN FILE CAPLUS (1967 TO DATE)

.41999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; (Japanese). CODEN: PIXXD2 TD, TG, TR. ZE' ZN' Wr' WB' NE' NT' LI' 'AD DE' EI' EK' CH' CB' CK' IE' IL' FN' MC' DK' EZ' CE' CC' CH' CI' CW' KC' BE' BT' KZ, MD, RU, TJ, TM; RW: AT, BE, BX, , ZA '∀Z ,MA ,WZ 'NX 'NA 'zດ 'sດ **'**១೧ 'MT 'LT 'TS 2K' 'IS **'**9s ,UA AU , ST TT, TT, ZE' ZD' KO, 'La NS' br' 'ON MD' MC' MK' MN' MX' MZ' , AM **'**Λ' 'LT 'ST  $\Gamma K$  $\Gamma K$ rc' rn' KE' KB' KT' IT' IN' IS' 15' KE' KG' HO' ID' CH' CW' HB' CD' CE' CB' EI' BY' BB' BC' BK' BK' BK' CH' CH' CH' CK' CC' DE' DK' DW' DK' EE' EC' Al 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 as remedies for diseases mediated by autophosphorylation of PDGF KEEEKENCE 1: 132:92649 Preparation of quinazoline and quinoline derivatives

OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCCH4O(CH5)S2' 4-CTCCH4(CH5)SNH' 3-BLCCH4CONHCRNH' CCH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC2NH' XNHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-CH3O' NOS: W = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECeH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

II

prepd. and biol. tested. intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases

DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20701002 IA 1867401002 OW .iqqA .jni TD4 Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXD2. (Japanese). TK. SE' SN' LD' LG' ME' NI' LL' ra' wc' Wr' WK' ŁI' 'AD 'IO CE' EB' GB' GB' IE' IL' EZ' DK' CW' DE' CH' ce' Bl, TM; RM: AT, BE, RU, WD' KC' ,UT 'ZX BX' 'ZY ,MA MZ ,AZ 'nx 'NΛ 'ZΩ 'sn , AU 'ZJ 'LL ,AT 'WI 'LT 'TS 'xs 'IS '9S ZE' 'ds **'**08 'Ld RO, 'ZX 'ZW 'XW 'MW 'NW WK' MA, MD, MG,  $\Gamma\Lambda$ rn' 'LT 'ST rk' ΓK' rc' CH' CW' EE' 'SI 'NI CD' CB' ŁI' E2' 'ZO 1b' KE' Ir' HE, HU, ID, CE' CF' CH' CN' CB' CO' CZ' DE' DK' DW' AU, AZ, BA, BB, BG, BR, BY, BZ,

CI

ЯΑ

19991224.

ТΛ

claimed compd. II was prepd. and biol. tested. Thus, the title mediated by autophosphorylation of PDGF receptors. pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3' OCHSCOOH:  $\chi = \text{perecocycle}$ , perecocyclyJajkyl and 4-CTCCH40(CHS)S2' 4-CTCCH4(CHS)SNH' 3-BICCH4CONHCRNH' CCH2COO' OH' CE3CeH4CHSOCONH'CH3(CHS)POCONH'(CH3CHS)SN(CHS)3NHCRNH'XNHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CH5CH5CH5CCONH' 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CJCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

341122-62-1 KECISLKK

ЗД СОИСОВД EZ methyl-1-piperazinyl)propyl]- (9CI) (CA INDEX NAME)

Urea, N-[4-{(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N'-[3-(4-

СИ ВИ

ANSWER 24 OF 179 REGISTRY COPYRIGHT 2002 ACS ГЗ

CA, CAPLUS

SIN Files:

CS H34 N O O O C

**GA** 

 $\Gamma C$ SE

WE

(CH2) 3 ΗŃ c = 0

**5PACE 2-A** 

PAGE 1-A

2 REFERENCES IN FILE CAPLUS (1967 TO DATE) S REFERENCES IN FILE CA (1967 TO DATE)

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ЯA

. \$2216661 PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXD2. WC' Wr' WB' . (əsənaqat) SE, SN, TD, TG, TR. NE' NT' LL' 'IO EI' EK' CH' CB' CK' IE' IL' E2' DK' DE' 'AD CH' CE' CW' ′ ອວ **К**О, T1, TM; RW: AT, BE, 'ZX BX**'** WD' KC' , ZA ,MA 'MZ ,AZ 'NX 'NA 'TS ,AU ,ST  $\mathtt{T}\mathtt{K}^{ullet}$ 'IS '១s 'MT ,UT ,UA 'LL 'xs ZE' aD, KO, 'Ld 'ZW 'XW 'MM' MM' WK' 'SM 'GM 'YM rn' rn' rc' 'LT 'ST ГB, ľK' GW' HK' HO' ID' IT' IN' IS' 1B' KE' CE' CB' ŁI' CH' CD' E2' CY' CH' CN' CK' CN' CZ' DE' DK' DW' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, DESIGNATED STATES: W: AE, AG, AL, AM, WO 2001047931 A1 20010705, 126 pp. PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF KEFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

prepd. and biol. tested. intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCCH4O(CHS)S2' 4-CTCCH4(CHS)SNH' 3-BICCH4CONHCRNH' CCH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' ANHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-CH30' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH'

Ι

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

OəM

ξЯ

OəM

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3' OCHSCOOH: X = perecocyc perecocyclylalkyl] and d-CTCCH4O(CHS)S2' d-CTCCHd(CHS)SNH' 3-BxCCHdCONHCRNH' CCH2COO' OH' CE3CeH4CHSOCONH'CH3(CHS)2OCONH' (CH3CHS)SN(CHS)3NHC2NH' XNHCONH' S-CICCH4CH(CH3)OCONH' S-CICCH4CHSCHSOCONH' 4-Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2CCONH, 3-CLC6H4CH3OCONH, 4-FC6H4CH2OCONH,

(CA INDEX NAME)

CA, CAPLUS **SLN Eiles:** ГC AD SE

347155-94-6 REGISTRY

byrrolidinyl)ethyl]- (9CI)

YNZMEK S2 OF 179 REGISTRY COPYRIGHT 2002 ACS

C54 H59 N2 O2

ЗД СОИСОВД

WE

EZ

CN

ВИ

ГЗ

ЯA

**,**AZ

**к**и**,** 

LR,

'NX

ко,

ΓK'

'NA

LT.

rc'

JP 1999-374494 19991228; JP 2000-177790 20000614.

'IS

ML, MR, NE, NL, PT, SE, SN, TD, TG, TR.

'YA 'ZA 'MA 'MZ

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ZE'

'ds

'9s

CI

CH2 CH2

HŃ

APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224;

CE' CC' CH' CI' CW' CX' DE' DK' EZ' EI' EB' CB' CB' IE' IL' TN' MC'

EI' CB' CD' CE' CH' CW' HB' HO' ID' IT' IN' IS' OB' KE' KC' KB' KS' BY' BB' BG' BK' BK' BC' CH' CH' CK' CC' CC' DE' DK' DW' DC' EE' EC'

receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha).

'TS

as remedies for diseases mediated by autophosphorylation of PDGF KEFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

> 2 REFERENCES IN FILE CAPLUS (1967 TO DATE) S REFERENCES IN FILE CA (1967 TO DATE)

'XS

(Japanese). CODEN: PIXXD2.

AU ,ST

'zn 'sn 'sn

KC' KZ' MD' KN' L1' LW; KM; FL' BE' BL' B1'

TT 'AT 'MT 'CT

PR' FL' FN' FN' WB' WB' WK' WN' WN' WX' WZ' NO' NZ' BF'

FAGE 2-A

PAGE 1-A

Вđ

БЯ

ЕЯ

9Я

OƏM

CH3O' NOS: V = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Tifle compds: [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

II

prepd. and biol. tested. intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3' OCHSCOOH:  $\chi = \text{perecockcye}$ ' perecockcy $\chi = \text{perecockcye}$  and d-CTCeH4O(CH5)58' d-CTCeHd(CH5)5NH' 3-BxCeHdCONHCRNH' CeH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH'(CH3CH5)5N(CH5)3NHC2NH'XNHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-

receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXD2. Mr' MB' NE' NI' LI' SE' SN' LD' LG' LB' rn' wc' CODEN: .(Japaneget). E2' CX' DE' 'IO CE' EB' GB' GB' IE' IL' ŁI' DK' CW' CH' **'**១၁ B1, WD' 'ZX KC' 'MZ 'AZ 'NX 'ZN TM; RM: AT, BE, 'LI **,**UA 'YA 'ZA ,MA 'NA 'នព AU , ST TR, 'WT 'LT 'TS 'XS 'IS 'ĐS 'ES 'ds ₽U, KO, LT, ₽Ľ, 'LL WD' WC' , AM רח' רת' rc' ON 'ZW 'XW 'MW 'NW 'MK 'LT 'ST LR, rk' Ir' ID' CE' EI' CB' E2' EE' 'SI 'NI CD' 'Zd 1b' KE' ен' ем' нв' на' CY' CH' CN' CB' CC' DE' DK' DW' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20701002 IA 1E97401002 OW Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu;

CI

**AA** 

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3' OCHSCOOH: X = perecocycle, perecocyclyJajkyj and 4-CTCeH4O(CHS)S2' 4-CTCeH4(CHS)SNH' 3-BxCeH4CONHCRNH' CeH2COO' OH' CE3CeH4CHSOCONH'CH3(CHS)2OCONH'(CH3CHS)5N(CH5)3NHC2NH' ANHCONH' S-CTCeH4CH(CH3)OCONH, S-CTC6H4CH2CH2CH2OCONH, 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH (CH3)OCONH' 4-ECeH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, ЯA

ΙI

ANSWER 26 OF 179 REGISTRY COPYRIGHT 2002 ACS

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N'-[2-(4-

CAPLUS **SLN Files:**  $\Gamma C$ SE КЪ C54 H59 N2 O6 WE

341122-33-2 KECIZIKA

worpholinyl)ethyl]- (9CI) (CA INDEX NAME)

ЗД СОИСОКД

EZ

СИ

.BN

ГЗ

Searched by: Mary Hale 308-4258 CM-1 12D16

CH2 CH2 CH2 NH NH

CHZ

PAGE 2-A

FAGE 1-A

 $\binom{0}{N}$ 

S REFERENCES IN FILE CA (1967 TO DATE)

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

Searched by: Mary Hale 308-4258 CM-1 12D16

. IS

ЯA

19991224.

APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 PIXXD2. .(Japaneget). rn' wc' wr' wk' ne' nr' bi' se' sn' id' ig' ik' CODEN: 'IO E2' CX' CW' CH' **'**၅၁ B1' CE' BE' EI' EB' CB' CB' IE' IL' DE' DK' T1, TM; RW: AT, BE, **'**ΩУ WD' 'ZX KC' BX' , SA 'MZ 'AZ 'NX 'NA 'ZΩ ,MA ′ទែល **,**AU 'CT 'TS 'XS '១s ZE' RU, KO, br' 'LL TB'MT 'IS 'ds  $_{
m LL}$ 'ZN 'ZI 'ON 'ZW 'XW 'NW WK' '9W WD' ,AM ۲Λ, rn' 'LT 'ST LR, rk' rc' 'ZX KK' 'MW KE' KG' 'TI 'NH нв' 1b, 'SI 'NI ID' CW' 'H9 CE' CD' EI' CB' EE' EZ' 'ZO CY' CH' CM' CB' CO' CZ' DE' DK' DW' 'ZB 'XB 'BB 'BB' BC' BK' BX' BZ' .qq 321 ,20701002 IA 1897401005 OW DESIGNATED STATES: W: AE, AG, AL, AM, Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF KELEKENCE 2: 132:76901 Preparation of quinazoline and quinoline derivatives

prepd. and biol. tested. intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCCH4O(CH5)52' 4-CTCCH4(CH5)5NH' 3-BLCCH4CONHCSNH' CCH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC2NH' XNHCONH' S-CTCCH4CH(CH3)OCONH, 2-CTCCH4CH2CH2CH2OCONH, 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH'

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

CAPLUS CAPLUS

d-CTCeH4O(CH5)52' d-CTCeH4(CH5)5NH' 3-BxCeH4CONHCRNH' CeH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' XNHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCCOONH' 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCEH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, C1, F, CH3,

mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and

ANSWER 27 OF 179 REGISTRY COPYRIGHT 2002 ACS claimed compd. II was prepd. and biol. tested.

ЯS AD C54 H3I N2 O2 WE 3D СОИСОКD EZ S-methoxyphenyl]- (9CI) (CA INDEX NAME) Urea, N-[2-(diethylamino)ethyl]-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-СИ

347155-92-4 REGISTRY

SIN Files:

 $\Gamma C$ 

ВИ

ГЗ

S REFERENCES IN FILE CAPLUS (1967 TO DATE) S REFERENCES IN FILE CA (1967 TO DATE)

**1**00 'TS 'XS 'ES 'ZN 'ន្ធា ,AU 'ZI 'LL TK, 'IS 'DS RU, 'MT 'LI 'ds KO, 'ON 'XW 'MW 'NW WD' , AM 'L'I 'ZN 'ZW WK' WC'  $\Gamma \Lambda ^{\boldsymbol{\prime}}$ rn'  $\Gamma K$ rc' 'ST rg' KK' Kb' KE' 1b, 'SI 'NI Ir' 'NH CE' CD' KC' 'dI 'H9 CB' **'**HB CW' CA' CZ' DE' DK' DW' DZ' EE' EZ' CN' CK' CH'  $^{\rm 'AD}$ BX' BZ' BC' BK' , 88 , A8 DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, .qq 8901 ,20701002 IA receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 as remedies for diseases mediated by autophosphorylation of PDGF KEFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

.AT '9I ZE' 'IN . (əsənaqat) 'NS 'Ld WP' WE' NE' CODEN: bixxDS TD, rn' 'TI CK' IE' ŁK' ŁI' E2' DK' DE' CX' 'ID **'**၅၁ GA, GB, CW' CH'  $\mathtt{BE}^{oldsymbol{\prime}}$ BE' 'LT 'ZX KC' 'Z∀ TA :WA **'**NB WD' BX' ,MA 'MZ ,AZ 'n :WT

PRIORITY: JP 1999-377486 19991224; 20001222. APPLICATION: WO 2000-JP9157

JP 1999-374494 19991228; JP 2000-177790 2000614.

OeM ςЧ 9И FAξЯ

NH - CO - NHΙ OeM

II OeM OeM NOS

prepd. and biol. tested. Thus, the title claimed compd. II was intimal thickening inhibitors. mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC2NH' XNHCONH' S-CICCH4CH (CH3) OCONH, S-CICCH4CH2CH2CH2OCONH, 4-CH3O' NOS: W = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Lifte compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

aa

CI

**SLN Files:** 

3D CONCOKD

C53 H57 N5 O5

AD

 $\Gamma C$ 

SE

MF.

EZ

ЯΑ

CI

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXD2, ML, MR, WE, UL, PT, SE, SW, TD, TG, TR. rn' WC' CODEN: .(asanaqat) 'ID E2' DK' DE' CE' EI' EB' GB' GB' IE' IL' CX, CW' CH' ce' Bl, TM; RM: AT, BE, 'LT **к**О, KZ' WD' KC' BX**'** , SA 'MZ '\Z 'NX 'ZN ,MA 'NΛ 'ន្ធា 'LI 'TS 'XS 'IS '9s **r**U**y** br' , au , Au 'ZJ 'LL  $_{
m TR}$ 'MT ZE' 'ds KO, 'Ld 'MW 'NW , AM rc' 'ZX 'XW WK'  $\Gamma L$ rg' ΓK' 'ON 'ZW WD' WC' רת' דת' 'S7 KK' KE' KC' 1b, 'SI 'NI CD' CE' 'ZO CH' CW' HB' HO' ID' IT' EI' CB' EE' ES' CY' CH' CN' CB' CN' CS' DE' DK' DW' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, DESIGNATED STATES: W: AE, AG, AL, AM, WO 2001047931 A1 20010705, 126 pp. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF KELEKENCE S: 132:10001 Preparation of quinazoline and quinoline derivatives

ΙI

34JI22-61-3 KECIZLKK

CN

mediated by autophosphorylation of PDGF receptors.

S-CJCeH#CH(CH3)OCONH' S-CJCeH#CHSCHSCHSOCONH' #-

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[2-(4-

OCHSCOOCH3' OCHSCOOH: X = perecoxcre' perecockcyX = perecoxcry and 4-CTCCH4O(CHS)S2' 4-CTCCH4(CHS)SNH' 3-BICCH4CONHCRNH' CCH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' ANHCONH'

pharmaceutically acceptable salts are prepd. as remedies for diseases

CH3O' NOS: V = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECeH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

Thus, the title

worpholiny) ethyl] - (9CI) (CA INDEX NAME)

CA, CAPLUS

.КИ COPYRIGHT 2002 ACS YN2MER 28 OF 179 REGISTRY  $\Gamma 3$ 

claimed compd. II was prepd. and biol. tested.

EI

CH2 ΗŃ

PAGE 2-A

FAGE 1-A

$$\binom{\mathsf{N}}{\mathsf{N}}$$

CHS

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

S REFERENCES IN FILE CA (1967 TO DATE)

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; TD, TG, TR. (Japanese), CODEN: PIXXDZ. Mr' MB' NE' NT' LL' SE' SN' CE' CG' CH' CI' CW' CX' DE' DK' E2' E1' EB' CB' CB' CE' IE' II' FN' WC' KG' KZ' MD' BN' LY' LW: BM: PL' BE' BL' BY' VN, YU, ZA, WA, WZ, AZ, UY, VV TZ, UA, UG, US, LZ, SK' ST' LT' LW' LK' LL' 'IS 'DS 'ES PT, RO, RU, SD, rc' rk' rb' r2' r1' rn' rn' wb' wb' wk' wn' wm' wx' wz' no' nz' br' EI' GB' GD' GE' GH' GW' HB' HA' ID' IT' IN' IS' 1B' KE' KG' KB' KB' BY' BB' BC' BK' BK' BK' CH' CH' CH' CK' CC' CK' DE' DK' DW' DK' EE' EC' AI 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

CL3CCH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC2NH' XNHCONH' S-CICCH4CH(CH3)OCONH, S-CICCH4CH2CH2CH2OCONH, 4-CH3O' NOS: W = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECeH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, C1, F, CH3,

II

intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCeH4O(CHS)SS' 4-CTCeH4(CHS)SNH' 3-BxCeH4CONHCRNH' CEH2COO' OH'

prepd. and biol. tested.

CH' CH' CK' CK' CC' DE' DK' DW' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, .qq 321 ,20701002 IA 1867401002 OW PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF KELEKENCE S: 132:76901 Preparation of quinazoline and quinoline derivatives

,UT ₽U**'** WD' 'ZX KC' , ZÁ 'MZ 'NΛ 'ZN ′ន∩ TA : WA : MT ,AZ 'NX BX' ,MA , AU TR, 'LT 'TS 'XS 'ĐS 'ES **¹**T₫ 'ZN 'MT 'IS 'ds **,**UA RO, 'Lđ 'ZJ 'LL 'ZW 'XW WK' WC' WD' , AM **Γ**Λ**'** 'LT ΓK' rc' 'ZX 'MM' NM  $\Gamma K$ KK' 'ON rn' 'ST KC' 1b' KE' 'SI 'NI 'TI ID' 'NH HB, 'M9 'H9 CE' CD' EI' CB' EE' ES' 'ZŒ DESIGNATED STATES: W: AE, AG, AL, AM,

. (asanaqat) .AT '9L LD' rn' wc' RE' RN' NE' NT' bL' Wr' WK' CODEN: CE' 'IO 'SE DK' DE' 'AD CH' **'**၅၁ BJ, BE' EI' EK' CH' CB' CE' IE' CW'

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. **DIXXDS** 

CI

ЯΑ

Title compds. [1; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, CH3COOCH3, OCH2COOCH3, OCH

. (dimethylamino)ethyl]- (9CI) (CA INDEX NAME)
CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[2-L3 ANSWER 29 OF 179 REGISTRY
COPYRIGHT 2002 ACS

ΙI

2*B* C<del>V</del> WE CSI HS2 N2 O4

3D СОИСОКD

ER

rc sin Files: CA, CAPLUS

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

26stcy6q pl: Mary Hale 308-4258 CM-1 12D16

S REFERENCES IN FILE CAPLUS (1967 TO DATE) S REFERENCES IN FILE CA (1967 TO DATE)

(Japanese). CODEN: PIXXD2 TD, TG, TR. MT' MK' NE' NT' bI' SE' SN' ŁI' 'AD 'ID DK' EZ' DE' CW' CH' '໑ວ CE' EB' GB' GB' IE' IL' TO' WC' , LT КU, BE' B1' BE' Ke' KS' WD' BX**'** 'Z∀ 'MZ 'NX TA :WA :MT ,MA ,AZ 'NA 'ຮ∩ **'**១៣ ,AU TT, TT, ,MT 'LT 'TS 'XS 'IS 'ss RU, 'ZΩ 'ZL 'ES RO, 'Ld 'dS ₽Ľ, 'ZN 'ON WK' WN' WM' WX' WZ' WC' WD' ,AM **'**\1 רח' 'TJ 'ST ΓK, ΓK' rc' CE' LI' CB' HB' HO' ID' IT' IN' IS' 15' KE' KG' KB' KB' CH' CW' CD' BY' BB' BC' BK' BK' BK' CH' CH' CH' CK' CC' CZ' DE' DK' DW' DK' EE' EC' AL 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Міма, as remedies for diseases mediated by autophosphorylation of PDGF 135:92649 Preparation of quinazoline and quinoline derivatives

PRIORITY: JP 1999-377486 19991224; APPLICATION: WO 2000-JP9157 20001222.

JP 1999-374494 19991228; JP 2000-177790 20000614.

OeM ςИ 9Я A  $\mathbb{F}^{4}$ ξЯ

- NH -- co --HN Ι MeO.

ΙI OəM OeM NO2

OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCCH4O(CHS)S2' 4-CTCCH4(CHS)SNH' 3-BICCH4CONHCRNH' CCH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' KNHCONH' S-CTC6H4CH(CH3)OCONH, S-CTC6H4CH2CH2CH2OCONH, 4-CH3O' NOS: V = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH'

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases

prepd. and biol. tested.

ЯA

CI

**KELEKENCE I:** 

19991224. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 PIXXD2. .AT ra' wc' wr' wk' ne' nr' bl' CODEN: . (əsənaqat) '91 'GI 'NS ZE' ŁI' EB' CB' CB' IE' IL' E2' DK' DE' 'AD CW' 'ID CH' **'**၅၁ B1' CE' BE' MD, RU, 'ZX KC' BX' , ZA 'MZ 'ZN TM; RM: AT, BE, 'LT ,MA ,AZ 'NX 'NΛ 'ຮ∩ 'LT 'TS 'XS 'IS **'**5S **'**Td , AU 'AT **к**и**, '**OY 'ZN 'ZI 'LL 'MT ZE' 'ds 'Ld WD' 'ZW 'NW WK' WC' ,AM **'**\\T rc' 'ZX 'XW 'LT 'ST  $\Gamma K$ KK' ON ГВ**'** 'MW 'nT KE' ŁI' **НВ**, CW' 'H9 CE' CD' CB' E2' EE' 'dr 'SI 'NI HO' ID' IF' 'ZO KG' DK' DW' CY' CH' CN' CK' CN' CZ' DE' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20701002 IA 1897401002 OW PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

I ЯΣ 83 И, ŢΛ

II

СЕЗСЕНФСН СОООН, СНЗ (СН2) БОСОИН, (СН3СН2) 2И (СН2) ЗИНСБИН, ТИНСОИН, S-CTCeH4CH(CH3)OCONH' S-CTCEH4CHSCHSCHSOCONH' 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 

ЗД СОИСОВД ES blarolidinyl)ethyl]- (9CI) (CA INDEX NAME) CN341122-83-3 KECIZLKA

ВИ

SIN Files:

CS3 HS1 N2 Of

AD

 $\Gamma C$ SE

WE

ЯΑ

CI

 $\Gamma3$ 

CA, CAPLUS

**PAGE 1-A** 

FAGE 2-A

$$\left\langle \begin{array}{c} N \\ 1 \end{array} \right\rangle$$

CH2

S KEEEKENCES IN EITE CAPLUS (1967 TO DATE)

S KEEEKENCES IN EITE CA (1967 TO DATE)

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. CE' CC' CH' CI' CW' CX' DE' DK' EZ' EI' EK' CB' CB' CB' IE' II' TN' WC' KG' KZ' MD' KN' LJ' LW; KM: WI' BE' BE' BJ' 'AZ 'YA 'ZA 'MA 'MZ 'עא אע SK' ST' L1' LW' LK' LL' 'IS ′១ន ZE' aD, RU, ко, LT, 'ZU 'SU 'ĐN 'YN 'ZI TB' TR' TR' TA' MB' MD' MC' MK' MM' MM' MX' MZ' NO' NZ' BF' rc' rk' EI' GB' GD' GE' GH' GW' HB' HO' ID' IT' IN' IS' DE' KE' KG' KB' KK' BY' BB' BC' BK' BX' BX' CH' CH' CH' CK' CC' DE' DK' DW' DX' EE' EC' Al 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

CI

OaM

OeM

CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, C1, F, CH3,

Ι

98

ςЯ

БЯ

Вđ

II

OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CTC6H4O(CHS)S2, 4-CTC6H4(CH2)ZNH, 3-BrC6H4CONHCSNH, C6H5COO, OH, CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' ANHCONH' S-CTCeH4CH(CH3)OCONH, S-CTC6H4CH2CH2CH2OCONH, 4-

prepd. and biol. tested. intimal thickening inhibitors. Thus, the title claimed compd. II was wediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases

KEFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

'១s 'TS 'IS , AU 'ZJ 'LL TR, 'MT 'LL 2K ZE' 'ds RU, RO, LT, 'LT 'DW '\T 'ZW 'XW 'MM' NM WK' , dM , AM rn' 'ST LR, rk' rc' ID' 'HĐ IN' IS' 15' KE' 'TI GW' HB' HO' CE' cp' CB' ŁI' E2' CY' CH' CN' CB' CO' DE' DK' DW' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, .qq 321 ,20701002 IA 1867401002 ow DESIGNATED STATES: W: AE, AG, AL, AM, Макапізьі, Satoshi (Куома Накко Кодуо Со., Ltd., Japan). РСТ Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF

SE' ZN' LD' LC' .AT rn' WC' .(Japaneget). ML, MR, NE, NL, PT, EI' EK' CH' CB' CE' IE' IL' DK' EZ' DE' 'AD 'ID **'**90 CE' 'W) CH' TM; RM: AT, BE, , LT **,**UA WD' 'ZX KC' BX, , ZA ,MA 'MZ 'YZ 'NX 'NΛ

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXD2.

EI

AA

mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCeH4O(CH5)52' 4-CTCeH4(CH5)5NH' 3-BTCeH4CONHCRNH' CEH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' XNHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-ЯA

.claimed compd. II was prepd. and biol. tested.

347155-69-5 REGISTRY

CA, CAPLUS

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N'-[1-CN

(byenlymethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

EŞ 3D СОИСОКD

STN Files:

CS6 H31 N2 O2 WE

ВИ

ГC

SE

 $\Gamma 3$ 

YNZMEK 31 OF 179 REGISTRY COPYRIGHT 2002 ACS

Searched by: Mary Hale 308-4258 CM-1 12D16

II

**LAGE 2-A** 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S KELEKENCES IN EITE CAPLUS (1967 TO DATE)

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; (Japanese). CODEN: PIXXD2. SE, SW, TD, TG, TR. ML, MR, NE, NL, PT, CA' DE' DK' ES' EI' EK' CB' CB' IE' IL' TO' MC' CE' CC' CH' CI' CW' KC' KZ' MD' KN' L1' LW; KM: FL' BE' BL' B1' BX, , ZA 'עא אע 'MZ '∀Z 'ZU 'SU 'DU 'AU 'ZI TT, TM, TR, TT, 'TS 'xs 'IS 'ĐS RU, ZE' ZD' 'Ld ΓΛ' WY' WD' WG' WK' WN' WX' WZ' NO' NZ' bΓ' 'LT רצ' רצ' rn' CD' CE' CH' CW' HB' HO' ID' IT' IN' IS' 1B' KE' KC' KB' KK' KZ' BY' BB' BC' BK' BK' BK' CH' CH' CH' CH' CH' CK' CL' DE' DK' DW' DK' EE' EC' Al 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Міма, as remedies for diseases mediated by autophosphorylation of PDGF KEFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

CI

ξЯ

d-CTCCH4O(CHS)S2' d-CTCCHd(CHS)SNH' 3-BxCCHdCONHCRNH' CCH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHCRNH' ANHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-CH30' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

ΙI

mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and

intimal thickening inhibitors. Thus, the title claimed compd. II was

as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives prepd. and biol. tested.

Mr' MB' NE' NT' LL' SE' SN' LD' LG' LB' rn' wc' CODEM: . (asanaqat) E2' 'IO CE' ŁI' DE' 'XD CH. **'**90 B1 CH' CB' CK' IE' IL' DK' CW' EK, LT RU, WD' 'ZX BX' 'Z\ 'MZ ,AZ 'NX 'ΖΩ TA : WA : MT KC' ,MA 'NΛ 'sn , AU  $\mathtt{T}\mathtt{K}^{ullet}$ 'WT 'rı 'Ts 'XS 'IS **'**5S 'ES 'as **В**О, RO, 'Td bΓ' 'ZJ 'LT 'ZX 'MM' NM 'ST rc' 'ON 'ZW 'XW WK' MA, MD, MG, רת' רת' 'LT רא' וצ' KC' 1b' KE' CE' CD' 'ZO 'SI 'NI CH' CW' HB' HO' ID' IT' EI' CB' EE' ES' YI' YN' YZ' BY' BB' BC' BK' BX' BZ' CY' CH' CN' CK' CN' CZ' DE' DK' DW' DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20701002 IA 1867401002 OW Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji;

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXD2.

T9

AΑ

pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3' OCHSCOOH: X = perecolccfe' perecockcyX = perecolc and d-CTCeH40(CHS)S2' 4-CTCeH4(CHS)SNH' 3-BxCeH4CONHCRNH' CeH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)POCONH'(CH3CH5)SN(CH5)3NHCRNH' ANHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSOCONH' 4-Title compds. [I; X = V, CH; R3, R4, R5, R6 independently = H, CL, F, CH3, CH3O, NO2; A = V - CH3C6H4CH2CCONH, 3-ClC6H4CH (CH3) OCONH, 4-FC6H4CH2OCONH, CH3O, NO2; A = V - CH3C6H4CH2OCONH, 3-ClC6H4CH3OCONH, 4-FC6H4CH2OCONH, 10-FC6H4CH2OCONH, 10-FC6H4CH2OCONH ЯÄ

ΙI

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title

347155-68-4 REGISTRY ВИ PN2MER 32 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma$ 3

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-N'-[1-CN

(byenylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

ЗД СОИСОВД EZ

CS8 HS8 Ne Oe WE

AD ЯS

**2LM Eiles:** CA, CAPLUS PC

26stcy6q ph: Wary Hale 308-4258 CM-1 12D16

FAGE 2-A

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S KEEEKENCES IN EITE CAPLUS (1967 TO DATE)

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; (Japanese). CODEN: PIXXD2. ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. CE' CG' CH' CI' CW' CX' DE' DK' ES' EI' EK' GB' GB' IE' IL' TN' WC' ZY' ZM' YW' YZ' BX' KC' KZ' WD' KN' LT' LW: KM: YL' BE' BL' BT' 'UX 'NA SK' ST' LY' LW' LE' LL' 'IS 'DS 'ES PT, RO, 'ZU 'SU 'DU 'AU 'ZT ัชด**'** ab' LT, LU, LV, MA, MD, MG, MK, MW, MX, MZ, NO, NZ, PL, rg' rg' rc' rk' EI' GB' GD' GE' GH' GW' HB' HA' ID' IT' IN' IS' AB' KE' KG' KB' KK' KK' BY' BB' BC' BK' BX' BX' CH' CH' CH' CK' CC' DE' DK' DW' DX' EE' EC' Al 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 тесертогс. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Такауикі; Міма, as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

TĐ

ξЯ

$$\begin{array}{c} \text{MeO} \\ \text{MeO} \\ \text{NOS} \\ \text{NH-CO-NH} \\ \end{array}$$

CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC2NH' XNHCONH'. S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-CH30' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and

intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases

receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives prepd. and biol. tested.

Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu;

ŁI' DE' 'IO CE' GA, GB, GR, IE, IT, E2' DK' CX' 'WD 'HO ŁB' **'**93 BJ, BE' TM; RM: AT, BE, 'LI ₽U, WD' 'ZX KC' BX**'** , ZA ,MA 'MZ , AS 'NX 'NΛ ʻZN 'TS AU ,ST 'LL  $_{\mathbf{7}}$ R 'MT 'LI 'xs 'IS 'DS ZE' ZD' RU, KO, 'Ld 'MW 'NW 'LT 'S7 'ON 'ZW 'XW WK' LV, MA, MD, MG, rn' LR, rk' rc' GH' GW' HB' HO' ID' IT' 1b' KE' KG' ŁI' 'SI 'NI CE' GD' CB' E2' YI' YN' YZ' BY' BB' BC' BK' BK' BK' CY' CH' CN' CK' CN' CZ' DE' DK' DW' DESIGNATED STATES: W: AE, AC, AL, AM, WO 2001047931 A1 20010705, 126 pp. PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan).

rn' wc' (Japanese). SE' SN' LD' LC' LK' NE' NI' bL' MK,

PIXXD2.

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222.

CI

ЯΑ

mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeH4O(CH5)S2' d-CTCeH4(CH5)SNH' 3-BTCEH4CONHCSNH' CEH2COO' OH' СЕЗСЕНФСН СОООН' СНЗ (СН СОООН (СНЗСН СОООН) ЗИНСВИН ДИНСОИН S-CICCH4CH(CH3)OCONH' S-CICCH4CHSCHSCHSOCONH' 4-Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3, CH3O, NO2; A = 4 - CH3C6H4CH2OCONH, A = 4 - CH3C6H4, A = 4 - CAA

ΙI

claimed compd. II was prepd. and biol. tested.

CN 347155-67-3 REGISTRY ВИ PN2MER 33 OF 179 REGISTRY COPYRIGHT 2002 ACS ГЗ

(byenlymethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME) Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[1-

ЗD СОИСОКD

ER

CS8 HS8 CJ NS Of ME

SE

CA, CAPLUS ГC STN Files:

269xcy6q ph: Wary Hale 308-4258 CM-1 12D16

FAGE 2-A

**byce 1-y** 

S REFERENCES IN FILE CA (1967 TO DATE)

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF

1999-374494 19991228; JP 2000-177790 2000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; (Japanese). CODEN: PIXXD2. ML, MR, WE, NL, PT, SE, SW, TD, TG, TR. CE' CC' CH' CI' CW' CX' DE' DK' ES' EI' EB' CB' CB' IE' II' TN' WC' KC' KZ' MD' KO' IT' LW: BM: FI' BE' BL' BT' BX, ,AS 'NX , SA , MA , WS 'NA 'TS 'XS 'IS **'**9S ZE' **,**UЯ 'zn 'sn 'sn AU ZT TT, TM, TE, TT, 2D' PT, RO, MY' MD' MC' MK' MN' MX' MZ' NO' NZ' bF'  $\Gamma\Lambda$ rs' rI' rn' ГВ, rc' rk' eD' GE' GH' GW' HB' HA' ID' IT' IN' IS' 15' KE' KG' KB' KB' KS' LI' CB' BY' BB' BC' BK' BX' BZ' CY' CH' CN' CK' CO' CZ' DE' DK' DW' DZ' EE' EZ' Al 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 as remedies for diseases mediated by autophosphorylation of PDGF

CI

**BA** 

. 42216661 PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. **DIXXDS** .AT Wr' . (asansqst) '9I MK, ZE' ZN' LD' 'NE' NI' bl' rn' wc' CODEN: ŁI' 'S∃ 'AD 'IO **'**50 CE' EB' GB' GB' IE' IL' 'WD B1 BE' DK' DE' CH' 'LI **,**UA KC' , SA 'MZ WD' 'AZ 'ZN TM; RM: AT, BE, 'ZX BX' ,MA 'nx 'NA 'ຮດ ,AU 'TT TE, 'MT 'LT 'TS 'XS 'IS **'**9s 'ES RO, LT, br' 'ZN 'ZJ 'ds  $B\Omega$ 'ZW 'NW WK' '9W WD' , AM 'ZX 'XW 'MW 'ΛT rn' 'LT 'ST רצ'. רצ' rc' KB' KE' KC' 'TI ID' ′₩Н 1b, 'NI 'ΩH E2' EE' 'ZO 'SI CW, 'H9 CE' CD' EI' CB' DK' DW' ,SA ,UA CY' CH' CN' CK' CO' CZ' DE' BY' BB' BC' BK' BX' BS' .qq 321 ,20701002 IA 1867401002 OW DESIGNATED STATES: W: AE, AG, AL, AM, PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF KEFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

prepd. and biol. tested. intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeH4O(CH5)S2' d-CTCeH4(CH5)SNH' 3-BxCeH4CONHC2NH' CeH2COO' OH' CL3CCH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' ANHCONH' S-CICCH4CH(CH3)OCONH, S-CICCH4CH2CH2CH2OCONH, 4-

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3, CH3, NO2; A = 4-CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH,

ξЯ

pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCCH4O(CH5)52, 4-CLCCH4(CH2)2NH, 3-BrCCH4CONHCSNH, CCH5COO, OH, CL3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC2NH' XNHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-

Thus, the title mediated by autophosphorylation of PDGF receptors.

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-1-piperidinyl-CN347155-65-1 REGISTRY ВИ

(CY INDEX NAME) (ID6)

ЗД СОИСОВД EZ

CSS HS2 N2 O4 ME

SIN Files:

 $\Gamma C$ SE

 $\Gamma 3$ 

CA, CAPLUS

ANSWER 34 OF 179 REGISTRY COPYRIGHT 2002 ACS

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3, CH3O, R5; R = 4-CH3C6H4CH2OCONH, R5, R6 independently = H, R5, R6, R6,

II

Searched by: Mary Hale 308-4258 CM-1 12D16

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S BEEEEBENCES IN EIFE CAPLUS (1967 TO DATE)

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; .(əsənaqat) TD, TG, TR. ZE' ZN' Mr' MB' NE' NT' LL' CODEN: BIXXDS ŁI' DK' EZ' 'XO CE' CG' CH' CI' EK' CH' CB' CK' IE' IL' TO' WC' DE' CW' WD' 'ZX KC' BX**'** 'Z¥ 'MZ TJ, TM; RW: AT, BE, ,MA 'AZ 'NX BE' B1' кu, TB, 'LT 'TS 'XS 'IS **'**98 **,**UA 'zn 'sn **'**50 ,AU 'ZI 'LL ,MT 'ES KO, LT, 'dS 'Ta 'ZN ON MD' WC' WK' WN' WM' WX' WZ' ,AM ۲۸, רח' 'LT 'ST ГВ,  $\Gamma$ K' rc' KB' KZ' Kb' CH' CW' HB' HO' ID' IT' IN' IS' 1B' KE' KC' CD' CE' EI' CB' BY' BB' BC' BK' BK' BK' CH' CH' CH' CK' CC' CK' DE' DK' DW' DK' EE' EC' receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

CI

CI

**BA** 

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. **DIXXDS** .AT rn' wc' CODEN: . (asanaqat) 'DL 'UL 'NS ZE' ML, MR, NE, NL, PT, ŁI' 'IO CE' E2' DK' DE' 'AD CW' CH' '໑ວ EK' CH' CB' IE' Bl, BŁ' 'LL **к**и**,** WD' 'ZX KG' BX**'** , ZA 'MZ ,AZ 'ZN TA : WA :MT ,MA 'NX 'NΛ 'sn , AU 'ZL 'AT 'MT 'LT 'TS 'XS 'IS '១s 2E' 'ds **к**и, RO, LT, br' 'ZN 'LL 'ZX 'ZW 'NW WC' WD' , AM ۲۸, 'nT rz' ΓK' rc' 'XW 'MW WK' 'LT ГВ**'** KB' 'TI KE' HB, 'H9 EI' CB' E2' EE' 1B, 'NI ID' CW, CE' CD' 'ZO 'SI 'nH CY' CH' CN' CK' CO' CZ' DE' DK' DW' YA' YZ' BB' BC' BK' BX' BZ' DESIGNATED STATES: W: AE, AG, AL, AM, WO 2001047931 A1 20010705, 126 pp. PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3O, NO2; A = 4-CH3C6H4CH2OCOHH, 3-CLC6H4CH(CH3)OCOHH, 4-FC6H4CH2OCOHH, CH3O, NO2; A -CLC6H4CH2OCOHH, CH3CH2OCOHH, CH3COCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and mediated by autophosphorylation of PDGF receptors, particularly useful as mediated by autophosphorylation of PDGF receptors, particularly useful as mediated by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was prepared by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was prepared by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was

 $\begin{array}{c|c} WeO \\ WeO \\ NHOO \\ NH-CO-NH \\ \end{array}$ 

 $\Lambda$ J

pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-BTCEHdCONHCRNH' CEH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' XNHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-ЯA

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(hexahydro-lH-

(CA INDEX NAME)

ANSWER 35 OF 179 REGISTRY COPYRIGHT 2002 ACS

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3, NO2; A = 4 - CH3C6H4CH2COOH, A = 4 - CH3C6H4CH2OCOOH, A = 4 - CH3C6H4CH

CA, CAPLUS

**SLN Files:** 

ЗД СОИСОВД

CS3 HS1 N2 O4

azepin-1-yl) - (9CI)

347155-64-0 REGISTRY

**AD** 

ГC

SE

ME

EZ

СИ

КИ

 $\Gamma 3$ 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S KELEKENCES IN EITE CAFINS (1964 TO DATE)

S KELEKENCES IN EITE CF (1964 TO DATE)

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; (Japanese). CODEN: PIXXD2. TD, TG, TR. Mr' MK' NE' NT' LI' SE' SN' CX' CH' CI' CW' DK' ES' EI' EK' GY' CB' CE' IE' IL' TO' WC' DE' CE' CC' RU, TJ, TM; RW: AT, BE, BF, BJ, BX' , ZA ,AZ Ke' KS' WD' ,MA ,WZ 'NX 'MT 'LI 'TS 2K 'IS **'**5s RU, ne' ns' ns' AU , IT TR, TT, ZE' 'us RO, 'Ta 'ZN ON LV, MA, MD, MG, MK, MW, MX, MZ, rn' 'LT 'ST ГВ, rk' rc' CH' CW' HB' HO' ID' IT' IN' IS' 1B' KE' KC' Kb' KB' KZ' CD' CE' EI' CB' BY' BB' BC' BK' BK' BK' CH' CH' CH' CK' CC' CE' DE' DK' DW' DS' EE' ES' as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

εя

Title compds. [I; 
$$X = N$$
,  $CH$ ;  $R3$ ,  $R4$ ,  $R5$ ,  $R6$  independently =  $H$ ,  $CL$ ,  $F$ ,  $CH3$ ,  $CH3$ ,  $R4$ ,  $R5$ ,  $R6$  independently =  $H$ ,  $R6$ 

intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and CE3CeH4CHSOCONH'CH3(CHS)2OCONH'(CH3CHS)SN(CHS)3NHC2NH' ANHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-CH30' NO5' V = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH'

as remedies for diseases mediated by autophosphorylation of PDGF KEFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives prepd. and biol. tested.

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222.

CI

AB

ŢΛ

PNRMER 36 OF 179 REGISTRY COPYRIGHT 2002 ACS ГЗ claimed compd. II was prepd. and biol. tested. Thus, the title mediated by autophosphorylation of PDGF receptors. pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTCCHdO(CHS)S2' d-CTCCHd(CHS)SNH' 3-B™CCHdCONHCSNH' CCH2COO' OH' S-CTCeH&CH(CH3)OCONH, 2-CTC6H&CH2CH2CH2OCONH, 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

347155-63-9 REGISTRY ВИ

(CA INDEX NAME) (ID6)

ЗД СОИСОКД ER Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]Phenyl]-N'-4-morpholinyl-CN

SRCSI HS3 N2 O2 ME

CAPLUS

 $\Gamma C$ 

SIN Files:

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S KELEKENCES IN EITE CAPIUS (1967 TO DATE)

S KELEKENCES IN EITE CA (1967 TO DATE)

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; ML, MR, NE, NL, PT, SE, SU, TD, TG, TR. (Japanese). CODEN: PIXXDZ. CE' CG' CH' CI' CW' CX' DE' DK' ES' EI' EB' GB' GB' IE' II' TN' MC' AN' AN' SY' SM' YW' YZ' BA' KG' KZ' WD' KN' LN' LW' KM: YL' BE' BE' B1' SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, PT, RO, RU, SD, SE' SC' TC' TK' TB' T2' T1' TA' WB' WD' WC' WK' WN' WM' WX' WZ' NO' NZ' 5F' EI' GB' GD' GE' GH' GW' HB' HO' ID' IT' IN' IS' 1B' KE' KG' KB' KS' BY' BB' BC' BK' BX' BZ' CY' CH' CN' CK' CN' CZ' DE' DK' DW' DZ' EE' EZ' Al 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

ΙĐ

ЯΑ

18881554 APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 PIXXD2, Wr' TG, NE' WR.AT 'dı 'NS 2E' NF' bL' rn' wc' (Japanese) CODEN: E2' DK' DE' 'AO 'IO **'**១၁ CE' Bl' BE' IE' EB' CB' CB' CB' ŁI' CW' CH' 'ZX  $\mathtt{BE}^{\boldsymbol{\backprime}}$ ,TA , ZA ,AZ 'ZΩ 'sn 'LL **r**U**,** WD' KC' BX' ,MA 'MZ **'**NX 'NA TM; RW: **1**00 ,AU 'ZI  $\mathtt{TR}_{m{\lambda}}$ 'MT 'TS 'IS **'**98 ZE' **в**а**' '**O' 'Tđ 'ZN 'LL 'LL 'XS 'us 'La 'ZW ,AM 'ZX ON 'XW 'MW 'NW WK' WC' WD' **'**\7 רח' 'LT 'ST ГВ**'**  $\Gamma K$ rc' KB' KE' Ir' **'**8H KG' CW' CE' CB' ŁI' EE' 1b, 'SI 'NI ID' 'nNH 'H9 CD' E2' 'ZŒ CH' CH' CK' , SA , UA ,TA DK' DW' DE' cn' cz' BY' BB' BC' BK' BX' .qq 321 ,20701002 IA 1867401005 OW YE' YE' YH' YW' DESIGNATED STATES: W: Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

prepd. and biol. tested. intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCCH4O(CH5)SS' 4-CTCCH4(CH5)SNH' 3-BICCH4CONHCRNH' CCH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC2NH' XNHCONH' S-CTCeH#CH(CH3)OCONH' S-CTCeH#CHSCHSCHSOCONH' #-CH3O' NOS: W = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH'

Lifte compds. [I: X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

ЕЯ

 $\Lambda_{J}$ 

pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-BxCeHdCONHCRNH' CeH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' XNHCONH' S-CTCeH&CH(CH3)OCONH, 2-CTC6H&CH2CH2CH2OCONH, 4-AA

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N'-

Title compds. [I; X = V, CH; R3, R4, R5, R6 independently = H, CL, F, CH3, CH30, NO2; A = V - CH3C6H4CH2COOH, A - CCH3C6H4CH2COOH, A - CCH3C6H4CH2COOH, A - CCH3C6H4CH2OCOOH, A - CCH3C6H4

CA, CAPLUS

(yexahydro-1H-azepin-1-yl)-(9CI) (CA INDEX NAME)

ANSWER 37 OF 179 REGISTRY COPYRIGHT 2002 ACS

**SIN Files:** 

ЗД СОИСОВД

C54 H59 N2 O2

347155-62-8 REGISTRY

AD

 $\Gamma$ C SE

ME

EZ

СИ

ВИ

ГЗ

Вζ

И2

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S REFERENCES IN FILE CAPLUS (1967 TO DATE) S REFERENCES IN FILE CA (1967 TO DATE)

REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

'XS

APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224;

PS' FL' FO' FA' WB' WB' WK' WN' WM' WX' WZ' NO'

GD' GE' GH' GW' HB' HO' ID' IT' IN' IS' 15' KE' KG' KB' KB' KS'

SL, TJ, TM, TR, TT,

(Japanese). CODEN: PIXXD2

AU , TT

ne**'** 

'zn 'sn

'Ta 'ZN

DK' ES' LI' LK' CH' CB' CB' IE' IL' TO' WC'

KG' KZ' WD' KN' IN' IN' BM: WI' BE' BE' BN'

JP 1999-374494 19991228; JP 2000-177790 20000614.

'IS '9S

ML, MR, NE, NL, PT, SE, SN, TD, TG, TR.

'YA 'ZA 'MA 'WZ

ZE'

CE' CC' CH' CI' CW' CX' DE'

'ds

,AS

RU,

LR,

'NX 'NA PT, RO, rc' rk' EI' CB' BY' BB' BC' BK' BX' BZ' CY' CH' CN' CK' CN' CZ' DE' DK' DW' DZ' EE' EZ' receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha). PCT Int. Appl. MO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha). PCT Int. Appl. MO 2001047890 Atushi (Kirin Beer Kabushi Kaisha). PCT Int. Appl. Atushi (Kirin Beer Kasha). PCT Int. Atushi (Kirin Beer as remedies for diseases mediated by autophosphorylation of PDGF

EI

 $R^{4}$ 

ςИ

ξЯ

9Я

OeM

CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-BxCeHdCONHCRNH' CeH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC2NH' XNHCONH' S-CICCH4CH(CH3)OCONH, S-CICCH4CH2CH2CH2OCONH, 4-

prepd. and biol. tested. intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases

KE' 'TI ŁI' KC' 1b, 'SI 'NI ID' **'**NH **'**HB 'HĐ CE' CD' E2' EE' 'ZO 'W9 CB' DE' CN' CK' CH' **,**AD BY' BB' BC' BK' DK' DW' Cn' CZ' BK, BZ, , SA , UA WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 PIXXD2. WL, . (asanaqat) TK. TD, TG, 'NS ZE' NF' bL' WE' NE' rn' wc' CODEN: ŁI' 'AD 'IO IE' DK' CW' **'**50 CE' BE' EB' GB' GB' E2' DE' CH' Bl, BE' ,TA WD' BX' , ZA ,AZ 'NΛ 'ZN 'LI RU, 'ZX KC' ,MA 'MZ 'nX 'ຮດ TM; RM: 'ອດ ,AU 'ZI 'TT TR'MT 'LT 'TS 'XS 'IS ZE' KO, LT, br' 'ZN '9S 'ds ки, 'ZW WD' 'ON 'XW 'MW 'NW WK' WC' , AM rn'  $\Gamma L$ 'SI ГВ' ľK' rc' 'ZX KK'

CI

ЯΑ

19991224,

CA, CAPLUS

SIN Files:

ЗД СОИСОВД

C55 H52 N2.06

worbholinyl- (9CI)

341122-01-7 REGISTRY

**CA** 

ГC 2B

WE

EZ

СИ

ВИ

 $\Gamma 3$ 

pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCCH4O(CH2)2S, 4-CLCCH4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, CL3CCH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC2NH' XNHCONH' S-CTCCH4CH(CH3)OCONH' S-CTCCH4CHSCHSCCHSOCONH' 4-ЯA

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N'-4-

(CY INDEX NAME)

PNRMER 38 OF 179 REGISTRY COPYRIGHT 2002 ACS

claimed compd. II was prepd. and biol. tested.

mediated by autophosphorylation of PDGF receptors. Thus, the title

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3, CH3O, NO2; A = 4 - CH3C6H4CH2OCONH, A = 4 - CH3C6H4, A = 4 - C

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S BELEBENCES IN EITE CAPIUS (1967 TO DATE)

S BELEBENCES IN EITE CA (1967 TO DATE)

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; (Japanese). CODEN: PIXXDZ. TD, TG, TR. Mr' MB' NE' NT' LT' SE' SN' CX' DE' DK' E2' LI' LB' CB' CB' IE' IL' TA' WC' CE' CC' CH' CI' CW' KC' KZ' MD' KN' LT' LW: KM: FT' BE' BT' BK' , SA , MA , WS , AS 'חג 'אה 'ZU 'SU '9U 'YU 'ZI SK' ST' LY' LW' LE' LL' 'IS ZE' **₽**UY PT, RO, '១ន aD, TA' WY' MD' WG' MK' WN' WM' WX' WZ' NO' NZ' bF' רצ' רצ' דו' רח' rc' rk' CH' CW' HB' HO' ID' IT' IN' IS' OB' KE' KC' KB' KK' KZ' CD' CE' EI' CB' BY' BB' BC' BK' BX' BZ' CY' CH' CN' CK' CN' CZ' DE' DK' DW' DZ' EE' EZ' Al 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

ΙĐ

ин — со — ин-

ςЯ

ξЯ

ЬЯ

ΙI

prepd. and biol. tested. intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as bysrmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTCCHdO(CHS)S2, d-CLCCHd(CH2)2NH, 3-BrCCHdCONHCSNH, CCH5COO, OH, CE3CeH4CHSOCONH'CH3(CHS)2OCONH'(CH3CHS)SN(CHS)3NHC2NH'XNHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-Title compds. [I; X = V, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = V - CH3C6H4CH2COOMH, 3-ClC6H4CH(CH3)OCOMH, 4-FC6H4CH2OCOMH,

Ι

9Я

PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

EI' EB' CB' CB' IE' IL' 'IO CE' DK' EZ' CX' DE' CW' CH' **'**90 Bl, BE' **к**и**,** WD' , ZA TM; RW: AT, BE, 'LT 'ZX KC' BX' 'MZ 'YZ 'nx 'NΛ 'ZΩ 'sn ,MA , AU TE, ,MT 'LT 'TS 'XS 'IS '9S 'ES ู่ กห RO, LT, 'ZI 'LL 'ds WK' WN' WM' WD' , AM 'ON 'ZW 'XW we' ľ۸'n rn' 'LT 'ST ГВ**'** ΓK' rc' 15' KE' 'SI 'NI 'TI CH' CD' CB' ID' 'ΩH CW' HE' CE' ŁI' E2' YI' YN' YZ' BY' BB' BC' BK' BK' CY' CH' CN' CK' CN' CZ' DE' DK' DW' DESIGNATED STATES: W: AE, AG, AL, AM, WO 2001047931 A1 20010705, 126 pp.

rn' WC' . (asansqst) SE' ZN' LD' LG' LB' Mr' MB' NE' NT' LL'

. \$2216661 PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXD2. CODEN:

T5

ЯΑ

OeM

O9M

OəM

OeM

mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCCH4O(CH5)58' 4-CTCCH4(CH5)5NH' 3-BTCCH4CONHCSNH' CCH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' XNHCONH' S-CICCH4CH (CH3) OCONH' S-CICCH4CHSCHSOCONH' 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, C1, F, CH3,

ΙI

claimed compd. II was prepd. and biol. tested.

piperidinyl- (9CI) (CA INDEX NAME) Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-N'-l-СИ

ЗД СОИСОВД

Searched by: Mary Hale 308-4258 CM-1 12D16

STN Files:

CSS HS4 Ne 0e WE

EZ

AD

ГC

SR

ВИ

ГЗ

CA, CAPLUS

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S KEEEKENCES IN EITE CAPIUS (1967 TO DATE)

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; CODEN: BIXXDS' . (asanagat) TD, TG, TR. L' RE' RN' Mr' MB' NE' NT' DK' E2' E1' EK' CB' CB' IE' IL' PA' WC' CE' CG' CH' CI' CW' CX' DE' KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, BX' 'AZ , SA , MA , WS 'מג 'אמ TZ, UA, UG, US, LZ, SK, SL, TJ, TM, TR, TT, 'IS ZE' 2C' PT, RO, **'**∆S 'NX LT, LU, LV, MA, MD, MG, MK, MW, MX, MZ, NO, NZ, PL, 'ST LR, rc' rk' HO' ID' IT' IN' IS' 1B' KE' KE' KB' KB' KS' CH' CW' HB' EI' CB' CD' CE' BY' BB' BC' BK' BK' BK' CH' CH' CH' CK' CC' DE' DK' DW' DK' EE' EC' Al 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

CI

ξЯ

ΙI OeM OeM

CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC2NH' XNHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

4-CTCCH4O(CH5)52' 4-CTCCH4(CH5)5NH' 3-BICCH4CONHCRNH' CCH2COO' OH'

pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and

intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as

as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives prepd. and biol. tested.

E2' 'IO CE' DK' DE' 'AD CW' CH' **'**១၁ EI' EK' CH' CB' CK' IE' BE' Bl, 'LT RU, WD' 'ZX KC' BX**'** , ZA 'MZ TA; RW: AT, 'AZ 'nx 'NA 'ZN 'ຮດ ,MA , AU 'ZI 'LL 'AT ,MT 'LT 'TS 'XS 'IS '9s 'ES 'ds RU, KO, LT, br' 'ZN WD' 'ZX 'ZW 'NW 'DW , AM ۲Λ, rn**'** 'ST ΓК, rc' ON 'XW 'MW WK' 'LT ГВ' KK' KE' Ir' HB, CW' CH' CE' ŁI' EE' KC' CD' CB' E2' 'ZO 'ar 'sı 'nı HO' ID' CY' CH' CN' CK' CO' CZ' DE' DK' DW' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, .qq 321 ,20701002 IA 1897401005 OW DESIGNATED STATES: W: AE, AG, AL, AM, PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji;

PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXDZ ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. ra' wc' CODEN: .(əsənaqat)

19991224.

CI

ΑA

CA, CAPLUS

piperidinyl- (9CI) (CA INDEX NAME)

ANSWER 40 OF 179 REGISTRY COPYRIGHT 2002 ACS

claimed compd. II was prepd. and biol. tested.

 $\Gamma C$ 

SE

WEEZ

CN

ВИ

 $\Gamma 3$ 

**SLN ETJGS:** 

ЗД СОИСОКД

CS3 HS1 N2 O2

347155-58-2 REGISTRY

AD

mediated by autophosphorylation of PDGF receptors. Thus, the title bysrmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3' OCHSCOOH: X = perecocycle, perecocycly and 4-CTCeH4O(CHS)SS' 4-CTCeH4(CHS)SNH' 3-BLCeH4CONHCRNH' CEH2COO' OH' CE3CeH4CHSOCONH, CH3 (CH2) 50CONH, (CH3CH2) 2N (CH2) 3NHCSNH, YNHCONH, S-CTCeH&CH(CH3)OCONH, 2-C1C6H&CH2CH2CH2OCONH, 4-CH3O' NOS: Y = 4-CH3C6H4CH5OCONH' 3-CTC6H4CH(CH3)OCONH' 4-FC6H4CH2OCONH, ЯA

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N'-1-

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S KELEKENCES IN EITE CAPIUS (1967 TO DATE)

S REFERENCES IN EITE CA (1967 TO DATE)

CI JP 1999-374494 19991228; JP 2000-177790 2000614: APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; CODEN: BIXXDS: .(əsənaqat) ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. CE' CG' CH' CI' CW' CX' DE' DK' E2' EI' EK' GB' GB' GE' IE' II' FN' WC' SY' SM' FY' FX' EK' KZ' MD' EM' LA' LM' EM: FL' BE' BA' 'ΩΧ 'NΛ TZ, UA, UG, US, LZT SD' SE' SC' SI' SK' ST' LN' LW' LK' LL' КU, PT, RO, TB' T2' T1' T1' T1' MY' MD' MC' MK' MN' MM' MX' MZ' NO' NZ' 5F' rc' rk' GD' GE' GH' GW' HK' HA' ID' IT' IA' IS' 75' KE' KG' KB' KK' BY' BB' BC' BK' BK' BK' CH' CH' CH' CK' CC' DE' DK' DW' DK' EE' EC' AI 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 тесертогс. Sakai, Тетиуикі; Senga, Тетићиті; Furuta, Такауикі; Міма, as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

Searched by: Mary Hale 308-4258 CM-1 12D16

₽Я

Вδ

ξЯ

9Я

OeM

S-CTCCH4CH(CH3)OCONH' S-CTCCH4CHSCHSCHSOCONH' 4-CH30' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

prepd. and biol. tested. intimal thickening inhibitors. Thus, the title claimed compd. II was wediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeH4O(CH5)52' d-CTCeH4(CH5)5NH' 3-BxCeH4CONHCRNH' CeH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC2NH' XNHCONH'

, AU 'ZI 'LL ,AT 'MT 'LI 'TS 'XS 'IS **ʻ**ĐS 'ES 'ds **В**О, **,**08 LT, ₽Ľ, 'ZN WD' 'ZX 'ZW 'NW WK' WC' , AM ۲۸, rn' 'ST rk' rc' 'XW 'MW 'LT LR, KB' 'TI ID' **'**8H 'HĐ ŁI' EE' KE' KC' 'SI 'NI CW' CE' CB' E2' 'ZO 1b' 'ΩH CD' , SA , UA DK' DW' CY' CH' CK' CK' CZ' DE' BY' BB' BC' BK' BX' BS' .qq 321 ,20701002 IA 1897401005 OW DESIGNATED STATES: W: AE, AG, AL, AM, PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF

KELEKENCE S: 132:76901 Preparation of quinazoline and quinoline derivatives

19991224. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 **DIXXD**5 .AT TC, .(Japanegel). 'dl 'NS 2E' ML, MR, NE, NL, PT, rn' wc' CODEN: ŁI' 'IO CE' E2' DK' DE' 'XD CH' **'**១၁ EB' GB' GB' IE' CW' Bl' BE' WD' 'ZX KG' , ZA 'MZ TA :WA :MT 'LT ,UA BX, ,MA 'AZ 'nx 'NΛ 'ZN 'sn

CI

ЯA

mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3' OCHSCOOH:  $\chi = \text{perecocycle}$ , perecocyclylylyl and 4-CTCCH4O(CHS)S2' 4-CTCCH4(CHS)SNH' 3-BICCH4CONHCRNH' CCH2COO' OH' CE3CeH4CHSOCONH'CH3(CHS) 2OCONH' (CH3CHS) SN(CHS) 3NHC2NH' ANHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSOCONH' 4-CH30' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECeH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

claimed compd. II was prepd. and biol. tested.

341122-21-1 KECIZLKI ANSWER 41 OF 179 REGISTRY COPYRIGHT 2002 ACS

Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-1-CN

piperidinyl- (9CI) (CA INDEX NAME)

ЗД СОИСОВД EZ

SECSS HS& CJ N2 O& WE

КИ

 $\Gamma$ 3

**SLN Files:**  $\Gamma C$ 

Searched by: Mary Hale 308-4258 CM-1 12D16

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

PT, RO, RU, SD, SE, SG,

S REFERENCES IN FILE CAPLUS (1967 TO DATE)

SK' ST' IN' IN' IL' IL'

TI, UA, UE, US, LZT

'IS

CI

ьЯ

ςЯ

ξЯ

9И

A

**O P** M

II OəM MeO

CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, C1, F, CH3,

S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-

prepd. and biol. tested. intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHCRNH' ANHCONH'

ra' WB' WD' WG' rn' rc' 'ZX 'ON 'ZW 'XW 'MM' NM WK' 'LT 'ST LR, ΓK' KB' E2' 'SI 'NI ен' ем' нв' но' ір' cD' 'ZO ήь' κΕ' II' CE' LI' CB' CH' CH' CH' CK' CC' DE' DK' DW' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, .qq 321 ,20701002 IA 1E97401002 OW DESIGNATED STATES: W: AE, AG, AL, AM, Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF KELEKENCE S: 132:76901 Preparation of quinazoline and quinoline derivatives

LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. . (seansqst) CODEN: DK' EZ' DE' 'XD 'IO CE' EI' EK' CH' CB' CK' IE' IL' CW' CH' 'ອວ Bl, BE' RU, Ke' KY' WD' , ZA 'MZ TM; RM: AT, BE, 'LT BX' ,MA 'YZ 'NX 'NΛ 'ZΩ 'ន្ធ , au , Au , TT TR, ,MT 'CI 'TS 'XS 'IS '9s ZE' КU, 'Ld **¹**T₫ 'ZN 'LL 'as KO,

PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXD2.

19991224.

EI

ЯA

CAPLUS

4-piperidinyl]- (9CI) (CA INDEX NAME)

SIN Files:

ЗД СОИСОКД

CS6 H3I N2 O4

34JI22-23-J KECIZIKK

ГC SE

WE

ŁZ

CN

ВИ

ANSWER 42 OF 179 REGISTRY COPYRIGHT 2002 ACS ГЗ claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CTC@H4O(CHS)S2' 4-CTC@H4(CHS)SNH' 3-BIC@H4CONHCRNH' C@H2COO' OH' CE3CeH4CHSOCONH'CH3(CHS)2OCONH'(CH3CHS)SN(CH5)3NHCRNH'XNHCONH' S-CICCH4CH (CH3) OCONH' S-CICCH4CHSCHSCHSOCONH' 4-

Urea, W-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-W'-[1-(phenylmethyl)-

ЯÄ

PAGE 2-A

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S KELEKENCES IN EITE CAPLUS (1967 TO DATE)

JP 1999-374494 19991228; JP 2000-177790 2000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; CODEN: 'bixxDS' . (əsənaqat) TD, TG, TR. MT' MK' NE' NT' 51' 2E' 2N' CE' CC' CH' CI' CW' CX' DE' DK' ES' EI' EB' CB' CB' IE' IL' TN' WC' KG' KZ' MD' KN' LY' LW: BM: BL' BE' BY 'YB 'ZA 'WA 'MZ '\Z 'NX 'NA TZ, UA, UG, US, LZT SL, TJ, TM, TR, TT, 'XS 'IS 'ĐS **,** עЯ 2E' 'QS KO, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, rt, ru, 'ST ГВ,  $\Gamma K$ CH' CW' HB' HO' ID' IT' IN' IS' DB' KE' KC' KB' KS' KS' CD' CE' BY' BB' BC' BK' BK' BK' CH' CH' CH' CK' CC' DE' DK' DW' DK' EE' EC' AI 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 кесертокз. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Такауикі; Міма, as remedies for diseases mediated by autophosphorylation of PDGF KEFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

C.T

 $\mathbf{F}\mathbf{A}$ 

ςИ

ξЯ

9Я

A

OeM

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2COOH, 3-C1C6H4CH(CH3)OCONH, 4-FC6H4CH2COOH, A-C1C6H4CH(CH3)OCONH, CH3CH2CH2COOH, CH3CH2CH3COOH, CH3CH2CH3COOH, CH3CH3CH3COOH, CH3CH3COOH, CH3CH3COOH, CH3CH3COOH, CH3CH3COOH, CH3CH3COOH, CH3CH3COOH, CH3CH3COOH, CH3CH4CH2CH3COOH, CH3CH4CH2CH3COOH, A-C1C6H4CH2CH3COOH, Y = heterocycle, heterocyclylalkyl] and OCH2COOCH3, OCH2COOH, Y = heterocycle, heterocyclylalkyl] and mediated by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was intimal thickening inhibitors. Thus, the title claimed compd. II was prefixed by autophosphorylation of PDGF receptors, particularly useful as intimal thickening inhibitors. Thus, the title claimed compd. II was intimal thickening inhibitors. Thus, the title claimed compd. II was intimal thickening inhibitors. Thus, the title claimed compd. II was intimal thickening inhibitors. Thus, the title claimed compd. II was intimal thickening inhibitors. Thus, the title claimed compd. II was intimal thickening inhibitors. Thus, the title claimed compd. II was intimal thickening inhibitors. Thus, the title claimed compd. II was intimal thickening inhibitors.

ΙI

intimal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji;

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXD2. rn' wc' wr' wk' (Japanese). SE, SN, TD, TG, TR. NE' NT' LL' CODEN: EI' E2' 'IO CE' DE' EK' CH' CB' CK' IE' IL' DK' 'XD 'WD CH' 'ອວ Bl, BE' RU, KZ' WD' TM; RW: AT, BE, , LT KC' BX, , ZA 'MZ 'YZ 'nx 'NA 'ZΩ 'នព , MA 'TS .əu .Au 'ZJ TE, TM, 'LI 'XS 'IS '9S 'EE RU, 'Ld **¹**T₫ 'LL 'as RO, WD' WG' 'ZX 'ON 'ZW 'XW MN' MM' WK' , AM 'nT 'LT 'ST LR, rk' rc' KB' 'dI 'NH 15' KE' KC' 'SI 'NI CW' 'H9 CE' CD' CB' ŁI' EE' EZ' 'ZO 'TI ΉВ, CH' CH' CH' CH' CS' DE' DK' DW' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,2001002 IA 1E97401002 OW Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji;

TĐ

AA

ŢΛ

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and d-CTC@HdO(CHS)SS' d-CTC@Hd(CHS)SNH' 3-BxC@HdCONHCRNH' C@H2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' XNHCONH' S-CTCeH&CH(CH3)OCONH, S-CTC6H&CH2CH2CH2OCONH, 4-TITLE compds. [I; X = N, CH; R3, R4, R5, R6 independently 4-FC6H4CH2OCONH, TITLE COMPS, A = 4-CH3C6H4CH2OCONH, A = 4-CH3CH4CH2OCONH, A = 4-CH3CH2OCONH, A = 4-CH3CH4CH2OCONH, A = 4-CH3CH4CH2OC

ЗД СОИСОКД

CAPLUS CAPLUS

 $\Gamma C$ 

SE

STN Files:

**KD** 

CS8 H34 Ne Oe WE EZ

quinazolinyl) oxy]-2-nitrophenyl]- (9CI) (CA INDEX NAME)

Urea, N-[1-(cyclohexylmethyl)-3-pyrrolidinyl]-N'-[4-[(6,7-dimethoxy-4-Urea, N-[1-(cyclohexylmethyl)-3-pyrrolidinyl]]

CN

ВИ 347155-49-1 REGISTRY ANSWER 43 OF 179 REGISTRY COPYRIGHT 2002 ACS ГЗ

**LYCE S-Y** 

HN 0 =HN OZN OeM OeM

CHS

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S REFERENCES IN FILE CAPLUS (1967 TO DATE) S REFERENCES IN FILE CA (1967 TO DATE)

SL, TJ, TM, TR, TT, 'xs 'IS 'DS 'ES 2D' **к**и, TZ, UA, UG, US, UZ, KO, TE' TR' TR' TR' MA' MD' MC' MK' MN' MX' MZ' NO' NT' BF' rc' rk' CD' CE' CH' CW' HB' HA' ID' IT' IN' IS' 15' KE' KC' KB' KS' BY' BB' BC' BK' BK' BS' CY' CH' CN' CK' CN' CS' DE' DK' DW' DS' EE' ES' Al 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Міма, as remedies for diseases mediated by autophosphorylation of PDGF

KEEEKENCE 1: 132:92649 Preparation of quinazoline and quinoline derivatives

APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; TD, TG, TR. CODEN: BIXXDS: .(asənaqat) Mr' MB' NE' NT' LT' SE' SN' **'**50 DK' E2' LI' LB' GB' GB' IE' IL' FN' WC' CH' CI' CW' CX' DE' 'nX KG' KZ' MD' KN' L1' LW; KM: YL' BE' BL' B1' ,YA ,ZA ,MA ,WZ , AZ.

JP 1999-374494 19991228; JP 2000-177790 20000614.

СI

ЕЯ

d-CTCCH4O(CH5)52' d-CTCCHd(CH5)5NH' 3-BICCHdCONHCRNH' CCH2COO' OH' CL3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' XNHCONH' S-CICCH4CH(CH3)OCONH' S-CICCH4CHSCHSCHSOCONH' 4-CH3O' NO5: V = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

II

mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and

prepd. and biol. tested. intimal thickening inhibitors. Thus, the title claimed compd. II was

PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

rn' wc' 'IO EI' EK' CH' CB' CE' IE' IL' CE' DK' EZ' DE' CX, **'**១၁ CW' CH' BE' Bl, TM; RM: AT, BE, ND, RU, TJ, 'ZX BX' , ZA 'MZ 'ZΩ KC' ,AZ 'NX ,MA 'NA 'នព , AU 'IS 'IS 'ES 'ds ู้ กห bľ' 'WI 'LI 'XS '9S KO\* 'Ld 'ZI 'LL TR, 'ZN 'ZW 'XW 'MW 'NW WK' MG, WD' ,AM **'**\7 rn' 'LT 'ST rk' rk' rc' 'ZX KK' 'TI 'SI 'NI ID' CH' CD' CB' ŁI' E2' EE' 15' KE' GW' HB' HO' CE' YI' YN' YY' BY' BB' BC' BK' BX' CY' CH' CN' CK' CN' CZ' DE' DK' DW' DESIGNATED STATES: W: AE, AG, AL, AM, WO 2001047931 A1 20010705, 126 pp.

CODEN: .(əsənaqat) SE' SN' ID' IC' IK' MT' MK' NE' NT' LL'

PIXXDZ.

PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222.

. \$2216661

EI

**AA** 

pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-BxCeHdCONHCRNH' CeH2COO' OH' CE3CeH4CHTOCONH'CH3(CH5)2OCONH'(CH3CH5)5N(CH5)3NHC2NH' ANHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSOCONH' 4-

mediated by autophosphorylation of PDGF receptors. Thus, the title

claimed compd. II was prepd. and biol. tested.

347155-48-0 REGISTRY

dnjuszolinyl) oxylphenyl] - (9CI) (CA INDEX NAME)

ЗД СОИСОВД EZ

Urea, N-[1-(cyclohexylmethyl)-3-pyrrolidinyl]-N'-[4-[(6,7-dimethoxy-4-

CN

ВИ

CAPLUS

**SLN Files:** 

CS8 H32 N2 O4

 $\Gamma C$ SE

WE

ANSWER 44 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma3$ 

OĐM

OeM

HN

HN

CHS

PAGE 2-A

FAGE 1-A

KG' KZ' MD' KN' LY' LW: BM: BL' BE' BY

'Zn 'Sn '9n

SL, TJ, TM, TR, TT, TZ, UA,

rs' r1' r0' r0' Mb' Mb' Wc' Wk' Wn' Wm' Wx' Wz' n0' Nz' br'

APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; CODEN: BIXXDS' (Japanese). TD, TG, TR. WT' WB' NE' NT' BL' SE' SN' DK' E2' LI' LB' CB' CB' IE' IL' TO' MC' CE' CC' CH' CI' CW' CX' DE'

EI' GB' GD' GE' GH' GW' HB' HO' ID' IT' IN' IS' 1B' KE' KG' KB' KK' KZ' BY' BB' BC' BK' BX' BZ' CH' CH' CH' CK' CC' DE' DK' DW' DZ' EE' EZ' Al 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, as remedies for diseases mediated by autophosphorylation of PDGF KELEKENCE 1: 132:35043 Lebaration of dninazoline and dninoline derivatives

'XS

S REFERENCES IN FILE CAPLUS (1967 TO DATE) S REFERENCES IN FILE CA (1967 TO DATE)

BX**'** 

'IS

**'**9S

JP 1999-374494 19991228; JP 2000-177790 20000614.

, ZA , MA , WZ

ZE'

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

'ds

,AZ

**,** ия

LR,

'NX

ко,

rc' rk'

'Ld

СI

ξЯ

$$\begin{array}{c} \text{MeO} \\ \text{MeO} \\ \text{N} \\ \text{N}$$

pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and 4-CJCeH4O(CHS)SS' 4-CJCeH4(CHS)SNH' 3-BICEH4CONHCRNH' CEH2COO' OH' CE3CeH#CH5OCONH'CH3(CH5)2OCONH'(CH3CH5)5N(CH5)3NHC2NH'XNHCONH' S-CTCeH¢CH(CH3)OCONH' S-CTCeH¢CHSCHSCHSOCONH' ¢-CH3O' NOS' Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives prepd. and biol. tested. intimal thickening inhibitors.

WD' 'ZX WC' WK' WN' WX' WZ' , AM **'**\\T rn' 'LT 'ST  $\Gamma K$ rc' rg, CH' CE' ŁI' GW' HB' HO' ID' IT' IN' IS' 15' KE' CD' CB' EE' ES' BY' BB' BC' BK' BX' BS' CY' CH' CN' CB' CO' CZ' DE' DK' DW' , SA , UA , TA DESIGNATED STATES: W: AE, AG, AL, AM, WO 2001047931 A1 20010705, 126 pp. PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF

DE' 'AD **'**១၁ EI' EB' GB' GB' IE' DK' ES' CI' CW' CH' B1' CE' 'ZX KC' BX**'** , ZA ,MA ,WZ 'ZN MD, RU, TJ, TM; RW: AT, BE, 'NX 'NΛ 'ຮດ ,AZ 'TS 'IS **'**5S 2E' **'**מצ ₽L, 'ZI AT ,MT ,UT 'XS 'ds LT. 'LL KO,

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXD2, . (əsənaqat) TO' WC' WT' WK' NE' NT' LT' SE' SN' LD' LG' LK' CODEN:

CI

ЯΑ

OCHSCOOCH3' OCHSCOOH: X = perecolor perecockcylylylyl sug 4-CTC@H4O(CHS)SS' 4-CTC@H4(CHS)SNH' 3-BxC@H4CONHCRNH' C@H2COO' OH' CE3CeH4CHTOCONH'CH3(CH5)POCONH'(CH3CH5)SN(CH5)3NHCRNH' ANHCONH' S-CTCeH&CH(CH3)OCONH' S-CTCeH&CHSCHSCHSOCONH' 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

ΙI

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases

YN2MEK 42 OF 179 REGISTRY COPYRIGHT 2002 ACS

347155-46-8 REGISTRY ВИ ГЗ

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-N'-[1-[[4-СИ

(CY INDEX NAME)

(1,1-dimethylethyl)phenyl]methyl]-3-pyrrolidinyl]- (9CI)

C35 H36 N6 O6 WEЗД СОИСОКД ŁZ

SE

CA, CAPLUS  $\Gamma C$ SIN Files:

Searched by: Mary Hale 308-4258 CM-1 12D16

APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; (Japanese). CODEN: PIXXD2. Mr' MK' NE' NT' TD, TG, TR. L' RE' RN' EI' EK' GY' GB' GK' IE' IL' FN' WC' E2' DK' DE' 'AO 'ID CH' '໑ລ CE' CW' IM; EM: PI, BE, BF, BJ, WD' 'ZX KC' 'NX 'LT צט, BX**'** , SA 'MZ 'AZ ,MA 'NΛ 'TS 2K' 'IS '១s AU , ST 'TT TR, 'WT 'LT 2E' 'dS кu, ĖО 'Zn 'Sn '9n 'Id WD' WC' WK' WN' WN' WS' NO' NS' BF' , AM 'ST rk' rc' LT, LU, ГĿ IT' IN' IS' 15' KE' KE' KB' KK' KZ' EI' CB' CD' CE' CH' CW' HB' HO' ID' BY' BB' BC' BK' BX' BZ' CH' CH' CH' CK' CC' CZ' DE' DK' DW' DZ' EE' EZ' Al 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

S BEFERENCES IN FILE CAPLUS (1967 TO DATE)
S REFERENCES IN FILE CAPLUS (1967 TO DATE)

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

PAGE 2-A

OeM

**BA** 

OeM

CI

JP 1999-374494 19991228; JP 2000-177790 20000614.

Thus, the title claimed compd. II was CE3CCH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHCRNH' KNHCONH' S-CICCH4CH(CH3)OCONH' S-CICCH4CHSCHSCHSOCONH' 4-CH30' NO5' Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

II

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives prepd. and biol. tested. intimal thickening inhibitors. mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3' OCHSCOOH: X = perecocycle, perecocycle, perecocycle, and 4-CTC@H4O(CHS)S2' 4-CTC@H4(CHS)SNH' 3-BIC@H4CONHCRNH' C@H2COO' OH'

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXD2. rn' wc' .(asanaqat) Mr' MB' NE' NT' LL' SE' SN' LD' LC' LK' CODEM: DK' EZ' 'IO CE' EI' EB' GB' GB' IE' DE' CX' CW' CH' 'ອວ ' ៤ឧ **к**и, , ZA ,MA 'MZ 'YZ 'nX 'NΛ 'zn 'នព TM; RW: AT,  $^{\prime}$ CJ KZ' WD' KC\* **'**X8 'TS 'XS 'IS , AU TR, 'MT 'LI '១ន 'ES 'ds RU, 'Ld **¹**Td 'ZJ 'LL RO, 'ZN  $\Gamma\Lambda$ 'ZX WK' WN' WM' WD' WG' ,AM 'LT 'ST rk' rc' 'ON 'ZW 'XW rn' LR, KB' CH' ŁI' E2' EE' 1b' KE' 'SI 'NI HB' HO' ID' IT' CW' CD' CE' CB. CH' CH' CH' CK' CC' DE' DK' DW' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20701002 IA 1867401005 OW Makanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF

OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-BxCeHdCONHCRNH' CeH2COO' OH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-ЯA

mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases

PHRMER 46 OF 179 REGISTRY COPYRIGHT 2002 ACS

34JI22-42-J KECISLKK

 $q_{i}w \in p_{i} + (OCi) = (OCi) = (OCi) = (OCi)$ Urea, M-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy] brenyl]-M-[1-[[4-(1,1-ginyl)oxy]]

ЗД СОИСОКД

SLN Files:

C35 H37 N5 O4 ME

EZ

 $\Gamma C$ 

SE

CN

ВИ

 $\Gamma3$ 

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3, CH3O, NO2; A = 4 - CH3C6H4CH2OCONH, A = 4 - CH3C

ΙI

CAPLUS

FAGE 2-A

(Japanese). CODEN: PIXXD2.

DK' ES' LI' LK' CH' CB' CB' IE' IL' TO' WC'

KC, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ,

SI' SK' ST' IN' IB' LI' IS' NB' NG' NS' NS'

LV, MA, MD, MG, MK, MW, MX, MZ, NO, NZ, PL,

APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224;

REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO. DZ, EE, ES, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. Mo. 2001047890

TD, TG, TR.

BX**'** 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

2 REFERENCES IN FILE CAPLUS (1967 TO DATE)

269xcyeq pl: Mary Hale 308-4258 CM-1 12D16

, SA , MA , WS

ZE' 2C'

Mr' MB' NE' NI' bI' SE' SN'

CE' CC' CH' CI' CW' CX' DE'

rc' rk' rk' ra' rı' ra'

'YZ

PT, RO, RU, SD,

'חג 'אה

ЯA

OƏW 🕻

OeM

EI

intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-BxCeHdCONHCRNH' CeH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHCRNH' KNHCONH' S-CICCHCCH(CH3)OCONH' S-CICCHCCHSCHSCHSOCONH' d-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCEH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

II

prepd. and biol. tested.

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXD2. MT' MK' NE' NT' LT' SE' SN' LD' LC' rn' wc' CODEM: . (asanaqat) .AT E2' 'XD 'IO CE' DK' DE' CW' 'HO **'**೨၁ EI' EK' CH' CB' CK' IE' Bl, BE' 'LI RU, WD' 'ZX KC' BX' , SA 'MZ 'YZ 'NX **'**NΛ 'ZN TM; RW: AT, BE, 'sn , MA bľ' , AU TR, 'LI 'TS 'XS 'IS '⅁S 'ES 'ds ,UA KO, 'T4 'ZN 'ZI 'LL 'WI rc' 'ZX 'XW 'NW WK' WD' WC' ,AM rn' rn' 'LT 'ST ΓK' 'ON 'ZW 'MW ΓK, KB' KE' 'za 1b, 'SI 'NI CH' CW' HB' HO' ID' IT' CD' CE' EI' CB' EE' ES' KC' CY' CH' CN' CK' CO' CZ' DE' DK' DW' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, DESIGNATED STATES: W: AE, AG, AL, AM, WO 2001047931 A1 20010705, 126 pp. PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

CI

OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCCH4O(CHS)SS' 4-CTCCH4(CHS)SNH' 3-BTCCH4CONHCSNH' CCH2COO' OH' СЕЗСЕНФСН СООИН СНЗ (СН СНЗ ССН СНЗ ССН ССН СВ ЗИНСВИН ХИНСОИН) S-CTCeH&CH(CH3)OCONH, S-CTC6H&CH2CH2CH2OCONH, 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

II

mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases

347155-43-5 REGISTRY ANSWER 47 OF 179 REGISTRY COPYRIGHT 2002 ACS claimed compd. II was prepd. and biol. tested.

Urea, N-[1-[(2-chlorophenyl)methyl]-3-pyrrolidinyl]-N'-[4-[(6,7-dimethoxy-СИ ВИ

4-quinazolinyl)oxy]-2-nitrophenyl]- (9CI) (CA INDEX NAME)

ЗД СОИСОВД EZ

CS8 HS1 CT N6 O6

. WE

ГЗ

CA, CAPLUS STN Files:  $\Gamma C$ SE

Searched by: Mary Hale 308-4258 CM-1 12D16

PAGE 2-A

FAGE 1-A

HN

ΗŃ

S KELEKENCES IN EITE CAPLUS (1967 TO DATE)

S KELEKENCES IN EITE CA (1967 TO DATE)

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

CI JB 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; .(əsənaqat) TD, TG, TR. 'NS Ld' CODEN: bixxDS ZE' ML, MR, NE, NL, ŁI' E2' DK' DE' 'ID EB' CB' CB' IE' IL' IN' MC' 'XD CW' CH' **'**၅၁ 'LT WD' TM; RM: AT, BE, BF, BJ, BX**'** צמ, 'ZX KC' , ZA 'MZ 'YZ 'NX ,MA 'NA 'sn **'**១៣ ,AU 'ZI TE, 'LT 'TS 'IS 'ZΩ 'LL 'WT 'XS '9s ZE' 'as ,UA ВO, 'Ld 'ZN ₽Ľ, 'ON 'ZW 'XW WC' WK' WM' WM' WD' ,AM **'**\7 rn' 'LT 'ST rk' LR, KK' 'ΩH KE' KG' Kb' 'dr' IR' IR' TB' ID' HK' CW, CH' CE' CD' CB' BC' BK' BX' BX' CY' CH' CN' CK' CO' CZ' DE' DK' DW' DZ' EE' EZ' 'AB 'AB PCT Int. Appl. WO 2001047890 as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

Вđ

ξЯ

CE3C6H4CH2OCONH, CH3 (CH2) 50CONH, (CH3CH2) 2N (CH2) 3NHCSNH, YHCONH, CH3O, NO2; A = 4 - CH3C6H4CH2CH2CH2CH2CH2CH3) CCH3O, NO2; A = 4 - CH3C6H4CH2CH2CH3) CCH3O, A = 4 - CH3C6H4CH2CH2CONH, A - CH3C6H4CH3CH3) CCH3, A = 4 - CH3C6H4CH3 CCH3, A = 4 - CH3C6H4 CCH

CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-CL6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, 2-CLC6H4CH(CH3)OCONH, 2-CLC6H4CH2CH2CH2CH2CH2CH2CH3) OCH2COOCH3, OCH2COOH; Y = heterocycle, heterocyclylation of PDGF receptors, particularly useful as mediated by autophosphorylation of PDGF receptors, particularly useful as mediated by autophosphorylation of PDGF receptors, particularly useful as mediated by autophosphorylation of PDGF receptors, particularly useful as mediated by autophosphorylation of PDGF receptors, particularly useful as mediated by autophosphorylation of PDGF receptors, particularly useful as mediated by autophosphorylations. Thus, the title claimed compd. II was preference and prof. Tested.

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF

PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXD2. CODEM: .(asənaqat) LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. 'IO CE' CC' CH' E2' LI' LK' CY' CB' CK' IE' CA' DE' DK' CW' Bl, 'LT KG' BX**'** , ZA ,MA ,WZ TM; RM: AT, BE, KZ' WD' BA' ,AZ 'NX 'NA 'ZN 'AT 'LT 'TS 'XS 'IS **'**១ಽ 'ES bľ' 'MT 'ds RU, 'Ld 'ZL 'LL RO, 'ZX 'ZW 'XW 'MW 'NW WD' WC' WK' 'AM 'NI 'NI 'LT 'ST rg' ΓK' rc' CE' ŁI' E2' KG\* 1b' KE' 'SI 'NI CH' CW' HB' HO' ID' IT' CD' CB' YI' YN' YZ' BY' BB' BC' BK' BK' CY' CH' CN' CK' CN' CZ' DE' DK' DW' DESIGNATED STATES: W: AE, AG, AL, AM, WO 2001047931 A1 20010705, 126 pp. PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji;

•

ΙĐ

ЯΑ

19991224.

CAPLUS

4-quinazolinyl)oxylphenyl]- (9CI) (CA INDEX NAME)

ANSWER 48 OF 179 REGISTRY COPYRIGHT 2002 ACS

claimed compd. II was prepd. and biol. tested.

SIN Files:

ЗД СОИСОВД

CS8 HS8 CJ N2 O4

347155-42-4 REGISTRY

CA

 $\Gamma C$ SE

WE

EZ

CN

ВИ

ГЗ

ŢΛ

pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-BxCeHdCONHCRNH' CEH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' XNHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSOCONH' 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCEH4CH(CH3)OCONH' 4-ECEH4CH5OCONH'

mediated by autophosphorylation of PDGF receptors. Thus, the title

Urea, N-[1-[(2-chlorophenyl)methyl]-3-pyrrolidinyl]-N'-[4-[(6,7-dimethoxy-urea, N-[1-[(2-chlorophenyl)methyl]-3-pyrrolidinyl]]

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

5¥CE S−¥

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S KEEEKENCES IN EITE CAPLUS (1967 TO DATE)

S KEEEKENCES IN EITE CAPLUS (1967 TO DATE)

JP 1999-374494 19991228; JP 2000-177790 2000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; TD, TG, TR. CODEN: BIXXDS: .(əsənaqat) Mr' MB' NE' NI' LL' SE' SN' DK' ES' EI' EB' GB' GB' IE' IL' TO' MC' CH' CI' CW' CX' DE' Ke' KZ' MD' KO' LT' LW' EM: FL' BE' BL' BT' XM, AM, AZ, BY, , AZ SK' ST' LO' LW' LK' LL' LS' OF' OC' OS' OS' 'IS '9S aD, ZE' КU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, LR, LS, LT, LU, CD' CE' CH' CW' HK' HA' ID' IT' IN' IS' 16' KE' KC' KB' KS' BY' BB' BC' BK' BX' BZ' CH' CH' CH' CK' CC' CZ' DE' DK' DW' DZ' EE' EZ' WI SOO10105, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Такауикі; Міма, as remedies for diseases mediated by autophosphorylation of PDGF KELEKENCE 1: 132:35043 Lebaration of dninazoline and dninoline derivatives

CI

$$\begin{array}{c} & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

ξЯ

S-CTCeH4CH(CH3)OCONH, S-CTC6H4CH2CH2CH2OCONH, 4-CH3O' NOS: W = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

Thus, the title claimed compd. II was

mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-cTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-BxCeHdCONHCRNH' CEH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHCRNH' ANHCONH'

prepd. and biol. tested. intimal thickening inhibitors.

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXDZ. Wr' WB' NE' NT' LI' rn' wc' CODEM: . (asanaqat) SE, SN, TD, TG, TR. EI' 'AD 'IO DK' EZ' CE' EK' CH' CB' CK' IE' IL' DE' CW, CH' ce' BJ, RU, TM; RM: AT, BE, 'LT KZ' WD' KC' BX**'** , SA ,MA ,WZ ,AZ ίΩX 'NΛ 'ZΩ 'LT 'TS 2K 'ZI 'LL TR, 'MT 'IS '9s ZE' 'ds RU, RO, LT, **Γ** ON 'ZW 'XW 'MW 'NW WD' WC' WK' , AM rn' rn' 'LT 'SI LR, ľK' rc' 'ZX 1b' KE' EE' 'SI 'NI 'TI GW, HR, HU, ID, 'H9 CE' CD' CB' ŁI' E2' YI' YN' YZ' BY' BB' BC' BK' BX' CY' CH' CN' CK' CN' CZ' DE' DK' DW' DESIGNATED STATES: W: AE, AG, AL, AM, WO 2001047931 A1 20010705, 126 pp. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF

CI

ΒA

. \$2216661

d-CTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-BICEHdCONHCSNH' CEH2COO' OH' CL3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' ANHCONH' S-CTCeH&CH(CH3)OCONH, 2-CTC6H&CH2CH2CH2OCONH, 4-CH30' NO5' V = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, **BA** 

ΙI

mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and

claimed compd. II was prepd. and biol. tested.

341122-40-2 RECIZLEY ВИ ANSWER 49 OF 179 REGISTRY COPYRIGHT 2002 ACS ГЗ

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-N'-[(3S)-1-CN

(byenylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

STEREOSEARCH EZ

CS8 HS8 Ne Oe WE

CA, CAPLUS SIN Files: ГC SE AD

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

Searched by: Mary Hale 308-4258 CM-1 12D16

S REFERENCES IN FILE CAPLUS (1967 TO DATE)

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; (Japanese). CODEN: PIXXD2 TD, TG, TR. ZE' ZN' 'Ld. 'IN Wr' WB' NE' ŁI' DK' DE' 'XD CI' CW' CH' '໑ລ CE' EK' GH' GB' GK' IE' IL' TO' WC' E2' 'LT ки, 'ZX KC' BX' , ZA 'MZ 'NX BE' B1' TM; RM: AT, BE, WD' ,MA 'YZ 'NA , AU ,AT 'LT 'TS 'XS 'IS '9S ZE' **В**О, 'ន្ធ ne' 'MT 'ds 'ZJ 'LL RO, 'Ld WD'  $\Gamma\Lambda$ 'ZN ON WK' WN' WM' WX' WZ' WC' ,AM rn' 'LT 'ST ГВ'  $\Gamma K$ rc' KK' Kb' нв, CB' HO' ID' IT' IN' IS' 15' KE' KG' CH' CW' CD' CE' BY' BB' BC' BK' BX' BZ' CY' CH' CN' CK' CN' CZ' DE' DK' DW' DZ' EE' EZ' DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, .qq 8901 ,20701002 IA Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3' OCHSCOOH:  $\chi$  = pererocycle, hererocyclylalkyl] and 4-CTC6H4O(CHS)S2' 4-CTC6H4(CHS)SNH' 3-BLC6H4CONHCRNH' C6H2COO' OH' CE3CeH4CH5OCONH, CH3(CH2) SOCONH, (CH3CH2) 2N(CH2) 3NHCSNH, YNHCONH, S-CTCeH4CH(CH3)OCONH, 2-CTC6H4CH2CH2CH2OCONH, 4-CH3O' MOS' Y = 4-CH3CeH4CH5OCONH' 3-CTCEH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

prepd. and biol. tested.

T.O

Searched by: Mary Hale 308-4258 CM-1 12D16

CAPLUS CAPLUS

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. **DIXXDS** .AT TG, rn' wc' . (asanaqat) 'dl 'NS ZE' MI' ME' NE' NI' LI' CODEN: ŁI' 'S3 DK' DE' 'AD 'IO CH' **'**၅၁ CE' Bl, BE' EK' CH' CB' CK' IE' CW' 'LT **'**NY WD' 'ZX 'MZ 'ZN TA : WA : MT KC' BX' , ZA ,MA 'AZ 'NX 'NA 'sn 'LT 'TS 'XS '១s RU, br' **1**00 ,AU 'ZI 'LL  $_{\mathsf{A}}$ 'WI 'IS ZE' KO, LT, 'ZN 'ds WD' ГΚ' rc' 'ZX ON 'ZW '9W 'LT 'S7 KB' ГВ, 'XW 'MW 'NW WK' , AM 'AT rn' ŁI' EE' KC' KE' 'TI HB, CD' E2' 'ZO 1b'SI 'NI **'**H9 CB' ID' 'NH CW' CE' DE' CH' CH' CK' CC' CZ' BK' BZ' AT, AU, AZ, BA, BB, BG, BR, DK' DW' .qq 321 ,20701002 IA 1897, 126 pp. YE' YE' YH' YW' DESIGNATED STATES: W: PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

Ι Вζ ŢΛ

bysrmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and 4-CTC@H4O(CHS)S2' 4-CTC@H4(CHS)SNH' 3-BIC@H4CONHCRNH' C@H2COO' OH' CE3CeH4CHSOCONH'CH3(CHS)2OCONH' (CH3CHS)SN(CHS)3NHC2NH' ANHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-CH3O' NOS: V = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

claimed compd. II was prepd. and biol. tested. Thus, the title mediated by autophosphorylation of PDGF receptors.

II

SE AD C58 H58 N6 O6 WF. STEREOSEARCH EZ (byenylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME) Urea, M-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-W'-[(3R)-1-

347155-39-9 REGISTRY

STN Files:

 $\Gamma C$ 

ΑA

CI

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S BELEBENCES IN LITE CYBENS (1967 TO DATE)
S BELEBENCES IN LITE CY (1967 TO DATE)

JP 1999-374494 19991228; JP 2000-177790 20000614. PRIORITY: JP 1999-377486 19991224; APPLICATION: WO 2000-JP9157 20001222. TG, TR. CODEN: BIXXDS: . (asanaqat) TD, 'NS ZE' LT, Wr' WB' NE' NT' 'IO EI' EK' CH' CB' CK' IE' IL' FN' MC' E2' DK' DE' 'XD CE, CG, CH, CW' 'ZX 'MZ TM; EM: AT, BE, BF, BJ, 'LT ĸпу WD' KC' BX' , SA , MA , AZ 'NX 'LT 'TS 'XS 'IS 'ds ′zດ ′sດ 'LL 'WT ne' AU , ST TR, '9S ZE' **,**иЯ WX' WZ' NO' NZ' bF' rn' LT, 'ST MD' MG' MK' MN' MM' רח' , AM LR, HO' ID' IT' IN' IS' 15' KE' KE' KB' KK' KZ' CW' CD' CE' HE, CH' BY' BB' BC' BK' BK' BC' CH' CH' CH' CK' CC' DE' DK' DW' DC' EE' EC' Al 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

$$\begin{array}{c} \mathbb{R}^{A} \\ \mathbb{R}$$

II

prepd. and biol. tested. REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

19991224. APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 PIXXD2. SN, TD, TG, TR. ZE' .(əsənaqat) Nr' bl' NE' WK' 'TW CODEN: 'IO DK' E2' EI' EB' GB' GB' IE' II' DE' 'XD CE' CW' CH' **'**90 TA; RW: AT, 'LT RU, WD' 'ZX KC' BX, , ZA 'MZ 'nX ,MA 'AZ 'NΛ 'AT 'TS 'ĐS , AU 'ZL 'TT 'MT 'LI 'XS 'IS 'EE 'ds RU, KO, 'Ld rn' 'LT 'ON 'MW' NW WK' MA, MD, MG, 'ZW 'XW 'Λ'n 'ST LR, rk' rc' II' KC' KE' 'Ar 'SI 'NI CH' CE' CD' ŁI' HB, HU, ID, CW, CB' E2' CY' CH' CN' CB' CO' CZ' DE' DK' DW' BY' BB' BC' BK' BX' BZ' DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20701002 IA 1887401002 OW Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF

ЕI

ЯΑ

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

Absolute stereochemistry.

CA, CAPLUS STN Files:  $\Gamma C$ 

ЯS

CS8 HS8 CT N2 O4 WE

STEREOSEARCH EZ

(byenylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME) Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N-[(33)-1-CN

ВИ

347155-38-8 REGISTRY

COPYRIGHT 2002 ACS PNRMER 51 OF 179 REGISTRY ГЗ

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases

OCHSCOOCH3' OCHSCOOH:  $\chi = \text{perecocyc}$ e' perecocyclylylklj sug

4-CTC6H4O(CHS)S2, 4-CTC6H4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC2NH' XNHCONH'

S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-

CH30' NO5' Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH'

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

ΙI

KELEKENCE 1: 132:92649 Preparation of quinazoline and quinoline derivatives

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; CODEN: BIXXDS .(Japanese). TD, TG, TR. RE' RN' LT, Mr' MB' NE' NT' DK' CX' DE' 'ID E2' E1' EK' CH' CB' CB' IE' IL' TN' WC' CW' CH' **'**90 BE' B1' TM; RM: AT, BE, 'LI KZ' WD' BN' KG' BX**'** 'Z¥ , MA 'MZ '∀Z 'nx 'NA TR, 'XS 'ទព ne' , AU 'ZL 'WT 'CI 'TS 'IS '9s ZE' 'dS RU, RO, 'Id ,TT 'ZN WK' WN' WM' WX' WZ' NO' MD' MG' , AM  $\Gamma\Lambda$ rn' 'LT 'ST LR, rk' rc' HO' ID' IT' IN' IS' OB' KE' KC' KB' KK' KZ' нв, CH' CW' CD' CE' CB' BY' BB' BC' BK' BX' BZ' CH' CH' CH' CK' CC' DE' DK' DW' DZ' EE' EZ' DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, .qq 8901 ,20701002 IA PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). кесергога: Закат, Тегиуикі; Senga, Тегићит; Furuta, Такауикі; Міма, as remedies for diseases mediated by autophosphorylation of PDGF

mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCCH40(CHS)S2' 4-CTCCH4(CHS)SNH' 3-BLCCH4CONHCRNH' CCH2COO' OH' CE3CeH4CHSOCONH'CH3(CHS)2OCONH'(CH3CHS)5N(CHS)3NHC2NH'XNHCONH' S-CICCH4CH(CH3)OCONH, S-CICCH4CH2CH2CH2OCONH, 4-CH30' NO5: V = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' 

II

intimal thickening inhibitors. Thus, the title claimed compd. II was

prepd. and biol. tested.

OəM

CI

26arched by: Mary Hale 308-4258 CM-1 12D16

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. **DIXXDS** .AT SE' SN' LD' LC' ra' wc' .(əsənaqab), Mr' MB' NE' NT' LI' CODEN: 'ID ŁI' E2' CE' DK' DE' CX' CW' CH' **'**90 Bl' BE' EK' CH' CB' CK' IE' IL' 'LI 'ZX KG' BX**'** , ZA 'MZ 'NX 'NA 'ZΩ TM; RM: AT, BE, MD, RU, ,MA 'YZ 'នព , AU 'LT 'IS 'XS 'IS '១s ZE' ₽Ľ, 'AT 'MT RU, RO, LL' 'ZN 'ZL 'LL 'dS 'ZW 'NW WD' , AM **'**Λ'Ί rn' 'LT 'ZX 'XW 'MW 'ST רצ' רצ' KB' ON WC' WK' rc' KE' CH' CE' KC' 1b, 'ZO 'SI 'NI HO' ID' IT' CW' HB' CD' EI' CB' EE' EZ' CH' CH' CK' CC' CZ' DE' DK' DW' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20701002 IA 1867401002 OW PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF KELEKENCE S: 132:76901 Preparation of quinazoline and quinoline derivatives

Ι ВS В3 И ŢΛ

II

claimed compd. II was prepd. and biol. tested. Thus, the title mediated by autophosphorylation of PDGF receptors. pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCCH4O(CHS)S2' 4-CTCCH4(CHS)SNH' 3-BICCH4CONHCRNH' CCH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHCRNH' ANHCONH' S-CTCeH&CH(CH3)OCONH, S-CTC6H&CH2CH2CH2OCONH, 4-CH30' NO5' Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-LCeH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3;

STEREOSEARCH EZ (byenylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME) Orea, M-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-M'-[(3R)-1-CN34JI22-3J-J KECIZLKK ВИ COPYRIGHT 2002 ACS YNRMEK 25 OF 179 REGISTRY  $\Gamma 3$ 

CS8 HS8 CJ N2 O4 MF.

**AD** SR

CA, CAPLUS

 $\Gamma C$ SIN Files:

AΒ

CI

Absolute stereochemistry.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S REFERENCES IN FILE CAPLUS (1967 TO DATE)

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; Wr' WE' NE' NT' CODEN: BIXXDS .(əsənaqat) .AT TG, TD, 'NS 2E, 'Id ŁB' ŁI' DK' DE' 'XO CW' 'IO CH' CE' GB' GK' IE' IL' TO' WC' ,AĐ E2' ' ອວ TM; RM: AT, BE, BF, BJ, 'LT KC' **,**UA WD' KZ, BX' 'Z\ 'MZ 'YZ 'NX ,MA 'NA 'TS 'zn 'sn 'LL TR, 'WT 'LT 'XS 'IS 'ĐS 'ES 'ds RU, RO, າອກ AU , ST 'T4 WD' NZ' br' 'ZW 'XW , AM ΓΛ' rn' 'LT rz' LR, ON 'MW WK' WN' WG' רא' rc' 'ΩH KE' KG' Kb' KB' KS' 'SI 'NI 'TI HE, 'WĐ CH' CE' CD' ŁI' 1b, ID' CB' BY' BB' BC' BK' BX' ES' CY' CH' CN' CK' CN' CS' DE' DK' DN' DS' EE' ES' AI 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

ΙI

prepd. and biol. tested. intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTCCH4O(CHS)S2' d-CTCCH4(CHS)SNH' 3-BxCCHdcONHCRNH' CCH2COO' OH' CE3CeH4CHSOCONH'CH3(CHS)2OCONH' (CH3CHS)SN(CHS)3NHC2NH' ANHCONH' S-CTCeH#CH(CH3)OCONH' S-CTCeH#CHSCHSCHSOCONH' #-

APPLICATION: WO 2000-JP9160 20001222. . (asanaqat) SE' SN' LD' LG' LK' WC' NE' NT' LT' WK' 'TW CODEM: 'IO EI' EK' CH' CB' CK' IE' E2' DK' DE' 'AD CW' CE' CH'. **'**90 Bl, WD' TA :WA :MT ,UT RU, 'ZX KC' BK**'** , SA 'MZ 'nx 'NA , MA 'AZ 'zn TK, '១s , AU 'ZL 'LL 'MT 'LT 'TS 'XS 'IS ZE' 'ds **к**и, RO, 'La 'MW' NW WK' MA, MD, MG, 'LT rk' rc' 'ZW 'XW ra' rn' 'ST rk' 'ZX 'SI 'NI GW' HB' HO' ID' IT' CH, CB' KE' 1b, CE' CD' E2' YI' YN' YZ' BY' BB' BC' BK' BX' CY' CH' CN' CK' CN' CZ' DE' DK' DW' DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20701002 IA 1E97401002 OW PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasakı, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

PRIORITY: JP 1999-366313

CI

19991224.

PIXXD2.

pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCeH4O(CH5)52' 4-CTCeH4(CH5)5NH' 3-BTCEH4CONHCSNH' CEH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' ANHCONH' 2-CICCH4CH (CH3) OCONH, 2-CICCH4CH2CH2CH2OCONH, 4-

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title

methylphenyl)methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME) Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[1-[(2-chloro-4-dimethoxy-4-quinazolinyl)oxy]phenyl]

ЗД СОИСОВД ER

**SLN Files:** 

WE

ГC ЯS

CN

ВИ

347155-35-5 REGISTRY  $\Gamma$ 3

CAPLUS

ANSWER 53 OF 179 REGISTRY COPYRIGHT 2002 ACS

PAGE 2-A

PAGE 1-A

ΗŃ

as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

> S REFERENCES IN FILE CAPLUS (1967 TO DATE) S REFERENCES IN FILE CA (1967 TO DATE)

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

KG' KZ' MD' KN' L1' LW; KM: FL' BE' BL' B1' 'TS 'ZU 'SU 'DU 'AU 'ZT 'TT 'AT 'MT 'CT 'XS 'IS ʁถ' ឧD' ឧE' ឧC' PT, RO, LV, MA, MD, MG, MK, MW, MX, MZ, NO, NZ, PL, LT, LU, 'ST ГВ' rc' rk' EI' GB' GD' GE' GH' GW' HB' HO' ID' IT' IN' IS' 1B' KE' KG' KB' KK' BY' BB' BC' BK' BX' BZ' CH' CH' CH' CK' CC' DE' DK' DW' DZ' EE' EZ' Al 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa,

. p1990-374494 19991228; JP 2000-177790 2000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (Japanese). CODEN: PIXXD2. CE' CG' CH' CI' CW' CX' DE' DK' ES' EI' EK' GF' GB' GE' IE' II' TA' WC' VN, YU, ZA, AM, AM, AZ, UY, VV

CI

mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCCH40(CHS)S2' 4-CTCCH4(CHS)SNH' 3-BLCCH4CONHCRNH' CCH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHCRNH' ANHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

II

prepd. and biol. tested. intimal thickening inhibitors. Thus, the title claimed compd. II was

. \$221666I APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 **DIXXDS** 2E' rn' wc' . (asanaqat) SN, TD, TG, TR. Mr' MB' NE' NT' LL' CODEN: ŁI' DK' EZ' DE' 'IO EK' CH' CB' CK' IE' CX' CE' CW' CH' 'ອວ RU, TJ, TM; RW: AT, BE, KZ' WD' BX**ʻ** , ZA KC' , MA 'MZ 'NX ,AZ 'NΛ 'IS , AU 'ZL 'AT ,MT LT, 'TS 'XS '១ಽ ZE' 'dS **В**О, KO, 'LT 'ZW 'XW 'ON 'MW' NW WK' MA, MD, MG, ra' רח' LT, 'ST LR, rk' rc' 1b' KE' 'TI 'SI 'NI HE' HO' ID' 'WĐ 'H9 CE' ŁI' E2' CD' CB' YI' YN' YZ' BY' BB' BC' BK' BX' CY' CH' CN' CK' CN' CZ' DE' DK' DW' DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20701002 IA 1897401002 OW Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

EI

ЯA

pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCCH4O(CH5)52, 4-CLCCH4(CH2)2NH, 3-BrC6H4CONHCSNH, CCH5COO, OH, CE3CeH4CHSOCONH'CH3(CHS)2OCONH' (CH3CHS)5N(CHS)3NHC2NH' XNHCONH' S-CTCeH4CH(CH3)OCONH, S-CTC6H4CH2CH2CH2CCONH, 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

II

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N'-[1-[(2-CN341122-33-3 KECIZLKK ВИ ANSWER 54 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma 3$ 

methylphenyl)methyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

ЗД СОИСОВД ŁZ

C30 H33 N2 O2 ME

SR

CA, CAPLUS STN Files:  $\Gamma C$ 

Searched by: Mary Hale 308-4258 CM-1 12D16

PAGE 2-A

S KELEKENCES IN EITE CAPLUS (1967 TO DATE)

S KELEKENCES IN EITE CAPLUS (1967 TO DATE)

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

JP 1999-374494 19991228; JP 2000-177790 2000614.

APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; Mr, MR, UE, UL, PT, SE, SU, TD, TG, TR. (Japanese). CODEU: PIXXD2. CE' CC' CH' CI' CW' CX' DE' DK' E2' E1' EK' CF' CB' CK' IE' II' FA' WC' AN' AN' ZY' ZM' YM' YZ' BA' KG' KZ' WD' KN' L1' LW: KM: YL' BE' BE' B1' SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, 'xs 'IS '9S 2E' PT, RO, RU, SD, rc' rk' rb' ra' rt' rn' rn' wy' wd' wc' wk' wn' wm' wx' wz' no' nz' br' EI' CB' CD' CE' CH' CW' HB' HA' ID' IT' IN' IS' AB' KE' KC' KB' KS' BY' BB' BC' BK' BX' EX' CH' CH' CK' CA' CA' DE' DK' DW' DZ' EE' EZ' AZ 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 as remedies for diseases mediated by autophosphorylation of PDGF KELEKENCE 1: 132:35043 Preparation of quinazoline and quinoline derivatives

Searched by: Mary Hale 308-4258 CM-1 12D16

ξЯ

CH30' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, C1, F, CH3,

ΙI

intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCCH4O(CHS)S2' 4-CTCCH4(CHS)SNH' 3-BLCCH4CONHCRNH' CCH2COO' OH' CE3CeH4CHSOCONH'CH3(CHS)2OCONH' (CH3CHS)SN(CHS)3NHCRNH' XNHCONH' S-CICCH4CH (CH3) OCONH, S-CICCH4CH2CH2CH2CCONH, 4-

as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives prepd. and biol. tested.

. (asanaqat) SE, SW, TD, TG, TR. WT' WB' NE' NT' LL' rn' WC' CODEN: DE' DK' ES' EI' EK' GY' GB' GK' IE' 'ID **'**50 CX, CW' CH' CE' BE' Bl, , ZA KC' KZ' MD' BN' LY' LW: BM: BL' BE' BX**'** ,MA 'MZ 'AZ 'nX 'NA 'ZΩ 'ទ្ធប SK' ST' L1' .au .Au 'ZI ,TT TR, 'WI 'IS '9s 2E' 'ds RU, RO, 'Ld rn' 'ZW 'XW 'LT ГВ' 'ON 'MM 'NW WK' MA, MD, MG, rn' 'ST rk' rc' 1b' KE' 'SI 'NI HE' HO' ID' IT' CH' CE' CD' E2' ew' CB' ŁI' YI' YN' YZ' BY' BB' BC' BK' BX' BZ' CY' CH' CN' CK' CN' CZ' DE' DK' DW' DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20701002 IA 1867401002 OW Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Jakasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji;

APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 **PIXXD2** 

19991224.

ЯΑ

CA, CAPLUS

ANSWER 55 OF 179 REGISTRY COPYRIGHT 2002 ACS

**SIN Files:** 

3D СОИСОКD

CS6 H30 Ne 0e

347155-32-2 REGISTRY

 $\Gamma C$ SB

WE

ES

CN

ВИ

ГЗ

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3' OCHSCOOH:  $\chi$  = pererocycle, hererocyclylalkyl] and 4-CTCCH4O(CH5)52, 4-CLCCH4(CH2)2NH, 3-BrC6H4CONHCSNH, C6H5COO, OH, CE3CeH4CH5OCONH'CH3(CH5)2OCONH'(CH3CH5)5N(CH5)3NHC2NH' XNHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-CH3O' NOS; Y = 4-CH3C6H4CH5OCONH, 3-CTC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, ЯA

wefphjbyenhj)wefphj]-3-pyrrolidinyl}- (9CI) (CA INDEX NAME)

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-N'-[1-[(2-

**Ь**∀CE S−Y

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S KELEKENCES IN EITE CALTOS (1967 TO DATE)

S KELEKENCES IN EITE CA (1967 TO DATE)

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; (Japanese). CODEN: PIXXD2. ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. CE' CG' CH' CI' CW' CX' DE' DK' E2' EI' EK' GF' GB' GK' IE' II' TN' WC' AN' AN' ZY' ZM' YM' YZ' BA' KG' KZ' WD' KN' LN' LW: BM: YL' BE' BL' BN' SK' ST' IN' IW' IL' IZ' OF' OC' OC' OC' 'IS 'DS ZE' PT, RO, RU, SD, TE' T2' T1' T1' T1' MY' MD' MC' MK' MN' MN' MX' MZ' NO' NZ' BT' CD' CE' CH' CW' HB' HA' ID' IT' IN' IS' AB' KE' KC' KB' KS' BY' BB' BC' BK' BK' BK' CH' CH' CH' CK' CC' CK' DE' DK' DW' DK' EE' EC' Al 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH3O, NO2; A = 4-CH3C6H4CH2OCONH, 3-CLC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, Q-CLC6H4CH2OCONH, CH3COOCH3, CH3COOCH3, CH2COOCH3, CH3COOCH3, CH3COOCH3,

II

phatmaceutically acceptable sales are prepa. As remedies for diseases intimal thickening inhibitors. Thus, the title claimed compd. II was prepa. and biol. tested.

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF sa remedies for diseases mediated by autophosphorylation of PDGF as remedies for diseases mediated by autophosphorylation of PDGF as remedies for diseases mediated by autophosphorylation of PDGF receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu;

19991224. PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. **DIXXDS** (Japanese). SN, TD, TG, TR. ZE' MT' MK' NE' NT' bL' ra' wc' CODEN: DK' ES' EI' EB' GB' GB' IE' IL' CE' DE' CX' CW' CI' CH' 'ອວ BJ, TM; RM: AT, BE, RU, TJ, Ke' KS' WD' BX' , ZA ,MA 'MZ ,AZ 'nx ΊΝΛ 'ZΩ , au , Ar , TT 'LL TE, TM, 'LT 'TS 'xs 'IS '9s 'ES 'ds КU, RO, 'Ld 'Tđ 'ZX , AM 'AT 'LT WK' WN' WM' WX' WZ' NO' MD' MC' rn' 'ST LR, rk' rc' HO' ID' HB, CW' ŁI' E2' IT' IN' IS' 15' KE' KG' CH' CE' CB' ep' CY' CH' CN' CK' CO' DE' DK' DW' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20701002 IA 1E97401002 OW Макапізлі, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). РСТ Int. Appl Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu;

ЕI

**BA** 

OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCCH4O(CHS)S2' 4-CTCCH4(CHS)SNH' 3-BxCCH4CONHCRNH' CCH2COO' OH' CE3CeH4CHSOCONH'CH3(CHS)2OCONH'(CH3CHS)SN(CHS)3NHCRNH' ANHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-ЯA

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases

Urea, M-[4-[(6,7-dimethoxy-4-quinazoliny])oxy] bhenyl]-M-[1-[(2-max)]

ΙI

wefphlphenyl)=3-pyrrolidinyl] - (9CI) (CA INDEX NAME)

ЗД СОИСОКД ŁŞ

CS6 H3I N2 O4 WE

CN

**SIN Files:** 

ВИ

ГЗ

 $\Gamma C$ SE

CA, CAPLUS

Searched by: Mary Hale 308-4258 CM-1 12D16

**FACE 2-A** 

'ZU 'SU 'ĐU 'AU 'ZT

2 REFERENCES IN FILE CAPLUS (1967 TO DATE) 2 REFERENCES IN FILE CA (1967 TO DATE)

TC' TK' TB' T2' T1' TA' WB' WD' WG' WK' WN' WM' WX' WZ' NO' NZ' bF' EI' CB' CD' CE' CH' CW' HK' HN' ID' IT' IN' IS' 15' KE' KC' KB' KS' BY' BB' BG' BK' BK' BS' CY' CH' CN' CK' CN' CS' DE' DK' DM' DS' EE' ES' Al 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Міма, as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; TD, TG, TR. (Japanese). CODEN: PIXXD2. MT' MB' NE' NT' LT' SE' SN' DK' ES' EI' EK' GF' GB' GK' IE' IL' TO' WC' CE' CC' CH' CI' CW' CA' DE' KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, AN' XA' YE' SM' WY YZ' BX' SL, TJ, TM, TR, TT, 'XS 'IS '9S ZE' PT, RO, RU, SD,

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

CI

$$\begin{array}{c|c} & \mathcal{E}_{\mathcal{A}} & & \\ & \mathcal{A} & & \\ &$$

S-CICCH4CH(CH3)OCONH, S-CICCH4CH2CH2CH2OCONH, 4-CH3O' NOS: Y = 4-CH3C6H4CH5OCONH' 3-CTC6H4CH(CH3)OCONH' 4-EC6H4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, C1, F, CH3,

ΙI

intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3' OCHSCOOH: X = perecoacte' perecocactalland d-CTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-BLCeHdCONHCSNH' CEH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHCRNH' ANHCONH'

KEFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives prepd. and biol. tested.

APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 PIXXD2. 'TW SE' SN' ID' IG' IK' .(əsənaqat) WE' NE' NI' LI' CODEN: EB' CB' CB' IE' IL' 'XO DE' DK' ES' LI' 'IO CE' CW' CH' ce' KO' IT' LW; KM: AT, BE, KC' KZ' WD' , ZA 'NA BX**'** 'MA 'MZ 'nx ,AZ '១ន 'ZJ 'LL  $\mathtt{T}\mathtt{R}^{ullet}$ 'MT 'CI 'TS 'XS 'IS 'EE 'dS **'**NY RO, WK' WD' WG' rc' 'ZW 'XW MN' MM' , AM ľΛ' **′**۩٦ 'LT 'ST LR, ľK' 15' KE' 'SI 'NI 'TI 'H9 GW' HB' HO' ID' CE' CD' CB' CY' CH' CM' CB' CO' CZ' DE' DK' DW' BY' BB' BC' BK' BX' BS' DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20701002 IA 1867401002 OW Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF

EI

ЯΑ

19991224.

ŢΛ

mediated by autophosphorylation of PDGF receptors. Thus, the title bysrmscenfically acceptable salts are prepares for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and 4-CTCCH4O(CHS)SS' 4-CTCCH4(CHS)SNH' 3-BxCCH4CONHCSNH' CCH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH'(CH3CH5)5N(CH5)3NHC2NH' XNHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CH5CH5CH5OCONH' 4-AA

claimed compd. II was prepd. and biol. tested.

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(2,2,6,6-CN347155-30-0 REGISTRY ВИ

tetramethyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

ЗD СОИСОКD EZ

ANSWER 57 OF 179 REGISTRY COPYRIGHT 2002 ACS

CS H33 N2 O4 WE

 $\Gamma 3$ 

CA, CAPLUS STN Files:  $\Gamma C$ SR

ЭΜ

CI

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ÐΜ

S KEEEKENCES IN FILE CAPLUS (1967 TO DATE)

. 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; TD, TG, TR. WL, MR, NE, NL, PT, (Japanese). CODEN: PIXXD2 ZE' ZN' CA' DE' DK' E2' E1' EK' CB' CB' CB' IE' IL' PN' WC' CI' CW' CE' CG' CH' BE' KG' KZ' WD' BN' L1' YZ' BX' ,MA ,WZ BE' B1' TA : WA : MT SK' ST' L1' LW' 'IS RU,  $\mathtt{T}\mathtt{R}^{ullet}$ 'ĐS 'as 'ຊກ 'ຮກ ne' ,AU 'ZI 'TT ZE' WY' WD' WC' WK' WN' WM' רח' רת' LR, LS, LT, NO' NZ' bF' 'ZW 'XW CD' CE' CH' CW' HB' HO' ID' IT' IN' IS' 15' KE' KC' KB' KB' KZ' BY' BB' BC' BK' BK' BK' CH' CH' CH' CH' CC' DE' DK' DW' DS' EE' ES' A1 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 as remedies for diseases mediated by autophosphorylation of PDGF KEEEKENCE 1: 132:55649 Preparation of quinazoline and quinoline derivatives

Searched by: Mary Hale 308-4258 CM-1 12D16

S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCHSOCONH' 4-CH30' NO5' Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECeH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3,

II

pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCH2COOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-BLCeHdCONHCRNH' CEH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHCRNH' ANHCONH'

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives prepd. and biol. tested. intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as

APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 PIXXD2. WC' SE' RN' LD' LC' .(Japanese). .AT NE' NT' MB, CODEN: 'La 'TW EB' CB' CB' IE' IL' DK' ES' EI' DE' 'XO 'ID CE' CW, '90 'HD ,SA TM; RM: AT, BE, , LT RU, KZ' WD' KC' BX, ,MA 'MZ 'NA 'ZN ,AZ 'NX 'TS 'LI 'IS , AU 'ZJ 'LL TR'WT 'XS 'ĐS 2E' 'ds ,UA KO, WK' **'**\1 'DW 'UW 'YW 'LT LR, rc' 'ZW 'XW 'MM' MM rn' 'ST rk' 1b, HB' HO' ID' IF' CW' cH, CD' KE' 'SI 'NI CE' CB' ŁI' EE' CY' CH' CN' CK' CN' CZ' DE' DK' DW' BY' BB' BC' BK' BX' BZ' DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20701002 IA 1897401002 OW Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). PCT Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF

CI

19991224.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

CE3CeH4CHSOCONH'CH3(CHS) 2OCONH' (CH3CHS) SN(CHS) 3NHC2NH' ANHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CH5CH5CH5OCONH' 4-CH30' NO5' V = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, C1, F, CH3,

pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3' OCHSCOOH:  $\chi = \text{perecocycle}$ , perecocyclylalkyl] and d-CTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-BICHdCONHCRNH' CEH2COO' OH'

mediated by autophosphorylation of PDGF receptors. Thus, the title

ча

claimed compd. II was prepd. and biol. tested.

CN

STEREOSEARCH ER (byenylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N-[(35)-1-

ΙI

341122-59-7 REGISTRY ВИ

ANSWER 58 OF 179 REGISTRY COPYRIGHT 2002 ACS

CA, CAPLUS

**SLN Files:** 

CS8 HS6 N2 O4

 $\Gamma 3$ 

AD

Absolute stereochemistry.

OeM

MeO.

ЯS

WE

ΑA

receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; CODEN: bixxD5 . (əsənaqat) TD, TG, TR. L' SE' SN' Mr' MB' NE' NT' ŁI' DE' 'AD CW' 'ID CH' **'**90 EB' GB' GB' IE' IL' FR' WC' DK' ES' CE' **'**08 KC' BX' , ZA 'MZ 'NX BE' TJ, TM; RW: AT, BE, KZ' WD' ,MA 'YZ 'NΛ 'ZN 'ន្ធា **1**00 , AU TR'MT 'rı 'ns 'XS 'IS '9S מט, 'ZI 'LL ZE' 'ds ко' br' 'ZN 'ΛΊ 'ST ON 'ZW 'XW 'MW MY' MD' MC' MK' MN' rn' 'LT ΓK, ΓK' rc' KB' 15' KE' KC' Kb' GW' HB' HO' ID' IT' IN' IS' CH' CD' CE' EI' CB' BY' BB' BC' BK' BX' BZ' CH' CH' CH' CK' CC' DE' DK' DW' DZ' EE' ES' AI 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890

9В ₽Я БЯ

## 190000Z 06/77I-000Z 95 ;82Z1696I \$4\$\$7E-9991 TD

OəM Ι OeM ЗЯ

ΙI OəM OeM NO2 — co — ин--HN

OCHNCOOCH3, OCHNCOOH; Y = heterocycle, heterocyclylalkyl and d-CTCeHdO(CHS)S2 d-CTCeHd(CHS)SNH' 3-BxCeHdCONHCRNH' CEH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHCRNH' LNHCONH' S-CTCCH4CH(CH3)OCONH' S-CTCCH4CHSCHSCHSOCONH' 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCEH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

prepd. and biol. tested. Thus, the title claimed compd. II was intimal thickening inhibitors. mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

Searched by: Mary Hale 308-4258 CM-1 12D16

ЯA

T9

Absolute stereochemistry.

CA, CAPLUS STN Files: PC

SE

CS8 HS6 N2 O4 ME

STEREOSEARCH EQ

(byenylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-[(3R)-1-CN

341122-58-6 RECISTRY ВИ

COPYRIGHT 2002 ACS YNRMEK 29 OF 179 REGISTRY  $\Gamma$ 3

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3' OCHSCOOH:  $\chi = \text{perecocyc}$ e' perecocyc $\chi$ lalk $\chi$ land d-CTCeH40(CH5)S2' d-CTCeH4(CH5)SNH' 3-BxCeH4CONHCRNH' CeH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC2NH' ANHCONH' S-CTCeH4CH(CH3)OCONH' S-CTCeH4CHSCHSCCOONH' 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH'

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

CI

19991224.

APPLICATION: WO 2000-JP9160 20001222. PRIORITY: JP 1999-366313 PIXXDZ. .(əsənaqab) ZE' WC' CODEN: TR. 'DL 'GL 'NS WE' NE' NI' LL' Wr' רח' E2' 'ID CE' ŁI' DK' 'AO CH' Bl, EK' CH' CB' CK' IE' IL' DE' CW' **'**90 BE' 'LT 'ZX 'zn TM; RW: AT, **В**О, WD' BX**'** , ZA 'YZ 'NA KC' ,MA ,WZ 'NX 'នព TR**'**∏d 'MT 'TS 'IS ZE' KO, LT, 'ZN ,AU , LT 'XS '9S aD, **'**Nצ 'ZJ 'LL 'ZX 'ON 'XW WK' MD' MG' , AM rn' 'LT 'ST  $\Gamma K$ rk' KK' 'ZW 'MM' MM' 'AT rc' 'SI 'NI HO' ID' IF' CH' EI' 'za 1ar CW' HB' CE' cB' cD' 'SE EE' CY' CH' CN' CB' CO' DE' DK' DW' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, DESIGNATED STATES: W: AE, AG, AL, AM, .qq 321 ,20701002 IA 1867401002 OW PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S KEFERENCES IN FILE CAPLUS (1967 TO DATE)

JP 1999-374494 19991228; JP 2000-177790 20000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; . (asanaqat) TD, TG, TR. CODEN: BIXXDS: 'NS ZE' 'Ld WP' WB' NE' NT' 'AD, DE' CW' 'IO CH' 'ອວ CE' EI' EK' GB' GB' IE' IL' IN' MC' DK' ES' BE' B1' 'LT MD, RU, BX' 'Z∀ 'YZ 'NX TM; RM: AT, BE, KC' KS' ,MA ,WZ 'NN 'TS 'IS 'ອດ 'TT TR, '១s 2E' 'ds צח, KO, 'zn 'sn AU , ST 'MT 'CT 'XS 'La NZ' br' 'ON LV, MA, MD, MG, MK, MW, MX, MZ, rn' LR, ΓK' rz' rı' GD' GE' GH' GW' HB' HO' ID' IT' IN' IS' 25' KE' KG' KB' KK' EI' CB' BY' BB' BC' BK' BX' BZ' CY' CH' CN' CK' CO' CZ' DE' DK' DW' DZ' EE' EZ' WI SOO10705, 1068 pp. DESIGNATED STATES: W: AE, AC, AL, AM, AT, AU, AZ, receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Takayuki; Miwa, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

$$\begin{array}{c|c} & & & & \\ & &$$

ЬЧ

εЯ

intimal thickening inhibitors. Thus, the title claimed compd. II was mediated by autophosphorylation of PDGF receptors, particularly useful as bysxwscenfics]] A scceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeHdO(CHS)SS' d-CTCeHd(CHS)SNH' 3-BxCeHdCONHCRNH' CeH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' ANHCONH' S-CJCeH¢CH(CH3)OCONH' S-CJCeH¢CHSCHSCHSOCONH' ¢-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, C1, F, CH3,

98

·II

prepd. and biol. tested.

Takasakı, Kotaro; Kusaka, Hideakı; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXD2. SN, TD, TG, TR. ZE' NE' NT' bL' rn' wc' wr' wb' .(əsənaqat) 'ID ŁI' 'AD CE' EK' CF' CB' CK' IE' IL' DK' ES' DE' CW, CH' **'**90 Bl' BE' 'MZ TM; RM: AT, BE, 'LT ВU, WD' , SA 'ZX KC' BX**ʻ** ,MA 'YZ ΥΩ, 'ΝΛ 'zn 'TS , au , at 'LL TK, 'MT 'CI 'XS 'IS '9S ZE' 'ds RU, KO, 'Ld 'ZW 'XW '9W 'UM 'WW 'ZX 'MM' WM' WK' rn' rn' LT, 'ST rg**'** rk' rc' IT' CD' 15' KE' KC' HB' HO' ID' CE' 'SI 'NI CW, CH' CB**'** ŁI' CY' CH' CN' CB' CO' DE' DK' DW' AT, AU, AZ, BA, BB, BG, BR, BY, BZ, WO 2001047931 A1 20010705, 126 pp. DESIGNATED STATES: W: AE, AG, AL, AM, PCT Int. Appl. Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan).

19991224.

ΙĐ

ЯΑ

OəM

pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl] and d-CTCeHdO(CHS)S2' d-CTCeHd(CHS)SNH' 3-B⊾CeHdCONHCRNH' CeH2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHC8NH' XNHCONH' S-CICCH4CH (CH3) OCONH' S-CICCH4CHSCHSOCONH' 4-Title compds. [I; X = N, CH; R3, R4, R5, R6 independently 4-FC6H4CH2OCONH, CH30, NO2; A = A - CH3C6H4CH2OCONH, 3-ClC6H4CH(CH3)OCONH, 4-FC6H4CH2OCONH, CH30, C

II

claimed compd. II was prepd. and biol. tested. Thus, the title mediated by autophosphorylation of PDGF receptors.

ANSWER 60 OF 179 REGISTRY COPYRIGHT 2002 ACS

Urea, M-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-N'-[2-(1-CN

piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

CA, CAPLUS

Searched by: Mary Hale 308-4258 CM-1 12D16

ЗД СОИСОВД EZ

C54 H58 N6 O6

**SLN Eiles:** 

WE

ВИ

 $\Gamma$ 3

AD

 $\Gamma C$ 

SE

PAGE 2-A

CH2

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S KELEKENCES IN LITE CAPINS (1967 TO DATE)
S KELEKENCES IN LITE CA (1967 TO DATE)

JP 1999-374494 19991228; JP 2000-177790 2000614. APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224; (Japanese). CODEN: PIXXDZ. TD, TG, TR. bl' SE' SN' Wr' WB' NE' Nr' DK' E2' LI' LK' CB' CB' IE' IL' TO' WC' CX' DE' CW' CE' CG' CH' CI' BX**'** KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, , SA , MA , WS 'עא אע 'LT 'TS 'XS 'IS 'ĐS aD, TM, TR, TT, TZ, UA, UG, US, UZ, 2E' MP' MD' MC' MK' MN' MX' MZ' NO' NZ' bF' rn' rn**'** rk' ra' LT, HO' ID' IT' IN' IS' 95' KE' KG' KB' KK' KZ' HB, CD' CE' CH' CW' BY' BB' BC' BK' BX' BZ' CY' CH' CN' CK' CN' CZ' DE' DK' DW' DZ' EE' EZ' AI 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, Atushi (Kirin Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2001047890 receptors. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Такауикі; Міма, as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

Œ

$$\begin{array}{c|c} & & & & & & & & & \\ & & & & & & & & \\ & & & & & & & \\ & & & & & & & \\ & & & & & & & \\ & & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & & \\ & & & & & \\ & & & & & \\ & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & \\ & & \\$$

Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, CH2O, NO2; A = 4-CH3C6H4CH2OCOH, 3-CLC6H4CH(CH3)OCOH, CH2COOCH3, OCH2COOCH3, OCH2COOH, Y = heterocycle, heterocyclylalkyl and A-ClC6H4CH2CH2COOCH, Y = heterocycle, heterocyclylalkyl and A-ClC6H4CH2CH2COOCH, Y = heterocycle, heterocyclylalkyl and A-ClC6H4CH2CH2CH2CH3COOH, A-ClC6H4CH4CH2CH3COOH, Y = heterocycle, heterocyclylalkyl and A-ClC6H4CH2CH2CH3COOH, Y = heterocyclylalkyl and A-ClC6H4CH2COOH, Y = heterocycle, hete

II

pharmaceutically acceptable saits are prepd. as remedies for diseases intimal thickening inhibitors. Thus, the title claimed compd. II was prepd. and biol. tested.

REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives as remedies for diseases mediated by autophosphorylation of PDGF as remedies for diseases mediated by autophosphorylation of PDGF as remedies for diseases mediated by autophosphorylation of PDGF are receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; mediated by autophosphorylation of PDGF are receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; mediated by autophosphorylation of PDGF are receptors.

19991224: PRIORITY: JP 1999-366313 APPLICATION: WO 2000-JP9160 20001222. PIXXD2. rn' wc' . (asanaqat) SN, TD, TG, TR. ZE' Mr' MB' NE' NT' LL' DK' EZ' EI' DE' 'ID EK' CH' CB' CK' IE' CE' CX' CW' 'ອວ CH' RU, TJ, TM; RW: AT, BE, KZ' WD' KC' BX' , ZA 'NX ,MA 'MZ '∀Z 'NΛ TM, TR, 'CI 'TS 'XS 'IS '9S 2E' RU, 'ZL 'LL 'ds WD' WC' WK' WN' WM' WX' WZ' NO' , AM 'ΛT rn' 'LT 'ST LR, rk' rc' IF' IN' IS' 1B' KE' KG' E2' HE' HO' ID' CW' CH, CE' CD' CB' CY' CH' CN' CK' CN' CZ' DE' DK' DW' BY' BB' BC' BK' BX' BZ' DESIGNATED STATES: W: AE, AG, AL, AM, WO 2001047931 A1 20010705, 126 pp. иакапізһі, Satoshi (Куома Накко Кодуо Со., Ltd., Japan). РСТ Int. Appl. Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu;

ЯA

CA, CAPLUS **SIN Files:** ГC

SE**GA** 

C53 H58 Ne 0e ME

ЗД СОИСОВД E2

S-nitrophenyl]- (9CI) (CA INDEX NAME) Urea, N-[2-(diethylamino)ethyl]-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-

СИ

346467-60-5 REGISTRY ВИ

COPYRIGHT 2002 ACS ANSWER 61 OF 179 REGISTRY ГЗ

claimed compd. II was prepd. and biol. tested. mediated by autophosphorylation of PDGF receptors. Thus, the title pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3' OCHSCOOH: X = perecocycle, perecocyclylalkyl] and 4-CJCeH4O(CHS)SS' 4-CJCeH4(CHS)SNH' 3-BICEH4CONHCSNH' CEH2COO' OH' CE3CeH4CH5OCONH, CH3 (CH2) 50CONH, (CH3CH2) 2N (CH2) 3NHCSNH, YNHCONH, S-CTCeH4CH(CH3)OCONH, 2-CTC6H4CH2CH2CH2OCONH, 4-

CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, AA

S REFERENCES IN FILE CAPLUS (1967 TO DATE) S REFERENCES IN FILE CA (1967 TO DATE)

KB' KZ' Kb' 'SI 'NI 'TI 'ΩH HK, CH' CE' CD' 'WĐ BY' BB' BC' BK' BX' BZ' CY' CH' CN' CK' CN' CZ' DE' DK' DW' DZ' EE' EZ' Al 20010705, 1068 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, PCT Int. Appl. WO 2001047890 Atushi (Kirin Beer Kabushiki Kaisha, Japan). тесертогз. Sakai, Teruyuki; Senga, Teruhumi; Furuta, Тakayuki; Міма, as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 1: 135:92649 Preparation of quinazoline and quinoline derivatives

'ZX KG' **,** บЯ WD' BX' , SA MZ '∀Z 'nx BE' B1' TO, TM; RW: AT, BE, ,MA 'NA ne'  $_{ au}$ LT 'TS 'XS 'IS '១s **'**Nצ 'zo 'so TM, TR, KO, ,AU  $^{\prime}\mathrm{Z}\mathrm{I}$ 'TT ZE' 'as 'Id 'ZN 'ZW WD' , AM **'**\7 'LT 'ST rk' rc' 'ON WC' WK' WN' WM' WX' rn' rk' KG' KE' 1b, ID' CB'

 $_{
m LL}$ CODEN: BIXXDS .(əsənaqat) TD, TG, TR. SE' SN' Mr' MB' NE' NT' EI' EB' CB' DE' 'XD CW' 'IO CH' **'**90 CE' GB, GR, IE, IT, LU, MC, DK' ES'

APPLICATION: WO 2000-JP9157 20001222. PRIORITY: JP 1999-377486 19991224;

JP 1999-374494 19991228; JP 2000-177790 20000614.

OeM ςЯ 9 Y Вđ ξЯ

OəM Ι

OeM OəM NOS - CO -- NH -HN

Thus, the title claimed compd. II was intimal'thickening inhibitors. mediated by autophosphorylation of PDGF receptors, particularly useful as pharmaceutically acceptable salts are prepd. as remedies for diseases OCHSCOOCH3, OCHSCOOH; Y = heterocycle, heterocyclylalkyl and d-CTCCH4O(CHS)S2' d-CTCCH4(CHS)SNH' 3-BxCCH4CONHCRNH' CCH2COO' OH' CE3CeH4CHSOCONH'CH3(CHS)POCONH' (CH3CHS)SN(CHS)BNHCRNH' ANHCONH' S-CTCeH#CH(CH3)OCONH' S-CTCeH#CH5CH5CH5OCONH' #-CH3O' NOS: V = 4-CH3CeH4CH5OCONH' 3-CTCeH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, CL, F, CH3,

II

Searched by: Mary Hale 308-4258 CM-1 12D16

prepd. and biol. tested.

ЯΑ

CI

'ZW 'XW 'MW ,AM **'**\7 rk' MD' WG' WK' WN' רח' LT, 'ST LR, rc' CH' CW' HB' HO' ID' IT' IN' IS' ŁI' 15' KE' KG' CE' CD' GB' E2' YI, AU, AZ, BA, BB, BG, BY, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DESIGNATED STATES: W: AE, AG, AL, AM, WO 2001047931 A1 20010705, 126 pp. .iqqA .jni TD4 Nakanishi, Satoshi (Kyowa Hakko Kogyo Co., Ltd., Japan). Takasaki, Kotaro; Kusaka, Hideaki; Yano, Hiroshi; Suzuki, Chiharu; receptors. Ueno, Kimihisa; Ogawa, Akira; Ohta, Yoshihisa; Nomoto, Yuji; as remedies for diseases mediated by autophosphorylation of PDGF REFERENCE 2: 135:76901 Preparation of quinazoline and quinoline derivatives

DE'

BX'

'IS

CX,

, ZA

**'**9S

SE, SN, TD, TG, TR.

DK'

KC'

'XS

ŁI'

'CI

E2'

'TS

KZ' WD'

PRIORITY: JP 1999-366313

TM; RM: AT, BE,

'ZJ

EB' GB' GB' IE' IL'

'LL

. (asanaqat)

LT,

TR,

КU,

'MT

19991224. APPLICATION: WO 2000-JP9160 20001222. PIXXD2. WE' NE' NT' LT' Wr'

CE'

'NΛ

'La

BJ,

'ZN

'SN

**'**90

'nx

RO,

 $\Lambda$ J

CH'

'AZ

RU,

'IO

'MZ

'as

CW'

,MA

ZE'

И ́

CI

ВS

OCHSCOOCH3' OCHSCOOH: X = perecocycle, perecocyclylalkyl] and d-CTC@HdO(CHS)SS' d-CTC@Hd(CHS)SNH' 3-BxC@HdCONHCRNH' C@H2COO' OH' CE3CeH4CH5OCONH'CH3(CH5)2OCONH' (CH3CH5)5N(CH5)3NHCRNH' ANHCONH' S-CICCH4CH(CH3)OCONH' S-CICCH4CHSCHSCHSOCONH' 4-CH3O' NOS: Y = 4-CH3CeH4CH5OCONH' 3-CTCEH4CH(CH3)OCONH' 4-ECEH4CH5OCONH' Title compds. [I; X = N, CH; R3, R4, R5, R6 independently = H, Cl, F, CH3, ЯA

claimed compd; II was prepd. and biol. tested. Thus, the title mediated by autophosphorylation of PDGF receptors. pharmaceutically acceptable salts are prepd. as remedies for diseases

COPYRIGHT 2002 ACS ANSWER 62 OF 179 REGISTRY  $\Gamma$ 3

586372-08-5 REGISTRY ВИ

ΙI

Urea, N-[2-chloro-4-[(7-hydroxy-6-methoxy-4-quinazolinyl)oxy]phenyl]-N'-CN

(CA INDEX NAME) wefhyl- (9CI)

ЗД СОИСОВД EZ

CIL HIZ CT NO OO ME

CA, CAPLUS, TOXCENTER **SLN Files:** ГC SE

269xcy6q ph: Wary Hale 308-4258 CM-1 12D16

0

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

CI 19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 CODEN: BIXXDS' . (asanaqat) TG. GY' GB' GE' IE' IL' FN' WC' WF' WE' NF' NF' EL' SE' SN' EI' EB' IM; EM; FI, BE, BJ, CF, CG, CH, CI, CM, CY, DE, WD' 'LT RU, , ZA , MA 'MZ 'YZ 'NX 'NA 'ZO 'SO , AU 19N 'ZI 'LL ₽L, ZE' RO, RU, SD, LT, '១ន 'ZN 'ON 'XW 'MW 'NW WK' WC' WD'  $\Gamma L$ 'SI KZ' TC' TK' TB' Kb' KB' 16' KE' 'NI 'TI 'ST KC' ID' DK' DW' EE' ES' EI' GB' GD' GE' GH' CH' CN' CB' CO' CT' DE' DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, .qq 802 Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 Al 20000727, and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

APPLICATION: WO 2000-JP255 20000120.

of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; R1-3 represent each H,

**BA** 

tested. CH; Z = CH; RI, R4, R5,R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal gjklj or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or

CN\$89372-07-4 REGISTRY ВИ PN2MER 63 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma 3$ 

chlorophenyl]-N, N-dimethyl- (9CI) (CA INDEX NAME) Urea, N'-[4-[[7-(3-bromopropoxy)-6-methoxy-4-quinazoliny1]oxy]-2-

ЗД СОИСОКД EZ

ЯS AD CSI HSS BL CI Nd Od WE

**2LN Liles:** CY' CYPLUS, TOXCENTER ГC

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS' . (asansqst) TD, TG. EI' EK' GB' GB' GB' IE' IL' PA' WC' WF' WB' NE' NF' BL' SE' SA' E2' DK' CX' CI' CW' CH' IM; EM: FI' BE' BE' CE' CC' 'LL RU, WD' 'NA 'NA 'ZN 'sn , MA 'MZ 'YZ ne' , AU 'ZL 'LL TR,MT 'CI 'TS RU, PT, RO, ₽Ľ, 'XW 'IS 'MW 'NW WK' WC' 'ĐS ZE' 'ds 'ZN 'ON WD' , AM rl' KE' KB' KZ' PC' 'SI 'NI 'TI ID' 'ST rk' rg' Kb' KG' 1b, **'**NH DK' DW' EE' ES' LI' GB' GD' GE' CH' CN' CB' CO' CS' DE' 'AD CH' YE' AF' BE' BE' BE' BE' BE' .qq 802 DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:132735 Preparation and anti-tumor, anti-atherosclerosis,

CI

CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal gjkyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H,

Ι

ЗД СОИСОКД ES (CY INDEX NAME) dimethyl- (9CI) Orea, N'-[2-chloro-4-[(7-hydroxy-6-methoxy-4-quinazolinyl)oxy]phenyl]-W,N-СИ 586372-06-3 REGISTRY ВИ ANSWER 64 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma 3$ 

CI8 HIL CI NO OO WE

ЯS

**BA** 

**SLN Eiles:** ГC

CA, CAPLUS, TOXCENTER

wеЅи—'Ċ-CJ OeM

0

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

Searched by: Mary Hale 308-4258 CM-1 12D16

Вς  $N - CO - N - B_{TT}$ БŢ ОĮЯ 6Я В6 ςЯ

CODEN: BIXXD5'

,AU

'XW

KE'

TA; WA ;MT

'ZJ

'MW

1b,

Cn' CZ' DE'

'TT

'NW

'SI

DESIGNATED STATES: W:

PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493

'ຮ∩

'ZN

Kb'

BE'

'ອດ

'ON

KC'

DK'

GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN,

'חג 'אא 'צח

LT,

RO,

DW' EE' ES' EI' CB' CD' CE'

BE' B1' CE' CC'

₽Ľ,

KB'

APPLICATION: WO 2000-JP255 20000120.

CH'

'AZ

**У**ПУ

KZ' rC' rK' rB'

AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR,

PCT Int. Appl. WO 2000043366 Al 20000727,

CI' CW'

,MA

2E'

'ST

'M7

2D'

CX,

**1**2∀

**1**98

'LT

CH'

'IS

רח'

CW'

 $\mathbb{F}^{4}$ ВЗ  $\mathbb{R}^7$ Вβ

19990521; TP 1999-253624 19990907.

'LL

TR,

WK'

'NI

·(១៩៦ជឝ៤៤)

EI' EB' CB'

RU,

'MT

WC'

'TI

CH' CN' CB'

Beer Kabushiki Kaisha, Japan).

'GW

1 C.J.

WD'

ID'

ЯA

EI

TD, TG. E2'

**1**2X

'TS

,AM

'OH

BX' CY'

.qq 802

DK'

KC'

'XS

'AT

**'**8H

tested. CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X = xcompns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal stkyl or alkylcarbonyl, and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [1; X and Z represent each CH or N; R1-3 represent each H,

CS HS3 BL ES Nd O2 WE 3D CONCORD EZ (CA INDEX NAME) methoxyphenyl]-N'-(2,4-difluorophenyl)- (9CI)Urea, M-[4-[[7-(3-bromopropoxy)-6-methoxy-4-quinazoliny1]oxy]-2-CNS893\I-66-I KECIZIKK КИ ANSWER 65 OF 179 REGISTRY COPYRIGHT 2002 ACS ГЗ

CA, CAPLUS, TOXCENTER STN Files: ГC AD SE

FAGE 2-A

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: .(Japanese). DK' ES' EI' EK' CB' CB' CB' IE' IL' TN' WC' WT' WB' NE' NT' 51' SE' SN' MD' Kn' Ln' LW: KM: YL' BE' BE' Bn' CE' CC' CH' CI' CW' CX' DE' 'YA 'ZA 'MA 'WZ 'AZ 'UY 'NV 'ZU 'SU ,əu ,Au ,IT 'LL TJ, TM, TR, WD' WC' WK' NO' NZ' bF' bL' BO' BN' SD' SE' SC' SI' 'XW 'MW 'NW KE' KE' KZ' TC' TK' TE' TR' TR' TR' ID' IT' IN' IS' KC' 1b' KE' DW' EE' ES' EI' GB' GD' GE' GH' GW' DK' CH' CN' CB' CO' CZ' DE' YE' YT' YM' YI' YN' YY' BB' BB' BB' BB' DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

EI

and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sjkyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all Title compds. [1; X and Z represent each CH or N; R1-3 represent each H,

Ι

tested. CH: Z = CH: RJ, RJ, RJ, RJ-RJ0 each an H: RJJ = 3.5-F2C6H3) was prepd. and optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each

duinazolinyl)oxy]-2-methoxyphenyl]- (9CI) (CA INDEX NAME) Urea, N-(2,4-difluorophenyl)-N'-[4-[(7-hydroxy-6-methoxy-4-CN586371-98-0 REGISTRY ВИ COPYRIGHT 2002 ACS

ЗД СОИСОКД EZ

C53 HI8 E5 N4 O2 WE

ГЗ

SE

CA, CAPLUS, TOXCENTER SIN Files:  $\Gamma C$ 

YNZMEK 00 01 179 REGISTRY

FAGE 1-A

Searched by: Mary Hale 308-4258 CM-1 12D16

I BEEEBENCES IN EITE CAPINS (1964 TO DATE)

I BEEEBENCES IN EITE CA (1964 TO DATE)

CI 19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: . (asansqst) GB' GK' IE' IL' TN' WC' WT' WK' NE' NT' LL' SE' EI' EB' CB' WD' CX' CI' CW' BE' BE' B1' CE' CC' TA : WA : MT CH' TJ, RU, **'**១៣ 'Z\ ,MA 'MZ **,**AS 'ΩX 'NA 'ZΩ 'នព , AU 'ZI 'WI 'LI 'LL TR, '9s **В**И, br' 'ON 'XW ZE' ap, RO, 'Lã 'ZN 'MW 'NW WK' WC' WD' KB' KC' KE' 'TI 'ST רא' רצ' KZ' TC' Kb' 1b, 'SI 'NI ID' 'OH Cn' Cz' DE' DW' EE' ES' EI' GB' GD' GE' DK' , AD CH' CN' CB' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, DESIGNATED STATES: W: .qq 802 PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:132835 Preparation and anti-tumor, anti-atherosclerosis,

ЯΑ

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl), pharmaceutically acceptable salts and solvates, and medicinal analkyl), pharmaceutically acceptable salts and solvates, and medicinal and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = tested.

CN Orea, W-[4-[[7-(3-bromopropoxy)-6-methoxy-4-quinazolinyl]oxy]-2-CN Orea, W-[4-[[7-(3-bromopropoxy)-6-methoxy-4-quinazolinyl]oxy]-2-

269xcy6q pl: Mary Hale 308-4258 CM-1 12D16

methoxyphenyl]-N'-propyl- (9CI) (CA INDEX NAME)

E2 3D CONCORD

WE CS3 HS1 Br N4 O2

SR CA

TC SIN Files: CA, CAPLUS, TOXCENTER

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BEEEBENCES IN EITE CAPINS (1967 TO DATE)

I BEEEBENCES IN EITE CA (1967 TO DATE)

CI 19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 .(əsənsqst) APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: .pr , TG. EI' EK' CH' CB' CK' IE' IL' TO' WC' WT' WK' NE' NT' BL' SE' SN' DK' ES' BE' TA :WA :MT 'LT **,** עЯ BE' B1' CE' CC' CH' CI' CW' CK' DE' WD' 'MZ ,AU 'TT AZ, BY, AZ 'UY 'NV 'ZU 'SU ,MA **'**១៣ 'ZI TR, 'MT 'LI 'ZN ZE' 'ds **В**И, 'XW 'NW 'IS '9S PL, PT, RO, 'ON 'MW WK' '9W WD' 'ST LR,  $\Gamma K$ Kb' KB' KZ' PC' KC' KE' 'SI LT, LU, lb, 'NI DW' EE' ES' EI' GB' GD' DK' DE' CE' CH' CW' CH' CN' CB' CD' CZ' DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 Al 20000727, and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

269xcy6q pl: Mary Hale 308-4258 CM-1 12D16

ЯA

Title compds. [1; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal aralkyl], pharmaceutically acceptable salts and solvates, and medicinal and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = tested.

Dropyl- (9CI) (CA INDEX NAME)

RM 286371-96-8 REGISTRY

CM Urea, N-[4-[(7-hydroxy-6-methoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N'
RM 286371-96-8 REGISTRY

CM Urea, N-[4-[(7-hydroxy-6-methoxy-4-quinazolinyl)oxy]-2-methoxyphenyl]-N'-

WE · CSO HSS N₹ O? E2 3D CONCOKD

SK CV

PC SIN Files: CA, CAPLUS, TOXCENTER

И

MeO MeO MeO MeO

CI

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BEFERENCES IN FILE CAPLUS (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. (Japanegel) CODEN: BIXXDS: .or ,ur CB' CK' IE' IL' TO' WC' WT' WK' NE' NT' L' SE' EI' EB' CB' DK' 'AO 'IO BE' B1' CE' CC' CH' BE' TM; RW: AT, CW' 'LT **'**08 'UW '੧ਸ਼ 'MZ ,2A ,AZ TW, ,MA 'UY 'NV 'ZU 'នព 'ອດ , AU 'ZI 'LL TR, 1CJ '9S ZE' 'ds YO, KO\* 'La **ЪГ** 'ZN 'ON 'XW 'MW 'NW WK' MG, WD' , AM 'ST רא' KY' TC' TK' KK' Kb' KC' KE' ıΒ, 'SI 'NI 'TI ID' 'OH DK' DW' EE' ES' LI' CB' CD' CE' CH' CH' CN' CB' CN' CZ' DE' BX' CY' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, DESIGNATED STATES: W: .qq 80S PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

.beteat CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X = compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sjkyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H,

CN586371-93-5 REGISTRY ВИ PARMER 69 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma 3$ 

cytorophenyt] - N' - (2, 4-diftuorophenyt) - (9CI)(CA INDEX NAME) Urea, N-[4-[[7-(3-bromopropoxy)-6-methoxy-4-quinazolinyl]oxy]-2-

CS2 HS0 Bt CT ES N4 O4 WEЗД СОИСОКД EZ

ЯΑ

CA, CAPLUS, TOXCENTER **2LN EIJes:**  $\Gamma C$ A) SE

PAGE 2-A

Ŧ

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BELEBENCES IN EITE CAPIUS (1967 TO DATE)

I BELEBENCES IN EITE CA (1967 TO DATE)

CI 19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 .(asansqst) CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. DK' ES' EI' EK' CB' CB' CB' IE' IL' FN' WC' WF' WK' NE' NF' EL' SE' SN' KG' KZ' WD' BN' L1' LW: BM: FL' BE' BE' B1' CE' CG' CH' CI' CW' CX' DE' TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, 'LT TJ, TM, TR, ZK' ZF' WA' WA' WX' NO' NZ' BT' BL' BO' BA' SD' SE' SC' SI' WD' WC' WK' Kb' KB' KZ' TC' TK' TB' T2' TL' TO' IS' 16' KE' KG' HB' HO' ID' IF' IN' DW' EE' ES' EI' GB' GD' GE' GH' GW' BX' CY' CH' CM' CK' CO' CZ' DE' DK' YE' YE' BA' BA' YA' YA' BY' BB' BC' BB' .qq 80S DESIGNATED STATES: W: Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 Al 20000727, and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

.bəjsəj CH; Z = CH; RI, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X = compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal stkyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [1; X and Z represent each CH or N; R1-3 represent each H,

Ι

Urea, N-[4-[[7-(2-bromoethoxy)-6-methoxy-4-quinazolinyl]oxy]-2-CN586371-92-4 REGISTRY ВИ COPYRIGHT 2002 ACS ANSWER 70 OF 179 REGISTRY ГЗ

chlorophenyl]-N'-(2,4-difluorophenyl)- (9CI) (CY INDEX NAME)

3D CONCOKD EZ

AA

CS# HI8 BT CT F2 N4 O4 WE

 $\Gamma C$ SE

CA, CAPLUS, TOXCENTER **SLN Files:** 

PAGE 1-A

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

CI 19990521; JP 1999-253624 19990907; PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS' . (əsənaqat) EI' EK' GY' GB' GK' IE' IL' TN' WC' WT' WK' NE' NT' EL' SE' DK' CW' CX' 'ID WD' BE' BE' B1' CE' CC' TA : WA : MT CH' , LT вΩ, 'MZ 'NA 'ZO , SA , MA 'YZ 'nx 'ຮດ າອດ , AU TR, 'LI''IS 'ZL 'LL 'MT '9S **В**И, bΓ' 'ds RO, 'Lđ 'ZN 'ON 'XW 'MW 'NW WK' WC' WD' 'LT  $\Gamma K$ 'ST LR, rc' 'ZX KB' Kb' KC' KE' la, 'SI 'NI 'TI ID' EE' ES' EI' CB' CD' CB' CO' CT' DE' cH, , AD CE' DW**'** DK' CH' CN' YE' YF' YW YI' YO' YZ' BB' BC' BB' DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines 

ВŢ N - CO - N - KJJ6Я Вјо Уβ 98

Ι Вđ ξЯ ВЯ ГЯ Вζ

ЯΑ

tested. CH: Z = CH: E': E'Thus, the title compd. I (X =and causing no morphol. change in cells. compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sjkyl or slkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [1; X and Z represent each CH or N; R1-3 represent each H,

Urea, N-[2-chloro-4-[(7-hydroxy-6-methoxy-4-quinazolinyl)oxy]phenyl]-N'-СИ 586371-91-3 REGISTRY КИ ANSWER 71 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma3$ 

(S, 4-difluorophenyl) - (9CI) (CA INDEX NAME)

зр соисовр

CSS HI2 CT ES N4 O4 WF. EZ

CA, CAPLUS, TOXCENTER STN Files: ГC AD SB

PAGE 1-A

PAGE 2-A

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

E

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. .(əsənaqat) TD, TG. DK' E2' E1' EK' GF' GB' GK' IE' IL' FN' WC' WF' WE' NE' NF' BE' SA' KS' MD' BN' 17' LW' BM: FL' BE' BE' B1' CE' CG' CH' CI' CW' CX' DE' KC' 'TT YA 'ZA ,MA ,WZ AZ 'UY 'NV 'ZU 'SU .au .ar TR, 'LT 'TS 'MT 'IS 'DS NZ, PL, PT, RO, RU, SD, 'XW 'MW 'NW WC' 2E 'ON WK' WD' , AM , V.I LT, LU, Kb' KB' KZ' TC' TK' TB' T2' KC' IZ' 15' KE' 'NI ID' IF' чв, нυ, BA' CY' CH' CN' CK' CO' CZ' DE' DK' DW' EE' ER' EI' GB' GD' GE' GH' GW' YE' YT' YW YI' YN' YZ' BY' BB' BC' BK' .qq 80S DESIGNATED STATES: W: Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 Al 20000727, and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KELEKENCE 1: 133:132732 Preparation and anti-tumor, anti-atherosclerosis,

and causing no morphol. change in cells. Thus, the title compd. I (X = compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal gjkyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [1; X and Z represent each CH or N; Rl-3 represent each H,

586371-84-4 REGISTRY ВИ PN2MER 72 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma 3$ 

(CY INDEX NAME) Orea, M-[2-chloro-4-[(7-methoxy-6-propoxy-4-quinazolinyl)oxy]phenyl]-N'-

bropyl- (9CI)

CSS HS2 CJ N4 O4 WE 3D CONCORD

SIN Files:

0

n-PrNH-CJ

U-PrO

Meo

**AD** 

ГC

SE

ES

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

CN

CA, CAPLUS, TOXCENTER

ΕЗ. ВЯ КZ  $N - CO - N - K_{IJ}$ ВŢ

01*A* 6Я В6 ςЯ

CI' CW' **'**50 TA : WA CH' BE' B1' CE' BE' ;MT 'LL ₽U, 'aw **1**2X 'MZ 'nx TK, , AZ 'NA 'ZO 'នព ne' , AU 'ZI 'LL 'WI 'CJ **'**⊓d RU, LT, , AM 'DS ZE' 'ds KO, 'ZN ON 'XW 'MW 'NW WK' WC' 'aw 'AT rc' Kb, Ir' rk' KK' 1b, 'SI 'nNH 'ST LR, 'ZX KC' KE' 'NI **'**at HE, DW' EE' ES' LI' GB' GD' GE' CB' CO' CZ' DE' BX' CY' DK' CH' CN' AE, AL, AM, AT, AU, AZ, BA, BB, BG, DESIGNATED STATES: W: .qq 802 PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493

GB' GK' IE' IL' TN' WC' WF' WK' NE'

CODEN: BIXXDS:

APPLICATION: WO 2000-JP255 20000120.

Nr' bI' SE'

16060651 4Z9ESZ-6661 dr :1Z506661

(Japanese)

EI' EB' CB'

Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all alkyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbonyl; and R11 represents alkyl or alkylcarbonyl; and R11 represents alkyl or alkylcarbonyl; and R11 represents alkyl or acceptable salts and solvates, and medicinal compns. contg. the same are prept. And tested having antitumor activity compns. contg. The same are prept. And tested having antitumor activity

Ι

chlorophenyl]-W'-propyl- (9CI) (CA INDEX NAME)

CH; Z = CH; Rl, R4, R5,R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd.

CM Urea, W-[4-[[6-(3-bromopropoxy)-7-methoxy-4-quinazolinyl]oxy]-2
ANSWER 73 OF 179 REGISTRY

CM Urea, W-[4-[[6-(3-bromopropoxy)-7-methoxy-4-quinazolinyl]oxy]-2
ANSWER 73 OF 179 REGISTRY

CM Urea, W-[4-[[6-(3-bromopropoxy)-7-methoxy-4-quinazolinyl]oxy]-2
CM Urea, W-[4-[[6-(3-bromopropoxy)-7-methoxy-4-quinazolinyl]oxy]-2-

TC SIN Files: CA, CAPLUS, TOXCENTER

CSS HS# BK CJ N# O#

3D СОИСОКD

 $R^{4}$ 

.DT , QT

DK'

E2'

CI

WE

EZ

$$Br = (CH_2)_3 = 0$$

$$MeO$$

$$MeO$$

I KEEEKENCES IN EITE CALTOS (1967 TO DATE)

I KEEEKENCES IN EITE CA (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 . (asansqst) APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: .DT , TG. DK' EI' EK' CF' CB' CK' IE' IL' TN' WC' WT' WK' NE' NT' EL' SE' 'S∃ CX' CI' CW' CH' BE' B1' CE' TM; RW: AT, BE,  $^{\prime}$ LT ,UA ce' 'UW **'**2X **'**១៣ , AU MZ 'AZ 'NX 'NA 'ZO 'ຮດ 'LL TR'LT ,MA 'ZL ,MT 'ss bľ' LT, ON 'NW WK' WC' WD' 'IS 'ES 'ds **'**ОЖ KO\* 'ZN 'XW 'MW , AM **'**\1 KE' 1b, 'SI 'NI 'TI 'UI '.L.T 'ST rk' rg' KK' KZ' PC' Kb' KC' **'**OH **'**ଧਮ DK' cH, EE' ES' LI' GB' GD' GE' DW' CH' CM' CB' CO' CZ' DE' CW' ,AD BX**ʻ** AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, DESIGNATED STATES: W: .qq 802 PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin sauttozentup bna anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEEEKENCE 1: 133:132732 Preparation and anti-tumor, anti-atherosclerosis,

Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent each H, alkynyl or alkyl or alkyl or alkyl carbonyl; and R11 represents alkyl, alkenyl, alkynyl or

Ι

αw

CI

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; Rl, R4, R5, R7-Rl0 each an H; Rll = 3,5-F2C6H3) was prepd. and tested

ZB CF
WE C10 H10 CT N4 O4
EZ 3D CONCOWD
Drobyl- (0Cl) (CF INDEX NFWE)
ZN CONCORD
ZN CONCORD
ZN CONCORD
ZN CONTON (CF INDEX NFWE)
ZN CONTON (CF INDEX NFWE)
ZN CONTON (CF INDEX NFWE)
ZN COLON (

CA, CAPLUS, TOXCENTER

**SLN Liles:** 

ГC

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BELEBENCES IN EITE CAPTOR (1967 TO DATE)

I BELEBENCES IN EITE CA (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 . (asaneqst) APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: EI' EK' CB' CB' CB' IE' IL' TA' WC' WF' WB' NE' NF' BL' SE' SA' TM; RM: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, 'LT RU, WD' **'**១៣ 'ZJ ,MA ,WZ ,AZ ,UY ,NV ,ZU ,2U , AU , ZA TR, LT, NZ' LT' LO' KO' ZD' 'DW 'ĐS ZE' 'ON 'XW 'MW MN' WK' MD, 'TI LT, 'ST Ke' Kb' KB' FC' TK' TB' IZ' 1b' KE' 'NI 'OH ID' DK' DW' EE' ES' EI' CB' CD' CE' CH' CW' CH' CN' CK' CN' CZ' DE' BX' CY' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:132235 Preparation and anti-tumor, anti-atherosclerosis,

AB Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal and cansing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = tested.

Ι

WE CSJ HSS Br CJ N4 O4
E2 3D CONCORD
CN Orea, N-[4-[[6-(2-bromoethoxy)-7-methoxy-4-quinazolinyl]oxy]-2CN S86371-81-1 REGISTRY
LS86371-81-1 REGISTRY
LS86371-1 REGIST

SR CA

TC 21M Files: CA, CAPLUS, TOXCENTER

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I KELEKENCES IN EITE CALTOS (1967 TO DATE)

J RELEKENCES IN EITE CA (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin

PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: .(Japanese). .DT , TG. DK' EI' EK' CB' CB' CB' IE' IL' FA' WC' WF' WB' NE' NF' BL' SE' SA' 'SE CI' CW' CH' IW; RM: AT, BE, BF, CF, CG, 'LT **к**и, CX' DE' 'GW **'**7X KG' 42.₩ MZ 'AZ 'NX 'NA 'ZN 'SN 190 ,AU TR'LT 'TS ,MA 'ZI 'LL 'W.L br' 'IS RU, RO, LT, 'ZN 'ON 'XW 'MW WC' WD' '១s ZE' 'ds WK' WN' , AM KB' KE' rn' KY' TC' TK' TB' Kb' 1b, 'SI ID' 'LT 'ST KC' 'NI 'TI 'ΩH чв, DW' EE' ES' EI' CB' CD' CH' CN' CB' CN' CZ' DE' BX' CY' 'H9 CE' DK' CW, YE' YI' YW' YI' YO' YZ' BY' BB' BC' BK' .qq. 802 DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan).

B4.ξЯ  $\mathbb{F}^7$ ВВ БZ N - CO - N - KJJВŢ 6Я *B*10 9И

19990521; JP 1999-253624 19990907.

of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H' pslogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all obfionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; RL-3 represent each H,

COPYRIGHT 2002 ACS ANSWER 76 OF 179 REGISTRY tested. CH: Z = CH; KJ, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal gjkyl or alkylcarbonyl; and Rll represents alkyl, alkenyl, alkynyl or

Ι

CS3 HS6 Br CJ N4 O4 WE 3D CONCORD EZ cyrocobyeul]-N.-broblj- (9CI) (CA INDEX NAME) Urea, N-[4-[7-(4-bromobutoxy)-6-methoxy-4-quinazolinyl]oxy]-2-CN

586371-80-0 REGISTRY

ВИ

 $\Gamma$ 3

CI

CA, CAPLUS, TOXCENTER **SLN Files:** rc SE

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

CI 19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: (Japanese). EI' EB' CB' CB' CB' IE' IL' FA' WC' WF' WB' NE' NF' BL' SE' SA' CH' CI' CW' IM; RM: AT, BE, BF, CF, CG, 'LI WD' 'MZ ,ZA , AS יטז אט יצט (מז' 'នព ne' , AU TR, ,MA 'ZL 'LT 'Td 'XW ZE' PT, RO, RU, SD, 'ZN 'ON 'MW WK' WC' '១ន 'NW WD' KB' KZ' FC' FK' FB' F2' FL' FA' KE' 'SI KC' 'NI Kb, 1b, DW' EE' ES' EI' CB' CD' CE' CH' CW' DK' BX' CY' CH' CN' CS' CD' DE' YE' YT' YW' YI' YO' YZ' BY' BB' BC' BK' DESIGNATED STATES: W: Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 Al 20000727, and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:132735 Preparation and anti-tumor, anti-atherosclerosis,

 $R^{7}$ ВЯ Вζ N - CO - N - BJJВŢ 6Я B<sub>T</sub>0 ςИ 9 Y

Ι  $B^{4}$ z = NΈЯ.

 ${\tt grk}{\tt l}{\tt l}$  or  ${\tt grk}{\tt l}{\tt rebreseut}$  and  ${\tt grk}{\tt l}{\tt l}$  tebreseuts  ${\tt grk}{\tt l}{\tt l}$ ,  ${\tt grk}{\tt l}{\tt l}{\tt l}$  or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents Η; R5-8 represent each Title compds. [1; X and Z represent each CH or N; R1-3 represent each H,

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I ( $X=CH;\ Z=CH;\ Rl,\ Rd,\ R5,R7-Rl0$  each an H; Rll = 3,5-F2C6H3) was prepd. and

SR CA HS1 C1 N4 O4

T3 POUCORD

CM Urea, N'-[2-chloro-4-[(7-hydroxy-6-methoxy-4-quinazolinyl)oxy]phenyl]-N,N
CM Urea, N'-[2-chloro-4-[(7-hydroxy-6-methoxy-4-quinazolinyl)oxy]phenyl]-N,N-

STN Files:

 $\Gamma C$ 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

CA, CAPLUS, TOXCENTER

I REFERENCES IN FILE CAPLUS (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. . (asanagat) CODEN: BIXXDS: EI' EK' CF' CB' CK' IE' IL' TO' WC' WT' WK' NE' NT' BL' SE' SN' DK' WD' TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, 'LT RU, , SA , MA , WS , AS , UY 'NΛ 'zn 'sn **'**១೧ , AU TR, 'TS 'LT 'ZJ '9S **к**а' ав' bΓ**'** , AM 'Td 'ON 'NW WK' WD' ZE' KO, 'ZN 'XW 'MW WC' LT, 'ST rc' rk' rb' 'ZX KB' KC' Kb' KE' 1b, 'SI 'NI Ir' HK, HU, 'UI DK' DW' EE' ES' EI' GB' GD' GE' GH' CH' CN' CB' CO' CS' DE' BX' CY' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KELEKENCE 1: 133:132732 Preparation and anti-tumor, anti-atherosclerosis,

CH: Z = CH; RJ, R4, R5,R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal stkyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [1; X and Z represent each CH or N; R1-3 represent each H,

Ι

Urea, N-[4-[(7-(5-bromopentyl)oxy]-6-methoxy-4-quinazolinyl]oxy]-2-CNS86371-78-6 REGISTRY ВИ COPYRIGHT 2002 ACS ANSWER 78 OF 179 REGISTRY  $\Gamma 3$ 

cyjorobyeulj-N.-propyl- (9CI) (CA INDEX NAME)

3D CONCORD EZ

tested.

ЯA

CS4 HS8 BL CI N4 O4 ИE

SE

CA, CAPLUS, TOXCENTER STN Files: PC

u-brnH-CJ OeM Bx = (CHS) 2 = 0

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:132235 Preparation and anti-tumor, anti-atherosclerosis,

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS' . (asanaqat) EI' EK' GY' GB' GK' IE' IL' PN' WC' WF' WK' NE' NF' EL' SE' SN' CI' CW' CH' ce' TM; RM: AT, BE, BT, CF, 'LI 'MZ , AZ **'**ΩX 'NA 'ZO 'នព 'ອດ , AU 'ZL 'LL TK, 'MT 'LT 'ĐS 'Td 'NW , AM ки, 'XW 'MW 'dS RO, 'Ld 'ZN ON WK' WC' WD' 'AT KE' KE' KZ' TC' TK' KE' 'SI 'TI 'ST KC' 1b, 'ΩH LR, 'NI ID' 'НВ CH' CN' CB' CO' CZ' DE' DK' DW' EE' ES' LI' CB' CD' CE' BX' CY' YE' YI' YW' YI' YO' YY' BB' BB' BB' BB' DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan).

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or acaptyl, or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or acaptyl, or and medicinal acapta or alkyl or acceptable salts and sectivity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = tested.)

Ι

SR CA CAPLUS, TOXCENTER

CSI HSS BY CI NO OF

WE

CI

I KEEEKENCER IN EITE CALIUR (1967 TO DATE)

J KEEEKENCER IN EITE CA (1967 TO DATE)

CI 19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: . (asanaqat) .DT , TT. E2' DK' EI' EK' CB' CB' CB' IE' IL' FA' WC' WF' WB' NE' NF' BL' SE' SN' 'ID CX' DE' CW' CH' **'**90 TM; KM: AT, BE, BF, BJ, CF, 'LT RU, 'ZX ′สพ 'NX 'ອດ , ZA ,MA 'MZ ,AZ 'NA 'ZN 'SN ,AU TR'MT 'LT 'IS 'ZT ,TT 'ss ₽Ľ, 'ZN 'IS ₽U, KO, 'Ld ON 'XW 'MW 'NW WK' WC' WD' , AM 'EE 'ds 'AT  $\Gamma K$ ľK' rc' KC' KE' 1b, 'SI 'NI 'TI ID' 'NH **'**0T '.I.T KK' KZ' Kb' HB, 'SI Cn' Cz' DE' 'AD BX' CH' CW' EE' ES' EI' CB' CD' CE' DK' DW' CH' CN' CB' YE' YI' YW' YI' YO' YZ' BY' BB' BC' BK' .qq 80S DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin snd quinazolines. anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

R4

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8

stkyl or alkylcarbonyl; and Rll represents alkyl, alkenyl, alkynyl or

ЯA

CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal

cyjorobyeulj-N.-propyl- (9CI) (CA INDEX NAME) Urea, N-[4-[7-(3-bromopropoxy)-6-methoxy-4-quinazolinyl]oxy]-2-CN586371-76-4 REGISTRY ВИ ANSWER 80 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma3$ 

CSS HS4 BL CJ N4 O4 WF. ЗД СОИСОКД EZ

A.) SE

CA, CAPLUS, TOXCENTER **SIN Files:**  $\Gamma C$ 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: .(əsənsqst) EI' EK' GY' GB' GK' IE' IL' TN' WC' WT' WK' NE' NT' BL' SE' CX' TM; EM: AT, BE, BF, BJ, CF, CG, CH, CI, CM,  $^{\prime}$ LI RU, WD' 'Z¥ ,MA ,WZ ,AZ ,UY 'NA 'ZO TR, 'ຮດ ′ ອດ , AU 'ZL 'MT 'LT 'DS ZE' bľ' KO, LT, 'XW 'MW 'NW ัยง ap, 'ZN ON WK' 'DW WD' , AM ΊĒ, 'ST rk' rb' KZ' TC' 'NI KK' Kb' KG' KE' 'SI IF' ID' 'NH 'НВ DW' EE' ES' EI' CB' CD' CE' CH' CH' CN' CB' CO' DE' (A) DK' YE' YT' YM' YI' YN' YY' BY' BB' BC' BB' DESIGNATED STATES: W: .qq 80S PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

ΙĐ

CH: Z = CH; RJ, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I  $(X \Rightarrow$ compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal στκλη οι στκληςσιρουλη: gud kll represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all obfionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [1; X and Z represent each CH or N; R1-3 represent each H,

Ι

СИ 586371-68-4 REGISTRY ВИ ANSWER 81 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma 3$ 

Urea, M-[2-chloro-4-[(7-hydroxy-6-methoxy-4-quinazoliny])oxy]phenyl]-M-6-methoxy-4-quinazoliny)

(CY INDEX NAME) bropyl- (9CI)

3D CONCORD E2

**AA** 

CIO HIO CI NO OO WE

SE

STN Files: CA, CAPLUS, TOXCENTER ГC

л**-**Ркин⊸'С-CJ **O P** M

0

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:132735 Preparation and anti-tumor, anti-atherosclerosis,

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. . (asanaqat) CODEN: BIXXDS: ΈΙ' ΕΚ' CF' CB' CK' ΙΕ' ΙΙ' ΓΩ' WC' WΓ' WK' ΛΕ' ΛΓ' ΔΙ' ΖΕ' ΖΝ' BE' B1' CE' GC' CH' CI' CW' BE' ,TA :WA 'LT ′ตพ :MT YП, ,MA ,WZ ,AZ ,UY ′ឌ្ឍ 'ຮດ **'**១៣ 'NΛ , AU 'ZJ 'LL TR, 'WT **'**T₫ 'DS ZE' KO, RU, SD, 'ZN 'NW 'La 'ON 'XW 'MW WK' WC' WD' rc' rk' rb' 'ZX KB' Kb' KE' 'SI 'TI 'SI KC' 'UI lΒ, 'NI EE' ES' EI' CB' CD' CE' CH' DW' DK' CH' CN' CB' CD' DE' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan).

Title compds. [1; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = tested.

Ι

CN OLER, N-[2-chloro-4-[[6-methoxy-7-(phenylmethoxy)-4-L3 ALGHT 2002 ACS L3 ALGHT 2003 ALGHT 2003 ACS L3 ALGHT 2003 ACS ALGHT 2003 ACS L3 ALGHT 2003 ACS ALGHT

driuszojinyl]oxylphenyl]-N.-propyl- (9CI) (CA INDEX NAME)

WE CSC HS2 CT N4 O4 E2 3D CONCOKD

ΙĐ

SK CA

LC STW Files: CA, CAPLUS, TOXCENTER

I BELEBENCES IN EITE CAPLUS (1967 TO DATE)

J RELEBENCES IN EITE CA (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: (Japanese). EI' EB' GB' GB' IE' IL' FN' WC' WF' WB' NE' NF' BL' SE' SN' E2' CI' CW' CX' TM; RM: AT, BE, BF, CF, CG, CH, 'LT 'ZX КU, WD' , ZA ,AU ,MA., WZ 'AZ 'UY 'NV 'ZU 'SU 'ZL 'LL 'CI 'ອດ TR, 'MT '១s ZE' 'ds PL, PT, RO, RU, 'ZN ON 'XW WK' 'MW 'NW WC' WD' 'TI KE' KE' KZ' TC' TK' TE' TZ' TL' KE' 1b, 'SI KC' 'NI ID' DK' DW' EE' ES' EI' CB' CD' CE' CH' CH' CN' CB' CO' CZ' DE' YE' YE' YW' YI' YN' YZ' BY' BB' BC' BK' DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Τοshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

R4

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, palogeno, alkyl, alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8

дH

CI

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X=AH; Z=CH; R1, R4, R5,R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and

EZ 3D CONCOKD

dniuszolinyl]oxy]phenyl]-N'-ethyl- (9CI) (CA INDEX NAME)

RN 286371-42-4 REGISTRY

LS ASSA1-42-4 REGISTRY

LS ANSWER 83 OF 179 REGISTRY

COPYRIGHT 2002 ACS

2*B* C*Y* W*E* C*S* C H3*S* C*T* N*Q* O*4* 

TC STN Files: CA, CAPLUS, TOXCENTER

MeO (CH2) 3-0 CL

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

0

EFNH-

I BEEEBENCES IN EITE CAPLOS (1967 TO DATE)

I BEEEBENCES IN EITE CA (1967 TO DATE)

СI 19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. . (asanaqat) CODEN: BIXXDS: EI' EK' CF' CB' CK' IE' IL' TN' WC' WF' WK' NE' NF' BL' SE' SN' EZ' CX, TM; RW: AT, BE, BF, EJ, CF, CG, CH, CI' CW' 'CT кu, WD' , ZA 'MZ , AU 'ΩX 'TT TR, , AZ 'NA 'ZO 'ຮດ ne' 'ZL ,MT , LT 'TS **'**⊓d 'ON 'XW '១ន RU, ZE' 'ds PT, RO, 'ZN 'MW 'NW WK' WC' WD' , AM 'LT 'ST  $\Gamma B$ ΓK' KK' KG' KZ' rC' 16' KE' 'SI HB, Kb' 'NI 'TI ID' 'OH DK' DW' EE' ES' LI' GB' GD' GE' CN' CB' CO' CZ' DE' CH' , AD CH' YE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, DESIGNATED STATES: W: .qq 802 PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal alkyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of 85-8 do not represent H simultaneously; 89 and 810 represent each H, H' palogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all obfrouglly substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H, ЯЯ

Ι

CN586371-41-3 REGISTRY ВИ ANSWER 84 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma 3$ 

quinazolinyl]oxy]phenyl]-N'-methyl- (9CI) (CY INDEX NAME) Orea, N-[2-chloro-4-[[6-methoxy-/-[3-(1-piperidinyl)propoxy]-4-

3D CONCOKD EZ

CS2 H30 CJ N2 O4 WE.

**CA** SR

CA, CAPLUS, TOXCENTER **SLN Files:**  $\Gamma C$ 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

T KEEEKENCES IN LIFE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:132735 Preparation and anti-tumor, anti-atherosclerosis,

1660621; JP 1699-253624 16990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. . (asanaqat) CODEN: BIXXDS: .DT , TG. GB' GK' IE' IL' TO' WC' WT' WK' NE' E2' DK' NF' bL' RE' , AĐ EI' EK' CX' CI' CW' **'**90 BE' B1' CE' TA; RW: AT, CH' **'**∃∃ 'LT RU, , ZA ,MA ,WZ , AZ 'nx 'NA 'ZO 'នា 190 , AU 'CT 'ZJ 'LL TR, 'MT '១s ₽Ľ, 'ZN 2E' RU, 'XW 'MW 'NW 'ds KO, LT, 'ON WK' WC' WD' rc' 'ST  $\Gamma B$ rk' 'ZX KB' Kb' KC' KE' 1ar 'SI 'TI ID' 'NI EZ' EI' CB' CD' CE' DW' EE' DK' CO' CZ' DE' CH' CN' CKAE, AL, AM, AT, AU, AZ, BA, BB, BG, DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan).

 $\mathbb{F}^{4}$ I ξЯ ВВ ГЯ ВS ВŢ N - CO - N - BTT6Я ВТО В6 ςЯ

CI

tested. CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X = compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sjkyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H' pslogeno, slkyl, slkoxy, slkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [1; X and Z represent each CH or N; R1-3 represent each H,

Urea, N' = [2-ch]oro-4-[[7-[3-[(2-hydroxyethyl)methyllamino]propoxy]-6-CN586371-40-2 REGISTRY ВИ PN2MER 85 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma3$ 

3D CONCORD EZ wefpoxy-4-duinazolinyl]oxy]phenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

SE C54 H30 CT N2 O2 WE

CA, CAPLUS, TOXCENTER STN Files: ГC

269xcy6q ph: Wary Hale 308-4258 CM-1 12D16

$$Me^{5}N - CH^{5} - CH^{5} - CH^{5} - CH^{5}$$
 $Me^{0}$ 
 $Me^{0}$ 
 $Me^{0}$ 
 $Me^{0}$ 

I BEEEBENCES IN EITE CAPIUS (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: . (seansqst) .DT , TG. EI' EK' CF' CB' CK' IE' IL' FN' WC' WF' WK' NE' NF' BL' SE' SN' E2' DK' 'ID YT, BE, CX' DE' CW' CH' **'**90 BE' B1' CE' 'LT **В**П, WD' 'ZX EM: ;MT 'NX 'ZN **'**១០ ,AU BX' 'MZ '∀Z 'NA 'ZI 'TS 'ZY ,MA 'នព 'LL TR, 'WI 'CI 'IS КU, KO, 'La ₽Ľ, 'MW 'NW we' '១ន ZE' 'ZN ON 'XW WK' WD' , AM 'ds rn' 'TI **'**0T 'LT 'ST LR, rk' KB' KZ' TC' Kb, KG' KE' 1ar 'SI 'NI ID' 'OH CH' CW' CE' EE' EZ' EI' CB' CD' 'AD DW' DK' Cn' CZ' DE' CH' CN' CB' BX' YE' YI' YW' YI' YO' YZ' BY' BB' BC' BK' .qq 802 DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin .eanilozeniup bne anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines 133:135235 Preparation and anti-tumor, anti-atherosclerosis, **KELEKENCE J:** 

ΙĐ

AA

Title compds. [1; X and Z represent each CH or N; R1-3 represent each H, halogeno, alkyl, alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all

269xcyeq ph: Wary Hale 308-4258 CM-1 12D16

of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = tested) and respect to the same are prepresented and causing no morphol.

L3 ANSWER 86 OF 179 REGISTRY COPYRIGHT 2002 ACS

ANSWER 86 OF 179 REGISTRY COPYRIGHT 2002 ACS

L3 ANSWER 86 OF 179 REGISTRY

CM Urea, N'-[2-chloro-4-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4
CM Urea, N'-[2-chloro-4-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4
CM Urea, N'-[2-chloro-4-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4
CM Urea, N'-[2-chloro-4-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4
CM Urea, N'-[2-chloro-4-[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-

CA, CAPLUS, TOXCENTER

**SLN EIJes:** 

ГC

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BELEBENCES IN EITE CAPLUS (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEM: BIXXDS: .(asənaqat) EI' EB' CB' CB' EB' IE' IL' FN' WC' WF' WB' NE' NF' BL' SE' CX' TM; RM: AT, BE, BF, BJ, CF, CG, CH, CI, CM, WD' 'LL , ZA 'MZ ,AS 'NA 'NA 'ZN ,MA 'នព າອດ , AU 'ZL TR, 'LT '១s ZE' RU, SD, PL, PT, RO, 'ZN 'ON 'XW 'MW 'NW WK' 'DW WD' 'LT Kb' KE' 1b, 'TI 'ST רא' רצ' KB' KZ' PC' KC' 'SI 'NI 'UI 'NH DW' EE' ES' EI' CB' CD' CE' DK' CH' CN' CB' CD' CS' DE' BX' CY' YE' YE' BW' YI' YO' YZ' BB' BC' BK' DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:132835 Preparation and anti-tumor, anti-atherosclerosis,

ΙĐ

Title compds. [1; X and Z represent each CH or N; Rl-3 represent each H, halogeno, alkyl, alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. CH: N3-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and

Ι

L3 ANSWER 87 OF 179 REGISTRY, COPYRIGHT 2002 ACS

RM 286371-38-8 REGISTRY

CM Acetic acid, [[4-[3-chloro-4-[[(dimethylamino)carbonyl]amino]phenoxy]-6
RM 286371-38-8 REGISTRY

CM Acetic acid, [[4-[3-chloro-4-[[(dimethylamino)carbonyl]amino]phenoxy]-6
RM 286371-38-8 REGISTRY

CM Acetic acid, [[4-[3-chloro-4-[[(dimethylamino)carbonyl]amino]phenoxy]-6
RM 286371-38-8 REGISTRY

CM Acetic acid, [[4-[3-chloro-4-[[(dimethylamino)carbonyl]amino]phenoxy]-6-

LC STW Files: CA, CAPLUS, TOXCENTER

tested.

ЯΑ

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I KEEEKENCER IN EITE CABINR (1964 TO DATE)
I KEEEKENCER IN EITE CA (1964 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: . (əsənaqat) .Dr , TG. EI' EB' CB' CB' CB' IE' IL' TN' WC' WT' WB' NE' NT' EL' SB' E2' DK' CX' CI' CW' **'**50 TM; RW: AT, BE, BF, BJ, CF, WD' CH' 'LI '೧४ **1**73 , MA ,AZ 'NX 'NA 'ZN 'SN 'ອດ TK, 'ZY 'M7 AU ,ST **1**0J. 'TS 'XS ,TT ,MT 'IS **'**5S '3S 'as кu, NZ' bF' bL' BO' 'ON 'XW 'MW 'NW WK' WC' **'**UW , AM 'AT 1b' KE' KC' Kb' KK' KZ' TC' TK' TB' 'SI 'NI HB, rn' 'LT 'ST II' ID' 'NH DW' EE' ES' EI' GB' GD' GE' GH' DK' Cn' CZ' DE' CH' CN' CK' , AD BX' CW' YE' YI' YM' YI' YO' YZ' BY' BB' BC' BK' .qq 80S DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin

Ι

L3 ANSWER 88 OF 179 REGISTRY COPYRIGHT 2002 ACS CN Urea, N'-[2-chloro-4-[[6-methoxy-7-(4-pyridiny]

CN Urea, N'-[2-chloro-4-[[6-methoxy-7-(4-pyridinylmethoxy)-4-quinazolinyl]oxy]phenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

ES 3D CONCORD

tested.

CI

WE CS4 HSS CT N2 O4

TC 2LM E;Jes: CY CAPLUS, TOXCENTER SR CA

0

I KEFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

EI 19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 . (asanaqat) APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: TG. NI' LI' SE' SN' EI' EB' GB' GB' IE' IL' TO' MC' MT' MB' NE' E2' 'IO 'AD CH' **'**១၁ BE' B1' CE' KM: AT, BE, CW' 'LT **'**NY ;MT 'NX ′ຮ∩ ne' 'ZY 'MZ ,AZ 'ΝΛ 'ΖΩ , AU 'ZJ TK'WI 'LT ,MA 'TT '១s ON L' LI 'MW 'NW WK' WC' 'IS **'**∃S 'ds 'กห 'ดห 'ZN 'XW MD, , AM KB' KZ' rc' KC' KE' 1b, 'SI 'NI  $r_{\rm L}$ ' 'ST רא' רצ' Kb' 'TT 'OH 'dI DK' DW' EE' ES' LI' GB' GD' GE' CH' CN' CB' CO' CZ' DE' ,AD CH' BX' CW' YE' YE' BW' YI' YO' YZ' BB' BB' BB' BB' DESIGNATED STATES: W: .qq 80S PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:132835 Preparation and anti-tumor, anti-atherosclerosis,

Z ΓЯ ВВ  $\mathbb{F}^{\mathbb{Z}}$ N - CO - N - BJJВŢ ВŢ0 6Я 98

Ι БĄ εЯ

sjkyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of 85-8 do not represent H simultaneously; 89 and 810 represent each H, H' palogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [1; X and Z represent each CH or N; Rl-3 represent each H,

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; Rl, Rd, RS, R7-Rl0 each an H; Rll = 3, S-F2C6H3) was prepd. and tested.

dninazolinyl]oxy]phenyl]-N, N-dimethyl- (9CI) (CA INDEX NAME) Urea, N'-[2-chloro-4-[[6-methoxy-7-[4-(4-morpholinyl)butoxy]-4-

WE CSC H3S CT N2 O2 E2 3D CONCOBD

2K CV WE CSC H3S CT N2 O2

LC STM Files: CA, CAPLUS, TOXCENTER

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

0

J KELEKENCES IN EITE CYPLUS (1967 TO DATE)

J KELEKENCES IN EITE CY (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. (Japanese) CODEN: bixxDS: EI' EB' GB' GB' IE' IL' FN' WC' WF' WB' NE' NF' BL' SE' SN' DK' RM: AT, BE, BF, BJ, CF, CG, CH, CI, CW' CX' DE' 'LT **В**О, WD' :MT ,MA AZ UY , ZA 'MZ 'NA 'ZO 'ន្ធ , AU ng' 'WT 'ZI 'TT TR, 'LT ₽Ľ, '១ន หด' ab' KO, 'Ld 'ZN ON 'NW ZE' 'XW 'MW WK' WC' WD' , AM 'L'I 'ST KZ' TC' TK' TB' KC' 'TI Kb' KB' 15' KE' 'SI 'NI ID' 'OH **'**'H CH' DK' DW' EE' ES' EI' GB' GD' GE' CH' CN' CB' CO' CZ' DE' ,AD AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, DESIGNATED STATES: W: .qq 80S PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

CI

CH; Z = CH; RI, R4, R5,R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal alkyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H,

Ι

CN**S86371-32-2 REGISTRY** ВИ ANSWER 90 OF 179 REGISTRY COPYRIGHT 2002 ACS ГЗ tested.

quinazolinyl]oxy]phenyl]-N, N-dimethyl- (9CI) (CA INDEX NAME) Urea, N'-[2-chloro-4-[[6-methoxy-7-[2-(4-morpholinyl)ethoxy]-4-

3D CONCOKD

EZ

ЯΑ

CS4 HS8 CJ N2 O2 WE

SE

CA, CAPLUS, TOXCENTER SIN Files: ГC

Me2M-СŢ M<sub>O</sub> CH5-CH5-

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

0

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

19990521; JP 1999-253624 19990907 PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: . (Japanese) .DT , TG. DK' EI' EK' GY' GB' GK' IE' IL' FN' WC' WF' WK' NE' NF' BL' SE' 'ST 'IO CX' BE' BE' B1' CE' CC' TA : WA : MT CW, CH' 'CJ **'**Nצ WD' **'**ZX ,2A 'MZ , A2 'NA 'NA 'ZN 'ຮດ **1**00 ,AU TR, 'W.L. **'**C.L. 'IS , MA 'ZL 'J.J. 'XS **¹**⊓d , AM 'IS PT, RO, 'ZN 'ON 'XW 'MW 'NW '9s ZE' 'ds кu, WK' WC' WD' 'AT KE' KZ' TC' KB' Kb' lb, 'SI rn' 'LT 'ST LR, ΓK' KC\* 'NI 'TI ID' 'OH 'HB DW' EE' ES' EI' CB' CD' DK' CH' CN' CB' CO' DE' CH' CE' , AD CW' BX**ʻ** YE' YE' BH' BH' BY BY BB' BB' BB' .qq 80S DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan).

CI

Title compds. [1; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal aralkyl), pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = tested.

Ι

EZ 3D CONCOBD

WOLDPOTINT) DECOPONT

OTHER 91 OF 179 REGISTRY

CM 286371-29-7 REGISTRY

LS ANSWER 91 OF 179 REGISTRY

COPYRIGHT 2002 ACS

WE C30 H31 E5 N2 O9
E2 3D CONCORD

TC 2LM Liles: CA, CAPLUS, TOXCENTER SR CA

PAGE 2-A

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BELEBENCES IN EITE CAPIUS (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 . (əsənsqst) APPLICATION: WO 2000-JP255 20000120: CODEN: bixxDS: DK' E2' E1' EK' GF' GB' GK' IE' IL' FN' WC' WF' WE' NF' BL' SE' SN' KY' MD' BA' LA' LW: BM: FL' BE' BL' BA' CE' CR' CH' CI' CW' CA' DE' TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, TJ, TM, TR, WA' WM' WX' NO' NZ' BT' BL' BO' BA' SD' SE' SC' SI' MD' MC' MK' IS' 15' KE' KG' KB' KK' FC' FK' FB' FS' FL' FN' 'NI CH' CN' CK' CN' CS' DE' DK' DW' EE' ES' EI' CB' CD' CE' CH' CW' BX' CY' YE' YI' YW YI' YO' YZ' BY' BB' BC' BK' DESIGNATED STATES: W: Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 Al 20000727, and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

Е

CI

CH; Z = CH; RI, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X = compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal στκλη οι στκλητοσιρουλη: gud kll represents alkyl, alkenyl, alkynyl or of 85-8 do not represent H simultaneously; 89 and 810 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; R1-3 represent each H,

Ι

Urea, N-[2-methoxy-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-CN586371-28-6 REGISTRY ВИ ANSWER 92 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma 3$ 

duinazolinyl]oxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)

ЗД СОИСОКД EZ

ЯA

CS1 H32 N2 O6 ME

CA, CAPLUS, TOXCENTER STN Files: PC SE

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) J REFERENCES IN FILE CA (1967 TO DATE)

and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 · (əsəueder) APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: .DT , TG. EI' EK' CF' CB' CK' IE' IL' TO' MC' MT' MK' NE' NT' bL' DK' CX' CI' CW' CH' BE' BE' B1' CE' TA; WA; MT **'**90 'LJ **'**08 'aw ne' , 2.A 'M7. , AZ 'NX 'ΝΛ 'ΖΩ 'sn ,AU TR, 'M.L ,MA 'ZI 'J.J. **'**C.L. ¹⊓d 'XW , AM 'IS ВU, RO, 'La 'NW '១ន 'EE' 'ds 'ZN 'ON 'MW WK' WC' WD' 'Λ'I Kb' KE' LR, ľK' KK' KZ' KC' 1b, 'SI rn' 'LT 'ST rc' 'NI 'TI ID' 'NH HB, CH' CM' CB' CD' DE' 'HĐ DW' EE' ES' EI' GB' GD' GE' DK' (A) CW' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, .qq 802 DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan).

Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H, halogeno, alkyl, alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or are lkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or are brankyl, and R11 represents and solvates, and medicinal are compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. CH: R1, R4, R5,R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and

Ι

ES 3D CONCOKD

#-dnruszofruyl]oxy]phenyl]-N'-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)

RU 286371-22-0 REGISTRY

L3 ANSWER 93 OF 179 REGISTRY COPYRIGHT 2002 ACS

.

2*B* C*Y* WE CS8 HS8 CT ES N2 O2

LC STW Files: CA, CAPLUS, TOXCENTER

tested.

ΙĐ

$$C = 0$$
 $C = 0$ 
 $C$ 

**PAGE 2-A** 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BEFERENCES IN FILE CAPLUS (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: bixxDS: .(Japanese). EI' EK' CF' CB' CK' IE' IL' TN' WC' WF' WE' NE' NF' EL' SE' SN' TM; RM: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, MD, RU, TJ, 'YB 'ZA 'MA 'WZ 'AZ 'UY 'NV 'ZD 'SD 'AD 'AD TM, TR, 'ZJ 'LL WD' NO' NZ' bF' bL' BO' BR' SD' SE' SC' SI' WC' WK' WN' WM' WX' KB' KZ' FC' FK' FB' FR' FR' FR' 'SI 'NI 'TI Ke' Kb' 1b' KE' ID' DK' DW' EE' ES' LI' CB' CD' CE' CH' CW' CH' CN' CB' CO' CS' DE' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, .qq 802 DESIGNATED STATES: W: Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 Al 20000727, and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines 

tested. CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X = compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sjkyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H' palogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H,

Ι

Urea, M-[2-chloro-4-[[6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-4-CN586371-21-9 REGISTRY ВИ ANSWER 94 OF 179 REGISTRY COPYRIGHT 2002 ACS ГЗ

ЗД СОИСОКД EZ dniuszolinyl]oxy]phenyl]-N'-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)

C30 H3I CT E5 Ne Od ME

ΒA

CA, CAPLUS, TOXCENTER **SLN LIJGS:** ГC AD

PAGE 2-A

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I KEEEKENCES IN EITE CALTOS (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: .(əsənaqst) DK' ES' EI' EK' GB' GB' GE' IE' IL' TO' WC' WT' WB' NE' NT' EL' SE' ZN' MD' KU' LT' LW' KM: FI' BE' BL' CE' CC' CH' CI' CW' CX' DE' 'YA 'ZA 'MA 'WZ 'AZ 'UY 'NA 'ZD 'SU 'AU 'ZT TT , TT , TT, ,UT RE' RG' RI' MD' MC' MK' MN' MN' MX' NO' NZ' BT' BL' BO' BN' BD' AM VI 15' KE' KG' Kb' KK' KZ' TC' TK' TB' TC' TL' TN' 'TI 'SI 'NI HE' HO' ID' CH' CN' CB' CO' CZ' DE' DK' DW' EE' EZ' EI' GB' GD' GE' GH' GW' BX' CY' YE' YE' YW' YI' YN' YX' BY' BB' BC' BK' DESIGNATED STATES: W: Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 Al 20000727, and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

CI

tested. CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X = compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sikyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, Η, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all obtionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; R1-3 represent each H,

Urea, N-[2-chloro-4-[[6-methoxy-7-[3-(4-morpholinyl)propoxy]-4-СИ S86371-20-8 REGISTRY ВИ PNZMEK 95 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma3$ 

ЗД СОИСОКД ES quinazolinyl]oxy]phenyl]-N'-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)

SECS6 HS8 CJ ES N2 O2 WE

AA

CY' CAPLUS, TOXCENTER **SLN Files:**  $\Gamma C$ AD

PAGE 2-A

E

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I KEEEKENCES IN EITE CAPLUS (1967 TO DATE)

19990521; JP 1999-253624 19990907; PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. .(əsənaqat) CODEN: BIXXDS: DK' E2' E1' EK' CF' CB' CK' IE' IL' FN' WC' WT' WK' NE' NT' BL' SE' SN' TM; RM: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE,  $^{\prime}$ LT KZ' WD' BN' 'TT TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, TE, ,MT  $_{ au}$ LT 'IS 'DS 'ES MM' MX' NO' NZ' BF' BI' BO' BN' SD' WC' , AM 'NW WK' WD' Kb' KB' KZ' TC' TK' TB' T2' TL' TN' IZ' 1b' KE' ID' IF' KC' нв, нυ, 'NI CH' CN' CB' CO' CZ' DE' DK' DW' EE' EZ' EI' GB' GD' GE' GH' GW' BX' CY' YE' YE' YA' YA' YA' YA' BB' BC' BK' .qq 802 DESIGNATED STATES: W: Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 Al 20000727, and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sikyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H,

Ι

tested. CH; Z = CH; RI, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and

Urea,  $N-\{2-chloro-4-[[6-methoxy-7-[2-(4-morpholinyl)ethoxy]-4-norea, N-\{2-chlory-4-norea, N-[2-chlory], N-[2-chl$ CN586371-19-5 REGISTRY ВИ PN2MER 96 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma 3$ 

dniuszojinyl]oxy]phenyl]-N'-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)

3D CONCORD ES

ЯA

CS8 HS CT ES N2 O2 WE

CA, CAPLUS, TOXCENTER SIN Files: ГC SE

PAGE 1-A

I BELEBENCES IN EITE CAPIUS (1967 TO DATE)

J RELEBENCES IN EITE CA (1967 TO DATE)

CI 19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 . (Japanese). APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: EI' EB' CB' CB' CB' IE' II' FN' MC' MF' MB' NE' NF' BL' SE' SN' E2' 'IO CW' CX' BE' B1' CE' CC' CH' BE' TA: WA: MT 'CL КU, WD' **'**១៣ , ZA 'MZ '∀Z 'טז 'אט 'צט 'sn ,AU TR, 'MT 'CI , MA 'ZL 'LL 'ON 'XW 'MW 'NW WK' WC' WD' 'IS 'SS ZE' 'ds PL, PT, RO, RU, 'ZN , AM KE' 'SI 'TI rn' T.L 'ST  $\Gamma E'$ KB' KZ' TC' TK' Kb' KC' 1b, 'NI ID' 'OH DK' DW' EE' ES' EI' GB' GD' CH' CE' , AD 'WĐ CH' CN' CB' CO' CZ' DE' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, DESIGNATED STATES: W: .qq 80S PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

ЯΑ

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = alkyl) alkyl or alkylcarbonyl; and R11 represent alkyl alkylyl or alkylcarbonyl; and R11 represent alkyl. I (X = alkyl) alkylcarbonyl; and R11 represent alkyl alkylor alkylor

CM Orea, W-[2-chloro-4-[[6-methoxy-7-(4-pyridinylmethoxy)-4-RM 286371-18-4 REGISTRY

CM Orea, W-[2-chloro-4-[[6-methoxy-7-(4-pyridinylmethoxy)-4-

3D CONCOBD  $dniugsofin\lambda f$ ]  $dniugsofin\lambda f$ 

WE CS8 HS0 CT ES N2 OF ER 3D CONCORD

SR CA CAPLUS, TOXCENTER

FAGE 1-A

FAGE 2-A

E

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BEEEBENCES IN EITE CAPINS (1967 TO DATE)

I BEEEBENCES IN EITE CA (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. . (asansqst) CODEN: **bixxD**5. .or , ar EI' EB' GB' GB' GE' IE' II' FN' WC' WF' WB' NE' NF' BL' SE' SN' E2' TM; RM: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, **'**กช 'ZX 'CL WD' , SA , MA , WS AS 'UY 'NV 'SU 'SU ,AU 'ZI າອດ TE, 'LT ·'IS '១ន ZE' NO, NZ, PL, PT, RO, RU, SD, 'NW WK' 'XW 'MW WG' WD' 'SI Kb' KK' KT' TC' TK' TB' KC' KE' IL, 'NH רצ' דע' דת' 1b, 'NI ID' DW' EE' ES' LI' CB' CD' CE' CH' CW' DK' CH' CN' CB' CO' CS' DE' BX' CY' YE' YI' YW' YI' YO' YS' BB' BB' BB' BB' .qq 80S DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:132235 Preparation and anti-tumor, anti-atherosclerosis,

**AA** 

tested. CH: Z = CH: ET: ETand causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sikyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all obfronally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H,

Ι

586370-97-6 REGISTRY КИ COPYRIGHT 2002 ACS ANSWER 98 OF 179 REGISTRY ГЗ

4-dnjuszojinyl]oxy}phenyl]-N'-propyl- (9Cl) (CA INDEX NAME) nrea, N-[2-chloro-4-[[6-[3-[(2-hydroxyethyl)methylamino]propoxy]-7-methoxy-СИ

ЗД СОИСОВД EZ

CS2 H35 CJ N2 O2 WE

SE**CA** 

 $\Gamma C$ 

CA, CAPLUS, TOXCENTER **SLN Files:** 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

GB' GK' IE' IL' TO' WC' WT' WK' NE' NT' LL' EB' CB' WD' CI' CW' CH' BE' BE' B1' CE' ,UT из. CG' ,TA :WA ;MT 'MZ **'**១៣ 'UX 'NA 'ZO 'LL , AZ 'ຮถ , AU 'ZL **¹**T₫ ON 'XW **'**5S RU, 'ZN WK' WC' 'ES 'dS RO, 'Ld 'MW 'NW 'dW 'ZX Kb' 'NI PK' PB' rc' KB' KE' 'TT 'OH 'ST KC' 1b, 'SI ID' DW' EE' ES' EI' CB' CD' CE' CH' CN' CB' CO' CZ' DE' 'H9 DK' YE' YI' YW' YI' YO' YZ' BY' BB' BC' BK' DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin .eanilozeniup bns anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KELEKENCE J: 133:132732 Breparation and anti-tumor, anti-atherosclerosis,

PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493

CODEN: BIXXDS:

APPLICATION: WO 2000-JP255 20000120.

19990521; JP 1999-253624 19990907.

. (asanaqat)

Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H, halogeno, alkyl, alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbonyl; and R11 represents and solvates, and medicinal and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. CH) and R11 represent each H, and causing no morphol. R10 each and tested having antitumor activity and causing no morphol. R10 each and tested having antitumor activity and causing no morphol. R10 each and tested having antitumor activity or alkyl or alkylcarbonyl; and R11 each R12 each H, R13 each H, R14 each R12 each H, R15 each H, R16 each R10 each R10

Ι

EZ 3D CONCOKD

drivacolinylloxylphenyll-N'-propyl- (9CI) (CA INDEX NAME)

CM Urea, N-[2-chloro-4-[[7-methoxy-6-[3-(4-morpholinyl)propoxyl-4RN 286370-96-5 REGISTRY

L3 ANSWER 99 OF 179 REGISTRY COPYRIGHT 2002 ACS

TC SLM EIJGS: CF' CYBFMS' LOXCENTEK

ZF CF

WE CSC H3S CJ N2 O2

tested.

CI

J BELEBENCES IN EITE CALTOS (1967 TO DATE)

J BELEBENCES IN EITE CA (1967 TO DATE)

СI 19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. (Japanese) CODEN: BIXXDS: .DT , TG. GB' GK' IE' IL' TA' WC' WT' WK' ME' MT' LL' SE' SA' EI' EK' CY' E2' DK' ู่ กช 'ZX IM; BM: FI, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, 'LT 'UM KC' AZ, BY, ,MA ,WZ ,AZ 'NA 'NA 'ZN 'SN TR, 'MT 'IS 'ອດ , AU 'ZL 'LL 'LT RO, RU, SD, 'XW 'NW WC' 'IS 'DS 'La 'Ta 'ZN 'ON 'MW , AM 'ES WK' WD' Kb' KB' KZ' TC' TK' TB' KE' 'SI II' rs' rt' rn' KC' 1b, **'**ПН ''ИН 'NI ID' DW' EE' ES' EI' GB' GD' GE' CH' CW' DK' DE' CH' CN' CB' CD' CZ' BX' CY' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, .qq 80S DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines 

Title compds. [I; X and  $\Delta$  represent each CH or N; Rl-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent H simultaneously; R9 and R10 represent or H, halogen  $\Delta$  alkyloarbonyl; and R11 represents alkyl, alkenyl, alkynyl or

Ι

ВA

CH: Z = CH; ET, ET, ET, ET RO, ET RO, ET RO each an H; ET RO = 3,5-F2C6H3) was prepd. and and causing no morphol, change in cells. Thus, the title compd. I (X = compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal

dninazolinylloxylphenyll-N'-propyl- (9CI) (CA INDEX NAME) Urea, N-[2-chloro-4-[7-methoxy-6-(2-pyridinylmethoxy)-4-CN586370-95-4 REGISTRY BNANSWER 100 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma 3$ 

CS2 HS4 CJ N2 O4 WE ЗД СОИСОКД EZ

AD SE

CA, CAPLUS, TOXCENTER **SLN EIJGS:** ГC

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. . (Japanese) CODEN: BIXXDS. EI' EB' GB' GB' IE' II' TN' WC' WT' WB' NE' NT' EL' SE' CX' BE' B1' CE' CC' CH' CI' CW' TM; RM: AT, BE, 'LT WD' КU, , ZA 'ຮດ **'**១៣ , AU ,MA ,WZ ,AZ ,UY ,WV ,ZU TR, 'ZL LT, '១s ZE' br' 'ON 'XW RO, RU, SD, 'ZN 'MW WK' WC' 'La 'NW 'dW KE' 'LT 'ST KB' KZ' TC' TK' TB' Kb' 1b, 'SI 'NI ID' KC' DW' EE' ES' EI' GB' GD' GE' cH, DK' CH' CN' CK' CN' CZ' DE' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:132735 Preparation and anti-tumor, anti-atherosclerosis,

CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X = compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sjkyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [1; X and Z represent each CH or N; R1-3 represent each H,

Ι

586370-94-3 REGISTRY ВИ ANSWER 101 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma 3$ 

Urea, M-[2-chloro-4-[7-methoxy-6-[3-(4-methyl-1-ptperaznny)propoxy]-4-CN

drivazojinyl]oxy]phenyl]-N.-propyl- (9CI) (CA INDEX NAME)

C57 H35 C1 N6 O4 ME3D CONCORD ES

ЯA

A)

SR

**2LM LTJ68:**  $\Gamma C$ 

CY' CYPLUS, TOXCENTER

- (CH2) 3-

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 .DI , TG. (Japaneget) APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: ZE' ZN' DK' GB' GK' IE' IL' PN' WC' WF' WK' NE' NT' LL' 'SE EI' EB' CB' CX' DE' KC' CI' CW' CG' CH' IM; RM: AT, BE, BF, BJ, CF, 'LT MD, RU, **'**73 **'**NX **'**១೧ , ZA ,MA 'MZ ,AZ 'NA 'ZΩ 'sn ,AU 'WI 'CJ. 'TS 'XS 'ZI 'LL TR, '១s ₽Ľ, 'ZN , AM КU, KO, LT, 'ON 'NW WK' WC' 'IS ZE' 'ds 'XW 'MW WD' 'ΛT rc' 'LT ГВ**'** ΓK' KC' 'SI 'TI ID' רח' Kb' KB' KZ' 1b' KE' 'NI 'ΩH HE, 'ST CH' CW' CE' DW' EE' ES' EI' CB' CD' Cn' Cz' DE' CA, BX**'** DK' CH' CM' CB' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, .qq 80S DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan).

EI

tested. CH; Z = CH; RI, R4, R5,R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sjkyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H,

Ι

S893,0-33-5 RECIZLEX ВИ ГЗ PARMER 102 OF 179 REGISTRY COPYRIGHT 2002 ACS

dnrugzolruyloxylphenyl-N'-propyl- (9CI) (CA INDEX NAME) Urea, N-[2-chloro-4-[17-methoxy-6-[2-(4-methy4-1-piperaziny1)ethoxy]-4-СИ

ЗД СОИСОВД

CS H33 CT NO Of WE EZ

CY' CYPLUS, TOXCENTER STN Files: ГC **AD** SB

I BELEBENCES IN LIFE CALINS (1967 TO DATE)

10000651; JP 1000-253624 1000007. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS' (Japanese). EI' EK' CF' CB' CK' IE' IL' TN' WC' WT' WK' NE' NT' LL' CE' CX, 'ID BE' B1' CE' CC' BE' TA : WA : MT 'LI WD' CW' CH, КU, 'MZ ,MA ,AZ 'NX 'NA 'ZN 'ຮດ ne' , AU 'ZL 'TT TR, 'MT 'Td 'XW '១ន ZE' 'ds КU, PT, RO, 'ZN ON 'MW 'NW WK' MC' WD' KB' KZ' PC' ĸe' 'ar  $\Gamma L$ 'ST רא' דא' 'ая KE' 'SI 'NI 'TI ID' DW' EE' ES' EI' GB' GD' GE' CH' CN' CB' CO' CS' DE' ,AD CH' DK' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEEEKENCE 1: 133:132732 breparation and anti-tumor, anti-atherosclerosis,

ΙĐ

Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent each H, alkyl or al

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = the figure of the first sample of the first samp

L3 ANSWER 103 OF 179 REGISTRY COPYRIGHT 2002 ACS

CM Urea, N-[2-chloro-4-[[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4CM Urea, N-[2-chloro-4-[6-methoxy-7-[3-(1-piperidinyl)propoxy]-4CM Urea, N-[2-chloro-4-[6-methoxy-7-[2-chloro-4-[6-methoxy-7-[6-methoxy

WE CSJ H34 CJ N2 O4 E2 3D CONCOKD

2*K* C*Y* WE C5*X* H34 C*T N*2 O4

TC SIN Files: CA, CAPLUS, TOXCENTER

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I KEEEKENCES IN EITE CAFINS (1967 TO DATE)

I KEEEKENCES IN EITE CA (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: (Japaneget) EI' EK' GY' GB' GK' IE' IL' TN' WC' WT' WK' NE' NT' BL' SE' DK' CI' CW' TM; RM: AT, BE, WD' CH' BE' B1' CE' CC' 'LT кu, , SA 'MZ 'NX , MA ,AZ AU , TT 'NA 'ZA 'SA 'LL TR, 'WT ne' 'LT ₽L, 'ds 'La 'NW , AM 'ns ZE' ки**,** 'ZN ON 'XW 'MW WK' RO, WC' WD' 'ST KZ' rC' KC' 'TI 'ΩH רא' רצ' Kb' KB' 1b' KE' 'SI 'NI ID' DK' DW' EE' ES' EI' GB' GD' GE' CH' CN' CB' CO' CS' DE' ,AD AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

I9

tested. CH; Z = CH; RI, R4, R5,R7-R10 each an H; R11 = 3;5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sikyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; R1-3 represent each H,

Urea, N-[2-chloro-4-[[6-methoxy-7-[3-[(1-methyl-lH-tetrazol-5-])]]CN**586370-89-6** REGISTRY ВИ COPYRIGHT 2002 ACS ANSWER 104 OF 179 REGISTRY

( BMAN  $\lambda_T$ ) ryro] brobox $\lambda_1 - \eta$  - driugzoj ru $\lambda_1$ ] ox $\lambda_1$  by  $\mu_1 - \mu_2$  - brob $\lambda_1 - \eta_3$  (CV INDEX

ЗД СОИСОКД ES

CS4 HS1 CJ N8 O4 S WE

ЯΑ

ВЗ.

ВЅ

 $\mathbb{F}^{4}$ 

ВŢ

AD SE

CA, CAPLUS, TOXCENTER STN Files: ГC

ВЯ

9Я

6Я

N - CO - N - BJJ

BIO

ГЯ

ςЯ

0 u-brnH— CJ OeM

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I KEEEKENCES IN FILE CA (1967 TO DATE)

anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin

CI

ЯA

and quinazolines.

Thus, the title compd. I (X =Title compds. [1; X and Z represent each CH or N; R1-3 represent each H,

tested. CH: Z = CH: KJ' K6, K5, K7-K10 each an H; Kll = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal alkyl or alkylcarbonyl; and kil represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all obfioually substituted alkoxy, etc.; R4 represents H; R5-8 represent each

CN 586370-88-5 REGISTRY ВИ COPYRIGHT 2002 ACS FUSINER 105 OF 179 REGISTRY ГЗ

3D CONCOKD ŁZ dnruszolinylloxylphenyll-N'-propyl- (9CI) (CA INDEX NAME) Urea, N-[2-chloro-4-[[6-methoxy-7-[3-(4-pyridinylthio)propoxy]-4-

C57 H28 C1 N5 O4 S WE

CA, CAPLUS, TOXCENTER STN Files: ГC SE

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 CODEN: BIXXDS: (Japanese). .DT , TG. APPLICATION: WO 2000-JP255 20000120. E2' DK' ZE' ZN' EI' EB' GB' GB' IE' IL' TO' WC' WT' WB' NE' NT' LL' CE' ,TA 'AO 'IO 'HO **'**១၁ BE' B1' BE' 'LT **,** บЯ 'ZX DE' CW' 'UW TM; RW: ′ຣ∩ , SA 'NX **'**១៣ BX' ,MA 'MZ 'NA 'ZN ,AU 'LT TK, 'WI 'TS ,AZ 'ZJ 'CI. 'XS '១s br' 'ZN 'ON КU, во**ʻ** 'XW 'MW 'NW WK' WC' 'IS ZE' 'ds 'Ld 'ตพ , AM rc' Kb' 'LT KC' KE' 1b, 'SI 'TI rn'  $\Gamma K$ KK' KZ' 'NI **'**NH 'ST ľK' 'ar **'**'8H CH' DK' **,**AD CW' DW' EE' ES' EI' CB' CD' Cn' CZ' DE' CH' CN' CB' BX' CE' YE' YI' YW' YI' YO' YZ' BY' BB' BC' BK' .qq 80S DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines 

CI 19990521; JP 1999-253624 19990907.

Вđ Ι ΈЯ  $z \sim$ ГЯ ВВ ВЪ N - CO - N - FIIВŢ ВТО 6Я В6

gjklj or gjkljcarbonyl; and Rij represents alkyl, alkenyl, alkynyl or of Rb-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H,

CH: Z = CH: ET: ETand causing no morphol. change in cells. Thus, the title compd. I (X = x)compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal

CS8 H30 CT N2 O0 ΜE 3D СОИСОКD ES byeuox\]-e-mefyox\-\lambda-\lambda-dniugzofin\formallox\]bropyl ester (9CI) (CA INDEX NAME) Carbamic acid, diethyl-, 3-[[4-[3-chloro-4-[[(diethylamino)carbonyl]amino] СИ 586370-87-4 REGISTRY ВИ ANSWER 106 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma$ 3

STN Files: ГC AD SE

CA, CAPLUS, TOXCENTER

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: . (asanaqat) EI' EK' GY' GB' GK' IE' IL' FN' WC' WF' WK' NE' NT' BL' SE' CI WD' CW' CX' CC' CH' IM; RM: AT, BE, BF, BJ, CF, 'LT RU, , SA , MA 'MZ AZ ,UY 'NA 'ZO 'SO 'en , AU 'ZI 'TT TK, ,MT LT, br' '9S ZE' 'Ld ON 'XW 'ds **В**О, RO, 'ZN 'MW 'NW WK' WC' WD' , AM 'ST KB' KZ' KC' KE' רא' רצ' rc' 1b, 'SI 'NI Kb' II' ID' 'ΩH CE' DW' EE' ES' EI' CB' CD' CH' CN' CB' CC' DE' , AD CH' DK' YE' YE' YW YI' YO' YZ' BY' BB' BC' BK' DESIGNATED STATES: W: .qq 802 PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines 

CI

Title compds. [1; X and Z represent each CH or N; Rl-3 represent each H, halogeno, alkyl, alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and

Ι

FS 3D CONCORD

GNTUSCOLINYLOXY]Phenyl]-N, N-diethyl- (9CI) (CA INDEX NAME)

RN 286370-86-3 REGISTRY

L3 ANSWER 107 OF 179 REGISTRY COPYRIGHT 2002 ACS

L3 ANSWER 107 OF 179 REGISTRY

L3 ANSWER 107 OF 179 REGISTRY

L4 ANSWER 107 OF 179 REGISTRY

L5 ANSWER 107 OF 179 REGISTRY

L6 ANSWER 107 OF 179 REGISTRY

L7 ANSWER 107 OF 179 REGISTRY

L8 A

WE CS4 HS6 CT N7 O4

 $\mathsf{A}\mathsf{A}$ 

PC SLM ETJ62: CY' CAPLUS' LOXCENTER SK CA

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

0

J KELEKENCEZ IN EITE CAPLOZ (1967 TO DATE)

T KELEKENCEZ IN EITE CA (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 . (asanaqat) APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: .DT , TG. SE' SN' rn' wc' wr' wk' ne' nr' bi' EI' EK' CH' CB' CK' IE' IL' E2' DK' 'IO CX' **'**50 BE' B1' CE' BE' ,TA RU, WD' 'ZX KG' CW' 'LT CH' TM; RW: , ZA 'ZN 'ຮດ **'**១៣ ,MA 'MZ ,AZ **'**NX ,AU 'ZJ 'LL TK'WT 'TS 'XS 'NA 'LT '១s br' 'ZN 'ON 'XW 'MW WK' WC' WD' , AM 'IS 2E' 'us RU, KO, 'La 'NW 'AT 'LT KB' Kb' KE' 'TI  $\Gamma B$ KZ, KC' 15**`** 'SI ID' rc' 'NI 'OH 'НВ 'SI rk' CH' CD' DK' CW' EI' CB' DW' EE' ES' CH' CN' CB' CN' DE' BX' CY' CE' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, .qq 80S DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan).

AA

CI

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal aralkyl], pharmaceutically acceptable salts and solvates, and medicinal and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = tested.)

TC SLM ETJ6S: CY CYBFNS' LOXCENLEK SK CY

I BELEBENCES IN LITE CAPTOR (1904 TO DATE)
I BELEBENCES IN LITE CA (1904 TO DATE)

10606651 \$79852-6661 dr :12506661 PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: . (asansqst) .DT , TG. EI' EB' CB' CB' CB' IE' IL' FO' MC' MF' MB' NE' NF' BL' SE' SN' E2' CX' DE' ′ອວ CI' CW' CH' BE' B1' CE' RM: AT, BE, 'LT **к**и, WD' 'ZX :MT 'NX ′ິຣດ **'**១៣ , AU 'MZ 'YZ 'IS 'ZY ,MA 'NA 'ZO 'ZJ 'LL TR, 'WI 'CJ 'IS **к**и, KO, 'Ld br' 'ZN 'NW WK' WC' '១ន ZE' ON 'XW 'MW MD, , AM ap, Kb' KC' 'TI rn'  $_{\rm LT}$ 'ST rc' rk' rb' KB' KZ' 1b' KE' 'SI 'NI ID' **'**OH 'НВ DW' EE' ES' EI' CB' CD' CE' ,AD CW' cH' DK' Cn' CZ' DE' CH' CN' CB' BX, YE' YI' YW' YI' YN' YZ' BY' BB' BC' BB' DESIGNATED STATES: W: .qq 802 PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

Title compds. [1; X and Z represent each CH or N; Rl-3 represent each optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all

Ι

ЯA

CI

of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I <math>(X = and causing no morphol. CH; R1, R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. Thested.

**SLN Liles:** 

 $\Gamma C$ 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

CA, CAPLUS, TOXCENTER

I BEFERENCES IN FILE CAPLUS (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: (Japanese) EI' EK' GB' GB' IE' IL' TN' WC' WT' WB' NE' NT' EL' SE' CX' BE' B1' CE' CG' CH' CI' CW' TM; RM: AT, BE, WD' DE' 'LI **r**U, 'NX , SA , MA 'MZ ,AZ 'NA 'ZN 'ຮກ 'LT ne' , AU TR, 'ZL bľ' 'DS LT, 'NW 'ES 'ds КΩ, RO, 'ZN 'ON 'XW 'MW WK' WC' WD' rc' KK' 'SI 'TI 'ST KC' KE' LT, רא' רצ' 'ZX Kb' 'dΓ 'NI ID' DK' EE' ES' EI' GB' GD' GE' DW' CH' CN' CB' CO' CZ' DE' YE' YT' YW' YI' YO' YZ' BY' BB' BC' BK' DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:132735 Preparation and anti-tumor, anti-atherosclerosis,

ΙĐ

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, halogeno, alkyl, alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all aralkyl or alkyltoarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl), pharmaceutically acceptable salts and solvates, and medicinal aralkyl or alkyltoarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl), pharmaceutically acceptable salts and solvates, and medicinal aralkyl), pharmaceutically acceptable salts and solvates, and medicinal aralkyl or alkyltoarbonyl; and R11 represents alkyl, alkynyl or aralkyl), pharmaceutically acceptable salts and solvates, and medicinal aralkyl or alkyltoarbonyl; and R11 salts and solvates, and medicinal aralkyl or alkyltoarbonyl, and R11 salts and solvates, and medicinal aralkyl or alkyltoarbonyl; and R11 salts and solvates, and medicinal aralkyl or alkyltoarbonyl, and R11 salts and solvates, and medicinal aralkyl or alkyltoarbonyl, and R12 salts and solvates, and medicinal aralkyl or alkyltoarbonyl, and R12 salts and solvates, and medicinal aralkyl or alkyltoarbonyl, and R12 salts and solvates, and medicinal aralkyltoarbonyl aralkyltoarbonyl

Ι

EZ 3D CONCOKD

MY 286370-83-0 REGISTRY

CM Urea, W-[2-chloro-4-[[6-methoxy-7-[2-(4-methyl-1-piperazinyl)ethoxy]-4
RM 286370-83-0 REGISTRY

L3 ANSWER 110 OF 179 REGISTRY

COPYRIGHT 2002 ACS

2В СУ WL C50 H33 CT N0 O4

tested.

ΑA

TC STN Files: CA, CAPLUS, TOXCENTER

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BELEBENCES IN EITE CAPIUS (1967 TO DATE)
I BELEBENCES IN EITE CA (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 .DT , TT. APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: (Japanese). DK' EI' EB' CB' CB' CB' IE' IL' FN' WC' WF' WB' NE' NF' BL' SE' SN' 'SE CI' CW' CH' BE' B1' CE' BE' ,TA :WA ;MT 'LT 'XO 190 **'**∩ਮ 'AW **1**23 KG' 'MZ 'YZ 'NΛ **'**១៣ ,AU TR'MT 'LI 'TS ,2A 'NX 'zo 'so 'TT **'**X8 , MA 'ZL 'XS 'XW '១ន ₽U, LT, 'Ta 'ZN ON 'MW 'NW WK' WC' 'UW , AM 'TS ZE' 'ds KO, ra' 'ZX KE' 'TI 'ST rc' rk' rk' Kb' KB' 1b, 'SI 'NI רח' 'LT KC' ID' 'OH HB, DK' CH' CN' CB' CO' CZ' DE' BX**'** DW' EE' ES' EI' CB' CD' CE' , AD CW' CH' YE' YE' YW' YI' YO' YZ' BY' BB' BC' BK' .qq 802 DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, halogeno, alkyl, alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all astalkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl), pharmaceutically acceptable salts and solvates, and medicinal aralkyl), pharmaceutically acceptable salts and solvates, and medicinal and causing no morphol. change in cells. Thus, the title compd. I (X = 0.000) and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = 0.000) and causing no morphol cach and H; R11 = 3,5-F2C6H3) was prepd. and

Ι

CN Dres, N-[2-chloro-4-[[6-methoxy-7-[4-(4-morpholinyl)butoxy]-L3 ANSWER 111 OF 179 REGISTRY COPYRIGHT 2002 ACS

EZ 3D CONCOWD

drivazolinylloxylphenyll-N'-propyl- (9CI) (CA INDEX NAME)

CM Urea, N-[2-chloro-4-[[6-methoxy-7-[4-(4-morpholinyl)butoxyl-4-

WE C57 H34 C1 N5 O5

SR CA STILLS TO

LC STN Files: CA, CAPLUS, TOXCENTER

Searched by: Mary Hale 308-4258 CM-1 12D16

CI

I KEEEKENCER IN EITE CAPINR (1964 TO DATE)
I KEEEKENCER IN EITE CA (1964 TO DATE)

.70909991 423524 19990991 PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 (Japanese). APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: E2' EI' EK' CB' CB' CK' IE' II' FA' WC' WF' WK' NE' NF' BL' SE' SA' DK' CX' DE' CI' CW' CH' **'**50 BE' B1' CE' TM; RM: AT, BE, 'LT **В**И, 'GW **'**23 KC' **'**90 , ZA 'MZ 'AZ 'NA 'NA 'ZN 'SN , AU TR, ,MT **'**C.L. 'XS BX, ,MA 'ZL 'LT 'Ld bľ' WK' 'IS 'ds 'NW WC' WD' '១ន 'AS ко, ки, 'ZN 'ON 'XW 'MW , AM 'AT KC' 15' KE' 'SI 'NI 'TI ID' T.T. 'ST KB' KZ' TC' TK' TB' Kb' 'OH DK' DW' EE' ES' EI' CB' CD' CE' CH' CN' CB' CO' CZ' DE' CW' CH' ,AD AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, DESIGNATED STATES: W: .qq 802 PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:132735 Preparation and anti-tumor, anti-atherosclerosis,

ΙĐ

Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent each H, alkylostonyl; and R11 represents alkyl or alkylostonyl; and R11 represents alkylostonyl; and R11 represents alkylostonyl; and R12 represents alkylostonyl; and R11 represents alkylostonyl; and R12 represents alkylostonyl; and R13 represents alkylostonyl; alkylostonyl; and R13 represents alkylostonyl; alkylostonyl; alkylostonylistics alkylostonyl

ЯA

aralkyl), pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; Rl, R4, R5,R7-Rl0 each an H; Rll = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 112 OF 179 REGISTRY COPYRIGHT 2002 ACS

CM Urea, N'-[2-chloro-4-[[6-methoxy-7-(4-pyridinylmethoxy)-4quinazolinylloxy]phenyll-N,N-diethyl- (9CI) (CA INDEX NAME)

CM 286370-81-8 REGISTRY

quinazolinylloxy]phenyll-N,N-diethyl- (9CI) (CA INDEX NAME)

WE CSC HSC CT N2 OF E2 3D CONCOKD

TC 2LM ETTES: CY' CAPLUS' LOXCENTER 2K CA

1007.110 110 100777.1117.07

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BELEBENCES IN EITE CAPINS (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 . (asanaqat) APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: EI' EB' GB' GB' IE' IL' TO' MC' MT' MB' NE' NT' BL' SE' CX' CI' CW' CH' IM; BM: FI, BE, BJ, CF, CG, 'LT WD' 'MZ **'**១៣ 'UX 'NA 'ZD 'ZJ 'LL TR, ,MA , AS 'ទព , AU ZE' br' 'XW 'MW WK' we' **В**И, 'ZN 'ON 2D PT, RO, 'NW WD' 'LT KB' KZ' PC' Kb' 'NI 'TI רא' רצ' KE' KC' ID' 'ST 1b, 'SI CH' CN' CB' CO' CZ' DE' DK' DW' EE' ES' EI' CB' CD' CE' CH' YE' YF' YW YI' YO' YZ' BY' BB' BC' BB' DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:132735 Preparation and anti-tumor, anti-atherosclerosis,

ЕI

ЯΑ

Title compds. [1; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = the composition of R5-8 and R6-1 and R6

TC STN Files: CA, CAPLUS, TOXCENTER

р-Ртин - Ç- ин СТ МеО МеО МеО МеО МеО МеО

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

0

J KELEKENCES IN EITE CAPLUS (1967 TO DATE)

J REFERENCES IN EITE CA (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: (Japanese) .DT , TG. GB' GK' IE' IL' TO' WC' WT' WK' NE' NT' LL' SE' SN' E2' EI' EB' CB' DK' CH' CI' CW' CX' DE' **'**၅၁ BE' B1' CE' BE' TA : WA :MT 'LT **,**UЯ WD' 'ZX KG' 'NX 'NA 'ZN 'ຮດ **'**១៣ , ZA 'MZ ,AZ ,AU 'ZI 'LL 'AT ,MT 'TS.'XS ,MA 'LI 'ĐS 'Ld br' 'ZN 'ON 'XW 'MW 'NW RU, WK' WC' WD' 'IS 2E' 'ds ВO, 'AM 'VJ Kb' 'TI LT, ГВ**'** ΓK' KC' KE' 1b, 'SI 'NH KE' KY' TC' 'NI 'ЯН **'**∩T 'ST 'dI 'H5 DK' CF, DW' EE' ES' EI' CB' CD' CE' CO' CZ' DE' CH' CN' CB' BX, AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, .qq 802 DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan).

Title compds. [1; X and Z represent each CH or N; Rl-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and

Ι

dnrugzojruk]oxk]bhenk]-N.-brobkl- (9CI) (CA INDEX NAME)
CM Orea, N-[2-chloro-4-[[6-methoxy-7-[[5-(4-morpholiny))pentyl]oxy]-4L3 ANSWER 114 OF 179 REGISTRY COPYRIGHT 2002 ACS

Lested.

PC STN Files: CA, CAPLUS, TOXCENTER

CS8 H30 CT N2 O2

ЗД СОИСОВД

WE.

EZ

ЯA

EI

I KEFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

CI 1060661 \$79897-6661 dr :12906661 PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. . (Japanese). CODEN: BIXXDS: .DT , TG. E2' EI' EK' CH' CB' CK' IE' IL' TN' WC' WT' WK' NE' NT' BL' ZE' CX' DE' CI' CW' 'HO **'**90 BE' B1' CE' TM; RM: AT, BE, 'LT **к**и, WD' 'ZX 'NX ne**'** , AU , ZA 'MZ 'YZ 'NA 'ZO 'SO 'ZL ,AT 'CI ,MA 'LL ,MT '១s LT, 'ON KO, 'Ta 'ZN 'NW WK' WC' 'IS ZE' 'ds 'በዝ 'XW 'MW 'dW , AM 'AT KZ' rc' 'SI LT, LU, Kb' KB' 15' KE' KC' 'NI ID' нв, 'ST רא' דא' 'TT' 'OH DK' DW' EE' ES' EI' GB' GD' GE' CH' CN' CB' CD' DE' , AD CH' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:132735 Preparation and anti-tumor, anti-atherosclerosis,

stkyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of  $R_2-8$  do not represent H simultaneously;  $R_3$  and  $R_10$  represent each  $R_1$ H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; R1-3 represent each H,

Ι

ЯA

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Kl, R4, R5, R7-R10 each an H; R11 = 3, S-F2C6H3) was prepd. and tested

L3 ANSWER 115 OF 179 REGISTRY COPYRIGHT 2002 ACS
CN Urea, U-[2-chloro-4-[[6-methoxy-7-(4-pyridinylmethoxy)-4-

3D CONCOBD

dnruszojruh] oxy] byenyl] - N, -propyl (9CI) (CA INDEX NAME)

WE CS2 HS4 CT N2 O4 E2 3D CONCOBD

TC ZLM ETJ62: CY' CYBLNS' LOXCENLEK ZK CY

NEOVOL /GOT WO /VO :COTTL NIG OF

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I KELEKENCES IN EITE CAPIUS (1967 TO DATE)

10606661 \$Z989Z-6661 dr :1Z906661 PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: . (Japanese) .DT , GT CB' CK' IE' IL' FN' WC' WF' WK' NE' NF' BL' SE' E2' DK' EI' EB' CB' 'ອວ CW' CX' 'IO CH' TM; KM: AT, BE, BF, BJ, CF, RU, WD' 'ZX 'LT KC' 'NX **'**១៣ , AU 'TS 'MZ 'AZ 'NA 'ZO 'SO 'ZI 'TT TR'MT 'LT 'XS BX' 'Z\ , MA ₽U, 'ON 'NW WK' WC' , AM 'ΛΊ 'IS 'DS 2E' KO, 'La WD' 'ds NS' br' 'XW 'MW KB' Kb' KC' 'SI 'TI 'LT 'ST LR, rk' 'NI ID' **′**ΩH KZ' rc' 1b' KE' **,**ЯН **'**חד CH' CE' DK' CN' CH' BY, CA, DW' EE' ES' EI' GB' GD' cn' cz' DE' CK' **'**W9 YE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, .qq 80S DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:132235 Preparation and anti-tumor, anti-atherosclerosis,

CH: Z = CH: KJ, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X = compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sikyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H' palogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [1; X and Z represent each CH or N; R1-3 represent each H,

Ι

Urea, N-[2-chloro-4-[7-(2-hydroxyethoxy)-6-methoxy-4-СИ S89310-11-S KECISLKK ВИ ANSWER 116 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma$ 3

drinazolinyl]oxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)

ЗД СОИСОВД ES

ЯΑ

CSI HS3 CT N4 O2 WE

AD SK

CY' CYPLUS, TOXCENTER SIN Files: ГC

Meo  $HO - CH^{5} - CH^{5} - O^{2}$ 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I KEEEKENCES IN EILE CA (1967 TO DATE)

and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:132235 Preparation and anti-tumor, anti-atherosclerosis,

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: . (əsənaqat) TD, TG. EI' EK' CH' CB' CK' IE' IL' FN' WC' WF' WK' NE' NF' BL' SE' SN' E2° DK' CI' CW' CK' BE' ,UT **,** עא WD' 'ZX KC' BE' B1' CE' CC' CH' TA : WA ;MT 'NX 'NA ′ຮ∩ **'**១៣ 'Z¥ 'MZ 'AZ 'ZΩ **,**AU 'ZI 'LL 'AT 'MT 'TS 'XS ,MA 'CL **У**ОУ KO, 'Id br' 'ZN 'ON 'ES 'XW 'MW 'NW WK' '9W , AM 'IS **1**98 'ds WD' rn' 'ZX KB' Kb' 'TI 'LT 'ST KG' KE' 1b, 'SI rc' rk' rk' 'NI ID' 'OH **ЧВ** rn' DK' CH, CH' **,**AD DW' EE' ES' EI' GB' GD' GE' CN' CK' CO' CZ' DE' CW, BK' YE' YI' YW' YI' YO' YS' BY' BB' BC' BK' .qq 80S DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan).

Title compds. [1; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or arelkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or arelkyl or alkylcarbonyl; and R11 represents and solvates, and medicinal arelkyl], pharmaceutically acceptable salts and solvates, and medicinal and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. CH: R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and

Ι

ME CSS HS2 CT N¢ O2

EZ GONCOKD

CN OLE&, N-[2-chloro-4-[[7-(3-hydroxypropoxy)-6-methoxy-4
CN S6370-76-1 REGISTRY

CN S6370-76-1 REGISTRY

CN S6370-76-1 REGISTRY

CN S6370-76-1 REGISTRY

CN INDEX NAME)

TC ZLM Eiles: CA, CAPLUS, TOXCENTER

tested.

ЯΑ

CI

I BELEBENCES IN LIFE CALUS (1967 TO DATE)

J RELEBENCES IN FILE CA (1967 TO DATE)

CI 10000651 tZ9827-6661 df :1Z906661 PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS' . (asanaqat) EI' EK' CB' CB' CK' IE' IL' FA' MC' MF' MB' NE' NF' EL' 2B' 'ID TM; RW: AT, BE, BF, BJ, CF, CG, CH, 'LT RU, 'NX 'MZ , A.Z 'NA 'ZO 'SO ne' , AU 'ZJ 'LL TR, TW, 'LT **В**О, KO, 'La 'Ta 'ZN 'XW 'NW '១ន 'dS ON 'MW WK' WC' KE' KE' KZ' TC' TK' TB' KC'  $\text{KE}^{oldsymbol{\prime}}$ 'SI 'LT 'ar 'NI 'TI ID' DK' DW' EE' ES' LI' CB' CD' CE' CH' CN' CB' CD' CZ' DE' (A) YE' YT' YW' YI' YN' YZ' BY' BB' BC' BB' DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:132235 Preparation and anti-tumor, anti-atherosclerosis,

Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, palkyl or alkylcarbonyl; and R11 represents alkyl or alkylcarbonyl; and R11 represents alkyl or

a H

CH:  $\Sigma$  = CH: KJ, R4, K5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X = compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal

CS2 H30 CJ N2 O2 3D CONCORD EZ dninazolinyl]oxy]phenyl]-N'-propyl- (9CI) (CY INDEX NAME) Urea, N-[2-chloro-4-[[6-methoxy-7-[2-(4-morpholinyl)ethoxy]-4-CM 786370-75-0 REGISTRY КИ ANSWER 118 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma3$ 

STN Files:  $\Gamma C$ AD SE

CY' CAPLUS, TOXCENTER

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 CODEM: BIXXDS: . (seansqst) APPLICATION: WO 2000-JP255 20000120. EI' EK' CF' CB' CB' IE' IL' IN' MC' MT' MK' NE' NI' BL' SE' MD' KN' L1' LW' BE' BE' BL' CE' CC' CH' CI' CM' CK' WD' CX' **'**១៣ ,AU 'LI 'nx 'TT TK, 'MT 'ZA ,MA 'MZ , AZ 'NA 'ZO 'នព 'ZI 'DS ₽Ľ, 'XW 'NW WK' 'IS KO, LT, ZE' 2D' КU, 'ZN ON 'MW WC' WD' rl' **rk' rb'** rc' 'ZX KB' KG' KE' 'SI 'NI רח' 'ST Kb' la, ID' EE' ES' EI' CB' CD' CH' CM' CB' CC' DE' 'AD CH' CE' DK' DW' YE' AL' AM' AT' AU' AZ' BB' BB' BB' DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEEEKENCE 1: 133:132732 Preparation and anti-tumor, anti-atherosclerosis,

CI

WE

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = tested.

Ι

СИ ОХЕВ, И-[2-сhloro-4-[[6-methoxy-7-[3-(4-morpholiny Ви 286370-74-9 REGISTRY LASMER 119 OF 179 REGISTRY COPYRIGHT 2002 ACS

drinazolinyl)oxy]phenyl]-N'-propyl- (9CI) (CA INDEX NAME)

quinazolinyl)propoxyl-4[[6-methoxy-7-[3-(4-morpholinyl)propoxyl-4-

WE CSC H3S CT N2 O2 E2 3D CONCOKD

ЯΑ

SK CA

LC STW Files: CA, CAPLUS, TOXCENTER

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

J KELEKENCES IN EITE CAFORS (1964 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin

N - CO - N - BII

6Я

В6

ςЯ

R10

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, nalogeno, alkyl, alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, aralkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl), pharmaceutically acceptable salts and solvates, and medicinal and causing no morphol. change in cells. Thus, the title compd. [(X = and causing no morphol. change in cells. Thus, the title compd. I (X = tested.)

qiwethyl- (9CI) (CA INDEX NAME)

CH; Z = CH; RI, R4, R5,R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and causing no morphol. Character.

and causing no morphol. Characters. Thus, the title compd. 1 (X = and causing no morphol. Characters.

CC STN Files: CA, CAPLUS, TOXCENTER

MF C19 H19 C1 N4 O4

ЗД СОИСОКД

ΤЯ

ΙĐ

EZ

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: bixxDS: . (asənaqat) .Dr TG. DK' EI' EK' CY' CB' CK' IE' IL' FO' WC' WF' WK' NE' NF' BL' SE' SN' E2' ,TA CX' DE' BE' B1' CE' CC' CH' CI' CW' BE' 'LI **,**ขя WD' 'ZX KC' TM; RW: 'ຮດ **1**90 , SA 'MZ 'AZ 'NA 'NA 'ZN ,AU 'ZI 'LL ,AT 'MT 'LI 'TS 2K' ,MA br' 'ZN 'XW '១s RU, PT, RO, 'ON 'NW WK' '9W WD' , AM 'IS ZE' 'ds 'MW rn' Kb' 'TI rn' rL' 'SI KE' KZ' PC' PK' PE' KC' KE' 'SI ID' 'ΩH 1B, 'NI **'**HB DW' EE' ES' EI' GB' GD' GE' DE' CH' DK' 'AD CW' cn' cz' CH' CN' CB' BX**'** YE' YI' YW' YI' YO' YY' BB' BB' BB' .qq 802 DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan).

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BELEBENCES IN EITE CALINS (1967 TO DATE)

J BELEBENCES IN EITE CA (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: . (asanaqat) .DT , TG. E2' EI' EK' CB' CB' CB' IE' IL' FA' WC' WF' WB' NE' NF' BL' SE' SA' DK' 'IO 'XD CW' CH' ′ອວ BE' B1' CE' TM; RM: AT, BE, 'LT **к**и, 'ตพ **'**ZX ne' 'Z∀ 'MZ ,AZ 'OX 'NA 'ZO 'SO ,AU ,TT T $\mathbf{F}$ ,MT 'C.L. 'TS ,MA 'ZT 'XW 'IS '9S ки, 'ON 'MW 'NW WK' WC' WD' 'ES 'ds PT, RO, 'Ta 'ZN , AM **'**^T KE' 1b, 'SI 'NI Ir' **'**0T T.T. 'ST רא' רצ' KE' KE' KZ' TC' KC' 'OH ID' **'**ਮਮ BX' CY' DW' EE' ES' EI' GB' GD' GE' DK' CH' CN' CB' CO' CZ' DE' CW' CH' YE' YE' BW' YI' YO' YZ' BY' BB' BC' BK' .qq 80S DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

Title compds. [1; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, palkyl or alkylcarbonyl; and R11 represents alkyl or of R5-8

ЯA

CI

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X= CH; Z= CH; R1, R4, R5, R7-R10 each an H; R11=3, S-F2C6H3) was prepd. and

CA, CAPLUS, TOXCENTER SIN Files:  $\Gamma C$ AD SECT8 HIA CT N4 O4 WE ЗД СОИСОВД EZ (CY INDEX NAME) (ID6) Orea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-methyl-CN586370-72-7 REGISTRY ВИ PN2MER 121 OF 179 REGISTRY COPYRIGHT 2002 ACS ГЗ

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BELEBENCES IN EITE CAPLUS (1967 TO DATE)

I BELEBENCES IN EITE CA (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 . (asanaqat) APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: TD, TG. EI' EK' CF' CB' CK' IE' IL' TN' WC' WT' WK' NE' NT' BL' SE' SN' E2' DK' CI' CW' CX' BE' TA : WA ;MT **к**и, 'ZX DE' BE' B1' CE' CC' CH' TI, WD' 'MZ AZ 'UY 'NV 'ZU 'SU ,AU 'ZI TR, 'TS BX' **,** 2A , MA ne' 'TT ,MT , CT NZ' br' 'IS PT, RO, RU, 'ON 'MW 'NW WK' '9W WD' , AM '១ន 2E 'ds 'XW 'AT KB' Kb' KE' 'SI 'TI 'LT 'ST KZ' TC' TK' TB' 1b, 'NI ID' 'NH rn' KC' нв, DW' EE' ES' EI' CB' CD' CE' CH' DK' CH' CN' CB' CO' CZ' DE' BX' CY' CW' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, DESIGNATED STATES: W: .qq 802 PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines 

CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal gjkyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H,

CN586370-71-6 REGISTRY КИ ANSWER 122 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma 3$ 

Urea, N'-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N,N-

ЗД СОИСОВД (CA INDEX NAME) diethyl- (9CI)

CSI HS3 CJ Nđ Ođ WE EZ

AA

SE

CA, CAPLUS, TOXCENTER **SLN ETTES:** ГC

Ef5N-CŢ O9M М€О

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 LD' CODEN: BIXXD5. APPLICATION: WO 2000-JP255 20000120. (Japanese) .DT E2' DK' GB' GK' IE' IL' TO' WC' WT' WK' NE' NT' 5L' SE' SN' EI' EB' CB' BE' B1' CE' CC' CH' CI' CW' CX' DE' BE' 'LT **к**и, WD' 'ZX TA : WA : MT KC' 'NX 'ຮ∩ **'**ອດ ,AU 'Z¥ 'MZ ,AZ 'NA 'ZN 'ZI 'LL TK, 'MT 'CT 'TS 'XS ,MA bľ' 'ZN 'ON '១ន צט, PT, RO, 'NW WK' we' WD' ,AM 'IS 2E' 'ds 'XW 'MW 'AT Kb' 'TI LT, 'ST ГВ**'** KC' 'NI ID' 'NH KE' KT' TC' TK' IS' 15' KE' 'НВ **'**∩⊤ DK' CW' DW' EE' ES' EI' GB' GD' GE' BX' CY' CH' CN' CB' CO' CZ' DE' CH' YE' YI' YW' YI' YO' YZ' BY' BB' BC' BK' .qq 80S DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan).

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl), pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. Change in cells. Thus, the title compd. I (X = and causing no morphol. Change in cells. Thus, the title compd. I (X = and causing no morphol. Change in cells. Thus, the title compd.

Ι

ES 3D CONCORD

Cyforophenyl)-W-methyl-.(9CI) (CA INDEX NAME)

CM Urea, N'-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-W-(4-L)

ES 3D CONCORD

CM Urea, N'-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-W-(4-L)

ES 3D CONCORD

CM Urea, N'-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-W-(4-L)

TC 2LM ETJ62: CY' CYBFN2' LOXCENLEK 2K CY

CS# HSO CJS N# O#

tested.

WE

ЯΑ

ΙĐ

FAGE 2-A

CJ |

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CAPLUS (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: . (əsənaqat) .DT , TG. DK' E2' E1' EK' GF' GB' GK' IE' IL' FN' MC' MF' ME' NE' AL' SE' SN' MD' Kn' In' IM; KM: FI' BE' BE' Bn' CE' CG' CH' CI' CW' CK' DE' US, UZ, VW, YU, AZ, AX, AM, AZ, BY, , au , st 'LL 'AT 'MT 'CT 'IS '9S 'ES MD' MC' MK' MN' MM' MX' NO' NZ' BF' BL' BO' BN' ZD' AM ,VJ KE' KE' KZ' TC' TK' TB' TZ' TL' TN' 15' KE' KC' 'SI 'NI ID' IF' CH' CN' CK' CO' CZ' DE' DK' DW' EE' EZ' EI' GB' GD' GE' GH' GW' BX' CY' YE' YI' YW' YI' YO' YZ' BY' BB' BC' BK' DESIGNATED STATES: W: Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 Al 20000727, and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KELEKENCE J: 133:132732 Breparation and anti-tumor, anti-atherosclerosis,

ЕI

CH: Z = CH: KJ, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal στκλτ οι στκλτασιρουλτ: συα κτι ιεριεεευε στκλτ' στκουλτ' στκλυλτ οι of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H' palogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H,

I

3D CONCORD EZ (CA INDEX NAME)  $wefp\lambda J-$  (aci) Orea, W-butyl-M'-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N-СИ 586370-69-2 REGISTRY ВИ PN2MER 124 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma 3$ 

CSS HS2 CJ N4 O4 WE

AD SK

AA

STN FILES:

CA, CAPLUS, TOXCENTER ГC

CJ Жe **O P** M MeO

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:132235 Preparation and anti-tumor, anti-atherosclerosis,

PCT Int. Appl. WO 2000043366 Al 20000727,

Beer Kabushiki Kaisha, Japan).

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or acaptyl, or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or acaptyl, or alkylcarbonyl; and R11 represents and solvates, and medicinal compns. contg. R4, R5,R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and CH; Z = CH; R1, R4, R5,R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and

EZ 3D CONCOKD

cybrobyl- (9CI) (CA INDEX NAME)

CM Urea, N'-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N,N
L3 ANSWER 125 OF 179 REGISTRY COPYRIGHT 2002 ACS

ZK CY WE CS3 HSJ CT N4 O4

CA, CAPLUS, TOXCENTER

ГC

ЯA

CI

SIN ETTES:

tested.

0

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BEEEBENCES IN EITE CAPLUS (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 . (Japanese). APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: .DT , TG. E2' DK' EI' EK' CB' CB' CK' IE' IL' FA' WC' WF' WK' NE' NF' BL' SE' SA' CA' DE' 'IO CH' BE' B1' CE' CC' TM; RM: AT, BE, 'LT ₽U, CW' WD' 'ZX ′នព ne' BX' 'MZ 'YZ 'NA 'NA 'ZN ,AU TR'MT 'CL ,MA 'ZJ 'TT 'IS '9S ₽Ľ, ON 'XW PT, RO, RU, 'ZN 'MW 'NW WK' WC' ZE' 'as 'UW , AM LT, KB' Kb' KC' KT' TC' KE' 1b, 'SI 'NI 'ST TK' ΓΚ' ידד' 'ar 'OH DW' EE' ES' EI' GB' GD' GE' DK' CH' CN' CB' CO' CZ' DE' ,AD CW' CH' BK' YE' YE' BW' YI' YO' YE' BB' BC' BK' DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:132235 Preparation and anti-tumor, anti-atherosclerosis,

Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent H simultaneously; R9 and R10 represent or alkylostonyl; and R11 represents alkyl or

Ι

ЯΑ

ЕI

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3, S-F2C6H3) was prepd. and

CA, CAPLUS, TOXCENTER **SLN Files:**  $\Gamma C$ SEAD CSS HS2 CJ N4 O4 WE ЗР СОИСОВР EZ (CA INDEX NAME) bropyl- (9CI) Urea, N'-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N-ethyl-N-СИ 586370-67-0 REGISTRY КИ ANSWER 126 OF 179 REGISTRY COPYRIGHT 2002 ACS ГЗ

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BELEBENCES IN LITE CALINS (1967 TO DATE)

I BELEBENCES IN LITE CA (1967 TO DATE)

CI 19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. . (seansqst) CODEN: BIXXDS' E2' E1' EK' GY' GB' GK' IE' IL' TN' WC' WT' WK' NE' NT' BL' SE' SN' CI' CW' CH' TM; RM: AT, BE, BF, CF, CG, WD' 'LL **'**Nצ 'OZ 'NA 'ZO 'SO 'DO 'ZJ 'LT TR, ,MA 'MZ , AS , AU TM, 'LT br' ,AM 'IS ĸп, 'Ld 'XW 'MW 'NW 'ĐS 'ES 'ds RO, 'ZN ON WK' WC' WD' 'LT rc' 'ZX KB' KC' II' Kb' 16' KE' 'SI 'NI 'ST ΓK, rk' ID' 'ΩH EE' ES' EI' CB' CD' CE' CH' CN' CB' CO' CZ' DE' 'AD CH' DK' DW' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sikyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of 85-8 do not represent H simultaneously; 89 and 810 represent each H, H' palogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [1; X and Z represent each CH or N; R1-3 represent each H,

Urea, N'-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy] Phenyl]-N-methyl-N-MethCN586370-66-9 REGISTRY ВИ PN2MER 127 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma 3$ 

(CA INDEX NAME) bropyl- (9CI)

ЗД СОИСОКД L2

CSI HS3 CI N4 O4 WE

AA

SRAD

**2LN Lijes:** CA, CAPLUS, TOXCENTER  $\Gamma C$ 

CJ Жe **O** > M Meo

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 . (Japanese) APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: 'UL GB' GK' IE' IL' TO' WC' WT' DK' MK' NE' NT' LL' SE' EI' EK' CH' E2' CX' 'IO **'**50 B1' CE' BE' ВЕ, TA :WA CW' CH' :MT 'CI RU, WD' 'nX **,** 2A 'M7 , AZ 'NA 'ZO 'នា **'**១೧ , AU 'ZJ LK' 'WT 'CI ,MA 'LL 'XS 'XW , AM LT' LT' 'IS 'ĐS 2E' 2D' КU, KO, 'ZN ON 'MW 'NW WK' WC' WD' 'AT 'LT KC' Ir' Kb' KB' KZ' TC' TK' TB' 1b' KE' 'SI 'nŢ 'ST 'NI ID' 'NH HB, DK' DW' EE' ES' EI' GB' GD' GE' Cn' CZ' DE' CN' CK' CH' CH' BX' CY' CW' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan).

ЯΑ

CI

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal aralkyl), pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = tested.

Ι

I (propylamine) carbonyl] - (9CI) (CA INDEX NAME)

[ (propylamine, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N
L3 ANSWER 128 OF 179 REGISTRY

CA INDEX NAME)

L3 ANSWER 128 OF 179 REGISTRY

COPYRIGHT 2002 ACS

2*B* C*Y* WE CSS HS3 CT N4 O2 E2 3D CONCO*Y*D

LC STW Files: CA, CAPLUS, TOXCENTER

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BELEBENCES IN LITE CHARRA (1964 TO DATE)
. I BELEBENCES IN LITE CF (1964 TO DATE)

. T9990521; TP 1999-253624 19990901. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 CODEN: bixxDS. . (Japaneget) TD, APPLICATION: WO 2000-JP255 20000120. . DT E2' DK' GB' GK' IE' IL' TO' WC' WT' WK' NE' NT' 5L' SE' SN' EI' EB' CB' CE' ,TA CX, CI', CW' CH' **'**၅၁ BE' BE' 'LT WD' 'ZX ;MT KC' La. :WA КU, , ZA 'MZ 'nx 'ຮດ BX' ,AZ 'NA 'ZN **'**១៣ ,AU 'ZI 'TT  $_{\mathsf{TR}}$ ,MT 'LT 'TS 'XS ,MA '9s ึกช 'La br' 'ZN ZE' KO, 'XW 'MW WC' , AM 'IS 'ds 'ON 'NW WK' WD' **'**\\T rc' 'ZX KK' 'LT rk' Kb' KC' KE' 'TI rn' 'ST rg, 'dr 'SI ID' **'**NH HE, 'NI E2' EE' DK' DE' CW' CH' EI' CB' CD' CE' cn' cz' CH' CN' CB' **C**W BX' DW' AL, AM, AT, AU, AZ, BA, BB, BG, BR, YE' DESIGNATED STATES: W: .qq 802 PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, halogeno, alkyl, alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylosrbonyl; and R11 represents alkyl, alkenyl, alkynyl or

ЯA

CI

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3, S-F2C6H3) was prepd. and tested.

ZB CA

NE C22 H25 C1 N4 O5

E3 CONCORD

CM Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N
RM 286370-64-7 REGISTRY

RM 286370-64-7 REGISTRY

CM Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N
RM 286370-64-7 REGISTRY

CM 286370-64-7 REGISTRY

CM 179 REGISTRY

CA, CAPLUS, TOXCENTER

SIN Files:

ГC

CI

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BELEBENCES IN EITE CALTOS (1967 TO DATE)

I BELEBENCES IN EITE CA (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. (Japanese) .DT , TG. CODEN: BIXXDS: GB' GK' IE' IL' FN' WC' WF' WK' NE' NF' BL' SE' SN' E2' DK' EI' EB' CB' ,TA WD' CX' DE' CE' CC' CH' CI' CW' BE' **,**иЯ 'ZX BE' B1' ;MT 'LT KC' EM:'ZN 'ຮດ **'**ອດ ,AU 'LT 'TS , ZA 'MZ 'AZ 'חג 'אא 'ZL 'TT TR'WT 'XS ,MA '១s **к**и**,** ₽Ľ, 'ZN 'ON 'XW WK' ,AM ZE' 'Td 'MW 'NW 'DW WD' **'**\1 'IS 'ds KO, rc' 'ZX **К**В' Kb' KC' KE' 'TI 'LT 'ST ΓK' 1b, 'SI ID' 'NH **'**BH rn'  $\Gamma K$ 'NI CH' CE' DE' 'HD CW' EZ' EI' CB' CD' DW' EE' cu' cz' CN' CK' DK' BX' CY' BC' BK' AB ,AB ,ZA ,UA ,TA ,MA ,JA .qq 802 YE' DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Jsoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:132835 Preparation and anti-tumor, anti-atherosclerosis,

Title compds. [1; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = tested.)

Ι

E2 3D CONCOKD

(ACI) (CF INDEX NAME)

(ACI) (CF INDEX NAME)

CN Ores, N-butyl-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]
L3 ANSWER 130 OF 179 REGISTRY COPYRIGHT 2002 ACS

WE CSJ HS3 N2 O9 E2 3D CONCOKD

SE CF HZ2 N2 OF

ЯΑ

CC STN Files: CA, CAPLUS, TOXCENTER

MeO MeO M

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I KELEKENCER IN EITE CALTOR (1964 TO DATE)

I KELEKENCER IN EITE CA (1964 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin

269xcy6q ph: Wary Hale 308-4258 CM-1 12D16

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: bIXXD5. TD, TG. (Japanese) E2' GB' GK' IE' IL' TO' WC' WT' WK' NE' NT' 5L' SE' SN' EI' EB' CB' DK' CX' DE' CH' CI' CW' **'**១၁ BE' BE' B1' CE' TA : WA :MT 'LI **,** עא WD' 'ZX KC' ′ິຣດ **'**១೧ , ZA 'MZ ,AZ 'NX 'NA 'ZN ,AU 'ZI 'TT TR, 'MT 'LI 'TS ,MA 'ON **,**UA BO, 'ZN 'XW 'MW 'NW WK' '9W WD' , AM 'IS '១ន ZE' 'dS 'Td 'Td 'AT Kb' KC' 'TI 'LT 'ST ΓK,  $\Gamma K$ KE' 1b, 'SI 'NI ID' **′**ΩH KE' KT' TC' **'**'8'H CH' CN' CK' CN' CZ' DE' **'**HĐ CE' DK' DW' EE' ES' EI' GB' GD' **,**AD **'**W5 BX' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, .qq 802 DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan).

Вđ Ι .ξЯ 8Я Вλ Вζ N - CO - N - BIIВŢ ВŢО 6Я 9И ςИ

compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sikyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H,

tested. CH; Z = CH; RI, R4, R5,R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X =

CA, CAPLUS, TOXCENTER **SLN Files:**  $\Gamma C$ AD SECSO HSI N2 00 ME

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-nitrophenyl]-N'-propyl-

(CY INDEX NAME)

PARMER 131 OF 179 REGISTRY COPYRIGHT 2002 ACS

586370-62-5 REGISTRY

ЗД СОИСОКД

(ID6)

ES

CN

КИ

ГЗ

ΑA

CI

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BEEEBENCES IN EIFE CABINS (1967 TO DATE)
I BEEEBENCES IN EIFE CA (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: (Japanese). .DT , dT E2' NF' LL' SE' SN' DK' EI' EK' CH' CB' CK' IE' IL' TN' WC' WT' WK' NE' 'ID CX' DE' CH' **'**១၁ BE' B1' CE' TM; RW: AT, BE, 'LT 'ZX MD, RU, CW' KC' 'ຮດ **'**ÐΩ ,AU 'Z\ ,MA 'MZ 'AZ 'הג 'אא 'צה TE, 'WI 'C.L. 'TS 'ZI 'TT 'XS 'ZN '9s EUKO, 'NW WK' WC' WD' , AM 'ES 'ds 'Id 'Id 'ON 'XW 'MW 'Λ'I Kb' 'ST  $\Gamma B$ ľK' KB' KZ' TC' 'SI 'TI ID' 'nNH LT, LU, KC' 1b' KE' 'NI **'**YH CE' CK'AD BX' ch' cw' DW' EE' ES' EI' CB' CD' DK' Cn' CZ' DE' CH' CN' YE' YI' YW' YI' YO' YZ' BY' BB' BC' BK' .qq 802 DESIGNATED STATES: W: Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 Al 20000727, and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H, halogeno, alkyl, alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or

ЯA

CI

CH; Z = CH; RI, R4, R5,R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal

CS2 HS4 N4 O2 MEЗД СОИСОВД EZ (CA INDEX NAME) werpoxlbpenll (9CI) Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methylphenyl]-N'-(2-CN586370-61-4 REGISTRY ВИ PN2MER 132 OF 179 REGISTRY COPYRIGHT 2002 ACS ГЗ

CA, CAPLUS, TOXCENTER **SLN Files:**  $\Gamma C$ SK

A<sub>D</sub>

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

CI 19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS. . (asanaqat) .DT , TG. GB' GK' IE' IL' FN' WC' WF' WK' NE' NF' BL' SE' SN' EI' EB' CB' DK' 'ID **'**90 TM; RM: AT, BE, BF, BJ, CF, WD' DE' CW' CH' 'LI ВU, 'ZX KC' CX\* 'MZ 'YZ 'NA 'NA 'ZN 'ຣ∩ ,AU TR'LT 'TS 12.∀ ne' 'LL 'MT BX' , MA 'ZL Ld' br**'** 'DS ВU, KO, 'ZN ON 'XW 'MW 'NW WK' WC' WD' , AM 'AT 'IS ZE' 'ds 'TI KK' KZ' TC' Kb' KE' 1b, 'SI 'NI ID' 'NH רח' 'LT 'ST רא' רצ' KC' 'ЯН DW' EE' ES' EI' CB' CD' CE' DK' CH' CH' CN' CB' CO' CZ' DE' BX' CY' CW, YE' YE' YW' YI' YO' YZ' BY' BB' BC' BK' .qq 802 DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:132235 Preparation and anti-tumor, anti-atherosclerosis,

**8A** 

Title compds. [1; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbopyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbopyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbopyl; and R11 represents and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = tested.

TC ZLM LTJ62: CY CYBFN2' LOXCENLEK ZK CY

MeO MeO MeO

**PAGE 2-A** 

POPERTY DATA AVAILABLE IN THE 'PROP' FORM

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BELEBENCES IN EITE CALINS (1967 TO DATE)
I BELEBENCES IN EITE CA (1967 TO DATE)

E

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 (lapanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. .DT , TG. DK' ES' EI' EK' GF' GB' GK' IE' IL' FA' MC' MF' MK' NE' NF' EL' SE' SA' KG' KZ' MD' KA' LA' LA' BK: FL' BE' BE' BA' GE' CG' CH' CI' CW' CK' DE' TZ, UA, UG, US, UX, VV, ZA, AM, AA, AZ, BY, 'TT 'TS TJ, TM, TR, 'XS RE' RG' RI' LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, HB' HA' ID' IT' IN' IS' AB' KE' KE' KB' KX' TC' TK' TB' TZ' TA' TA' CH' CN' CB' CO' CZ' DE' DK' DW' EE' EZ' LI' GB' GD' GE' GH' GW' BX' CY' YE' YT' YM' YI' YN' YY' BB' BB' BB' BB' DESIGNATED STATES: W: .qq 80S PCT Int. Appl. WO 2000043366 AL 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

CI

Title compds. [I; X and Z represent each CH or N; RI-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkylox contg. the same are prepd. and tested having antitumor activity axalkyl], pharmaceutically acceptable salts and solvates, and medicinal axalkyl], pharmaceutically acceptable salts and solvates, and medicinal axalkyl], pharmaceutically acceptable salts and solvates, and medicinal exalkyl], pharmaceutically acceptable salts and solvates, and medicinal represents alkyl or alkynyl or alkylcarbonyl; and R11 represents alkyl or alkynyl or alkynyl or alkylcarbonyl; and R12 represent alkylcarbonyl; and R13 represent as alkylcarbonyl; alkoxylcarbonyl; and R14 represent as alkylcarbonyl; alkoxylcarbonyl; and R14 represent as alkylcarbonyl; and R14 represent as alkylcarbonyl; and R15 represent as alkylcarbonyl; and R

I

ZB CS HSO ES N4 O4

WE CST HSO ES N4 O4

EZ 3D CONCOBD

Wethylphenyl] - (9CI) (CA INDEX NAME)

CM Orea, N-(2,4-difluorophenyl)-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2
RN 286370-58-9 REGISTRY

LS ANSWER 134 OF 179 REGISTRY

LS ANSWER 179 REGISTRY

LS AN

PAGE 1-A

CA, CAPLUS, TOXCENTER

**SLN LIJGS:** 

TC

**BA** 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

CI 19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: . (asanaqat) .DT , TG. GB' GK' IE' IL' TO' WC' WT' WK' NE' NT' bL' SE' SN' DK' ES' EI' EK' CH' 'IO TM; RW: AT, BE, CX' DE' BE' B1' CE' CC' RU, WD' 'ZX CH' 'LT CW' KC' 'NX **1**90 ,AU 'TS , ZA 'MZ ,AZ 'พก 'ซก 'รก TR'MT ,MA 'ZI 'LL 'LT 2K' br' '១ន **,**UЯ KO, LT, 'ZN 'ON 'XW 'MW 'NW WK' WC' WD' , AM 'IS ZE' 'ds 'ΛT rc' Kb' KC' 'TI 'LT 'ST rg' rk' KB' KZ' 15' KE' 'SI 'NI ID' 'NH HB, DK' CH' CW' CE' DW' EE' ES' EI' CB' CD' Cn' CZ' DE' CH' CM' CK' , AD BX\* YE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, DESIGNATED STATES: W: .qq 802 PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:132735 Preparation and anti-tumor, anti-atherosclerosis,

N - CO - N - BJJ $\cap$ ВŢ 01<sub>A</sub> 6Я Вę БЯ

Ι Вđ ЪЯ 8Я  $\mathbb{F}^7$ ВS

ЯA

tested. CH; Z = CH; RI, RI, RI, RI, RI = 3, RI = 3, RI = 3, RI = 3, RIand causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal stkyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of Rb-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all obfronally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [1; X and Z represent each CH or N; R1-3 represent each H,

Urea, W-butyl-M'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-methylphenyl]-СИ Z86370-56-7 REGISTRY ВИ PN2MER 132 OF 179 REGISTRY COPYRIGHT 2002 ACS ГЗ

CI 19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 CODEN: BIXXDS. APPLICATION: WO 2000-JP255 20000120. .(Japanese). .DT , TG. DK', E2' E1' EK' CF' CB' CK' IE' IL' TN' WC' WT' WK' NE' NT' BL' SE' SN' CX' DE' CI' CW' IM; EM: FI' BE' B1' CE' CG' CH' Ke' KZ' WD' Bn' L1' 'NX AZ, BY, 'MZ ,AZ 'NA 'ZN 'SN ,au ,ar 'TT TM, TR, 'CI 'TS ,MA 'ON 'IS 'DS 'ds RO, 'Id 'Td 'ZN WK' **'**Λ٦ ZE' BU'XW 'MW 'NW MA, MD, MG, LT, LU, 'ST ΓK, Kb' KB' KZ' KG' 'SI rc' rk' 15' KE' 'NI 'TI HB' HO' ID' CH' CW' CE' BX' CY' DW' EE' ES' EI' CB' CD' DK' Cn' CT' DE' CH' CN' CK' YE' YI' YW' YI' YO' YZ' BY' BB' BG' BK' .qq 80S DESIGNATED STATES: W: Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 Al 20000727, and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

I REFERENCES IN FILE CAPLUS (1967 TO DATE)

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

TC ZLM ETTGE: CY' CYBINS' LOXCENLEK ZK CY

WE CSS HS RN OF ES 3D CONCOKD

3D CONCOBD (ACI) (CV INDEX NAME)

 $\Gamma C$ 

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl), pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = the same are prepd. and tested having antitumor activity and season and causing no morphol. change in cells. Thus, the title compd. I (X = the same are prepd. and tested having antitumor activity and season and causing no morphol. change in cells. Thus, the title compd. I (X = the same are prepd. and tested having antitumor activity and season and se

CA, CAPLUS, TOXCENTER

**SIN Files:** 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I KELEKENCES IN EITE CALTOS (1967 TO DATE)

CI 19990521; JP 1999-253624 19990901 PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. ·(Japanese)· . DI TD, CODEN: BIXXDS: EI' EK' CH' CB' CK' IE' IL' FN' WC' WF' WK' NE' NF' LL' SE' SN' DK' 'IO TM; RW: AT, BE, CW' CX' DE' BE' B1' CE' CC' CH' RU, TJ, KZ' WD' KC' ,AU , ZA ,AZ 'UX 'NA 'ZD 'SD ′ອດ 'WI 'LI 'TS BX' ,MA 'MZ 'ZI 'LL TR, AM 'DS ZE' ВO, 'ON WK' WC' WD' 'IS **к**и, 'Ia 'Ta 'ZN 'XW 'MW 'NW 'ds 'SI LT, LU, 'ST KE' KE' KZ' TC' TK' TE' KG' ID' 'OH 1b' KE' 'NI 'TI HE' CH' CW' DW' EE' ES' EI' GB' GD' GE' DK' , AD BX' CH' CN' CB' CO' CZ' DE' YE' YE' YW YI' YN' YS' BY' BB' BC' BK' .qq 802 DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

tested. CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sjkyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H,

ЗД СОИСОВД ESwefpoxypenyl (9CI) (CA INDEX NAME) Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-3-methylphenyl]-N'-(2-CN586370-54-5 REGISTRY ВИ PN2MER 137 OF 179 REGISTRY COPYRIGHT 2002 ACS ГЗ

AD SECS2 HS4 N4 O2 WE

CA, CAPLUS, TOXCENTER SIN Files: ГC

MeO.

AA

## I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: . (asansqst) .or .dr GB' GK' IE' IL' TO' WC' WT' WK' NE' NT' LL' SE' EI' EK' CY' E2' DK' CX' CI' CW' CH' **'**១၁ BE' B1' CE' TM; RM: AT, BE, , LT RU, 'ZX WD' **'**១೧ 'MZ 'AZ , AU 'AT 'CI 'TS 'ZY 'NA 'NA 'ZN 'SN 'LL 'MT BX**'** ,MA 'ZL 'NW 'IS '១s 'as ₽U**'** ON WK' WC' WD' , AM ZE' NZ' BT' BA' BO' 'XW 'MW 'AT 'ST Kb' KB' KZ' TC' TK' TB' KC' 15' KE' 'SI 'NI 'TI 'NH 'LT ID' CH' DK' DW' EE' ES' EI' CB' CE' Cn' CZ' DE' CH' CN' CB' ,AD CW\* YE' YI' YW' YI' YO' YZ' BY' BB' BC' BK' DESIGNATED STATES: W: Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 Al 20000727, and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KELEKENCE 1: 133:132732 breparation and anti-tumor, anti-atherosclerosis,

CH; Z = CH; RI, R4, R5,R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal 97kAT or 97kAtcarbonyl; and Rll represents 31kyl, 31kynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H,

Ι

Urea, M-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-3-methylphenyl]-M'-(4-CN586370-53-4 REGISTRY ВИ YNZMEK 138 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma3$ 

[] Inoxobyenly = (9CI) (CY INDEX NAME)

ЗД СОИСОКД EZ

ME

ЯA

CI

CS4 HSI E N4 O4

SE

CA, CAPLUS, TOXCENTER SIN FILES: TC

MeO MeO MeO MeO

PAGE 2-A

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I KEEEKENCER IN EITE CAPINR (1964 TO DATE)
I KEEEKENCER IN EITE CA (1964 TO DATE)

E

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 CODEN: BIXXDS. APPLICATION: WO 2000-JP255 20000120. .(əsənaqst) .DT , TG. EI' EB' GB' GB' IE' IL' TO' WC' WT' WB' NE' NT' LA' SE' SN' E2' DK' TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, KZ' MD' En' L1' KG' ZM, AM, AZ, BY, AZ 'UY 'NV 'ZU 'SU , au , ar  $\mathtt{T}\mathtt{K}^{ullet}$ ,MT 'TS ,TT  $_{ au\Gamma}$ 'XS 'IS 'DS ZE' ZD' NZ' br' bL' BO' BN' 'ON 'XW 'MW 'NW WC' WK' WD' , AM **'**ΛΊ rs' rt' rn' KE' KE' KZ' TC' TK' TB' IS' 15' KE' KG' ID' IF' IN' **'**NH HB, DK' DW' EE' ES' EI' GB' GD' GE' GH' GW' BX' CY' Cn' CZ' DE' CH' CN' CB' YE' YI' YM YI' YN' YY' BY' BB' BC' BB' .qq 80S DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

Searched by: Mary Hale 308-4258 CM-1 12D16

ЕI

Title compds. [1; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = cmp. Z = CH; R1, R4, R5,R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and

Ι

L3 ANSWER 139 OF 179 REGISTRY COPYRIGHT 2002 ACS

CM Urea, .W-(2,4-difluorophenyl)-W'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-3methylphenyl]- (9CI) (CA INDEX WAME)

ME CSV HSU ES NV OV ER 3D CONCOBD

WE CS4 HS0 ES N4 O4

ЯA

TC 2LM LTJG2: CY' CYBLN2' LOXCENLEK 2K CY

PAGE 1-A

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I KELEKENCES IN LIFE CW (1967 TO DATE)

CI 19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 . (asanagat) .DT , TG. APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: E2' GB' GK' IE' IL' FN' WC' WF' WK' NE' NF' BL' SE' SN' EI' EB' CB' DK' TM; RW: AT, BE, CX' DE' CI' CW' BE' B1' CE' CC' CH' 'ZX AD, RU, TJ, , SA 'NX 'NA າອດ ,AU MZ 'zn 'sn 'ZI 'TT 'MT  $_{ au}$ LT 'TS ,MA '\Z 'TR, '5S **к**и**,** 'Ld ₽L, 'ZN 'ON 'NW WK' WC' WD' , AM 'IS ZE' 'us RO, 'XW 'MW 'AT rc' 'ZX KB' Kb' KC' KE' 'TI 'LT 'ST LR, rk' 1b, 'SI 'NI 'dI 'NH HE' DK' DW' CH' CN' CB' CH' EE' E2' EI' CB' CD' CE' Cn' CZ' DE' CW' BX' YE' YT' YW' YI' YO' YZ' BY' BB' BC' BK' .qq 80S DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KELEKENCE J: 133:132732 breparation and auti-fumor, anti-atherosclerosis,

Ι В₫ `£Я ВЪ ВВ БЯ N - CO - N - BJJВŢ ΟĺЯ 9Я В6

ЯA

and causing no morphol. Change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sikyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or W; Rl-3 represent each H,

rested. CH: Z = CH; R1, R4, R5,R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and

Urea, W-butyl-M'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-3-methylphenyl]-CN 586370-50-1 REGISTRY ВИ PN2MER 140 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma3$ 

WE CSS HSe N4 O4 E2 3D CONCOBD (6CI) (CF INDEX NFWE)

PC SIM Files: CA, CAPLUS, TOXCENTER SR CA

MeO MeO MeO MeO

0

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I KEFERENCES IN FILE CAPLUS (1967 TO DATE)

CI 19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 . (seansqst) APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: .or , ar EI' EB' CF' CB' CE' IE' IL' TN' WC' WF' WB' NE' NF' EL' SE' SN' E2' DK' CX' DE' CH' CI' CW' BE' B1' CE' CG' TM; RM: AT, BE, AD, RU, TJ, 'ZX BX' 'Z\ 'MZ ,AZ 'NA 'NA 'ZN 'SN **'**១៣ ,AU ,ST 'LL ,AT 'MT 'LT 'TS ,MA ₽Ľ, 'ĐS RU, 'Ld 'ZN 'ON 'IS 'ES 2D KO, 'XW 'MW 'NW WK' WC' WD' , AM 'ST ГВ**'** KZ' rc' KB' Kb' KE' KC' 1b, 'SI 'TI LT, LU,  $\Gamma$ K' 'NI ID' 'NH GH, GM, BX' CY' CE' DW' EE' ES' EI' GB' GD' DK' CO'CY'DE' CH' CN' CB' YE' YE' BY BY YA' YA' YA' BY BB' BC' BK' DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEEERENCE 1: 133:132535 Preparation and anti-tumor, anti-atherosclerosis,

TC

SE

Title compds. [1; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or arelkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or arelkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or arelylyl; and R11 represents alkyl, alkenyl, alkynyl or and compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = both S = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd.

WE CSJ HS4 N4 O4
E2 3D CONCOKD
(6CI) (CV INDEX NVME)
CN OLES' N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-3-methylphenyl]-N'-propylRN 286370-48-7 REGISTRY
L3 ANSWER 141 OF 179 REGISTRY COPYRIGHT 2002 ACS

MeO

**SLN Files:** 

AD

и-Ртин— С— ИН

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

CA, CAPLUS, TOXCENTER

I BELEBENCES IN EITE CAPINS (1967 TO DATE)

CI 19990521; JP 1999-253624 19990907; PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. . (əsənaqat) CODEN: BIXXDS' EI' EK' CB' CB' CB' IE' IL' TA' WC' WT' WB' NE' NT' EL' SE' SA' CX, BE' B1' CE' CC' CH' CI' CW' TM; RM: AT, BE, 'LT WD' , SA ,MA ,WZ ,AZ ,UY ,NV ,ZU ,2U 'ອດ , AU TK, , LT 'ZI '១s ZE' PT, RO, RU, SD, NS' BF' 'ON 'XW 'MW 'NW WK' WG' WD' 'LT 'ST KY' PC' PK' PB' Kb' KB' ıb, KE, 'TI 'nNH KC' 'SI 'NI 'dI ,AD DK' DW' EE' ES' EI' CB' CD' CE' CH' CN' CB' CO' CZ' DE' .qq 80S YE' YF' YW YI' YA' YZ' BY' BB' BC' BK' DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines 

Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl), pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = tested.

Ι

ZB CF
WE CS4 HS1 E N4 O2
EZ 3D CONCOWD
WetpoxAbyeuAT) = (6CI) (CF INDEX NAME)
WetpoxAbyeuAT) = (6CI) (CF INDEX NAME)
Wf S86370-47-6 REGISTRY
EX ANSWER 142 OF 179 REGISTRY
COPYRIGHT 2002 ACS
L3 ANSWER 142 OF 179 REGISTRY
L4 ANSWER 142 OF 179 REGISTRY
L5 ANSWER 142 OF 179 REGISTRY
L6 ANSWER 143 OF 179 REGISTRY
L6 ANSWER 145 O

TC SIN Files: CA, CAPLUS, TOXCENTER

ЯA

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: (Japanese) TD, TG. NF' LL' RE' GB' GK' IE' IL' FN' WC' WF' WE' NE' EI' EB' CB' E2' DK' CX' CI' CW' BE' BE' B1' CE' TA : WA ;MT MD, RU, CH' **'**90 , LT 'ZX KC' 'MZ ne' ,AU 'Z\ ,AZ 'NX 'NA 'ZN 'SN 'LL TE, 'MT 'CJ 'TS 2K' BX' ,MA 'ZL RU, 'NW WK' WC' 'IS 'ĐS 2D' NO, NZ, PL, PT, RO, 'XW 'MW WD' , AM 'ΛT ZE' 'LT LR,  $\Gamma K$ 15' KE' KG' Kb' KK' CC' 'SI 'TI 'NH rn' 'ST 'NI ID' нв, CH' DK' DW' EE' ES' EI' CB' CD' CE' Cn' CZ' DE' CH' CN' CB' ,AD BX**'** CW' YE' YI' YW' YI' YO' YZ' BY' BB' BC' BK' DESIGNATED STATES: W: .qq 802 Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 Al 20000727, and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines 133:132735 Preparation and anti-tumor, anti-atherosclerosis, **KELEKENCE J:** 

Ι Вđ z > NВЗ  $\mathbb{R}^7$ ВВ Х БZ N - CO - N - BJJВŢ 6Я ВТО 9И

tested. CH; Z = CH; RI, R4, R5,R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal gjkyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [1; X and Z represent each CH or N; Rl-3 represent each H,

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-fluorophenyl]-N'-(2-CN586370-46-5 REGISTRY ВИ COPYRIGHT 2002 ACS PN2MER 143 OF 179 REGISTRY  $\Gamma 3$ 

(CA INDEX NAME) wethylphenyl) - (9CI)

3D СОИСОКD EZ

CS4 HSI E N4 O4 WE.

CI

SE

CA, CAPLUS, TOXCENTER **SLN Files:**  $\Gamma C$ 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BEEEBENCER IN EITE CAPINR (1964 TO DATE)

I BEEEBENCER IN EITE CA (1964 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 . (asansqst) APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: .DT , TG. E2' E1' EK' CF' CB' CK' IE' IL' FN' WC' WF' WE' NE' NF' SE' SN' CI' CW' CX' DE' IM; EM: AT, BE, BF, BJ, CF, CG, CH, WD' RU, TJ, 'ZX BX**'** 'ZY ,MA ,WZ ,AZ 'NA 'NA 'ZN 'SN , au , Au 'ZI TR, 'MI LT, 'TS ,TT **8**0 NZ' br' bL' BO' WC' 'IS '9S ZE' 'ds 'ON 'XW 'MW 'NW WK' WD' , AM 'TI rs' rt' rn' 1b' KE' KG' Kb' KK' CC' CK' CB' 'SI 'NI ID' 'ΩH DK' DW' EE' ES' LI' CB' CD' CE' CH' CW' CH' CN' CB' CO' CZ' DE' BX' CY' YE' YI' YW' YI' YO' YZ' BY' BB' BG' BK' .qq 802 DESIGNATED STATES: W: Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 Al 20000727, and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines 

EI

AB Title compds. [1; X and Z represent each CH or N; Rl-3 represent each H,

optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal aralkyl], pharmaceutically acceptable salts and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = compus. S1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

L3 ANSWER 144 OF 179 REGISTRY COPYRIGHT 2002 ACS

RM 286370-45-4 REGISTRY

CM Urea, W-(2,4-difluorophenyl)-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2
FS 3D CONCORD

CM 286370-45-4 REGISTRY

CM INDEX WAME)

TC ZLM ETTGE: CY' CYBENZ' LOXCENTER ZB CA

CS3 HIA E3 Nd Od

ME

FAGE 1-A

MeO MeO MH

PAGE 2-A

Ŧ

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BELEBENCES IN EITE CALINS (1967 TO DATE)
I BELEBENCES IN EITE CA (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS' (Japanese) .br ,dr E2' CB' CK' IE' IL' FO' WC' WF' WK' NE' NF' LL' DK' ZE' EI' EB' CB' 'IO CX' BE' B1' CE' TM; RM: AT, BE, WD' DE' Ce' CH' 'LT **В**О, 'ZX CW' KC' 'NX 'en MZ 'YZ ,AU 'MT 'IS **1**2.∀ 'ทุง 'รูก 'รูก 'LL TE, 'LI ,MA 'ZJ 'XS '9S 'Ld br' 'ZN 'NW WK' , AM RO, RU, ON 'XW 'MW 'ΛT ZE' 'ds WC' 'dW 'nT 'LT ΓK, rc' rk' 'ZX Kb' KB' KC' 1b' KE' 'SI 'NI Ir' ID' **'**ΩΗ **'**ΉΗ 'ST DK' 'H9 CW' DW' EE' ES' EI' GB' GD' GE' Cn' CZ' DE' CH' CN' CB' BX' CY' YE' YT' YW YI' YO' YZ' BY' BB' BC' BB' .qq 80S DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines

 $\mathbb{F}^{4}$ .εЯ  $R^{\gamma}$ 8Я Вζ N - CO - N - BJJ0  $_{\rm FJ}$ 01Я 6Я 9 Y

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H,

tested. CH: Z = CH: KI, K4, K5, K7-K10 each an H; KII = 3, S-ESC6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sjkyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each

CS4 HIB E3 N4 O4 MEЗД СОИСОВД EZ driuszolinyl) oxy]-Z-fluorophenyl]- (9CI) (CA INDEX NAME) Urea, M-[(2,4-difluorophenyl)methyl]-N'-[4-[(6,7-dimethoxy-4-CN 586370-44-3 REGISTRY КИ

ANSWER 145 OF 179 REGISTRY COPYRIGHT 2002 ACS

CA, CAPLUS, TOXCENTER SLN Eiles:  $\Gamma C$ AD SB

 $\Gamma3$ 

ЯΑ

CI

19990521; JP 1999-253624 19990907.

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

CHZ

HN

E

FAGE 2-A

FAGE 1-A

I REFERENCES IN FILE CAPLUS (1967 TO DATE)

PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. (Japanese). CODEN: PIXXD2. TD, TG. DK' E2' E1' £K' CB' CB' CE' IE' II' FN' WC' WF' WK' NE' NT' BI' SE' SN' KZ' MD' Bn' L1' LW: BM: FL' BE' BL' CE' CG' CH' CI' CW' CA' DE' KC' TZ, UA, UG, US, UZ, VV, YU, ZA, ZW, AM, AZ, BY, 'LL TJ, TM, TR, 'TS 'XS MN' MM' MX' NO' NZ' bF' 'IS 'DS 'ES PT, RO, RU, SD, ra' wy' wd' we' wk' 15' KE' KG' Kb' KB' 'SI rs' rı' rn' KZ' rC' rK' rB' HE' HO' ID' IT' IN' BX' CY' CH' CN' CK' CN' CZ' DE' DK' DW' EE' ES' EI' GB' GD' GE' GH' GW' YE' YI' YW' YI' YO' YZ' BY' BB' BC' BK' .qq 80S DESIGNATED STATES: W: Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 Al 20000727, and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

ΙĐ

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbonyl; and R11 represents and medicinal to a stational and causing no morphol. change in cells. Thus, the title compd. I (X = tested.)

Ι

L3 ANSWER 146 OF 179 REGISTRY COPYRIGHT 2002 ACS RN 286370-43-2 REGISTRY CN Urea, N-[4-[(6,7-dimethoxy-4-quinazoliny])oxy]-2

CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-fluorophenyl]-N'-2-

ьг зр соисовр

ЯΑ

TC STW Files: CA, CAPLUS, TOXCENTER

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

T KEEEKENCES IN EIFE CYPLUS (1967 TO DATE)

T KEEEKENCES IN EIFE CY (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS' . (seensqst) EI' EK' CF' CB' CK' IE' IL' FN' WC' WF' WK' NE' NF' EL' 2E' 2N' E2' nk' CX' CI' CW' BE' B1' CE' TM; RM: AT, BE, CH' 'LT **'**90 **'**೧୪ 'AW **'**73 KG\* 'nX 'MZ 'YZ 'នព ne' ,AU TR, 'TS 'ZA 'NA 'ZO 'CL 'XS ,MA 'ZT - 'LT ,MT '១ន ВU, bΓ**'** ON 'IS **'**∃S **'**08 RO, LT, 'ZN 'XW 'MW 'NW WK' WC' ′ตพ , AM **'**\\T Kb' KB' KZ' PC' PK' PB' KE' KG' ω. 'SI 'NI rn' 'LT 'ST 'TI ID' 'OH HE, DK' DW' EE' ES' EI' GB' GD' GE' CH' CH' CN' CB' CO' CZ' DE' , AD BX**'** CW' YE' AL' AM, AT, AU, AZ, BA, BB, BG, BR, .qq 802 DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin

CH: Z = CH: B': B'and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal grkyl or alkylcarbonyl; and Ril represents alkyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, Η' palogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all obfrouglly substructed alkoxy, etc.; R4 represents H; Rb-8 represent each Title compds. [I; X and Z represent each CH or N; RI-3 represent each H,

Ι

586370-42-1 REGISTRY ВИ ANSWER 147 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma 3$ 

(CA INDEX NAME) bropenyl- (9CI) Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-fluorophenyl]-N'-2-CN

ЗД СОИСОВД EZ

CSO HIB E Nd Od WE

CI

SE A.)

CA, CAPLUS, TOXCENTER STN Files:  $\Gamma C$ 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CAPLUS (1967 TO DATE) T REFERENCES IN FILE CA (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: . (asanaqat) TD, TG. E2' DK' EI' EK' CB' CB' CB' IE' IL' TO' WC' WF' WB' NE' NF' BL' SE' SN' 'IO CX' DE' CH' **'**50 BE' B1' CE' TM; RW: AT, BE, 'LT RU, 'ZX CW' 'dW KC' **'**១៣ **,**AU 'Z\ ,MA 'M7. , AZ 'NA 'NA 'ZN 'SN 'LL TR, 'MT 'C.L. 'TS 'XS 'ZJ '9s 'ZN 'IS 2D' ZE' PL, PT, RO, RU, 'ON 'XW 'MW 'NW MD' WC' WK' , AM  $\Gamma \Lambda$ Kb' ΓĖ' 'SI 'NI 'TI ID' 'NH rn' T.T. 'ST KB' KZ' TC' TK' 15' KE' KC' **'**'ਮਮ DK' CH' CW' CE' DW' EE' ES' EI' CB' CD' CH' CN' CB' CO' CZ' DE' BX' CY' YE' YT' YW' YI' YO' YZ' BY' BB' BC' BK' .qq 802 DESIGNATED STATES: W: Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 Al 20000727, and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

CI

 $\mathbb{F}^{4}$ `ЕЯ  $z \sim$ 8Я  $F^7$ БЯ N - CO - N - KIIВЈ  $\cap$ ВЭ ВТО 9И

stkyl or alkylcarbonyl; and Rll represents alkyl, alkenyl, alkynyl or of 85-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all obfronally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [1; X and Z represent each CH or N; R1-3 represent each H,

Ι

ЯA

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; RI, R4, R5, R7-R10 each an H; R11 = 3, S-F2C6H3) was prepd. and tested.

ZB CY
WE CSI HS3 E N4 O4
EZ CY CY

WE CSI HS3 E N4 O4

EZ CONCOBD

WECFhylpropyl) (CA INDEX NAME)

RM S86370-41-0 REGISTRY

LACATER COPYRIGHT 2002 ACS

LACATER COPYRIGHT 2002 ACS

CA, CAPLUS, TOXCENTER

**SLN ETTES:** 

ГC

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BELEBENCES IN EITE CAPTOR (1967 TO DATE)

T BELEBENCES IN EITE CA (1967 TO DATE)

ΙĐ 19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 . (Japanese) APPLICATION: WO 2000-JP255 20000120. CODEN: bixxDS: EI' EK' CB' CB' CK' IE' IL' FA' WC' WF' WK' NE' NF' BL' SE' SN' 'LT WD' BE' B1' CE' CC' CH' CI' CW' CX' ,UA TM; RM: AT, BE, , SA , MA , WS , AS , UY , VV , SU 'ຮ∩ **'**១೧ ,AU 'ZL '9s ₽Ľ, 'NW PT, RO, RU, SD, 'ZN WK' ZE' 'XW 'MW ON WG, WD' KZ' TC' TK' TB' TZ' TL' 'SI 'NI Kb' KB' KC' 1b' KE' HB, HU, ID' CH' CN' CK' CN' CZ' DE' DK' DW' EE' ES' EI' GB' GD' GE' CH' YE' YE' YW' YI' YO' YY' BY' BB' BC' BK' DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEEEKENCE 1: 133:132732 Preparation and anti-tumor, anti-atherosclerosis,

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all atalkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl or alkylcarbonyl; and R11 represents and solvates, and medicinal and causing no morphol. change in cells. Thus, the title compd. I (X = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and tested.

Ι

OB CST HS3 E NO OO

SR CA

ЯΑ

LC STW Files: CA, CAPLUS, TOXCENTER

D-BUNH-C-NH

WEO
MEO
MEO

0

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

J BELEBENCES IN EITE CAPTOR (1964 TO DATE)

J BELEBENCES IN EITE CA (1964 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 (Japanese) APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: LD, NF' LL' SE' SN' GB' GK' IE' IL' FN' WC' WF' WE' NE' ,AĐ EI' EK' E2' DK' CX' CI' CW' CH' **'**១၁ BE' B1' CE' TA : WA : MT 'LI 'ਤਰ RU, WD' 12A 'M7 'AZ 'NX 'NA 'ZN 'SN **'**50 , AU TR, 'WT 'CT 'XS , MA 'ZL 'LL , AM 'IS ВU, 'NW WK' 'ĐS 'ES 'as PT, RO, 'Ta 'ZN ON 'XW 'MW WC' WD' rn' 'TI Kb' KB' KZ' TC' 'SI 'ΩH rn' 'LT 'ST LR, ΓK' KC' 1b' KE' 'NI ID' 'HB' DW' EE' ES' EI' CB' CD' DK' Cn' Cz' DE' CH' CN' CB' 'HĐ CE' BX' CY' CW' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, .qq 80S DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan).

Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all alkyl or alkyloarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or arelkyl], pharmaceutically acceptable salts and solvates, and medicinal arelkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. Change in cells. Thus, the title compd. I (X = and causing no morphol. Change in cells. Thus, the title compd. I (X = and causing no morphol. Change in cells. Thus, the title compd. I (X = and causing no morphol. Change in cells. Thus, the title compd. I (X = and causing no morphol. CH.) R1, R1, R3, R5,R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and

Ι

WE CS0 HSI E N4 O4
E2 3D CONCOKD
CN Ores, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]-2-fluorophenyl]-N'-propylL3 ANSWER 150 OF 179 REGISTRY
L2 ANSWER 150 OF 179 REGISTRY COPYRIGHT 2002 ACS
L2 ANSWER 150 OF 179 REGISTRY COPYRIGHT 2002 ACS

CA, CAPLUS, TOXCENTER

Searched by: Mary Hale 308-4258 CM-1 12D16

ЯA

ГC

SE

ΙĐ

**SLN EIJes:** 

**CA** 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BEEEBENCES IN EITE CALTOS (1967 TO DATE)
I BEEEBENCES IN EITE CA (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 CODEN: BIXXDS: . (asenaqat) .DT , TG. APPLICATION: WO 2000-JP255 20000120. E2' EI' EK' CF' CB' CK' IE' IL' TO' WC' WT' WK' NE' NT' BL' SE' SN' DK' CE' CX' DE' CH' **'**90 TM; RM: AT, BE, 'LI RU, WD' 'ZX CI' CW' BE' B1' KC' 'NX 'NA 'ZN 'ຮດ **'**១೧ ,AU 'ZA , MA 'MZ ,AZ 'ZL 'TT TK, 'MT 'LT 'TS '១ន br' 'ZN 'ON ,AM 'IS RU, RO, LT, 'NW WK' YE, ZE' 'dS 'XW 'MW WD' rc' KB' rn' 'LT 'ST LR, ΓK' 'ZX 'SI 'NI II' ID' 'NH Kb' KC' 15' KE' HB, CH' CE' DK' CW' DW' EE' ES' EI' CB' CD' CH' CN' CK' CC' DE' , AD BX' YE' YI' YW' YI' YO' YZ' BY' BB' BC' BK' .qq 802 DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEEEKENCE 1: 133:132732 breparation and anti-tumor, anti-atherosclerosis,

Title compds. [1; X and Z represent each CH or N; Rl-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkyl or alkylearbonyl; and R11 represents alkyl, alkenyl, alkynyl or

Ι

ЯA

CI

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3, S-F2C6H3) was prepd. and

WE CSS HIJ CTS N2 O4
E2 3D CONCOBD
cyloro-S-byridinyl)- (9CI) (CA INDEX NAME)
CN UTea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(5-R)
RN 286370-38-5 REGISTRY
L3 ANSWER 151 OF 179 REGISTRY COPYRIGHT 2002 ACS

CA, CAPLUS, TOXCENTER

ГC

ЯS

STN Files:

AD

B∀CE I-∀

FAGE 2-A

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BELEBENCES IN EITE CALTOS (1967 TO DATE)
I BELEBENCES IN EITE CA (1967 TO DATE)

CJ

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 (Japanese) APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: .DJ 'UL EI' EK' CB' CB' CB' IE' II' FA' WC' WF' WB' NE' NF' BL' SE' SA' E2' DK' CX' 'IO CH' BE' B1' CE' TM; RM: AT, BE, 'LT CW' **'**90 RU, WD' 'ZX KC' , SA ,MA 'AZ 'NX 'NA 'ZO 'ຮກ 'ອດ , AU 'WT 'LT 'TS 'XS 'MZ 'ZJ 'LL TR, 'ZN , AM '១ន **В**И, KO, br' br' 'ON 'XW WC' 'IS 'MW 'NW WK' WD' '\u01 'EE 'ds רת, בט, 'ST 15' KE' KG' Kb' KK' CC' TK' TB' 'SI 'NI **'**HB 'TI ID' 'ΩH CH' CA' CZ' DE' DK' DW' EE' EZ' LI' CB' CD' CE' CB, 'ND CH' ,AD BX, CW'

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or are lylicarbonyl; and R11 represents alkyl, alkenyl, alkynyl or are lylicarbonyl; and R11 represents alkyl, alkenyl, alkynyl or achivity or alkylcarbonyl; and R11 represents and redictinal are grant alkyl or alkylcarbonyl; and R11 represents and redictinal are grant alkyl. I (X = alkylcarbonyl; R1, R4, R5,R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and CH; Z = CH; R1, R4, R5,R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and

Ι

and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; Rl, R4, R5,R7-RlO each an H; Rll = 3,5-F2C6H3) was prepd. and tested:

CM Urea, U-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(2-methoxyphenyl)- (9Cl) (CA INDEX NAME)

methoxyphenyl)- (9Cl) (CA INDEX NAME)

methoxyphenyl)- (9Cl) (CA INDEX NAME)

PC STN Files: CA, CAPLUS, TOXCENTER

CS# HSI CT N# OP

ЗД СОИСОКД

ME

EZ

AA

CI

CI

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

J KELEKENCES IN EITE CAPINS (1967 TO DATE)

J KELEKENCES IN EITE CA (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 (Japanese). APPLICATION: WO 2000-JP255 20000120. CODEN: bixxDS. EI' EK' GF' GB' GE' IE' IL' FN' WC' WF' WE' NF' BL' SE' SN' AD, RU, TJ, IM; EM: FI, BE, BJ, CF, CG, CH, CI, CM, CY, DE, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, ,AU ,ST 'AT 'LT 'IS 'DS 'ES NO, NZ, PL, PT, RO, RU, SD, 'XW 'MW 'NW WK' WC' WD' KE' 'SI Kb' KB' KZ' TC' TK' TB' T2' TL' TO' KC' 1b, 'NI CH' CN' CB' CO' CZ' DE' DK' DW' EE' ES' EI' GB' GD' GE' GH' GW' YE' YE' BR' BB' BB' BB' BB' BB' DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines 

AB Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H,

Ι

optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal aralkyl], pharmaceutically acceptable salts and solvates, and medicinal aralkyl], pharmaceutically acceptable salts and solvates, and medicinal acceptable salts and solvates, and medicinal aralkyl], pharmaceutically acceptable salts and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = tested.)

ME CS3 H18 CT E N4 O4

EZ 3D CONCOBD

CN Orea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(4-Chrorophenyl) (CA INDEX NAME)

Lase, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(4-Chrorophenyl) (CA INDEX NAME)

TC ZLM ETTES: CY' CAPLUS' LOXCENTER ZK CA

FAGE 1-A

CT O O WEO WEO WEO

PAGE 2-A

Ē

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS' . (Japanese) .DT , TG. GB' GK' IE' IL' TO' WC' WT' WK' NE' NT' 5L' SE' LI' LB' CB' DK' CX' 'IO BE' B1' CE' BE' TA; RW: AT, CW' CH' • ອວ 'CI RU, WD' KC<sup>1</sup> 'YZ 'NΛ ,AU TR, 'IS 'M7 'nx 'zn 'sn 190 'LI. 'XS , MA 'ZJ 'LL ,MT 'IS 'Id δΓ**'** ON 'NW WK' , AM **'**98 **'**∩ਮ 'ZN 'XW 'MW **'**9W **'**GW 'as 'ds RO, **'**^T KB' רח' 'LT KZ' TC' TK' TB' Kb' KC' 1b' KE' 'SI 'NI TT' TD\* 'OH 'ST **'**ਮਮ CH' CN' CB' CC' DE' BX**'** CW' CH' DK' DW' EE' ES' LI' GB' GD' GE' , AD YE' YT' YW' YI' YN' YN' BY' BB' BC' BK' .qq 80S DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines

19990521; JP 1999-253624 19990907.

Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or arelyyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or arelyyl, pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. CH) each an H; R11 = 3,5-F2C6H3) was prepd. and

Ι

CK STN Files: CA, CAPLUS, TOXCENTER

CS3 HS0 CI N2 Of

3D СОИСОВD

WE

EZ

ЯΑ

CI

PAGE 2-A

FAGE 1-A

CH2

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1060621; JP 1999-253624 19990907; PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: . (asanagat) DK' E2' E1' EB' GB' GB' GB' IE' IL' FN' WC' WF' WB' NE' NF' EL' SE' SN' TM; RM: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, ND, RU, TJ, **'**១៣ , AU 'LT 'YA 'ZA 'MA 'WZ 'AZ 'UY 'NV 'ZU 'SU TR, 'MT 'ZT 'LT WC' LI' RO' RU' SD' SE' SC' SI' δΓ**'** WK' WN' WM' WX' 'ZN 'ON WD' AM VJ KZ' PC' PK' PB' PR' PT' PN' KC' 16' КЕ' 'SI 'NI 'TI Kb' KB' ID' HB, HU, DK' DW' EE' ES' EI' CB' CD' CE' CH' CW' CH' CN' CB' CN' CZ' DE' YE' YI' YM' YI' YO' YZ' BY' BB' BC' BK' DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KELEKENCE J: 133:132732 Breparation and anti-tumor, anti-atherosclerosis,

CI

**SIN Files:** 

 $\Gamma C$ 

ЯΑ

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, halogeno, alkyl, alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal aralkyl], pharmaceutically acceptable salts and solvates, and medicinal and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = exted.

Ι

CA, CAPLUS, TOXCENTER

PAGE 2-A

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I KELEKENCES IN EITE CAPLUS (1967 TO DATE)

19990521; JP 1999-253624 19990907; PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 CODEN: BIXXDS: APPLICATION: WO 2000-JP255 20000120. . (əsənaqat) DK' E2' E1' EK' GF' GB' GK' IE' I1' FN' MC' MF' ME' NF' BL' SE' SN' IM; BM: FI, BE, BJ, CF, CG, CH, CI, CM, CY, DE, MD, RU, TJ, 'ຮ∩ , au , ar UZ, VN, YU, ZA, AM, AZ, BY, TK'WT 'LI 'LL ₽Ľ, 'ZN WK' 'IS '9S PT, RO, RU, SD, SE, MN, MW, MX, NO, WD' WC' KK' Kb' KZ' TC' TK' TB' TA' TA' 15' KE' KC' 'SI 'NI ID' CH' CN' CB' CO' CZ' DE' DK' DW' EE' ES' EI' CB' CD' CE' CH' CW' YE' YE' BW' YI' YO' YZ' BY' BB' BC' BK' .qq 802 DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KELEKENCE 1: 133:132732 Preparation and anti-tumor, anti-atherosclerosis,

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, halogeno, alkyl, alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all aralkyl), pharmaceutically acceptable salts and solvates, and medicinal experience.

Ι

. COPYRIGHT 2002 ACCISTRY COPYRIGHT 2002 ACS CN Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazoli

propynyl- (9CI) (CA INDEX NAME)

propynyl- (9CI) (CA INDEX NAME)

E2 3D CONCORD

RE CSO HIL CT NO OO

ЯΑ

LC STW Files: CA, CAPLUS, TOXCENTER

0

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I KEEEKENCES IN EILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines

2691Cy6q pl: Mary Hale 308-4258 CM-1 12D16

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. . (asanaqat) LD' LC CODEN: BIXXDS ŁI' E2' rn' wc' wr' wb' ne' nr' bi' se' sn' CB' CK' IE' IL' EB' CB' DK' 'XD BŁ' 'HO **'**50 ,TA WD' 'ZX 'ID CE' B1 KC' CW' BE' 'LI КU, EM::MT , ZA **'**ΩX 'ZN 'sn **'**១៣ 'TS ,MA MZ ,AZ ,AU 'LL  $\mathrm{T} R^{\boldsymbol{\star}}$ ,MT 'XS 'ΝΛ 'LT 'ZI bľ' 'IS 'ss ZE' ВO, 'Lđ 'ZN 'XW WC' WD' , AM 'dS КU, 'ON 'MW 'NW WK' '\u01 'LT rc' Kb' Ir' rn' 'ST ГВ' ľK' KZ' KK' KC' KE' 1b, 'SI 'NI ID' 'NH HE' ŁI' EE' cH, CE' E2' DE' 'zɔ CK**'**YO CW' cp' CB' DW' DK' 'no CM' CH' BX' YE, вв, BC' BB' AB 'ZA 'UA 'TA 'MA 'JA .qq 802 DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan).

and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin

Ι  $\mathbb{F}^{4}$ ΕЗ. Z ЯЯ ГЯ X ΣЯ ВŢ N - CO - N - BII0 6Я 01<sub>A</sub> ςЯ ВQ

ЯΑ

CI

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sikyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all obfiouslly substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H,

ANSWER 157 OF 179 REGISTRY COPYRIGHT 2002 ACS tested. CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. Change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity

brobenyl- (9CI) (CA INDEX NAME) Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-2-СИ 586370-31-8 REGISTRY ВИ ГЗ

ЗД СОИСОКД EZ

SE CS0 HI CT N4 O4 WE

CA, CAPLUS, TOXCENTER STN Files: ГC

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BEEEBENCES IN LIFE CAPLUS (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: . (asansqst) .DT , dT E2' DK' EI' EK' CB' CB' CK' IE' IL' TO' WC' WT' WK' NE' NT' BL' SE' SN' CX' DE' CI' CW' IM; EM: PI' BE' B1' CE' КU, WD' 'ZX CC' CH' ,UT KC' 'NX 'NA 'zn ,AU YA 'ZA 'MZ 'YZ 'sn 'sn 'ZI 'LL 'AT 'MT 'TS 'XS ,MA 'LT 'XW **8**0, ВO, LT, 'MW 'NW WK' WC' WD' ,AM 'IS: '9S ZE' 'ds NO' NZ' bF' **'**\\'T rc' KK' Kb' KC' KE' 'ST LR, rk' 'ZX 1b' 'SI 'TI 'NH 'LT 'NI HB, ID' DK' CH' CW' CE' CH' CN' CB' CN' CZ' DE' DW' EE' ES' EI' CB' CD' , AD YE' YI' YW' YI' YO' YS' BY' BB' BC' BK' .qq 80S DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFEKENCE 1: 133:132835 Preparation and anti-tumor, anti-atherosclerosis,

Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent H simultaneously; R9-8 do not res

Ι

ЯA

CI

aralkyl), pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = tested.

ZH CSJ HS3 CT N4 O4

WE CSJ HS3 CT N4 O4

ES 3D CONCOKD

WE CSJ HS3 CT N4 O4

CN Orea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(1-R)

RN 286370-30-7 REGISTRY

LOPER 158 OF 179 REGISTRY

COPYRIGHT 2002 ACS

CA, CAPLUS, TOXCENTER

**2LM Eiles:** 

ГC

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BELEBENCES IN EITE CAPTOR (1964 TO DATE)

T BELEBENCES IN EITE CAPTOR (1964 TO DATE)

ΙĐ 19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. (Japanese) .DT , TG. CODEN: BIXXDS' CB' CK' IE' IL' FA' WC' WF' WK' NE' NF' LL' SE' SA' E2' DK' LI' LE' CY' CA' DE' TM; RM: AT, BE, Ru, WD' 'ZX BE' B1' CE' CC' CH' CI' CW' 'LT KC' 'MZ ,AU 'Z\ 'YZ 'ZL 'TT TR, 'WT 'LI 'TS ,MA 'NA 'NA 'ZN 'SN ne' '១s RU, **'**⊓a 'ZN 'ON 'NW WK' WC' , AM 'IS 'Id WD' ZE' 'as RO, 'XW 'MW 'LT KK' Kb' KC' 'SI 'TI 'S7 ГВ, ΓK' 'NI ID' 'ΩH HB, rn' KZ' TC' 1b' KE' 'H5 CE' DK' BX' CY' EZ' EI' CB' CD' DW' EE' CH' CN' CK' CN' CZ' DE' YE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, .qq 802 DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines 

CH: Z = CH; KJ, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X = compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sikyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H' palogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all obfioually substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [1; X and Z represent each CH or N; R1-3 represent each H,

Ι

\$89370-29-4 REGISTRY ВИ ANSWER 159 OF 179 REGISTRY COPYRIGHT 2002 ACS ГЗ

(CY INDEX NAME) (ID6) Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-pentyl-CN

3D CONCORD

CSS HS2 CT N# O# ME

tested.

OĐW

ES

ЯΑ

SEAD

CY' CYPLUS, TOXCENTER **SLN Files:** ГC

OeM

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: bIXXDS: (Japanese) GB' GK' IE' IL' FA' WC' WF' WK' NE' NF' LL' SE' SA' EZ' DK' EI' EB' CB' CA' DE' CH' CI' CW' **'**၅၁ BE' B1' CE' BE' 'LT RU, WD' 'ZX KC' TA : WA ; MT 'nX 'NA 'ZΩ ′ິຣດ 'ອດ 'ZY 'MZ 'AZ ,AU 'ZL 'LL ,AT 'MT  $_{ au}$ L $_{ au}$ 'TS 'XS ,MA br' 'ZN 'MW ,AM '១s RU, RO, 'Ld 'ON 'XW 'NW WK' 'DW WD' 'IS ZE' 'ds rc' 'ZX KB' Kb, 'TI 'LT ГВ**'** ΓK' KC' 'SI ID' 'ΩH rn' 1b' KE' 'NI HB, 'ST 'H5 CE' DW' DK' EE' ES' EI' CB' CD' CH' CN' CB' CN' CS' DE' BX' CY' CW' AL, AM, AT, AU, AZ, BA, BB, BG, BR, YE, .qq 80S DESIGNATED STATES: W:

PCT Int. Appl. WO 2000043366 Al 20000727,

19990521; JP 1999-253624 19990907. .DT , TG.

 $\mathbb{F}^{4}$ Ι ΈЯ ГЯ ВЯ  $B_{5}$ N - CO - N - BJJВŢ ВJО 6Я ςЯ 9Я

Beer Kabushiki Kaisha, Japan).

ЯA

CI

and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sikyl or alkylcarbonyl; and Ril represents alkyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H,

586370-28-3 REGISTRY ВИ ANSWER 160 OF 179 REGISTRY COPYRIGHT 2002 ACS ГЗ tested. CH: Z = CH: KJ' K4' K2'KJ-KJO each an H; KJJ = 3'2-ESC6H3) was prepd. and

ЗД СОИСОВД EZ (CA INDEX NAME) (IO6) Urea, N-butyl-N'-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-CN

AD SECSI HS3 CT N4 O4 ME

CA, CAPLUS, TOXCENTER **SLN Files:**  $\Gamma C$ 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BEEEBENCES IN EITE CAPINS (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 . (asansqst) APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: .DT , TG. EI' EB' CB' CB' CB' IE' II' FN' MC' WF' WB' NE' NF' BL' SE' SN' EZ' DK' CX' CI' CW' ce' ch' BE' B1' CE' BE' ,TA :WA ;MT 'LT RU, WD' 'ZX 'n 'MZ 'ZY 'YZ 'NA 'ZN 'នព **'**90 , AU 'ZI 'LL TK, 'WI 'LT , MA '១s ₽Ľ, 'IS 'dS 'Ld ON 'XW 'MW 'NW WK' WD' ZE' 'กห 'ดห 'ZN WC' 'AM', VJ Kb' KB' KZ' TC' TK' TB' KE' 1b, 'SI 'NI **'**0T 'JT 'ST KG' **'**TT ID' 'OH 'NH DK' DW' EE' E2' E1' GB' GD' GE' GH' CY' CH' CN' CK' CN' CS' DE' BX' CW' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, .qq 80S DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEEEKENCE I: 133:132732 breparation and anti-tumor, anti-atherosclerosis,

Title compds. [1; X and Z represent each CH or N; Rl-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent B11, alkyltostonyl; and R11 represents alkyl, alkenyl, alkynyl or

Ι

ЯA

CI

aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = SH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and

CA, CAPLUS, TOXCENTER  $\Gamma C$ STN Files: SECIO HIO CT NO OF WE ЗД СОИСОВД EZ (CY INDEX NAME) (ID6) Urea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-ethyl-CN586370-27-2 REGISTRY ВИ ANSWER 161 OF 179 REGISTRY COPYRIGHT 2002 ACS ГЗ

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I KELEKENCER IN EITE CAPTOR (1964 TO DATE)
I KELEKENCER IN EITE CA (1964 TO DATE)

CI 19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 (Japanese) .DT , TG. APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: CB' CK' IE' IL' TO' WC' WT' WK' NE' NT' LL' SE' SN' 'S∃ DK' EI' EB' CB' CX' TM; RM: AT, BE, BF, BJ, CF, CG, CH, CI, 'CT 'ZX DE' CW' MD, RU, 'ອດ , AU 'TS , SA 'MZ ′zດ 'sດ 'TT TR, 'WT 'LT , MA AZ 'UY 'NV 'ZJ 'XS кu, KO, LT, ₽Ľ, 'ZN 'ON 'NW WK' WC' , AM 'IS 'ΛT **'**9s 2E 'dS 'XW 'MW WD' KB' Kb' KC' 'SI 'TI 'NH rl' 'ST KS' rc' 'NI ID' רא' רצ' 15' KE' HB, BX' CY' CE' CH' EE' ES' EI' GB' GD' DK' DW' CO' CZ' DE' CH' CN' CB' YE' YI' YW' YI' YO' YY' BB' BB' BB' BB' .qq 802 DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KELEKENCE 1: 133:132732 breparation and auti-tumor, anti-atheroscletosis,

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkynyl or aralkyl), pharmaceutically acceptable salts and solvates, and medicinal aralkyl), pharmaceutically acceptable salts and solvates, and medicinal and causing no morphol. change in cells. Thus, the title compd. I (X = CH; Z = CH; R1, R4, R5,R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and

Ι

ZB CF
WE CS4 HSS N4 O4
EZ 3D CONCOBD
(6CI) (CF INDEX NFWE)
CN OLGS' N-[4-[(e',1-qimethoxy-4-quinazolinyl) oxy]phenyl]-N.-(S-methylphenyl)KN S86370-26-1 REGISTRY
LS66370-26-1 REGISTRY
LS66370-

TC ZLM ETJGS: CA, CAPLUS, TOXCENTER

AA

## I KEEEKENCES IN EITE CYBINS (1967 TO DYTE) I KEEEKENCES IN EITE CY (1967 TO DYTE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: bIXXDS: (Japanese) . DT TD, E2' GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, EI' EK' CF' DK' TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CX' 'LT **к**и, WD' 'ZX DE' KC' , ZA 'NX **'**១៣ ,AU 'AT 'TS 'MZ 'NA 'ZN 'SN 'ZL 'TT 'LI ,MA ,AZ 'MT 'IS '១ន צט, LT, br' 'ZN 'ON 'NW WK' , AM 'XW 'MW WD' rn' ZE' 'ds KO, 'DW 'ZX KB' 'LT 'ST  $\Gamma K$ rc' Kb' KG' 1b' KE' 'SI 'NI 'TI ID' 'ΩH rn' rk' HB, DW' DK' CH' CE' EE' ES' EI' CB' CD' Cn' CZ' DE' CN' CK' CA, CH, BX' YE, SO8 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl), pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and

TC SIN Files: CA, CAPLUS, TOXCENTER

tested.

EI

**FAGE 2-A** 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I KEFERENCES IN FILE CA (1967 TO DATE)

DESIGNATED STATES: W: Beer Kabushiki Kaisha, Japan). anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: .(əsənaqat) TD, TG. DK' E2' E1' EK' GF' GB' GK' IE' IL' FA' WC' WF' WE' NE' NT' BL' SE' SA' Ke' KZ' WD' BA' IN' IN' EM: FI' BE' BE' CE' CE' CE' CI' CW' CX' DE' 'YA 'ZA 'MA 'WZ 'AZ 'UY 'NV 'ZU 'SU 'AU 'AT 'TT 'IS 'XS AT ,MT ,CT SE' SC' SI' MK' WN' WN' MX' NO' NZ' BT' BL' BO' BN' SD' WD' WC' AM ,VJ 'TI IS' 16' KE' KE' KB' KK' KZ' FC' FK' FB' FS' FL' FN' ID' 'NI CH' CN' CK' CN' CS' DE' DK' DW' EE' ES' EI' GB' GD' GE' GH' GW' BX' CY' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, PCT Int. Appl. WO 2000043366 Al 20000727, and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin

E

CI

19990521; JP 1999-253624 19990907.

CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity stalkyl], pharmaceutically acceptable salts and solvates, and medicinal sikyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [1; X and Z represent each CH or N; R1-3 represent each H,

Ι

driuszolinyl) oxylphenyl] - (9CI) (CA INDEX NAME) Urea, N-(2,4-difluorophenyl)-N'-[4-[(6,7-dimethoxy-4-CN586370-24-9 REGISTRY ВИ ANSWER 164 OF 179 REGISTRY COPYRIGHT 2002 ACS ГЗ

CS3 HI8 ES N4 O4 . ЗД СОИСОКД EZ

WE

ΑA

SE

CA, CAPLUS, TOXCENTER **SLN ETJGS:**  $\Gamma C$ 

**LYCE I-A** 

\*\*PROPERTY DATA AVAILABLE IN. THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 (Japanese) . ĐI TD, APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: CB' CK' IE' IL' TO' WC' WT' WK' NE' NT' LL' SE' SN' 'S∃ DK' EI' EK' CH' B1, CX' 'IO BE' ,TA WD' DE' CW' Ce' CH' CE' 'LI RU, 'ZX KC' BE' EW: :MT , ZA 'NX 'AZ 'ZN ,AU 'MT 'CI 'TS 'XS ,MA 'MZ 'NA 'sn **1**90 'LL TR'ZJ 'ss ZE' **в**п• 'Ld br' ON WC' WD' ,AM 'IS 'ds RO, 'ZN 'XW 'MW 'NW WK' **'**\7 KE' 'LT 'ST  $\Gamma B$ ΓK' rc' 'ZX KK' Kb' KG' 1b, 'SI 'NI 'TI ID' **'**NH HB, רח' ŁI' 'HĐ EE' DK' DE' CM' CW' CE' CD' CB' E2' DW' cn' cs' CB' 'HO ,AD BX' AB , AB , SA , UA , TA , MA , LA .qq 802 BC' BK' YE, DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEEEKENCE 1: 133:132732 Preparation and anti-tumor, anti-atherosclerosis,

Ι БĄ Ν ЪЯ  $z \sim$ ГЯ ВЯ Χ ВЪ N - CO - N - BII $\cap$ ВŢ BI0 6Я В6 УΖ

and causing no morphol. change in cells. Thus, the title compd. I (X = comprs. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal gjkyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of K5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; R1-3 represent each H,

resred. CH: Z = CH: RI' R4' R2'R4-R10 each an H: RII = 3'2-ESC6H3) was prepd. and

S86370-23-8 REGISTRY ВИ PN2MER 165 OF 179 REGISTRY COPYRIGHT 2002 ACS ГЗ

**AA** 

CI

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy] phenyl]-N'-(2-СИ

3D CONCOKD by the contract of the contract of

WE CS3 HSI N2 OF E2 3D CONCOBD

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

PAGE 1-A

PAGE 2-A

·

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE)

NI' EB' CB' ZE' ZN' 'Ld II' rn' WC' Wr' WB' ŁI' E2' NE' IE' GB, CB' DK' DE' 'XD CW' 'ID 'H) **'**50 CE' Bl, BE' BE' ,TA ;MT , LT **и**у WD' 'ZX FW:KC' 'nX 'ຮດ **'**១៣ 'TS BX' , ZA ,MA 'MZ 'AZ 'NA 'ZO , AU 'ZJ 'TT TR, 'MT 'LT 2K ₽Ľ, '១s LT, 'ZN 'ON 'XW WC' , AM 'IS ZE' 'ds ВU, 'MW 'NW WK' WD' ко**,** '\u01 Kb' KC' KE' 'TI 'ΩH rn' 'ST LR, ΓK' 1b, 'SI 'NI ID' LT, rc' KB' KZ' 'ИН CH' CE' DE' cn, cz, **,**AD DK' DW' EE' ES' EI' CB' CD' CH' CN' CB' CW' BX' DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, .qq 802 PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:132235 Preparation and anti-tumor, anti-atherosclerosis,

.DT , TG.

CN

ВИ  $\Gamma 3$ 

ΑA

19990521; JP 1999-253624 19990907.

286370-22-7 REGISTRY

tested.

CH: Z = CH; RJ, R4, R5,R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H,

and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal 97k/J or 91k/Jcarbonyl; and Rll represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all

PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493

(Japanese). CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120.

CA, CAPLUS, TOXCENTER SIN Files:  $\Gamma C$ CA SB CS4 HS0 ES N4 O4 WE 3D CONCORD EZ duinazolinyl)oxy]phenyl]- (9CI) (CA INDEX NAME)

Urea, N-[(2,4-difluorophenyl)methyl]-N'-[4-[(6,7-dimethoxy-4-

ANSWER 166 OF 179 REGISTRY COPYRIGHT 2002 ACS

FAGE 2-A

ΗŃ HN OeM MeO

CHS

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE) I REFERENCES IN FILE CA (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: . (asanagal) .Dr , TG. DK' E2' E1' EK' CY' CB' CK' IE' I1' FN' WC' WF' WK' NE' NF' SE' SN' CH' CI' CW' CX' DE' TM; RW: AT, BE, WD' 'ZX BE' B1' CE' CC' 'LT RU, KC' 'MZ , au , ar 'TT TR'WT 'LT 'TS 'xs YA 'ZA ,MA , A.S. 'UX 'NA 'ZO 'SO 'IS 'SS ZE' . เก. เก. PT, RO, NS' br' 'ON 'XW 'MW 'NW WK' WC' WD' AM ,VJ KZ' rc' Kb' KB' 1b' KE' KC' 'SI 'TI ID' LT, LU, 'ST רא' רצ' 'NI ив, нυ, BX' CY' CH' CN' CB' CO' CS' DE' DK' DW' EE' ES' EI' GB' GD' GE' GH' GW' YE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, DESIGNATED STATES: W: .qq 802 Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 Al 20000727, and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines

CI

Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H, halogeno, alkyl, alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all as R5-8 do not represent H simultaneously; R9 and R10 represent each H, alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl), pharmaceutically acceptable salts and solvates, and medicinal aralkyl), pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. CH: Z = CH; R1, R4, R5,R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and

Ι

WE CS0 H18 N4 O4
EZ 3D CONCOKD
(CF INDEX NFWE)
CN Oles, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-2-propynyl- (9CI)
RN 286370-21-6 REGISTRY
LS ASSTRATION REGISTRY
LS ANSWER 167 OF 179 REGISTRY COPYRIGHT 2002 ACS

LC STN Files: CA, CAPLUS, TOXCENTER

AD

tested.

SB

ЯΑ

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BEFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines

PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 .DT , dT APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: . (asanaqat) DK' EI' EB' CB' CB' EB' IE' IL' FO' MC' MF' MB' NE' NF' BL' SE' SN' 'S∃ CX' 'IO **′**၅၁ ,TA WD' 'ZX 'HO BE' 'LT **к**и, KC' CW' BE' B1' CE' TM; RW: , ZA 'AZ 'NX 'ຮດ **'**១៣ ,AU 'TT  $_{\mathrm{TR}}$ 'LI 'IS ,MA 'MZ 'NA 'ZN 'ZL 'WI 'XS 'ZN 'XW , AM 'IS '9s **,**UA ВO, L' PT, 'ON 'MW 'NW WK' WC' WD' 'ΛT ZE' 'ds 'ZX KB' Kb, 'LT 'ST  $\Gamma B$ ΓK' KC' KE' 1b, 'SI 'NI 'NH rn' rc' ID' IF' 'ЯН EE' ES' EI' GB' GD' CH' CE' DW' DK' ,AD CW' Cn' CZ' DE' CH' CN' CB' BX**'** DESIGNATED STATES: W: BK' YE' YE' YW' YI' YO' YE' BB' BB' .qq 80S Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 Al 20000727, and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin

10606661 \$7989-523654 16606061

ЯA

CI

H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all obtionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H,

I

CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal gjkyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H,

CN S89310-S0-2 KECISLKI КИ PN2MER 168 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma 3$ 

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-2-propenyl- (9CI)

ЗД СОИСОКД EZ (CY INDEX NAME)

SECSO HSO Nd Od WE

CY' CYPLUS, TOXCENTER SIN Files: ГC

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I REFERENCES IN FILE CAPLUS (1967 TO DATE,) I REFERENCES IN FILE CA (1967 TO DATE)

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS' . (asanaqat) .DT , TG. E2' DK' EI' EB' GB' GB' GE' IE' II' FA' WC' WF' WB' NE' NF' BL' SE' SN' CX' DE' CI' CW' CH' '90 BE' B1' CE' YY' BE' RU WD' 'ZX TM; RM:  $^{\prime}$ LL KC' **'**១೧ BX**'** 'Z\ 'M7. 'YZ 'NX 'NA 'ZO 'ຮດ ,AU 'ZL 'LL TK'WT 'LI 'TS 'XS **,**MA 'ss ₽Ľ, 'ZN ON WD' 'ds ₽U, BO' LT, 'XW 'MW 'NW WK' '9W ,AM 'IS **'**∃S KC' II' LR, rk' rc' KE' 1b, 'SI ID' 'NH **'**0T T.T. 'ST Kb' KB' KZ' 'NI HB, DK' Cn' CZ' DE' 'AD CW' CH' DW' EE' ES' EI' GB' GD' GE' CH' CN' CB' BX**'** YE' YI' YW' YI' YO' YZ' BY' BB' BG' BK' .qq 80S DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin .eanilozeniup bne anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

X Вζ 0 ГЯ 6Я Уе ВΣ

 $\mathbb{F}^{4}$ ВЗ. zВЯ Вλ  $N - CO - N - K_{IJ}$ 91A

gjklj or alkylcarbonyl; and Rll represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [1; X and Z represent each CH or N; R1-3 represent each H,

Ι

ЯA

CI

CA, CAPLUS, TOXCENTER **SLN Files:**  $\Gamma C$ AD SE CSI HS# N# O# WF. ЗД СОИСОКД ER (CY INDEX NAME) (ID6) Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]Phenyl]-N'-(1-methylpropyl)-CN586370-19-2 REGISTRY ВИ ANSWER 169 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma 3$ 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BELEBENCES IN EITE CAPINS (1967 TO DATE)
I BELEBENCES IN EITE CA (1967 TO DATE)

CI 19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 . (asanaqat) APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: EI' EK' CF' CB' CE' IE' IL' FN' WC' WF' WE' NF' BL' SE' E2' BE' B1' CE' CC' CH' CI' CW' CX' TA : WA : MT 'LT ₽U, BE' WD' ne' , AU 'WZ 'AZ 'UY 'NA 'ZO 'LL TR, 'MT 'ZY , MA ′នា 'ZJ 'LI 'TS br' LT. ON ZE' 'ds 'NW WK' WC' 'IS '១ន RO, RU, 'ZN 'XW 'MW 'ตพ , AM 'AT KB' Kb' Ir' 'LT 'ST KZ' TC' TK' TB' 1b' KE' 'SI 'NI ID' rn' KG' **1**0H чВ, CH' DK' DW' EE' ES' EI' GB' GD' GE' CH' CN' CB' CO' CZ' DE' BX' CY' CW, DESIGNATED STATES: W: YE' YE' YE' YA' YI' YO' YZ' BB' BB' BB' BB' .qq 80S Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 Al 20000727, and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEEEKENCE J: 133:132732 Breparation and anti-tumor, anti-atherosclerosis,

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal aralkyl], pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = alkyl) and proposed substituted and causing no morphol. Change in cells. Thus, the title compd. I (X = alkyl) and proposed substituted and causing no morphol. Change in cells. Thus, the title compd. I (X = alkyl) and proposed substituted and causing no morphol. Change in cells. Thus, the title compd. I (X = alkyl) alkyl or alkyloarbonyl and proposed substituted and proposed substi

Ι

FIGURE 100 OF 179 REGISTRY

CM UTGE N-[4-1(6.7-dimethoxy-4-quinesoliny))oxylph

CN Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-pentyl- (9CI)

E2 3D CONCOBD (CF INDEX NAME)

WE CSS HSe N4 O4

ΑA

SR CA

TC STW Files: CA, CAPLUS, TOXCENTER

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BELEBENCES IN EITE CAPLUS (1967 TO DATE)

I BELEBENCES IN EITE CA (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin

26grcyed by: Mary Hale 308-4258 CM-1 12D16

19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: (Japanese) .DT , TG. E2' DK' GB' GK' IE' IL' TO' WC' WT' WK' NE' NT' 5L' SE' SN' EI' EB' CB' CX' CH' CI' BE' B1' CE' CC' TM; RM: AT, BE, ВU, KC' CW' 'CI 'UM **1**23 , ZA 'ຮກ **'**១៣ ,MA 'MZ ,AZ 'NX 'NA 'ZO ,AU 'ZI 'LL TR, 'MT 'LT 'TS 'XS **,**UA 'Td 'ZN 'ON '១ន ВO, LT, 'NW WK' WC' WD' , AM 'ΛT 'IS ZE' 'ds 'XW 'MW Kb' KC' 'LT ΓK, KK' KZ' TC' TK' 'SI 'TI ID' 'NH 'nT 1b' KE' 'NI HE, 'ST 'HĐ CE' CA' CZ' DE' DK' DW' EE' EZ' EI' CB' CD' BX' CY' CH' CN' CB' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, .qq 802 DESIGNATED STATES: W: Beer Kabushiki Kaisha, Japan). PCT Int. Appl. WO 2000043366 Al 20000727,

CH: Z = CH: KJ' K4' K2'KJ-KJO each an H: KJJ = 3'2-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sjkyl or alkylcarbonyl; and Rll represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all obtionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H,

CSO HSS N# O# ЗД СОИСОВД LS (CA INDEX NAME) Urea, M-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-M-propyl- (9CI) CN586370-17-0 REGISTRY ВИ ANSWER 171 OF 179 REGISTRY COPYRIGHT 2002 ACS ГЗ

CA, CAPLUS, TOXCENTER ГC **AD** SE

ME

ЯΑ

CI

tested.

0

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BELEBENCES IN EITE CAPLOS (1967 TO DATE)
I BELEBENCES IN EITE CA (1967 TO DATE)

19990521; JP 1999-253624 19990907; PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 · (əsəueder) APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: TD, TG. E2' NF' LL' SE' SN' EI' EB' GB' GB' IE' IL' FO' MC' MF' MB' NE' DK' CA' DE' CI' CW' CH' BE' B1' CE' CC' TM; RM: AT, BE, 'CT RU, 'dW **'**73 KC' **'**១៣ , AU **'**Z∀ 'MZ ,AZ 'NA 'NA 'ZN 'SN 'LL TR'MT 'CI 'TS 'XS , MA 'ZL 'ss 'ON 'IS ZE' PT, RO, RU, 'Ta 'ZN WK' WC' WD' 'ds 'XW 'MW 'NW , AM 'AT KB' Kb' KC' 'TI rn' KY' rc' 15' KE' 'SI 'NI  $\Gamma_{\rm L}$ 'ST רא' יאר **'**at 'OH **'**ଧਮ DK' DW' EE' ES' LI' CB' CD' CE' cn' cz' DE' CH' CN' CK' ,AD CH' CW' BX' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, DESIGNATED STATES: W: .qq 80S PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEEEBENCE 1: 133:132832 Preparation and anti-tumor, anti-atherosclerosis,

Title compds. [1; X and Z represent each CH or N; Rl-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent H simultaneously; R9 and R10 represent each H, of R5-8 do not represent H simultaneously; R9-8 do not represent each H, of R5-8 do not represent each H, alkylostonyly of R5-8 do not represent each H, alkylostonyly alkylostonyly alkylostonyly alkylostonyly each H, alkylostonyly alkylostonyly each H, alkylostonyly alkylostonyly each H, a

Ι

α₩

CI

L3 ANSWER 172 OF 179 REGISTRY COPYRIGHT 2002 ACS

EN 286370-16-9 REGISTRY

CM Urea, W-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-W'-ethyl- (9CI) (CA Urea, W-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-W'-ethyl- (9CI) (CA Urea, W-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-W'-ethyl- (9CI) (CA Urea, W-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl-W'-ethyl- (9CI) (

STN Files:

 $\Gamma C$ 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

CA, CAPLUS, TOXCENTER

I BELEBENCES IN EITE CAPLUS (1967 TO DATE)

CI 19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 (Japanese) APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: .DT , TG. EI' EK' CH' CB' CB' IE' IL' FN' WC' WF' WE' NE' NE' SE' E2' DK' BE' B1' CE' CC' CH' CI' CW' CX' TM; RM: AT, BE, ,UT кu, WD' 'ZX **'**១៣ ,AU 'MZ 'ZW , MA AZ 'UY 'NV 'ZU 'SU 'ZJ 'TT TR, ,MT 'LT 'IS 'ZN ZE' 'ds 'NW WK' WC' WD' rn' 'IS 'SS PL, PT, RO, RU, 'ON 'XW 'MW , AM 'TI 'ST Kb' KB' KZ' TC' TK' TB' 'SI 'NI ID' 'NH  $\Gamma_{\rm L}$ KC' 1b' KE' HB, **'**∩T CH' CE' DK' DW' EE' ES' EI' CB' CD' CH' CN' CE' CN' CS' DE' BX' CY' CW' AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, DESIGNATED STATES: W: .qq 802 PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

CH; Z = CH; R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and and causing no morphol. change in cells. Thus, the title compd. I (X =compns. contg. the same are prepd. and tested having antitumor activity aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sikyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or of R5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H,

Ι

3D СОИСОКD EZ (ID6) (CY INDEX NAME) Orea, N-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-propyl-CNВИ **586370-15-8** REGISTRY ANSWER 173 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma$ 3

CSO HSI CJ Nđ Ođ WE

SR

CA, CAPLUS, TOXCENTER **SLN Files:** rc

**л−**Бкин—'С-CJ OəM MGO

ЯΑ

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1 REFERENCES IN FILE CAPLUS (1967 TO DATE) J REFERENCES IN FILE CA (1967 TO DATE)

and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

Searched by: Mary Hale 308-4258 CM-1 12D16

19990521; JP 1999-253624 19990907.

'LT

TR,

WK'

'NI

'LL

'NW

'SI

DESIGNATED STATES: W:

(Japanese)

EI' EB' CB'

**,** עא

'MT

WC'

'TI

СН' СИ' СВ'

Beer Kabushiki Kaisha, Japan).

'GW

**1** C.L.

'dI

'dM .'AM

AA

CI

.DT , TG.

'SE

'ZX

'TS

'ΩH

BX' CB'

.qq 80S

DK'

'XS

'AT

чв,

CH: S = CH: BT, BA, BS, B7-BT0 each an BT1 = 3, B-BT0643) was prepd. and aralkyl], pharmaceutically acceptable salts and solvates, and medicinal sikyl or alkylcarbonyl; and Ril represents alkyl, alkenyl, alkynyl or ot K5-8 do not represent H simultaneously; R9 and R10 represent each H, H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each Title compds. [1; X and Z represent each CH or N; Rl-3 represent each H,

PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493

BE' BE' B1' CE'

'ZN

Kb'

'ทุง 'รูก 'รูก

br'

KB'

'Ld

'ZX

DW' EE' ES' EI' CB' CD'

GB' GK' IE' IL' FN' WC' WF'

ne'

ON

KC'

DK'

CODEN: BIXXDS:

, AU

'XW 'MW

1b' KE'

TA; RW: AT,

'ZL

cn' cz' DE'

APPLICATION: WO 2000-JP255 20000120.

CH'

'AZ

**В**И,

ΓK'

**'**ອວ

**'**NX

BO,

rc'

YE' YI' YW' YI' YO' YZ' BY' BB' BC' BK'

PCT Int. Appl. WO 2000043366 Al 20000727,

WE' NE' NI' LL' SE'

'ID

'M7

'as

LR,

'XD

**,**2A

'9S

'LT

'HĐ

'IS

rn'

CW'

CW'

,MA

ZE'

'ST

CE'

qılluorophenyl)- (9CI) (CA INDEX NAME) Orea, M-[2-chloro-4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(2,4-CN 586370-14-7 REGISTRY КИ PN2MER 174 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma 3$ tested. and causing no morphol. change in cells. Thus, the title compd. I (X = xcompns. contg. the same are prepd. and tested having antitumor activity

CA, CAPLUS, TOXCENTER STN Files: ГC AD SE CS3 HIL CT ES N4 O4 ME3D CONCORD EŞ

**PAGE 2-A** 

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I BELEBENCES IN LIFE CAPTOR (1964 TO DATE)

I BELEBENCES IN LIFE CA (1964 TO DATE)

E

CI 19990521; JP 1999-253624 19990907. PRIORITY: JP 1999-14858 19990122; JP 1999-26691 19990203; JP 1999-142493 CODEN: PIXXD2. APPLICATION: WO 2000-JP255 20000120. .(əsənaqat) .DT , QT DK' E2' E1' EK' GF' GB' GK' IE' IL' FN' WC' WF' WE' NF' BL' SE' SN' KZ' MD' BA' LA' LW: BM: FL' BE' BL' CE' CC' CH' CI' CW' CK' DE' KC' 'MZ TZ, UY, VU, SU, SU, AU, XT, 'TT 'TS AZ, BY, TJ, TM, TR, ,MA 'XS 'IS '9S 2E' MN' MM' MX' NO' NZ' BI' BL' BO' BN' SD' WD' WG' WK' AM VJ רת' דת 'ST ID' IS' 15' KE' KE' KB' KK' C' TK' TB' 'NI 'TI HE, HU, BX' CY' CH' CN' CB' CO' CZ' DE' DK' DW' EE' ES' EI' GB' GD' GE' GH' GW' YE' YI' YW' YI' YO' YZ' BY' BB' BG' BK' .qq 802 DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis,

Title compds. [1; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all atkyl or alkyl, alkoxy, alkylthio, nitro or amino, provided that all atkyl or alkyloarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal aralkyl], pharmaceutically acceptable salts and solvates, and medicinal and causing no morphol. change in cells. Thus, the title compd. I (X and causing no morphol. change in cells. Thus, the title compd. I (X and causing no morphol. change in cells. Thus, the title compd. I (X and causing no morphol. change in cells. Thus, the title compd. I (X and causing no morphol. change in cells. Thus, the title compd. I (X and causing no morphol. change in cells. Thus, the title compd. I (X and causing no morphol. change in cells. Thus, the title compd. I (X and causing no morphol. change in cells. Thus, the title compd. I (X and causing no morphol. CH; Z = CH; R1, R1, R4, R5, R7-R10 each an H; R11 = 3,5-F2C6H3) was prepd. and

Ι

INDEX NAME)

CN UTea, N-butyl-N'-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]- (9CI) (CA

L3 ANSWER 175 OF 179 REGISTRY

COPYRIGHT 2002 ACS

EZ 3D CONCOKD

2K CY WE CSI HS4 N4 O4

ЯΑ

TC ZIM EŢJGS: CY' CYBLUS, TOXCENTER, USPATFULL

MeO MeO MeO MeO

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

S REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 133:135235 Preparation and anti-tumor, anti-atherosclerosis, anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin

Zesrched by: Mary Hale 308-4258 CM-1 12D16

CI

ЯΑ

Title compds. [I; X and Z represent each CH or N; R1-3 represent each H, optionally substituted alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all alkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or araikyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or araikyl], pharmaceutically acceptable salts and solvates, and medicinal araikyl), pharmaceutically acceptable salts and solvates, and medicinal compns. contg. the same are prepd. and tested having antitumor activity and causing no morphol. change in cells. Thus, the title compd. I (X = and causing no morphol. Change in cells. Thus, the title compd. I (X = and causing no morphol. Change in cells. Thus, the title compd. I (X = and causing no morphol. Change in cells. Thus, the title compd. I (X = and causing no morphol. Change in cells. Thus, the title compd. I (X = and causing no morphol. Change in cells. Thus, the title compd. I (X = and causing no morphol. Change in cells. Thus, the title compd. I (X = and causing no morphol. Change in cells. Thus, the title compd. I (X = and causing no morphol. Change in cells. Thus, the title compd. I (X = and causing no morphol. Change in cells. Thus, the title compd. I (X = and causing no morphol. Change in cells. Thus, the title compd. I (X = and causing no morphol.)

tested.

REFERENCE 2: 127:34137 Preparation of quinoline and quinazoline derivatives
inhibiting platelet-derived growth factor receptor autophosphorylation.
Kubo, Kazuo; Ohvama, Shinichi; Shimizu, Toshiyuki; Nishitoba, Tsuyoshi;

PRIORITY: JP 1995-313555 19951107; JP 1996-62121 MO 1996-1P3229 19961105. 'NS APPLICATION: CODEN: BIXXDS: . (asansqst) TG. LD' ZE' 'Ld CH' EI' EK' GF' GB' GE' IE' IL' TO' WC' WT' E2' DK' CW' 'IO DE' KZ' WD' BE' BE' TA : WA : MT , LT кu, KC' BX' , ZA ,MA 'ΝΛ " ទល 'ds 'XS 'IS ʻ9S ZE' КU, RO, 'Ld 'Td 'ZN 'ON 'XW 'MW 'LL TR, 'MT 'LT KC' WK' WG' ΓΚ' ΓΒ' Γ2' Γ1' ΓΛ' ΜD' rc' 'ZX KK' KE' 1b, 'SI 'NW BG' BK' BK' CF' CH' CN' CN' CS' DE' DK' EE' ES' EI' GB' GE' HN' , SA , UA , TA , MA , JA .qq £42 ,21207691 IA 9287179 DESIGNATED STATES: W: Toshiyuki; Nishitoba, Tsuyoshi; Kato, Shinichiro). PCT Int. Appl. WO Kabushiki Kaisha, Japan; Kubo, Kazuo; Оhуата, Shinichi; Shimizu, Kato, Shinichiro; Murooka, Hideko; Kobayashi, Yoshiko; et al. (Kirin Beer Kubo, Kazuo; Ohyama, Shinichi; Shimizu, Toshiyuki; Nishitoba, Tsuyoshi;

EI

.ESZ0966I

cells by 130%. 9 days) increased the survival of mice with transplanted leukemic P388 etc. The title compd. II (prepn. given) (at 100 mg/kg i.p. once daily for autophosphorylation and are useful in the treatment of cancer, arthritis, prepd. I inhibit platelet-derived growth factor receptor CH or N; and Q represents substituted aryl or substituted heteroaryl] are R2 together form C1 to C3 alkylene; X represents O, S or CH2; W represents The title compds. I [Rl and R2 represent each H or Cl-4 alkyl, or Rl and ЯΑ

CS3 HI E Nd Od 3D СОИСОВD ЕŞ (CA INDEX NAME) (ID6) Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(2-fluorophenyl)-CN190728-00-8 REGISTRY ВИ YNZMEK 116 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma 3$ 

SE**KD** 

CA, CAPLUS, TOXCENTER, USPATFULL SIN Files:  $\Gamma C$ 

ИŁ

26arched by: Mary Hale 308-4258 CM-1 12D16

## 1 REFERENCES IN FILE CAPLUS (1967 TO DATE) J REFERENCES IN FILE CA (1967 TO DATE)

19960223. PRIORITY: JP 1995-313555 19951107; JP 1996-62121 MO 1996-JP3229 19961105. . (asanaqat) Nr' 'NS ZE' LT, CODEN: BIXXDS: TD, TG. WE' NE' APPLICATION: E2' DK' DE' CW' 'ID CH' **'**9၁ CE' rn' wc' wr' EI' EK' CH' CB' CK' IE' IL' BŁ' 'ZX Bl' BE'  $_{\mbox{\scriptsize TA}}$ FW:;MT 'LI ₽U, WD' KC' BX' , ZA ,MA ΊΝΛ 'ZΩ 'ຮດ **'**១៣ 'IS '១s ZE' 'ds **,**UЯ LT, 'ON ,AU 'LL  $\mathsf{T}\mathsf{R}_{\boldsymbol{\lambda}}$ 'MT 'LI 'XS **в**О'  $\mathtt{b}\mathtt{\Gamma'}$ 'ZN 'XW 'MW WK' WC' **'**ΛΊ rl' 'ST ГВ**'**  $\Gamma K^{ullet}$ rc' 'ZX KG' KE' 1b, 'NW WD' rn' KK' 'SI 'TI EZ' EI' CB' CE' HO' Cn' CZ' DE' DK' EE' BC' BK' BA' CH' CH' , aa , Aa , ZA , UA , TA' , MA , JA .qq E#S ,21207691 IA 92E7179 DESIGNATED STATES: W: PCT Int. Appl. WO Toshiyuki; Wishitoba, Tsuyoshi; Kato, Shinichiro). Kabushiki Kaisha, Japan; Kubo, Kazuo; Ohyama, Shinichi; Shimizu, Kato, Shinichiro; Murooka, Hideko; Kobayashi, Yoshiko; et al. (Kirin Beer Kubo, Kazuo; Ολγαπα, Shinichi; Shimizu, Toshiyuki; Nishitoba, Tsuyoshi; inhibiting platelet-derived growth factor receptor autophosphorylation. RELERENCE 1: 127:34137 Preparation of quinoline and quinazoline derivatives

9 days) increased the survival of mice with transplanted leukemic P388 The title compd. II (prepn. given) (at 100 mg/kg i.p. once daily for autophosphorylation and are useful in the treatment of cancer, arthritis, prepd. I inhibit platelet-derived growth factor receptor CH or N; and Q represents substituted aryl or substituted heteroaryl] are R2 together form C1 to C3 alkylene; X represents O, S or CH2; W represents The title compds. I [R1 and R2 represent each H or C1-4 alky1, or R1 and

100727-99-2 REGISTRY ВИ ANSWER 177 OF 179 REGISTRY COPYRIGHT 2002 ACS  $\Gamma$ 3

(CA INDEX NAME) (ID6) Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(3-methoxyphenyl)-CN

cells by 130%.

ЗД СОИСОКД EZ

CI

CS# HSS N# OP ИF.

SK

CA, CAPLUS, TOXCENTER, USPATFULL SIN FILES: ГC

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

J BELEBENCES IN EITE CALINS (1967 TO DATE)

J BELEBENCES IN EITE CA (1967 TO DATE)

19960223. PRIORITY: JP 1995-313555 19951107; JP 1996-62121 MO 1996-JF3229 19961105. APPLICATION: (Japanese). CODEN: PIXXDZ. MK, NE, NL, PT, SE, SN, TD, TG. CE' CG' CH' CI' CW' DE' DK' ES' EI' EK' CF' CB' CB' IE' IL' FN' WC' WF' KG' KZ' MD' KN' LT' LW; KM: FL' BE' BL' BT' 'YA 'ZA 'MA 'NV 'ZU 'SU 'DU PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, 'ZN 'ON 'XW 'MW ке' кв' кз' гс' гк' гв' гз' гл' гл' мр' ме' мк' ми' 15' KE' BY' BB' BC' BK' BK' CY' CH' CN' CN' CZ' DE' DK' EE' EZ' EI' CB' CE' HN' , ZA , UA , TA , MA , JA 9717329 A1 19970515, 243 pp. DESIGNATED STATES: W: PCT Int. Appl. WO Toshiyuki; Nishitoba, Tsuyoshi; Kato, Shinichiro). Kabushiki Kaisha, Japan; Kubo, Kazuo; Ohyama, Shinichi; Shimizu, Kato, Shinichiro; Murooka, Hideko; Kobayashi, Yoshiko; et al. (Kirin Beer Kubo, Kazuo; Оһуата, Shinichi; Shimizu, Тоshiyuki; Nishitoba, Тsuyoshi; ruprprfrud brafefef-derraed drowth factor receptor autophosphorylation. REFERENCE 1: 127:34137 Preparation of quinoline and quinazoline derivatives

ANSWER 178 OF 179 REGISTRY COPYRIGHT 2002 ACS cells by 130%. 9 days) increased the survival of mice with transplanted leukemic P388 etc. The title compd. II (prepn. given) (at 100 mg/kg i.p. once daily for autophosphorylation and are useful in the treatment of cancer, arthritis, prepd. I inhibit platelet-derived growth factor receptor CH or N; and Q represents substituted aryl or substituted heteroaryl] are RZ together form Cl to C3 alkylene; X represents O, S or CH2; W represents The title compds. I [Rl and RZ represent each H or Cl-4 alkyl, or Rl and ЯA

(CY INDEX NAME) (ID6) СИ 100727-98-1 REGISTRY ВИ  $\Gamma 3$ 

Urea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(2-methoxyphenyl)-

ЗД СОИСОКД ES

CS# HSS N# OP ME

SEAD

**O P** M

CA, CAPLUS, TOXCENTER, USPATFULL  $\Gamma C$ SIN Files:

S KEEEKENCES IN EITE CAFINS (1964 TO DATE)

S KEEEKENCES IN EITE CA (1964 TO DATE)

. (seeneget) APPLICATION: WO 2000-JP255 20000120. CODEN: BIXXDS: TG. 'UL GB' GK' IE' IL' FA' WC' WF' WK' NE' NF' BL' SE' SN' EI' EB' CY' E2' DK' WD' CX' CH' CC' BE' B1' CE' BE' TA; WA; MT 'ZX CI' CW' 'LL **к**и, 'MZ 'NX 'NA 'ZΩ **'**១៣ ,AU ,ZA 'AZ ′នា TR, 'MT 'LI ,MA 'ZL 'LL BU, 'Ld ¹7d 'ZN 'ON 'NW WK' , AM 'IS 'ĐS KO, 'XW 'MW WC' WD' ZE' 'ds '\\T rn'  $\Gamma L$ 'ST  $\Gamma B$ ΓK' rc' KK' KZ' Kb' KC' 1b' KE' 'SI 'NI 'TI 'dI 'OH HE, DW' DK' CH' CE' EE' ES' EI' CB' CD' Cn' CZ' DE' CH' CN' CB' ,AD BX**'** BK' .qq 80S AE, AL, AM, AT, AU, AZ, BA, BB, BG, DESIGNATED STATES: W: PCT Int. Appl. WO 2000043366 Al 20000727, Beer Kabushiki Kaisha, Japan). and quinazolines. Kubo, Kazuo; Fujiwara, Yasunari; Isoe, Toshiyuki (Kirin anti-psoriasis, anti-diabetes, and anti-arthritis activities of quinolines KEEEKENCE 1: 133:132732 Stebaration and auti-fumor, anti-atherosclerosis,

18890521; JP 1899-253624 18990907.

tested.

ЯA

CI

Title compds. [I; X and Z represent each CH or N; Rl-3 represent each H, halogeno, alkyl, alkoxy, etc.; R4 represents H; R5-8 represent each H, halogeno, alkyl, alkoxy, alkylthio, nitro or amino, provided that all aralkyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or alkylcarbonyl; and R11 represents alkyl, alkenyl, alkynyl or aralkyl], pharmaceutically acceptable salts and solvates, and medicinal aralkyl), pharmaceutically acceptable salts and solvates, and medicinal aralkyl), pharmaceutically acceptable salts and solvates, and medicinal acceptable salts and solvates, and medicinal aralkyl or alkylcarbonyl; and R11 represent each H, (X = 1, Y =

.ESS0966I PRIORITY: JP 1995-313555 19951107; JP 1996-62121 MO 1896-JP3229 18961105. CODEN: BIXXDS: . (asanaqat) .DI LD' SE' SN' EI' EB' CB' CB' IE' II' FR' WC' WF' E2' DK' DE' CW' KZ, MD, RU, TJ, TM; RW: AT, BE, BF, , ZA KC' BX' ,MA 'XS 'IS 'DS 'EE' CC' KO, 'Ld br' КU, MT ,UT 'ON 'ZX rc' TK' TB' TZ' TL' TA' MD' MC' MK' MM' KC' KK' BG' BK' BX' CY' CH' CN' CO' CS' DE' DK' EE' ES' EI' GB' GE' HO' , SA , UA , TA , MA , JA 9717329 A1 19970515, 243 pp. DESIGNATED STATES: W: Toshiyuki; Nishitoba, Tsuyoshi; Kato, Shinichiro). PCT Int. Appl. WO Kabushiki Kaisha, Japan; Kubo, Kazuo; Ohyama, Shinichi; Shimizu, Kato, Shinichiro; Murooka, Hideko; Kobayashi, Yoshiko; et al. (Kirin Beer Kubo, Kazuo; Ohyama, Shinichi; Shimizu, Toshiyuki; Nishitoba, Tsuyoshi; inhibiting platelet-derived growth factor receptor autophosphorylation. KELEKENCE S: 151:34137 Preparation of quinoline and quinazoline derivatives

ANSWER 179 OF 179 REGISTRY COPYRIGHT 2002 ACS ГЗ cells by 130%. 9 days) increased the survival of mice with transplanted leukemic P388 etc. The title compd. II (prepn. given) (at 100 mg/kg i.p. once daily for autophosphorylation and are useful in the treatment of cancer, arthritis, prepd. I inhibit platelet-derived growth factor receptor CH or N; and Q represents substituted aryl or substituted heteroaryl] are RZ together form Cl to C3 alkylene; X represents O, S or CHZ; W represents The title compds. I [Rl and R2 represent each H or Cl-4 alkyl, or Rl and ЯA

(CY INDEX NAME) (ID6) Orea, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-N'-(4-methoxyphenyl)-СИ 100727-97-0 REGISTRY ВИ

CS# HSS N# O2 WE ЗД СОИСОВД EZ

SE

CA, CAPLUS, TOXCENTER, USPATFULL SIN Files:  $\Gamma C$ 

Searched by: Mary Hale 308-4258 CM-1 12D16

Searched by: Mary Hale 308-4258 CM-1 12D16

MeO MeO MeO

PAGE 2-A

OMe |

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

I KEEEKENCER IN EITE CYBFOR (1801 TO DATE)

19960233. PRIORITY: JP 1995-313555 19951107; JP 1996-62121 MO 1996-JP3229 19961105. (Japanese). CODEN: PIXXD2. MR, NE, NL, PT, SE, SN, TD, TG. 'IO CW' DE' DK' ES' EI' EK' GB' GB' IE' IL' TN' WC' WT' KZ' MD' KN' LT' LW; KM: FT' BE' BE' BT' KC' BX**'** , SA , MA 'AT SD' SE' SG' SI' SK' IN' IM' RO, RU, 'Id 'Ta ON KG' KK' KZ' TC' TK' TB' T2' T1' TA' MD' MG' MK' MA' BY' BB' BC' BK' BK' CY' CH' CN' CC' DE' DK' EE' ES' EI' CB' CE' HO' 9717329 A1 19970515, 243 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, Toshiyuki; Wishitoba, Tsuyoshi; Kato, Shinichiro). PCT Int. Appl. WO Kabushiki Kaisha, Japan; Kubo, Kazuo; Ohyama, Shinichi; Shimizu, Kato, Shinichiro; Murooka, Hideko; Kobayashi, Yoshiko; et al. (Kirin Beer Kubo, Kazuo; Ohyama, Shinichi; Shimizu, Toshiyuki; Nishitoba, Tsuyoshi; ruprprirud bracefec-derived growth factor receptor autophosphorylation. KEFERENCE 1: 127:34137 Preparation of quinoline and quinazoline derivatives

CI

**SEZZION** ENLKX

-IIO:33

**IATOT** SINCE LIFE

COST IN U.S. DOLLARS

=> fil reg

ЯA

=> del his y

0 P3 ÞΤ

more information.

all substance data from the REGISTRY file. Enter HELP FIRST for This file supports REGISTRY for direct browsing and searching of

display formats. printed between 1907-1966 are available in the PAGE TIFF images of CA abstracts now searchable from 1907-1966. assignees, and patent information, e.g., patent numbers, are substance identification. Title keywords, authors, patent This file contains CAS Registry Numbers for easy and accurate

> FILE LAST UPDATED: 01 May 1997 (19970501/UP) LIFE CONERS 1907-1966

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS) PLEASE SEE "HELP USAGETERMS" FOR DETAILS. MRE IS ROBRECT TO THE TERMS OF YOUR STW CUSTOMER AGREEMENT.

EIFE 'CAOLD' ENTERED AT 08:51:50 ON 09 APR 2002

19:501-CY SUBSCRIBER PRICE

**SEZZION** FILLER

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) JATOT SINCE LIFE

S\$.886 ₱L.918 FULL ESTIMATED COST **SESSION** ENLKX

COST IN U.S. DOLLARS **IATOT** ZINCE LIFE

=> fil caol;s l3

cells by 130%. 9 days) increased the survival of mice with transplanted leukemic P388

etc. The title compd. II (prepn. given) (at 100 mg/kg i.p. once daily for RZ together form Cl to C3 alkylene; X represents O, S or CH2; W represents

autophosphorylation and are useful in the treatment of cancer, arthritis, prepd. I inhibit platelet-derived growth factor receptor CH or N; and Q represents substituted aryl or substituted heteroaryl] are The title compds. I [R1 and R2 represent each H or C1-4 alky], or R1 and

$$\mathbb{R}^{2}\mathbb{Q}$$

$$\mathbb{R}$$

ИНСИН || **9MO**